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DISCLAIMER 
The use of company or product name(s) is for identification only and does not imply endorsement by the 
Agency for Toxic Substances and Disease Registry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii COBALT  
UPDATE STATEMENT 

A Toxicological Profile for cobalt, Draft for Public Comment was released in July 2001.  This edition 
supersedes any previously released draft or final profile.   
Toxicological profiles are revised and republished as necessary.  For information regarding the update 
status of previously released profiles, contact ATSDR at: 
Agency for Toxic Substances and Disease Registry
 
Division of Toxicology/Toxicology Information Branch 

1600 Clifton Road NE,  

Mailstop F-32 

Atlanta, Georgia 30333 
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Background Information
The toxicological profiles are developed by ATSDR pursuant to Section 104(i) (3) and (5) of the 
Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or 
Superfund) for hazardous substances found at Department of Energy (DOE) waste sites.  CERCLA 
directs ATSDR to prepare toxicological profiles for hazardous substances most commonly found at 
facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat 
to human health, as determined by ATSDR and the EPA.  ATSDR and DOE entered into a Memorandum
of Understanding on November 4, 1992 which provided that ATSDR would prepare toxicological profiles 
for hazardous substances based upon ATSDR=s or DOE=s identification of need. The current ATSDR 
priority list of hazardous substances at DOE NPL sites was announced in the Federal Register on July 24, 
1996 (61 FR 38451). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
        
    
 
 
vii COBALT  
QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
Primary Chapters/Sections of Interest 
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure. 
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health. 
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are 
reported in this section. 
NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects 
observed following exposure. 
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues: 
Section 1.6 How Can (Chemical X) Affect Children? 

Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)? 

Section 3.8 Children’s Susceptibility 

Section 6.6 Exposures of Children 

Other Sections of Interest: 
Section 3.9 Biomarkers of Exposure and Effect 
Section 3.12 Methods for Reducing Toxic Effects 
ATSDR Information Center  
Phone:  1-888-42-ATSDR or (404) 498-0110 Fax: (770) 488-4178 
E-mail:  atsdric@cdc.gov Internet: http://www.atsdr.cdc.gov 
The following additional material can be ordered through the ATSDR Information Center: 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided.  Other case studies of interest include Reproductive and Developmental 
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Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies. 
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials. 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances. 
Other Agencies and Organizations 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341­
3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH. 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212. 
Radiation Emergency Assistance Center/Training Site (REAC/TS) provides support to the U.S. 
Department of Energy, the World Health Organization, and the International Atomic Energy
Agency in the medical management of radiation accidents.  A 24-hour emergency response 
program at the Oak Ridge Institute for Science and Education (ORISE), REAC/TS trains, 
consults, or assists in the response to all kinds of radiation accidents.  Contact: Oak Ridge 
Institute for Science and Education, REAC/TS, PO Box 117, MS 39, Oak Ridge, TN 37831-0117 
• Phone 865-576-3131 • FAX 865-576-9522 • 24-Hour Emergency Phone 865-576-1005 (ask for 
REAC/TS) • e-mail: cooleyp@orau.gov • website (including emergency medical guidance): 
http://www.orau.gov/reacts/default.htm 
Referrals 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact: 
 
 
 
 
 
 
 
 
 
 
 
 
 
ixCOBALT  
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 •
FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact: ACOEM, 55 West Seegers Road, Arlington Heights, IL 
60005 • Phone:  847-818-1800 • FAX:  847-818-9266. 
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PEER REVIEW 
A peer review panel was assembled for cobalt.  The panel consisted of the following members:  
1. 	 Dr. Herman Cember, C.H.P., Ph.D., PE., Adjunct Professor, School of Health Sciences, Purdue 
University, Lafayette, Indiana; 
2.	 Dr. James Hansen, Ph.D., Environmental Contaminant Specialist, U.S. Fish and Wildlife Service, 
Spokane, WA; 
3.	 Dr. Dominique Lison, M.D., Ph.D., Vice-Chairman of the Doctoral School in Genetics and 
Immunology, Catholic University of Louvain, Brussels, Belgium, and 
4. 	 Dr. Nancy Pedigo, Ph.D., Research Assistant Professor, Department of Pharmacology, University
of Kentucky Medical Center, Lexington, KY. 
These experts collectively have knowledge of cobalt's physical and chemical properties, toxicokinetics, 
key health end points, mechanisms of action, human and animal exposure, and quantification of risk to 
humans.  All reviewers were selected in conformity with the conditions for peer review specified in 
Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as 
amended. 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.  A list of databases reviewed and 
a list of unpublished documents cited are also included in the administrative record. 
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
content. The responsibility for the content of this profile lies with the ATSDR. 
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1 COBALT  
1. PUBLIC HEALTH STATEMENT
This public health statement tells you about cobalt and the effects of exposure.   
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation. These sites make up the National Priorities List (NPL) and are the sites targeted for 
long-term federal cleanup activities.  Stable cobalt has been found in at least 426 of the 
1,636 current or former NPL sites.  Radioactive cobalt, as 60Co, has been found in at least 13 of 
the 1,636 current or former NPL sites.  However, the total number of NPL sites evaluated for this 
substance is not known. As more sites are evaluated, the sites at which cobalt is found may 
increase. This information is important because exposure to this substance may harm you and 
because these sites may be sources of exposure. 
When a substance is released from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  This release does not always lead to 
exposure. You are exposed to a substance only when you come in contact with it.  You may be 
exposed by breathing, eating, or drinking the substance, or by skin contact.  External exposure to 
radiation may occur from natural or man-made sources.  Naturally occurring sources of radiation 
are cosmic radiation from space or radioactive materials in soil or building materials.  Man-made 
sources of radioactive materials are found in consumer products, industrial equipment, atom
bomb fallout, and to a smaller extent from hospital waste and nuclear reactors. 
If you are exposed to cobalt, many factors determine whether you'll be harmed.  These factors 
include the dose (how much), the duration (how long), and how you come in contact with it.  
You must also consider the other chemicals you're exposed to and your age, sex, diet, family 
traits, lifestyle, and state of health. 
  
 
 
 
 
 
 
 
 
 
 
 
2 COBALT  
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1.1 WHAT IS COBALT?
Cobalt is a naturally-occurring element that has properties similar to those of iron and nickel.  It 
has an atomic number of 27.  There is only one stable isotope of cobalt, which has an atomic 
mass number of 59.  (An element may have several different forms, called isotopes, with 
different weights depending on the number of neutrons that it contains.  The isotopes of an 
element, therefore, have different atomic mass numbers [number of protons and neutrons], 
although the atomic number [number of protons] remains the same.)  However, there are many 
unstable or radioactive isotopes, two of which are commercially important, cobalt-60 and 
cobalt-57, also written as Co-60 or 60Co and Co-57 or 57Co, and read as cobalt sixty and cobalt 
fifty-seven. All isotopes of cobalt behave the same chemically and will therefore have the same
chemical behavior in the environment and the same chemical effects on your body.  However, 
isotopes have different mass numbers and the radioactive isotopes have different radioactive 
properties, such as their half-life and the nature of the radiation they give off.  The half-life of a 
cobalt isotope is the time that it takes for half of that isotope to give off its radiation and change 
into a different isotope. After one half-life, one-half of the radioactivity is gone.  After a second 
half-life, one-fourth of the original radioactivity is left, and so on.  Radioactive isotopes are 
constantly changing into different isotopes by giving off radiation, a process referred to as 
radioactive decay. The new isotope may be a different element or the same element with a 
different mass. 
Small amounts of cobalt are naturally found in most rocks, soil, water, plants, and animals, 
typically in small amounts.  Cobalt is also found in meteorites.  Elemental cobalt is a hard, 
silvery grey metal.  However, cobalt is usually found in the environment combined with other 
elements such as oxygen, sulfur, and arsenic.  Small amounts of these chemical compounds can 
be found in rocks, soil, plants, and animals.  Cobalt is even found in water in dissolved or ionic 
form, typically in small amounts.  (Ions are atoms, collections of atoms, or molecules containing 
a positive or negative electric charge.) A biochemically important cobalt compound is 
vitamin B12 or cyanocobalamin.  Vitamin B12 is essential for good health in animals and humans.  
Cobalt is not currently mined in the United States, but has been mined in the past.  Therefore, we 
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obtain cobalt and its other chemical forms from imported materials and by recycling scrap metal 
that contains cobalt. 
Cobalt metal is usually mixed with other metals to form alloys, which are harder or more 
resistant to wear and corrosion. These alloys are used in a number of military and industrial 
applications such as aircraft engines, magnets, and grinding and cutting tools.  They are also used 
in artificial hip and knee joints. Cobalt compounds are used as colorants in glass, ceramics, and 
paints, as catalysts, and as paint driers.  Cobalt colorants have a characteristic blue color; 
however, not all cobalt compounds are blue.  Cobalt compounds are also used as trace element 
additives in agriculture and medicine.   
Cobalt can also exist in radioactive forms.  A radioactive isotope of an element constantly gives 
off radiation, which can change it into an isotope of a different element or a different isotope of 
the same element.  This newly formed nuclide may be stable or radioactive.  This process is 
called radioactive decay.  60Co is the most important radioisotope of cobalt.  It is produced by 
bombarding natural cobalt, 59Co, with neutrons in a nuclear reactor.  60Co decays by giving off a 
beta ray (or electron), and is changed into a stable nuclide of nickel (atomic number 28).  The 
half-life of 60Co is 5.27 years. The decay is accompanied by the emission of high energy 
radiation called gamma rays.  60Co is used as a source of gamma rays for sterilizing medical 
equipment and consumer products, radiation therapy for treating cancer patients, and for 
manufacturing plastics.  60Co has also been used for food irradiation; depending on the radiation 
dose, this process may be used to sterilize food, destroy pathogens, extend the shelf-life of food, 
disinfest fruits and grain, delay ripening, and retard sprouting (e.g., potatoes and onions).  57Co is 
used in medical and scientific research and has a half-life of 272 days.  57Co undergoes a decay 
process called electron capture to form a stable isotope of iron (57Fe). Another important cobalt 
isotope, 58Co, is produced when nickel is exposed to a source of neutrons.  Since nickel is used in 
nuclear reactors, 58Co may be unintentionally produced and appear as a contaminant in cooling 
water released by nuclear reactors. 58Co also decays by electron capture, forming another stable 
isotope of iron (58Fe). 60Co may be similarly produced from cobalt alloys in nuclear reactors and 
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released as a contaminant in cooling water.  58Co has a half-life of 71 days and gives off beta and 
gamma radiation in the decay process. 
Quantities of radioactive cobalt are normally measured in units of radioactivity (curies or 
becquerels) rather than in units of mass (grams).  The becquerel (Bq) is a new international unit, 
and the curie (Ci) is the traditional unit; both are currently used.  A becquerel is the amount of 
radioactive material in which 1 atom transforms every second, and a curie is the amount of 
radioactive material in which 37 billion atoms transform every second.  For an overview of basic 
radiation physics, chemistry, and biology see Appendix D of this profile.  For more information 
on radiation, see the ATSDR Toxicological Profile for Ionizing Radiation. 
To learn more about the properties and uses of cobalt, see Chapters 4 and 5. 
1.2 WHAT HAPPENS TO COBALT WHEN IT ENTERS THE ENVIRONMENT?
Cobalt may enter the environment from both natural sources and human activities.  Cobalt occurs 
naturally in soil, rock, air, water, plants, and animals.  It may enter air and water, and settle on 
land from windblown dust, seawater spray, volcanic eruptions, and forest fires and may 
additionally get into surface water from runoff and leaching when rainwater washes through soil 
and rock containing cobalt.  Soils near ore deposits, phosphate rocks, or ore smelting facilities, 
and soils contaminated by airport traffic, highway traffic, or other industrial pollution may 
contain high concentrations of cobalt. Small amounts of cobalt may be released into the 
atmosphere from coal-fired power plants and incinerators, vehicular exhaust, industrial activities 
relating to the mining and processing of cobalt-containing ores, and the production and use of 
cobalt alloys and chemicals.  58Co and 60Co may be released to the environment as a result of 
nuclear accidents (i.e, Chernobyl), radioactive waste dumping in the sea or from radioactive 
waste landfills, and nuclear power plant operations. 
Cobalt cannot be destroyed in the environment.  It can only change its form or become attached 
or separated from particles.  Cobalt released from power plants and other combustion processes 
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is usually attached to very small particles.  Cobalt contained in windborne soil is generally found 
in larger particles than those released from power plants.  These large particles settle to the 
ground or are washed out of the air by rain. Cobalt that is attached to very small particles may 
stay in the air for many days.  Cobalt released into water may stick to particles in the water 
column or to the sediment at the bottom of the body of water into which it was released, or 
remain in the water column in ionic form.  The specific fate of cobalt will depend on many 
factors such as the chemistry of the water and sediment at a site as well as the cobalt 
concentration and water flow. Cobalt deposited on soil is often strongly attached to soil particles 
and therefore would not travel very far into the ground.  However, the form of the cobalt and the 
nature of the soil at a particular site will affect how far cobalt will penetrate into the soil.  Both in 
soil and sediment, the amount of cobalt that is mobile will increase under more acidic conditions.  
Ultimately, most cobalt ends up in the soil or sediment.  
Plants can accumulate very small amounts of cobalt from the soil, especially in the parts of the 
plant that you eat most often, such as the fruit, grain, and seeds.  While animals that eat these 
plants will accumulate cobalt, cobalt is not known to biomagnify (produce increasingly higher 
concentrations) up the food chain. Therefore, vegetables, fruits, fish, and meat that you consume 
will generally not contain high amounts of cobalt.  Cobalt is an essential element, required for 
good health in animals and humans, and therefore, it is important that foodstuffs contain 
adequate quantities of cobalt. 
60Co and 58Co are moderately short-lived, manufactured radioactive isotopes that are produced in 
nuclear reactors. Although these isotopes are not produced by nuclear fission, small amounts of 
these radioisotopes are also produced by the neutron interaction with the structural materials 
found in the reactor of nuclear plants, and are produced during the routine operation of nuclear 
plants. Small amounts may be released to the environment as contaminants in cooling water or 
in radioactive waste. Since these isotopes are not fission products, they are not produced in 
nuclear weapons testing and are not associated with nuclear fallout.  In the environment, 
radioactive isotopes of cobalt will behave chemically like stable cobalt.  However, 60Co and 58Co 
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will also undergo radioactive decay according to their respective half-lives, 5.27 years and 
71 days. 
For more information about what happens to cobalt in the environment, see Chapter 6. 
1.3 HOW MIGHT I BE EXPOSED TO COBALT? 
Cobalt is widely dispersed in the environment in low concentrations.  You may be exposed to 
small amounts of cobalt by breathing air, drinking water, and eating food containing it.  Children 
may also be exposed to cobalt by eating dirt.  You may also be exposed by skin contact with soil, 
water, cobalt alloys, or other substances that contain cobalt.  Analytical methods used by 
scientists to determine the levels of cobalt in the environment generally do not determine the 
specific chemical form of cobalt present.  Therefore, we do not always know the chemical form
of cobalt to which a person may be exposed.  Similarly, we do not know what forms of cobalt are 
present at hazardous waste sites. Some forms of cobalt may be insoluble or so tightly attached to 
particles or embedded in minerals that they are not taken up by plants and animals.  Other forms 
of cobalt that are weakly attached to particles may be taken up by plants and animals. 
The concentration of cobalt in soil varies widely, generally ranging from about 1 to 40 ppm
(1 ppm=1 part of cobalt in a million parts of soil by weight), with an average level of 7 ppm.
Soils containing less than about 3 ppm of cobalt are considered cobalt-deficient because plants 
growing in them do not have sufficient cobalt to meet the dietary requirements of cattle and 
sheep. Such cobalt-deficient soils are found in some areas in the southeast and northeast parts of 
the United States.  On the other hand, soils near cobalt-containing mineral deposits, mining and 
smelting facilities, or industries manufacturing or using cobalt alloys or chemicals may contain 
much higher levels of cobalt. 
Usually, the air contains very small amounts of cobalt, less than 2 nanograms (1 nanogram=one­
billionth part of a gram) per cubic meter (ng/m3). The amount of cobalt that you breathe in a day 
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is much less than what you consume in food and water.  You may breathe in higher levels of 
cobalt in dust in areas near cobalt-related industries or near certain hazardous waste sites.   
The concentration of cobalt in surface and groundwater in the United States is generally low— 
between 1 and 10 parts of cobalt in 1 billion parts of water (ppb) in populated areas; 
concentration may be hundreds or thousands times higher in areas that are rich in cobalt-
containing minerals or in areas near mining or smelting operations.  In most drinking water, 
cobalt levels are less than 1–2 ppb. 
For most people, food is the largest source of cobalt intake.  The average person consumes about 
11 micrograms of cobalt a day in their diet.  Included in this food is vitamin B12, which is found 
in meat and diary products.  The recommended daily intake of vitamin B12 is 6 micrograms 
(1 microgram=one-millionth part of a gram). 
You may also be exposed to higher levels of cobalt if you work in metal mining, smelting, and 
refining, in industries that make or use cutting or grinding tools, or in other industries that 
produce or use cobalt metal and cobalt compounds.  If good industrial hygiene is practiced, such 
as the use of exhaust systems in the workplace, exposure can be reduced to safe levels.  
Industrial exposure results mainly from breathing cobalt-containing dust. 
When we speak of exposure to 60Co, we are interested in exposure to the radiation given off by 
this isotope, primarily the gamma rays.  The general population is rarely exposed to this radiation 
unless a person is undergoing radiation therapy.  However, workers at nuclear facilities, 
irradiation facilities, or nuclear waste storage sites may be exposed to 60Co or 58Co. Exposures to 
radiation at these facilities are regulated and carefully monitored and controlled.  
You can find more information on how you may be exposed to cobalt in Chapter 6. 
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1.4 HOW CAN COBALT ENTER AND LEAVE MY BODY? 
Cobalt can enter your body when you breathe in air containing cobalt dust, when you drink water 
that contains cobalt, when you eat food that contains cobalt, or when your skin touches materials 
that contain cobalt. If you breathe in air that contains cobalt dust, the amount of inhaled cobalt 
that stays in your lungs depends on the size of the dust particles.  The amount that is then 
absorbed into your blood depends on how well the particles dissolve.  If the particles dissolve 
easily, then it is easier for the cobalt to pass into your blood from the particles in your lungs.  If 
the particles dissolve slowly, then they will remain in your lungs longer.  Some of the particles 
will leave your lungs as they normally clean themselves out.  Some of the particles will be 
swallowed into your stomach.  The most likely way you will be exposed to excess cobalt is by 
eating contaminated food or drinking contaminated water.  Levels of cobalt normally found in 
the environment, however, are not high enough to result in excess amounts of cobalt in food or 
water. The amount of cobalt that is absorbed into your body from food or water depends on 
many things including your state of health, the amount you eat or drink, and the number of days, 
weeks, or years you eat foods or drink fluids containing cobalt.  If you do not have enough iron 
in your body, the body may absorb more cobalt from the foods you eat.  Once cobalt enters your 
body, it is distributed into all tissues, but mainly into the liver, kidney, and bones.  After cobalt is 
breathed in or eaten, some of it leaves the body quickly in the feces.  The rest is absorbed into the 
blood and then into the tissues throughout the body.  The absorbed cobalt leaves the body slowly, 
mainly in the urine.  Studies have shown that cobalt does not readily enter the body through 
normal skin, but it can if the skin has been cut. 
Further information on how cobalt can enter or leave your body can be found in Chapter 3. 
1.5 HOW CAN COBALT AFFECT MY HEALTH? 
To protect the public from the harmful effects of toxic chemicals and to find ways to treat people 
who have been harmed, scientists use many tests.   
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One way to see if a chemical will hurt people is to learn how the chemical is absorbed, used, and 
released by the body. In the case of a radioactive chemical, it is also important to gather 
information concerning the radiation dose and dose rate to the body.  For some chemicals, 
animal testing may be necessary.  Animal testing may also be used to identify health effects such 
as cancer or birth defects. Without laboratory animals, scientists would lose a basic method to 
get information needed to make wise decisions to protect public health.  Scientists have the 
responsibility to treat research animals with care and compassion.  Laws today protect the 
welfare of research animals, and scientists must comply with strict animal care guidelines. 
Cobalt has both beneficial and harmful effects on human health.  Cobalt is beneficial for humans 
because it is part of vitamin B12, which is essential to maintain human health.  Cobalt 
(0.16–1.0 mg cobalt/kg of body weight) has also been used as a treatment for anemia (less than 
normal number of red blood cells), including in pregnant women, because it causes red blood 
cells to be produced. Cobalt also increases red blood cell production in healthy people, but only 
at very high exposure levels. Cobalt is also essential for the health of various animals, such as 
cattle and sheep. Exposure of humans and animals to levels of cobalt normally found in the 
environment is not harmful. 
When too much cobalt is taken into your body, however, harmful health effects can occur.  
Workers who breathed air containing 0.038 mg cobalt/m3 (about 100,000 times the concentration 
normally found in ambient air) for 6 hours had trouble breathing.  Serious effects on the lungs, 
including asthma, pneumonia, and wheezing, have been found in people exposed to 0.005 mg 
cobalt/m3 while working with hard metal, a cobalt-tungsten carbide alloy.  People exposed to 
0.007 mg cobalt/m3 at work have also developed allergies to cobalt that resulted in asthma and 
skin rashes. The general public, however, is not likely to be exposed to the same type or amount 
of cobalt dust that caused these effects in workers. 
In the 1960s, some breweries added cobalt salts to beer to stabilize the foam (resulting in 
exposures of 0.04–0.14 mg cobalt/kg).  Some people who drank excessive amounts of beer (8– 
25 pints/day) experienced serious effects on the heart.  In some cases, these effects resulted in 
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death. Nausea and vomiting were usually reported before the effects on the heart were noticed.  
Cobalt is no longer added to beer so you will not be exposed from this source.  The effects on the 
heart, however, may have also been due to the fact that the beer-drinkers had protein-poor diets 
and may have already had heart damage from alcohol abuse.  Effects on the heart were not seen, 
however, in people with anemia treated with up to 1 mg cobalt/kg, or in pregnant women with 
anemia treated with 0.6 mg cobalt/kg.  Effects on the thyroid were found in people exposed to 
0.5 mg cobalt/kg for a few weeks.  Vision problems were found in one man following treatment 
with 1.3 mg cobalt/kg for 6 weeks, but this effect has not been seen in other human or animal 
studies. 
Being exposed to radioactive cobalt may be very dangerous to your health.  If you come near 
radioactive cobalt, cells in your body can become damaged from gamma rays that can penetrate 
your entire body, even if you do not touch the radioactive cobalt.  Radiation from radioactive 
cobalt can also damage cells in your body if you eat, drink, breathe, or touch anything that 
contains radioactive cobalt. The amount of damage depends on the amount of radiation to which 
you are exposed, which is related to the amount of activity in the radioactive material and the 
length of time that you are exposed.  Most of the information regarding health effects from
exposure to radiation comes from exposures for only short time periods.  The risk of damage 
from exposure to very low levels of radiation for long time periods is not known.  If you are 
exposed to enough radiation, you might experience a reduction in white blood cell number, 
which could lower your resistance to infections.  Your skin might blister or burn, and you may 
lose hair from the exposed areas. This happens to cancer patients treated with large amounts of 
radiation to kill cancer.  Cells in your reproductive system could become damaged and cause 
temporary sterility.  Exposure to lower levels of radiation might cause nausea, and higher levels 
can cause vomiting, diarrhea, bleeding, coma, and even death.  Exposure to radiation can also 
cause changes in the genetic materials within cells and may result in the development of some
types of cancer. 
Studies in animals suggest that exposure to high amounts of nonradioactive cobalt during 
pregnancy might affect the health of the developing fetus.  Birth defects, however, have not been 
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found in children born to mothers who were treated with cobalt for anemia during pregnancy.  
The doses of cobalt used in the animal studies were much higher than the amounts of cobalt to 
which humans would normally be exposed. 
Nonradioactive cobalt has not been found to cause cancer in humans or in animals following 
exposure in the food or water. Cancer has been shown, however, in animals who breathed cobalt 
or when cobalt was placed directly into the muscle or under the skin.  Based on the animal data, 
the International Agency for Research on Cancer (IARC) has determined that cobalt is possibly 
carcinogenic to humans. 
Much of our knowledge of cobalt toxicity is based on animal studies.  Cobalt is essential for the 
growth and development of certain animals, such as cows and sheep.  Short-term exposure of 
rats to high levels of cobalt in the air results in death and lung damage.  Longer-term exposure of 
rats, guinea pigs, hamsters, and pigs to lower levels of cobalt in the air results in lung damage 
and an increase in red blood cells. Short-term exposure of rats to high levels of cobalt in the 
food or drinking water results in effects on the blood, liver, kidneys, and heart.  Longer-term
exposure of rats, mice, and guinea pigs to lower levels of cobalt in the food or drinking water 
results in effects on the same tissues (heart, liver, kidneys, and blood) as well as the testes, and 
also causes effects on behavior. Sores were seen on the skin of guinea pigs following skin 
contact with cobalt for 18 days. Generally, cobalt compounds that dissolve easily in water are 
more harmful than those that are hard to dissolve in water.   
Much of what we know about the effects of radioactive cobalt comes from studies in animals.  
The greatest danger of radiation seen in animals is the risk to the developing animal, with even 
moderate amounts of radiation causing changes in the fetus.  High radiation doses in animals 
have also been shown to cause temporary or permanent sterility and changes in the lungs, which 
affected the animals’ breathing.  The blood of exposed animals has lower numbers of white 
blood cells, the cells that aid in resistance to infections, and red blood cells, which carry oxygen 
in the blood. Radioactive cobalt exposures in animals have also caused genetic damage to cells, 
cancer, and even death. 
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More information on how cobalt can affect your health can be found in Chapter 3. 
1.6 HOW CAN COBALT AFFECT CHILDREN?
This section discusses potential health effects from exposures during the period from conception 
to maturity at 18 years of age in humans.  
Children can be exposed to cobalt in the same ways as adults.  In addition, cobalt may be 
transferred from the pregnant mother to the fetus or from the mother to the infant in the breast 
milk.  Children may be affected by cobalt the same ways as adults.  Studies in animals have 
suggested that children may absorb more cobalt from foods and liquids containing cobalt than 
adults. Babies exposed to radiation while in their mother’s womb are believed to be much more 
sensitive to the effects of radiation than adults. 
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO COBALT 
If your doctor finds that you have been exposed to significant amounts of cobalt, ask whether 
your children might also be exposed.  Your doctor might need to ask your state health 
department to investigate. 
Since cobalt is naturally found in the environment, people cannot avoid being exposed to it.  
However, the relatively low concentrations present do not warrant any immediate steps to reduce 
exposure. If you are accidentally exposed to large amounts of cobalt, consult a physician 
immediately. 
Children living near waste sites containing cobalt are likely to be exposed to higher 
environmental levels of cobalt through breathing, touching soil, and eating contaminated soil.  
Some children eat a lot of dirt.  You should discourage your children from eating dirt.  Make sure 
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they wash their hands frequently and before eating.  Discourage your children from putting their 
hands in their mouths or hand-to-mouth activity. 
You are unlikely to be exposed to high levels of radioactive cobalt unless you are exposed as part 
of a radiotherapy treatment, there is an accident involving a cobalt sterilization or radiotherapy 
unit, or there is an accidental release from a nuclear power plant.  In such cases, follow the 
advice of public health officials who will publish guidelines for reducing exposure to radioactive 
material when necessary.  Workers who work near or with radioactive cobalt should follow the 
workplace safety guidelines of their institution carefully to reduce the risk of accidental 
irradiation. 
1.8 	 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN
EXPOSED TO COBALT? 
We have reliable tests that can measure cobalt in the urine and the blood for periods up to a 
few days after exposure. The amount of cobalt in your blood or urine can be used to estimate 
how much cobalt you had taken into your body.  The tests are not able to accurately predict 
potential health effects following exposure to cobalt.   
It is difficult to determine whether a person has been exposed only to external radiation from
radioactive cobalt unless the radiation dose was rather large.  Health professionals examining 
people who have health problems similar to those resulting from radiation exposure would need 
to rely on additional information in order to establish if such people had been near a source of
radioactivity.  It is relatively easy to determine whether a person has been internally exposed to 
radioactive cobalt, as discussed in Chapter 7.  More information on medical tests can be found in 
Chapters 3 and 7. 
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1.9 	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
The federal government develops regulations and recommendations to protect public health.  
Regulations can be enforced by law. Federal agencies that develop regulations for toxic 
substances include the Environmental Protection Agency (EPA), the Occupational Safety and 
Health Administration (OSHA), the Food and Drug Administration (FDA), and the U.S. Nuclear 
Regulatory Commission (USNRC).   
Recommendations provide valuable guidelines to protect public health but cannot be enforced by 
law. Federal organizations that develop recommendations for toxic substances include the 
Agency for Toxic Substances and Disease Registry (ATSDR), the National Institute for 
Occupational Safety and Health (NIOSH), and the FDA. 
Regulations and recommendations can be expressed in not-to-exceed levels in air, water, soil, or
food that are usually based on levels that affect animals; they are then adjusted to help protect 
people. Sometimes these not-to-exceed levels differ among federal organizations because of 
different exposure times (an 8-hour workday or a 24-hour day), the use of different animal 
studies, or other factors. 
Recommendations and regulations are also periodically updated as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. Some regulations and recommendations for cobalt include the following: 
EPA requires that the federal government be notified if more than 1,000 pounds of cobalt (as the 
bromide, formate, and sulfamate compounds) are released into the environment in a 24-hour 
period. OSHA regulates levels of nonradioactive cobalt in workplace air.  The limit for an 
8-hour workday, 40-hour workweek is an average of 0.1 mg/m3. The USNRC and the 
Department of Energy (DOE) regulate occupational exposures as well as exposures of the 
general public to radioactive cobalt. 
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1.10 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, your regional Nuclear Regulatory Commission office, or 
contact ATSDR at the address and phone number below. 
ATSDR can also tell you the location of occupational and environmental health clinics.  These 
clinics specialize in recognizing, evaluating, and treating illnesses resulting from exposure to 
hazardous substances. 
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You 
may request a copy of the ATSDR ToxProfiles CD-ROM by calling the information and 
technical assistance toll-free number at 1-888-42ATSDR (1-888-422-8737), by email at 
atsdric@cdc.gov, or by writing to: 
Agency for Toxic Substances and Disease Registry 

Division of Toxicology 

1600 Clifton Road NE 

Mailstop F-32 

Atlanta, GA 30333 

Fax: 1-770-488-4178 

For-profit organizations may request a copy of final profiles from the following: 
National Technical Information Service (NTIS) 

5285 Port Royal Road 

Springfield, VA 22161 

Phone: 1-800-553-6847 or 1-703-605-6000 

Web site: http://www.ntis.gov/ 
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2.1 	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO COBALT IN THE UNITED 
STATES 
Cobalt is a naturally-occurring element that has properties similar to those of iron and nickel. The largest 
use of metallic cobalt is in superalloys that are used in gas turbine aircraft engines.  Cobalt compounds are 
used as pigments in glass, ceramics, and paints; as catalysts in the petroleum industry; as paint driers; and 
as trace element additives in agriculture and medicine. 
Cobalt may be released to the environment by human activities, as well by weathering of rocks and soil.  
The primary anthropogenic sources of cobalt in the environment are from the burning of fossil fuels, 
application of cobalt-containing sludge or phosphate fertilizers, mining and smelting of cobalt-containing 
ores, processing of cobalt-containing alloys, and industries that use or process cobalt compounds.  Cobalt 
released to the atmosphere is deposited onto soil or water surfaces by wet and dry deposition.  In soils, 
cobalt generally has low mobility and strong adsorption.  However its mobility increases in moist, acidic 
soils. In water, cobalt largely partitions to sediment and to suspended solids in the water column; 
however, the amount that is adsorbed to suspended solids is highly variable.   
Exposure of the general population to cobalt occurs through inhalation of ambient air and ingestion of 
food and drinking water. In general, intake from food sources is much greater than from drinking water 
and air. The cobalt intake in food has been estimated to be 5.0–40.0 µg/day.  Occupational exposure to 
cobalt occurs for workers in the hard metal industry (tool production, grinding, etc.) and in industries such 
as coal mining, metal mining, smelting and refining, cobalt dye painters, and the cobalt chemical 
production industry.  The concentrations of cobalt in the air of hard metal manufacturing, welding, and 
grinding factories may range from 1 to 300 µg/m3, compared to normal atmospheric levels of 0.4– 
2.0 ng/m3. 
While there is only one stable isotope of cobalt, 59Co, there are many radioactive isotopes of cobalt.  Of 
these radioactive isotopes, two are commercially important, 60Co and 57Co. 60Co is produced by
irradiating 59Co with thermal neutrons in a nuclear reactor, and is used as a source of gamma rays for 
sterilizing medical equipment or consumer products, food irradiation, radiation therapy for treating cancer 
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patients, and for manufacturing plastics.  The general population is not significantly exposed to 
radioactive forms of cobalt.  Cancer patients being treated with radiation therapy may be exposed to 
gamma rays from a 60Co source; however, the effects of external exposure to gamma radiation is not 
unique to 60Co, but is similar for all gamma-emitting radionuclides. Workers at nuclear facilities and 
nuclear waste storage sites may be exposed to potentially high levels of radioactive cobalt. 
2.2 SUMMARY OF HEALTH EFFECTS  
As a component of cyanocobalmin (vitamin B12), cobalt is essential in the body; the Recommended 
Dietary Allowance of vitamin B12 is 2.4 µg/day, which contains 0.1 µg of cobalt.  Cobalt has been 
identified in most tissues of the body, with the highest concentrations found in the liver. 
Following inhalation exposure to cobalt-containing particles, the primary target of exposure is the 
respiratory tract.  Occupational exposure of humans to cobalt metal or cobalt-containing hard metal have 
reported primarily respiratory effects, including decreased pulmonary function, asthma, interstitial lung 
disease, wheezing, and dyspnea; these effects were reported at occupational exposure levels ranging from
0.015–0.13 mg Co/m3. Animal studies have further identified respiratory tract hyperplasia, pulmonary
fibrosis, and emphysema as sensitive effects of inhaled cobalt on respiratory tissues.  Many of the 
respiratory tract effects are believed to be the result of the generation of oxidants and free radicals by the 
cobalt ion. In particular, hard metal (a tungsten carbide/cobalt alloy) is a potent generator of free 
electrons, resulting in the generation of active oxygen species.  However, some of the respiratory effects, 
such as cobalt-induced asthma, are likely the result of immunosensitization to cobalt. 
Other sensitive targets of cobalt inhalation in humans include effects on the thyroid and allergic 
dermatitis, manifesting as eczema and erythema; it is believed that the allergic dermatitis is due, at least in 
part, to concurrent dermal exposure and the development of immunosensitization to cobalt. 
Adequate chronic studies of the oral toxicity of cobalt or cobalt compounds in humans and animals are 
not presently available.  The most sensitive endpoint following oral exposure to cobalt in humans appears 
to be an increase in erythrocyte numbers (polycythemia).  This effect has been observed in both normal 
subjects and in patients who were anemic as a result of being anephric.  However, treatment of pregnant 
women with cobalt did not prevent the reduction in hematocrit and hemoglobin levels often found during 
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pregnancy.  Exposure of humans to beer containing cobalt as a foam stabilizer resulted in severe effects 
on the cardiovascular system, including cardiomyopathy and death, as well as gastrointestinal effects 
(nausea, vomiting) and hepatic necrosis.  However, the subjects in these studies were alcoholics, and it is 
not known what effect excessive alcohol consumption may have played in the development of the 
observed effects. 
Following dermal exposure, the most commonly observed effect is dermatitis, as demonstrated by a large 
number of human studies.  Using patch tests and intradermal injections, it has been demonstrated that the 
dermatitis is probably caused by an allergic reaction to cobalt, with the cobalt ion functioning as a hapten. 
Available studies of the carcinogenic effects of cobalt in occupationally-exposed humans have reported 
mixed results, with both positive and negative results.  Lifetime inhalation of cobalt sulfate resulted in 
increased tumor incidences in both rats and mice; NTP reported that there was some evidence of 
carcinogenicity in male Fischer 344 (F344) strain rats, and clear evidence of carcinogenicity in female 
F344 strain rats and male and female B6C3F1 strain mice following inhalation exposure.  Oral data on the 
carcinogenic effects of cobalt and cobalt compounds are not available.  IRIS does not report a cancer 
classification for cobalt or cobalt compounds.  IARC has classified cobalt and cobalt compounds as 
possibly carcinogenic to humans (Group 2B). 
A more detailed discussion of the health effects of cobalt and cobalt compounds is presented in Chapter 3.  
An enhanced discussion of sensitive end points of stable cobalt toxicity is presented below. 
Respiratory Effects.    The primary effects of cobalt on respiratory tissues are seen following 
inhalation exposure, and include diminished pulmonary function, increased frequency of cough, 
respiratory inflammation, and fibrosis; reported effect levels in occupationally-exposed humans have 
ranged from 0.015–0.13 mg Co/m3. Animal studies have further identified respiratory tract hyperplasia, 
pulmonary fibrosis, and emphysema as sensitive effects of cobalt on respiratory tissues.  A number of 
these effects are believed to be the result of the generation of oxidants and free radicals by the cobalt ion. 
In vitro exposure to soluble cobalt increases indices of oxidative stress, including diminished levels of 
reduced glutathione, increased levels of oxidized glutathione, activation of the hexose monophosphate 
shunt, and free-radical-induced DNA damage. Cobalt exposure also results in sensitization of the 
immune system, which may result in asthmatic attacks following inhalation of cobalt in sensitized 
individuals. 
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Hard metal is a metal alloy with a tungsten carbide and cobalt matrix.  It is used to make cutting tools 
because of its hardness and resistance to high temperature.  Exposure to hard metal has been shown in a 
number of studies to cause respiratory effects, including respiratory irritation, diminished pulmonary
function, asthma, and fibrosis, at exposure levels lower than those that would produce similar effects 
following exposure to cobalt metal alone (0.007–0.14 mg Co/m3). Studies suggest that cobalt and not 
tungsten carbide is the probable causative agent for the respiratory effects observed in hard metal workers 
(see Section 3.5). A mechanism by which hard metal may exert its effects has been proposed by a group 
of Belgian researchers.  In this proposed mechanism, tungsten carbide, which is a very good conductor of 
electrons, facilitates the oxidation of cobalt metal to ionic cobalt (presumably Co2+) by transferring 
electrons from the cobalt atom to molecular oxygen adjacent to the tungsten carbide molecule.  The result 
is an increased solubility of cobalt, relative to cobalt metal alone, and the generation of active oxygen 
species. In vitro evidence for this mechanism includes the ability of hard metal particles, but neither 
cobalt nor tungsten carbide alone at the same concentrations, to generate oxidant species and cause lipid 
peroxidation.  Hard metal particles have also been shown to increase the levels of inducible nitric oxide 
synthase (iNOS), a gene responsive to oxidant stress. 
Hematological Effects.    Exposure to cobalt and cobalt compounds has been demonstrated to increase 
levels of erythrocytes and hemoglobin in both humans and animals.  Davis and Fields reported increased 
(~16–20%) erythrocyte levels in six of six healthy men exposed orally to cobalt chloride (~1 mg Co/kg-
day); erythrocyte counts returned to normal 9–15 days after cessation of cobalt administration.  Increased 
levels of erythrocytes were also found following oral treatment of anephric patients (with resulting 
anemia) with cobalt chloride.  The increase in hemoglobin resulted in a decreased need for blood 
transfusions. Treatment of pregnant women for 90 days with cobalt chloride, however, did not prevent 
the reduction in hematocrit and hemoglobin levels often found during pregnancy. 
Increased levels of hemoglobin were observed in rats and guinea pigs, but not in dogs, exposed to cobalt 
hydrocarbonyl by inhalation.  Polycythemia was reported in rats, but not mice, exposed to airborne cobalt 
sulfate. Significantly increased erythrocyte (polycythemia), hematocrit, and hemoglobin levels were
found in animals treated orally with cobalt as either a single dose or with longer-term exposure.  Of 
particular note is an 8-week study in rats, which reported dose- and time-related increases in erythrocyte 
number following oral administration of cobalt chloride. 
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The mechanisms regarding cobalt-induced polycythemia are not well understood.  Cobalt is thought to
inhibit heme synthesis in vivo by acting upon at least two different sites in the biosynthetic pathway.  This 
inhibitory activity might result in the formation of cobalt protoporphyrin rather than heme.  Cobalt 
treatment also stimulates heme oxidation in many organs, due to the induction of heme oxygenase.  
Conversely, cobalt acts, through a mechanism believed to involve a heme-containing protein, to increase 
erythropoietin, which stimulates the production of red blood cells.  The regulatory mechanisms behind 
this apparent dichotomy have not been fully elucidated. 
Cardiac Effects.    Cardiomyopathy has been reported in both humans and animals following exposure 
to cobalt. Occupational exposure of humans to cobalt-containing dust, either as cobalt metal or as hard 
metal, is believed to result in cardiomyopathy characterized by functional effects on the ventricles and 
enlargement of the heart, but the exposure levels associated with cardiac effects of inhaled cobalt in 
humans have not been determined.  Rats exposed to 11.4 mg Co/m3 for 13 weeks developed a mild 
cardiomyopathy; however, rats and mice exposed to 1.14 mg Co/m3 for 2 years showed no signs of 
cardiomyopathy.    
Beer-cobalt cardiomyopathy was observed in people who heavily consumed beer that contained cobalt 
sulfate as a foam stabilizer.  The beer drinkers ingested an average of 0.04 mg Co/kg/day to 0.14 mg
Co/kg/day for a period of years.  The cardiomyopathy was characterized by sinus tachycardia, left 
ventricular failure, cardiogenic shock, diminished myocardial compliance, absence of a myocardial 
response to exercise or catecholamine, enlarged heart, pericardial effusion, and extensive intracellular 
changes (changes in the myofibers, mitochondria, glycogen, and lipids).  The beer-cobalt cardiomyopathy 
appeared to be similar to alcoholic cardiomyopathy and beriberi, but the onset of beer-cobalt 
cardiomyopathy was very abrupt.  It should be noted, however, that the cardiomyopathy may have also 
been due to the fact that the beer-drinkers had protein-poor diets and may have had prior cardiac damage 
from alcohol abuse.  Studies in animals, and limited human data, have supported this possibility, as much 
greater oral exposure levels (on the order of 8-30 mg Co/kg-day) are necessary to induce cardiac effects.   
The mechanism for cobalt-induced cardiomyopathy is not presently understood.  Exposure to cobalt may
result in accumulation in cardiac tissues, and is thought to stimulate carotid-body chemoreceptors, 
mimicking the action of hypoxia.  Microscopic analysis of the hearts of those with beer-cobalt 
cardiomyopathy revealed fragmentation and degeneration of myofibers and aggregates of abnormal 
mitochondria. These mitochondrial changes are indicative of disturbances in energy production or 
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utilization may possibly be related to cobalt effects on lipoic acid.  Cobalt irreversibly chelates lipoic 
acids under aerobic conditions.  Lipoic acid is a required cofactor for oxidative decarboxylation of 
pyruvate to acetyl CoA and of α-ketoglutarate to succinate.  In the myocardium of rats treated with cobalt, 
oxidation of pyruvate or fatty acids is impaired.  However, the relative contribution of these mechanisms 
to the cardiac effects of cobalt has not been determined. 
Dermal Effects.    Dermatitis is a common result of dermal exposure to cobalt in humans.  Using patch 
tests and intradermal injections, it has been demonstrated that the dermatitis is probably caused by an 
allergic reaction to cobalt. Exposure levels associated with the development of dermatitis have not been 
identified. It appears that cobalt metal may be a more potent allergen than some cobalt salts, as Nielsen et 
al. demonstrated that daily repeated exposure to aqueous cobalt salts did not result in hand eczema in 
patients known to have cobalt allergy.  In animals, scabs and denuded areas were found after six doses of 
51.75 mg Co/kg (5 days/week) as dicobalt octacarbonyl were applied to the shaved abdomens (uncovered 
area of approximately 50 cm2) of guinea pigs. By the 11th dose, the lesions disappeared.  No adverse 
effects were observed in vehicle controls (methyl ethyl ketone).  It is not known whether or not a similar 
reaction would result from metallic or inorganic forms of cobalt.  
Immunological Effects.    Exposure of humans to cobalt by the inhalation and dermal routes has 
resulted in sensitization to cobalt.  Exposure to inhaled cobalt chloride aerosols can precipitate an 
asthmatic attack in sensitized individuals, believed to be the result of an allergic reaction within the lungs.  
Similarly, the dermatitis seen in dermally-exposed subjects is likely the result of an allergic reaction, with 
cobalt functioning as a hapten.  IgE and IgA antibodies specific to cobalt have been reported in humans.  
There is evidence that cobalt sensitivity in humans may also be regulated by T-lymphocytes; a human 
helper T-lymphocyte cell line specific for cobalt (CoCl2) has been established. Cobalt may also interact 
directly with immunologic proteins, such as antibodies or Fc receptors, to result in immunosensitization.  
In vitro, cobalt(III) has been shown to reduce the proliferation of both B and T lymphocytes, as well as 
the release of the cytokines IL-2, IL-6, and IFN-Gamma.  Interrelationships exist between nickel and 
cobalt sensitization, with cross-reactivity between the two having been reported in several studies. 
Radioactive Cobalt.  Exposure to radioisotopes of cobalt is also a human health concern.  Energy released 
by radioactive isotopes can result in significant damage to living cells.  Both 60Co and 57Co emit beta 
particles and gamma rays, which may ionize molecules within cells penetrated by these emissions and 
result in tissue damage and disruption of cellular function.  The most important exposure route for 
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radioisotopes of cobalt is external exposure to the radiation released by the radioisotopes.  It should be 
noted that there is nothing unique about the effects of external exposure to 60Co and 57Co when compared 
to other gamma- and beta-emitting radionuclides. 
Generally, acute radiation doses below 15 rad (0.15 Gy) do not result in observable adverse health effects.
At doses in the range of 15–50 rad (0.15–0.5 Gy), subclinical responses such as chromosomal breaks and 
transient changes in formed elements of the blood may be seen in sensitive individuals.  Symptoms of 
acute radiation syndrome begin to be observed at radiation doses above 50 rad, characterized by transient 
hematopoietic manifestations, nausea and vomiting, and moderate leukopenia at doses near 100 rad 
(1 Gy), progressing through more serious hematopoietic symptoms, clinical signs, and gastrointestinal 
symptoms with increasing dose (100–800 rad or 1–8 Gy), and usually death in persons receiving total 
doses ≥1,000 rad (10 Gy).  Other health effects from acute or continued high-level exposure to ionizing 
radiation may include reproductive, developmental, and latent cancer effects. 
Signs and symptoms of acute toxicity from external and internal exposure to high levels of radiation from
60Co and 57Co are typical of those observed in cases of high exposure to ionizing radiation in general.  
Depending on the radiation dose, symptoms may include those typical of acute radiation syndrome 
(vomiting, nausea, and diarrhea), skin and ocular lesions, neurological signs, chromosomal abnormalities, 
compromised immune function, and death. 
Acute or repeated exposure of humans or animals to ionizing radiation (from radioisotopes of cobalt or 
other radioactive elements) may result in reduced male fertility, abnormal neurological development 
following exposure during critical stages of fetal development, and genotoxic effects such as increased 
frequencies of chromosomal aberrations, sister-chromatid exchanges, and micronucleus formation. 
Due to the ionizing properties of radionuclides such as 60Co and 57Co, increased cancer risk would be 
expected among exposed individuals.  However, studies of increased cancer risk specifically associated 
with exposure of humans to radioactive cobalt isotopes were not located.  Similarly, studies of the 
carcinogenic effects of radioactive cobalt isotopes in animals were not located. 
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2.3 MINIMAL RISK LEVELS (MRLs)  
Inhalation MRLs 
•	 An MRL of 0.0001 mg cobalt/m3 has been derived for chronic-duration inhalation exposure 
(>365 days) to cobalt. 
An MRL for inhalation exposure to cobalt was derived for chronic duration only.  The chronic inhalation 
MRL of 0.0001 mg cobalt/m3 was based on a no-observed-adverse-effect-level (NOAEL) of 0.0053 mg
cobalt/m3 and a LOAEL of 0.0151 mg cobalt/m3 (both NOAEL and LOAEL values were adjusted for 
continuous exposure prior to MRL derivation) for decreases in forced vital capacity (FVC), forced 
expiratory volume in one second (FEV1), forced expiratory flow between 25 and 75% of the FVC 
(MMEF), and mean peak expiratory flow rate (PEF) in diamond polishers (Nemery et al. 1992); a further 
discussion of the results and limitations of this study is presented in Appendix A.   
The National Toxicology Program (NTP) has conducted a chronic-duration carcinogenicity study in rats 
and mice.  Exposure of rats and mice to aerosols of cobalt (as cobalt sulfate) at concentrations ranging 
from 0.11 to 1.14 mg cobalt/m3 for 2 years resulted in a spectrum of inflammatory, fibrotic, and 
proliferative lesions in the respiratory tract of male and female rats and mice (NTP 1998).  Squamous 
metaplasia of the larynx occurred in rats and mice at exposure concentrations of 0.11 mg cobalt/m3, with 
severity of the lesion increasing with increased exposure concentration.  Hyperplastic lesions of the nasal 
epithelium occurred in rats at concentrations of 0.11 mg cobalt/m3, and in mice at concentrations of 
0.38 mg cobalt/m3. Both sexes of rats had greatly increased incidences (>90% incidence) of alveolar 
lesions at all exposure levels, including inflammatory changes, fibrosis, and metaplasia.  Similar changes 
were seen in mice at all exposure levels, though the changes in mice were less severe.  The study in 
diamond polishers, being a well-conducted study in humans, was selected as the critical study for the 
derivation of a MRL because it examined a human population and identified a NOAEL, neither of which 
occurred in the NTP study.  The chronic inhalation MRL was derived by adjusting the NOAEL of 
0.0053 mg Co/m3 for intermittent exposure (adjusted to 0.0013 mg/m3 to simulate continuous exposure), 
and applying an uncertainty factor of 10 (for human variability).  It should be noted that this MRL may
not be protective for individuals already sensitive to cobalt. 
An acute inhalation MRL was not derived because the threshold was not defined for human effects and 
animal studies reported effects that were serious and occurred at levels above those reported in the few 
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human studies.  An acute-duration study of hard metal exposure in humans (Kusaka et al. 1986b) was not 
utilized for MRL derivation because the toxicity of hard metal is not directly due to cobalt metal, but 
rather to an interaction between cobalt metal and tungsten carbide.  An intermediate-duration MRL was 
not derived because available studies did not examine the dose-response relationship at low doses; the 
chronic inhalation MRL should be protective for intermediate exposures (see Appendix A). 
Oral MRLs 
•	 An MRL of 0.01 mg Co/kg-day has been derived for intermediate-duration oral exposure 

(<365 days) to cobalt. 

An intermediate-duration MRL of 0.01 mg Co/kg/day was derived based on a LOAEL of 1 mg cobalt/kg-
day for polycythemia as reported in a study by Davis and Fields (1958).  The authors exposed six men to 
120 or 150 mg/day of cobalt chloride (~1 mg Co/kg/day) for up to 22 days.  Exposure to cobalt resulted in 
the development of polycythemia in all six patients, with increases in red blood cell numbers ranging 
from 0.5 to 1.19 million (~16–20% increase above pre-treatment levels).  Polycythemic erythrocyte 
counts returned to normal 9–15 days after cessation of cobalt administration.  An 8–week study in rats 
(Stanley et al. 1947) also reported increases in erythrocyte number, with a no-observed-effect-level 
(NOEL) of 0.6 mg/kg-day and a lowest-observed-effect-level (LOEL) of 1 mg/kg/day.  The intermediate 
oral MRL was derived by dividing the LOAEL of 1 mg Co/kg-day by an uncertainty factor of 100 (10 for
use of a LOAEL and 10 for human variability). 
Oral MRL values were not derived for acute or chronic exposure to cobalt.  An acute MRL was not 
derived because the reported effects in animals were serious and occurred at levels above those reported 
in the few human oral studies. No chronic oral studies were available in animals; the chronic studies of 
beer-cobalt cardiomyopathy (Alexander 1969, 1972; Bonenfant et al. 1969; Morin et al. 1967, 1971; 
Sullivan et al. 1969) were not used because the effects were serious (death) and because the effects of 
concurrent alcoholism were not controlled for.  Therefore, a chronic oral MRL was not derived for cobalt.
MRLs for External Exposure to Cobalt Isotopes 
Two MRLs have been derived for ionizing radiation (Agency for Toxic Substances and Disease Registry
1999) and are applicable to external exposure to radioisotopes of cobalt: 
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An MRL of 400 mrem (4.0 mSv) has been derived for acute-duration external exposure to 
ionizing radiation (14 days or less). 
The acute MRL is based on results of a study by Schull et al. (1988) in which neurological effects of 
radiation, measured by intelligence test scores, were evaluated in children 10–11 years of age who had 
been exposed at critical stages of fetal development (gestation weeks 8–15) during the atomic bombing of 
Hiroshima and Nagasaki.  When IQ scores were regressed on radiation dose estimates, IQ diminished 
linearly with increasing dose, resulting in an estimated decrease in IQ score of approximately 25 points 
per 100 rad (or 100 rem in dose equivalent) or 0.25 points/rem (25 points/Sv).  To derive the MRL of 
400 mrem (4.0 mSv), Agency for Toxic Substances and Disease Registry (1999) divided the dose 
associated with a predicted change of 0.25 IQ points/rem by an uncertainty factor of 3 (for human 
variability and/or the potential existence of sensitive populations).  Agency for Toxic Substances and 
Disease Registry (1999) noted that a change in IQ points of 0.25 is less than the reported difference of 
0.3 IQ points between separated and unseparated identical twins (Burt 1966). 
The USNRC set a radiation exposure limit of 500 mrem (5 mSv) for pregnant working women over the 
full gestational period (USNRC 1991). For the critical gestational period of 8–15 weeks, Agency for 
Toxic Substances and Disease Registry believes that the acute MRL of 400 mrem (4 mSv) is consistent 
with the USNRC limit and could be applied to either acute (0–14-day) or intermediate (15–365-day) 
exposure periods. 
C An MRL of 100 mrem/year (1.0 mSv/year) above background has been derived for chronic-
duration external ionizing radiation (365 days or more). 
The MRL is based on the BEIR V (1990) report that the average annual effective dose of ionizing 
radiation to the U.S. population is 360 mrem/year (3.6 mSv/year), a dose not expected to produce adverse 
noncancerous health effects.  This dose is obtained mainly by naturally-occurring radiation from external 
sources, medical uses of radiation, and radiation from consumer products.  An uncertainty factor of 3 (for 
human variability) was applied to the NOAEL of 360 mrem/year to derive the MRL of 100 mrem/year. 
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3.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of cobalt.  It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.  
Section 3.2 contains a discussion of the chemical toxicity of stable cobalt; radiation toxicity associated 
with exposure to radioactive cobalt (primarily 60Co) is discussed in Section 3.3. The chemical properties 
of stable and radioactive cobalt isotopes are identical and are described in Chapter 4. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE  
Section 3.2 discusses the chemical toxicity of stable cobalt.  Radiation toxicity resulting from exposure to 
radioactive cobalt is discussed in Section 3.3. 
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest­
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
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or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health. 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
Estimates of exposure levels posing minimal risk to humans (Minimal Risk Levels or MRLs) have been 
made for cobalt. An MRL is defined as an estimate of daily human exposure to a substance that is likely
to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of 
exposure. MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of 
effect or the most sensitive health effect(s) for a specific duration within a given route of exposure.  
MRLs are based on noncancerous health effects only and do not consider carcinogenic effects.  MRLs can 
be derived for acute, intermediate, and chronic duration exposures for inhalation and oral routes.  
Appropriate methodology does not exist to develop MRLs for dermal exposure. 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
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bronchitis. As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised. 
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
Studies have shown that soluble cobalt compounds are generally more acutely toxic than insoluble cobalt 
compounds.  When expressed in terms of the cobalt ion for the sake of comparison, however, the 
differences in lethality values from the available studies are within an order of magnitude and therefore do 
not warrant presentation in separate LSE tables and figures.  Therefore, data regarding both soluble and 
insoluble cobalt compounds are presented in Tables 3-1, 3-2, and 3-3. 
3.2.1 Inhalation Exposure 
3.2.1.1 Death 
Conclusive evidence for human deaths related to inhalation exposure to cobalt has not been reported; 
however, results of several studies and case reports suggest a possible relationship between exposure and 
deaths from lung cancer and cardiomyopathy, respectively.  
In general, available cohort studies in humans have not reported a significant increase in total mortality as 
a result of cobalt exposure. Several studies have noted increased mortality rates resulting from lung 
cancer following occupational exposure to cobalt, either as a mixture of cobalt compounds (Mur et al. 
1987) or as hard metal, a metal alloy with a tungsten carbide and cobalt matrix (Lasfargues et al. 1994; 
Moulin et al. 1998).  Fatal cases of hard metal disease (Figueroa et al. 1992; Ruokonen et al. 1996) and 
cardiomyopathy (Barborik and Dusek 1972) believed to have resulted from occupational cobalt exposure 
have also been reported. However, in the majority of these and other reported occupational studies, co­
exposure to other substances was common, and was unable to be corrected for in the analysis. 
Cobalt inhalation can be lethal in animals if exposure is sufficiently high or prolonged.  The acute 
LC50 for a 30-minute inhalation exposure in rats was 165 mg cobalt/m3 as cobalt hydrocarbonyl (Palmes 
et al. 1959). Exposure to 9 mg cobalt/m3 as cobalt hydrocarbonyl for 6 hours/day, 5 days/week for 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COBALT  30 
3. HEALTH EFFECTS 
3 months resulted in 16 deaths out of 75 rats (Palmes et al. 1959). Death was reported in rats and mice 
exposed to 19 mg cobalt/m3 (but not 1.9 mg cobalt/m3) as cobalt sulfate over 16 days, but exposure to 
11.4 mg cobalt/m3 over 13 weeks was lethal only to mice and not to rats (Bucher et al. 1990; NTP 1991).  
Exposure to 1.14 mg cobalt/m3 as cobalt sulfate for 104 weeks resulted in no increase in mortality in rats 
and mice of either sex (Bucher et al. 1999; NTP 1998).  Lethal levels for each species and duration 
category are recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.1.2 Systemic Effects  
No data were located regarding dermal effects in humans or animals after inhalation exposure to stable 
cobalt. Inhalation of stable cobalt by humans and/or animals resulted in respiratory, cardiovascular, 
hematological, hepatic, renal, endocrine, ocular, and body weight effects.  For each effect, the highest 
NOAEL values and all reliable LOAEL values for each species and duration category are reported in 
Table 3-1 and plotted in Figure 3-1. 
Respiratory Effects.  Hard metal is a metal alloy with a tungsten carbide and cobalt matrix.  It is used to 
make cutting tools because of its hardness and resistance to high temperature.  Studies (Davison et al. 
1983; Harding 1950) suggest that cobalt (and not tungsten carbide) is the probable causative agent for the 
respiratory effects observed in hard metal workers (see Section 3.6). 
The effects of chronic occupational exposure to cobalt and cobalt compounds on the respiratory system in 
humans are well-documented.  These effects include respiratory irritation, diminished pulmonary
function, wheezing, asthma, pneumonia, and fibrosis and occurred at exposure levels ranging from
0.007 to 0.893 mg cobalt/m3 (exposure from 2 to 17 years) (Anttila et al. 1986; Davison et al. 1983; 
Demedts et al. 1984a, 1984b; Deng et al. 1991; Gennart and Lauwerys 1990; Gheysens et al. 1985;
Hahtola et al. 2000; Hartung et al. 1982; Kusaka et al. 1986a, 1986b, 1996a, 1996b; Nemery et al. 1992;
Raffn et al. 1988; Rastogi et al. 1991; Ruokonen et al. 1996; Shirakawa et al. 1988, 1989; Sprince et al. 
1988; Sundaram et al. 2001; Swennen et al. 1993; Tabatowski et al. 1988; Van Cutsem et al. 1987;
Zanelli et al. 1994). These effects have been observed in workers employed in cobalt refineries, as well 
as hard metal workers, diamond polishers, and ceramic dish painters (painting with cobalt blue dye). 
Table 3-1 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Inhalation 
a
Key to Species 
figure (Strain) 
Exposure/ 
Duration/
Frequency 
(Specific Route) System 
NOAEL 
(mg/m³) 
LOAEL 
Reference 
Chemical Form 
Less Serious 
(mg/m³) 
Serious 
(mg/m³) 
1 
2 
3 
4 
5 
ACUTE EXPOSURE 
Systemic 
Human 6 hr 
1
Rat 5 hr 
SD-Jcl 
2
Rat 4 d 
SD-Jcl 
3
Rat 30 min 
4
INTERMEDIATE EXPOSURE 
Death 
Rat 16 d 5 d/wk 6 hr/d 
6
Resp 
Resp 
Resp 
Resp 
2.72
7 
1.9 
2.72
7
1.9
0.038 (bronchial irritation, reduced 
FVC) 
0.038
2.12 M (Slight damage to respiratory 
tissues, assessed by electron 
microscopy) 
2.12
26 (edema) 
26
83 
19 
(severe edema) 
83
(2/5 males died) 
19
Kusaka et al. 1986b 
Hard Metal
Kyono et al. 1992
Metal 
Kyono et al. 1992 
Metal 
Palmes et al. 1959 
Hydrocarbonyl 
NTP 1991 
Sulfate 
Table 3-1 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Inhalation	 (continued) 
a
Key to Species 
figure (Strain) 
Exposure/ 
Duration/

Frequency 
(Specific Route) System 
NOAEL 
(mg/m³) 
LOAEL
 
Reference 
Chemical Form 
Less Serious 
(mg/m³)	 
Serious 
(mg/m³) 
6 
7 
8 
Mouse 
7
Systemic 
Rat 
14
Rat 
15
13 wk 5 d/wk 6 hr/d	 
13 wk 5 d/wk 6 hr/d 
3 mo 5 d/wk 7 h/d 
Resp 
Cardio 
Hemato	 
Renal 
Bd Wt 
Resp 
Hemato 
Bd Wt 
3.8	 
11.4 
9 
3.8
11.4
9
0.11 (laryngial squamous metaplasia 
and polyps) 
0.11
11.4	 (increase in severity of
 
cardiomyopathy)
 
11.4
b 
1.14 M (polycythemia) 
1.14
11.4	 (15% lower body weight in
 
males)
 
11.4
9 (lung inflamm) 
9
b 
9	 (10% increase in hemoglobin) 
9
11.4 
0.38 
(2 males died) 
11.4
(chronic inflammation of larynx) 
0.38
NTP 1991 
Sulfate 
NTP 1991 
Sulfate
Palmes et al. 1959 
Hydrocarbonyl 
Table 3-1 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Inhalation (continued) 
a
Key to 
figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Specific Route) System 
NOAEL 
(mg/m³) 
LOAEL 
Reference 
Chemical Form 
Less Serious
(mg/m³) 
Serious 
(mg/m³) 
9 Mouse 
16
16d 5 d/wk 6 hr/d 
Resp 
Cardio 
Gastro 
Musc/skel 
Hepatic 
Renal 
Dermal 
0.2 
76 
76 
76 
76 
76 
0.2
76
76
76
76
76
1.9 (respiratory tract inflammation) 
1.9
19 
19 
(necrosis) 
19
(necrosis) 
19
NTP 1991 
Sulfate 
Table 3-1 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Inhalation (continued) 
a
Key to 
figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Specific Route) System 
NOAEL 
(mg/m³) 
LOAEL 
Reference 
Chemical Form 
Less Serious
(mg/m³) 
Serious 
(mg/m³) 
10 
11 
Mouse 
17
Gn Pig 
(Hartley) 
18
13 wk 5 d/wk 6 hr/d 
66 d 
Resp 
Gastro 
Hemato 
Musc/skel 
Hepatic 
Renal 
Dermal 
Bd Wt 
Resp 
11.4 
11.4 
11.4 
11.4 
11.4 
11.4 
11.4
11.4
11.4
11.4
11.4
11.4
0.11 
11.4 
(larynx metaplasia) 
0.11
(13-20% decrease in body 
weight) 
11.4
3.8 M (acute inflam of nose) 
3.8
c 
1.14 F (acute inflam of nose) 
1.14
2.4 F (Increased lung weight, 
increased retention of lavage 
fluid) 
2.4
NTP 1991 
Sulfate 
Camner et al. 1993 
Chloride 
Table 3-1 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Inhalation (continued) 
a
Key to Species 
figure (Strain) 
Exposure/ 
Duration/
Frequency 
(Specific Route) System 
NOAEL 
(mg/m³) 
LOAEL 
Reference 
Chemical Form 
Less Serious 
(mg/m³) 
Serious 
(mg/m³) 
12 
13 
14 
15 
16 
Gn Pig 
19
Dog 
384
Rabbit 
24
Rabbit 
25
Rabbit 
26
3 mo 5 d/wk 7 h/d 
3 mo 3d/wk 7h/d 
4 mo 5 d/wk 6 h/d 
4 mo 
4 mo 
Hemato 
Hemato 
Bd Wt 
Resp 
Resp 
Resp 
9 
0.5 M 
9
0.5
b 
9 (5% increase in hemoglobin) 
9
9 (wt loss) 
9
0.4 (moderate lung inflammation) 
0.4
0.6 M (Histologic alterations in 
pulmonary tissue; altered BAL 
parameters) 
0.6
2 (severe lung inflammation) 
2
Palmes et al. 1959 
Hydrocarbonyl 
Palmes et al. 1959 
Hydrocarbonyl 
Johansson et al. 1987 
Johansson et al. 1991 
Chloride 
Johansson et al. 1992 
Chloride 
Table 3-1 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Inhalation	 (continued) 
a
Key to Species 
figure (Strain) 
Exposure/ 
Duration/

Frequency 
(Specific Route) System 
NOAEL 
(mg/m³) 
LOAEL
 
Reference 
Chemical Form 
Less Serious 
(mg/m³)	 
Serious 
(mg/m³) 
17 
18 
19 
20 
21 
Pig 3 mo 5d/wk 6hr/d 
389
Immuno/ Lymphoret 
Rat 16 d 5 d/wk 6 hr/d 
392
Mouse 13 wk 5 d/wk 6 hr/d	 
393
Neurological 
Rat 16 d 5 d/wk 6 hr/d 
395
Mouse 16 d 5 d/wk 6 hr/d 
398
Resp 
Cardio	 
Hepatic 
Renal 
Bd Wt	 
1 
1 
1
1
0.1 
0.1 
0.1 
19 
11.4	 
19 
19 
(decr compliance) 
0.1
(EKG changes) 
0.1
(decr wt gain) 
0.1
(necrosis of thymus) 
19
(lymph node hyperplasia) 
11.4
(congestion of vessels in brain) 
19
(congestion of vessels in brain) 
19
Kerfoot 1975 
Metal 
NTP 1991 
Sulfate 
NTP 1991 
Sulfate 
NTP 1991 
Sulfate 
NTP 1991 
Sulfate 
Table 3-1 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Inhalation	 (continued) 
Exposure/ LOAEL
 
Duration/

a Frequency Reference Key to Species NOAEL Less Serious Serious 
(Specific Route)figure (Strain) System (mg/m³) (mg/m³)	 (mg/m³) Chemical Form 
Reproductive 
22 Rat 16 d 5 d/wk 6 hr/d NTP 199119 M (testes atrophy) 
19 Sulfate 
399
23 Mouse 13 wk 5 d/wk 6 hr/d	 NTP 1991 
1.14 M (decreased sperm  	motility) 11.4 (testes atrophy- increased 
Sulfate 1.14 length estrous cycle) 
11.4
401
CHRONIC EXPOSURE 
Systemic 
24 Human occup Deng et al. 1991
Resp 0.0175
(occup)	 Metal 0.0175
31
25 Human occup Gennart and Lauwerys 1990
Resp 0.1355 (Decreased FEV1 and FVC
(occup)	 Hard-Metal~10%; increased cough, 
sputum, dyspnea) 
0.1355
33
26 Human occup d Nemery et al. 1992
Resp 0.0053 0.0151 (Decreased FEV1, FVC
(occup)	 Metal0.0053 increased cough and upper 
airway irritation) 
0.0151
37
27 Human occup Prescott et al. 1992 
Endocr 0.05 F (Decreased thyroid volume; 
(occup) Zinc-Silicate Dye increases in T4 and FT4I levels) 
0.05
39
Table 3-1 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Inhalation	 (continued) 
a
Key to Species 
figure (Strain) 
Exposure/ 
Duration/

Frequency 
(Specific Route) System 
NOAEL 
(mg/m³) 
LOAEL
 
Reference 
Chemical Form 
Less Serious 
(mg/m³)	 
Serious 
(mg/m³) 
28 
29 
30 
31 
32 
Human 
418
Human 
420
Human 
41
Rat 
(Fischer- 344) 
43
Mouse 
(B6C3F1)	 
44
occup	 
occup	 
8 yr 
(occup)	 
104 wk	 
104 wk 
Resp 
Resp 
Resp 
Hemato 
Endocr 
Dermal 
Resp 
Resp 
0.125 
0.125	 
0.125	 
0.125	 
0.11 
(Dyspnoea and wheezing)
0.125
(Decreased red cell counts
 
~5%; decreased total
 
hemoglobin ~4%)
 
0.125
(Slight (~7%) decrease in T3 
levels) 
0.125
(Eczema and erythema) 
0.125
(Laryngial metaplasia)
0.11
0.007 
0.051 
0.11 
(asthma) 
0.007
(interst lung dis) 
0.051
(Hyper- and metaplasia of

respiratory tract tissues; 
pulmonary fibrosis) 
0.11
Shirakawa et al. 1988 
Hard Metal 
Sprince et al. 1988
Hard Metal 
Swennen et al. 1993 
Metal 
NTP 1998 
Sulfate

NTP 1998 
Sulfate 
Table 3-1 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Inhalation	 (continued) 
a
Key to Species 
figure (Strain) 
Exposure/ 
Duration/

Frequency 
(Specific Route) System 
NOAEL 
(mg/m³) 
LOAEL
 
Reference 
Chemical Form 
Less Serious 
(mg/m³)	 
Serious 
(mg/m³) 
33 
34 
35 
36 
Hamster life 5d/wk 7h/d	 
424
Immuno/ Lymphoret 
Human occup 
425
Human 8 yr	 
(occup)	 
46
Cancer 
Rat 104 wk 
(Fischer- 344) 
53
Resp 
Bd Wt 7.9 
7.9
0.007	 
0.125 
(sensitization) 
0.007
(Increased white cell count by
19%) 
0.125
7.9 (emphysema) 
7.9
1.14 M (alveoloar/bronchiolar
 
neoplasms) 
1.14
1.14 F (pheochromocytoma) 
1.14
0.38 F (alveoloar/bronchiolar 
neoplasms) 
0.38
Wehner et al. 1977 
Oxide 
Shirakawa et al. 1986a 
Hard Metal 
Swennen et al. 1993 
Metal
NTP 1998
Sulfate
 
Table 3-1 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Inhalation (continued) 
a
Key to Species 
figure (Strain) 
Exposure/ 
Duration/

Frequency 
(Specific Route) System 
NOAEL 
(mg/m³) 
LOAEL
 
Reference 
Chemical Form 
Less Serious 
(mg/m³) 
Serious 
(mg/m³) 
37 Mouse 
(B6C3F1) 
54
104 wk 
1.14 M (Combined alveolar/bronchiolar
 
adenoma/carcinoma) 
1.14
0.38 F (Combined alveolar/bronchiolar 
adenoma/carcinoma) 
0.38
NTP 1998
Sulfate

a The number corresponds to entries in Figure 3-1.
 
b An increase in hemoglobin or red blood cells (polycythemia) is not necessarily considered an adverse effect.
 
c Differences in levels of health effects and cancer effect between males and females are not indicated in Figure 3-1. Where such differences exist, only the levels of effect for the
 
   most sensitive gender are presented. 
d Used to derive a chronic inhalation Minimal Risk level (MRL) of 0.0001 mg Co/m3., dose adjusted for intermittent exposure, and divided by an uncertainty factor of 10 (for human 
   variability). 
Bd = body weight; Cardio = cardiovascular, d = day(s); Derm = dermal; Endocr = endocrine; F = female; Gastro = gastrointestinal; Gn Pig = guinea pig; Hemato = hematological; hr = 
hour(s); LOAEL = lowest-observed-adverse-effect level; M = male; mo = month(s); Musc/skel = muscular/skeletal; NOAEL = no-observed-adverse-effect level; (occup) = 
occupational; Resp = respiratory; wk = week(s); yr = year(s). 
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Figure 3-1. Levels of Significant Exposure to Cobalt - Chemical Toxicity - Inhalation 
Acute (≤14 days) 
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Figure 3-1. Levels of Significant Exposure to Cobalt - Chemical Toxicity - Inhalation (Continued) 
Intermediate (15-364 days) 
Systemic 
mg/m3 
9m 9m 9m 9m 9m 
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6m 7r 10m 10m 10m 10m 10m 7r 10m 10m 7r 
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Figure 3-1. Levels of Significant Exposure to Cobalt - Chemical Toxicity - Inhalation (Continued) 
Intermediate (15-364 days) 
mg/m3 
18r 21m 20r 22r 
19m 23m 
10 
23m 
1 
0.1 
c-Cat -Humans f-Ferret n-Mink   Cancer Effect Level-Animals   Cancer Effect Level-Humans  LD50/LC50d-Dog k-Monkey j-Pigeon o-Other  LOAEL, More Serious-Animals  LOAEL, More Serious-Humans  Minimal Risk Levelr-Rat m-Mouse e-Gerbil LOAEL, Less Serious-Animals  LOAEL, Less Serious-Humans    for effectsp-Pig h-Rabbit s-Hamster   NOAEL - Animals   NOAEL - Humans  other thanq-Cow a-Sheep g-Guinea Pig 
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Figure 3-1. Levels of Significant Exposure to Cobalt - Chemical Toxicity - Inhalation (Continued) 
Chronic (≥365 days) 
Systemic 
mg/m3 
33s 33s 
37m 36r 36r1
 
37m 36r 
25
 30
 30
 30
 30
 35
32m 31r0.1 
29
 27
 
24
 26
 
0.01 
28
 34
 
26
 
0.001 
*Doses represent the lowest dose tested per study that produced a tumorigenic 
response and do not imply the existence of a threshold for the cancer endpoint. 
0.0001 
c-Cat -Humans f-Ferret n-Mink   Cancer Effect Level-Animals   Cancer Effect Level-Humans  LD50/LC50d-Dog k-Monkey j-Pigeon o-Other  LOAEL, More Serious-Animals  LOAEL, More Serious-Humans  Minimal Risk Levelr-Rat m-Mouse e-Gerbil LOAEL, Less Serious-Animals  LOAEL, Less Serious-Humans    for effectsp-Pig h-Rabbit s-Hamster   NOAEL - Animals   NOAEL - Humans  other thanq-Cow a-Sheep g-Guinea Pig 
Cancer 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COBALT  45 
3. HEALTH EFFECTS 
Kusaka et al. (1986b) described an acute exposure of 15 healthy young men to atmospheres of hard metal 
dust containing 0.038 mg cobalt/m3 for 6 hours.  Forced vital capacity (FVC) was reduced, but no dose-
response relation could be discerned.  By contrast, 42 workers occupationally exposed to hard metal 
showed no decrease in ventilatory function at 0.085 mg cobalt/m3, but significant changes in FEV1 
(forced expiratory volume in 1 second) at 0.126 mg cobalt/m3 (Kusaka et al. 1986b).  Several other 
studies of hard metal workers have shown respiratory effects, including decreased ventilatory function, 
wheezing, asthma, and fibrosis (Kusaka et al. 1996a, 1996b; Ruokonen et al. 1996; Zanelli et al. 1994), 
but have had less complete reports of exposure. 
Swennen et al. (1993) performed a cross-sectional study on 82 workers in a cobalt refinery. Workers 
were examined for cobalt in blood and urine, a number of erythropoietic variables, thyroid metabolism, 
pulmonary function, skin lesions, and several serum enzymes.  The concentrations of cobalt in blood and
in urine after the shift were significantly correlated with those in air.  Workers exposed to airborne cobalt 
metal, salts, or oxides (mean concentration 0.125 mg/m3, range 0.001–7.7 mg/m3) showed an increased 
(p<0.05) prevalence of dyspnea and wheezing and had significantly more skin lesions (eczema, erythema) 
than control workers.  A dose-effect relation was found between the reduction of the FEV1 and the 
intensity of the current exposure to cobalt, as assessed by measurement of cobalt in blood, air, or urine. 
Gennart and Lauwerys (1990) examined the ventilatory functions of 48 diamond polishing workers, 
relative to 23 control workers.  Exposure occurred mainly in one of two rooms, with mean airborne 
concentrations of 0.0152 and 0.1355 mg cobalt/m3; control subjects worked in other areas of the facilities, 
where no exposure to cobalt occurred.  Significant decreases in ventilatory function were found in the 
exposed workers relative to the control workers.  Duration of exposure played a significant factor, with no 
significant differences in workers who had been exposed for ≤5 years; reported decreases in ventilatory
function were noted in workers exposed for > 5 years.  Inhalation exposure to cobalt salts (exposure 
levels not reported) among glass bangle workers resulted in decreases in decreased ventilatory function, 
generally restrictive in nature, relative to controls (Rastogi et al. 1991).  
Nemery et al. (1992) conducted a cross-sectional study of cobalt exposure and respiratory effects in 
diamond polishers.  Exposure occurred mainly from the generation of airborne cobalt resulting from the 
use of cobalt-containing polishing discs.  The study groups were composed of 194 polishers working in 
10 different workshops, and were divided into control, low-, and high-exposure groups.  The low-
exposure group (n=102) was exposed to an average of 0.0053 mg cobalt/m3, based on personal sampling 
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3. HEALTH EFFECTS 
measurements, while the exposure level for the high dose group (n=92) was 0.0151 mg cobalt/m3; there 
was considerable overlap in the total range of concentrations for the low- and high-exposure groups.  
Workers in the high-exposure group were more likely than those in the other groups to complain about 
respiratory symptoms; the prevalence of eye, nose, and throat irritation and cough, as well as the fraction 
of these symptoms related to work, were significantly increased in the high-exposure group.  Workers in 
the high-exposure group also had significantly reduced lung function compared to controls and low-
exposure group workers, as assessed by FVC, FEV1, MMEF (forced expiratory flow between 25 and 75%
of the FVC) and mean PEF (peak expiratory flow rate).  Results in the low-exposure group did not differ 
from controls.  Based on the NOAEL of 0.0053 mg cobalt/m3 for decreased ventilatory function in 
exposed workers, a chronic inhalation MRL of 1x10-4 mg cobalt/m3 was calculated as described in 
footnote (d) in Table 3-1.  It should be noted that this MRL value may not be protective for some 
hypersensitive individuals. 
As with exposures in humans, exposures of animals to cobalt-containing aerosols have resulted in 
pronounced respiratory effects.  Animals exposed to aerosols of cobalt oxides and cobalt sulfate 
developed respiratory effects that varied in severity with exposure level and duration.  A single 30-minute 
exposure of rats to relatively high levels (26–236 mg cobalt/m3 as cobalt hydrocarbonyl) resulted in 
congestion, edema, and hemorrhage of the lung (Palmes et al. 1959).  Prolonged exposure (3–4 months) 
of rats and rabbits to mixed cobalt oxides (0.4–9 mg cobalt/m3) resulted in lesions in the alveolar region 
of the respiratory tract characterized histologically by nodular accumulation of Type II epithelial cells, 
accumulations of enlarged highly vacuolated macrophages, interstitial inflammation, and fibrosis 
(Johansson et al. 1984, 1987, 1991, 1992; Kyono et al. 1992; Palmes et al. 1959).  In at least one instance, 
the lesions appeared to regress when exposure was terminated (Palmes et al. 1959).  Guinea pigs 
sensitized to cobalt by repeated dermal application and then exposed to 2.4 mg cobalt/m3 as cobalt 
chloride showed pulmonary inflammatory changes (altered BAL fluid recovery, increased neutrophils and 
eosinophils in the recovered BAL fluid) that were different than those in exposed animals not sensitized 
to cobalt (Camner et al. 1993).  Decreased lung compliance was found in pigs exposed to 0.1 mg
cobalt/m3 as cobalt dust for 3 months (Kerfoot 1975).  Lifetime exposure of hamsters to 7.9 mg
cobalt/m3 as cobalt oxide resulted in emphysema (Wehner et al. 1977). 
Necrosis and inflammation of the respiratory tract epithelium (nasal turbinates, larynx, trachea, 
bronchioles) were reported in rats exposed to 19 mg cobalt/m3 and mice exposed to 1.9 mg cobalt/m3 or 
greater as cobalt sulfate over 16 days (Bucher et al. 1990; NTP 1991).  Exposure of rats and mice to 
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cobalt as cobalt sulfate for 13 weeks resulted in adverse effects on all parts of the respiratory tract, with 
the larynx being the most sensitive part (Bucher et al. 1990; NTP 1991).  At concentrations of ≥0.11 mg 
cobalt/m3, rats and mice developed squamous metaplasia of the larynx.  Histiocytic infiltrates in the lung 
were also reported at similar levels in both the rats and mice.  In rats, chronic inflammation of the larynx 
was found at ≥0.38 mg cobalt/m3, and more severe effects on the nose, larynx, and lung were reported at 
higher exposures.  In mice, acute inflammation of the nose was found at ≥1.14 mg cobalt/m3, and more 
severe effects on the nose, larynx, and lung were reported at higher exposures.  Exposure of rats and mice 
to aerosols of cobalt (as cobalt sulfate) at concentrations from 0.11 to 1.14 mg cobalt/m3 for 2 years 
resulted in a spectrum of inflammatory, fibrotic, and proliferative lesions in the respiratory tract of male
and female rats and mice (Bucher et al. 1999; NTP 1998).  Squamous metaplasia of the larynx occurred in 
rats and mice at exposure concentrations of ≥0.11 mg cobalt/m3, with severity of the lesion increasing 
with increased cobalt concentration.  Hyperplastic lesions of the nasal epithelium occurred in rats at 
concentrations of ≥0.11 mg cobalt/m3, and in mice at concentrations of ≥0.38 mg cobalt/m3. Both sexes 
of rats had greatly increased incidences (>90% incidence) of alveolar lesions at all exposure levels, 
including inflammatory changes, fibrosis, and metaplasia.  Similar changes were seen in mice at all 
exposure levels, though the changes in mice were less severe. 
Cardiovascular Effects. Occupational exposure of humans to cobalt-containing dust, either as 
cobalt metal or as hard metal, has been shown to result in cardiomyopathy, characterized by functional 
effects on the ventricles (Horowitz et al. 1988) and/or enlargement of the heart (Barborik and Dusek 
1972; Jarvis et al. 1992), but the exposure levels associated with cardiac effects of inhaled cobalt in 
humans have not been determined.  Jarvis et al. (1992) reported on two patients (exposure histories not 
specified) who had been admitted to the emergency room for cardiac failures; these failures were believed 
to be associated with cobalt exposure.  Barborik and Dusek (1972) reported a case of a 41-year-old man 
who was admitted to the hospital with cardiac failure following occupational exposure to cobalt; cobalt 
concentrations in heart, liver, lung, spleen, and kidney were elevated over two control patients.  Horowitz 
et al. (1988) reported that in a cohort of 30 hard metal workers (exposure histories not specified), 
significant decreases in exercise right ventricular ejection fraction (EF) were seen in workers with 
abnormal chest x-rays relative to those with normal chest x-rays.  It is possible that these effects were 
secondary to the respiratory effects of inhaled cobalt.  It was concluded that cobalt is a weak 
cardiomyopathic agent following occupational exposure (Horowitz et al. 1988). Cardiomyopathy is a 
characteristic toxic effect of cobalt following oral exposure in both humans and animals (Section 3.2.2.2). 
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In rats, exposure to 11.4 mg cobalt/m3 as cobalt sulfate over 13 weeks resulted in a marginal increase in 
the severity of cardiomyopathy as compared to controls (minimal-mild in treated animals versus minimal 
in controls; 3/10 animals affected in either group) (Bucher et al. 1990; NTP 1991).  Cardiomyopathy was 
not observed in mice exposed to ≤76 mg cobalt/m3 as cobalt sulfate over 16 days (Bucher et al. 1990; 
NTP 1991), nor in mice or rats exposed to up to 1.14 mg cobalt/m3 for 2 years (Bucher et al. 1999; NTP 
1998).  Electrocardiogram abnormalities that may reflect ventricular impairment have been observed in 
miniature swine (n=5) exposed to 0.1 mg cobalt dust/m3 for 6 hours/day, 5 days/week for 3 months 
(Kerfoot 1975). 
Gastrointestinal Effects.    No studies were located regarding gastrointestinal effects in humans after 
inhalation exposure to stable cobalt. 
No histological lesions were reported in the esophagus, stomach, duodenum, ileum, jejunum, cecum, 
colon, or rectum of rats or mice of either sex exposed to 76 mg cobalt/m3 or less as cobalt sulfate for 
16 days, up to 11.4 mg cobalt/m3 for 13 weeks, or up to 1.14 mg cobalt/m3 for 104 weeks (Bucher et al. 
1990, 1999; NTP 1991, 1998). 
Hematological Effects. Swennen et al. (1993) reported slightly, but statistically significantly, 
decreased levels of red cells and total hemoglobin (~4–5% decreases) in a group of 82 workers 
occupationally exposed to a mean concentration of 0.125 mg cobalt/m3 as cobalt metal dust.  No other 
studies were located regarding hematological effects in humans after inhalation exposure to cobalt. 
Increased levels of hemoglobin and increased numbers of basophils and monocytes have been observed in 
rats and guinea pigs, but not in dogs, exposed to 9 mg cobalt/m3 as cobalt hydrocarbonyl for 3 months 
(Palmes et al. 1959).  Polycythemia was reported in rats, but not mice, exposed to 1.14 mg cobalt/m3 as 
cobalt sulfate for 13 weeks (Bucher et al. 1990; NTP 1991). 
Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans after 
inhalation exposure to cobalt. 
No histological lesions were reported in the sternebrae (segments of the sternum), including the bone 
marrow, of rats or mice exposed to ≤76 mg cobalt/m3 as cobalt sulfate for 16 days, up to 11.4 mg
  
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
COBALT  49 
3. HEALTH EFFECTS 
cobalt/m3 for 13 weeks, or up to 1.14 mg cobalt/m3 for 104 weeks (Bucher et al. 1990, 1999; NTP 1991,
1998) (see the above section on respiratory effects for detailed descriptions of exposure conditions). 
Hepatic Effects. Congestion of the liver was observed upon autopsy of a metal worker (exposure 
history not reported) who had been occupationally exposed to an unknown level of cobalt for 4 years 
(Barborik and Dusek 1972).  The cause of death was determined to be cardiomyopathy. 
Necrosis and congestion of the liver were observed in both rats and mice that died following exposure to 
19 mg cobalt/m3 as cobalt sulfate over 16 days (Bucher et al. 1990; NTP 1991). No histological effects 
on the liver were found in pigs exposed to up to 1.0 mg cobalt/m3 as cobalt metal dust for 3 months 
(Kerfoot 1975). 
Renal Effects. Congestion of the kidneys was observed upon autopsy of a metal worker who had 
been occupationally exposed to an unknown level of cobalt for 4 years (Barborik and Dusek 1972).  The 
cause of death was determined to be cardiomyopathy.
A significant increase in the relative weight of the kidneys was reported in male rats exposed to 0.11 mg
cobalt/m3 or greater as cobalt sulfate for 13 weeks (Bucher et al. 1990; NTP 1991).  No effects were 
observed upon histological examination of the kidneys in rats or mice following exposure to ≤76 mg 
cobalt/m3 as cobalt sulfate for 16 days, up to 11.4 mg cobalt/m3 for 13 weeks, or up to 1.14 mg cobalt/m3 
for 104 weeks (Bucher et al. 1990, 1999; NTP 1991, 1998).  No histological effects on the kidneys were 
found in pigs exposed to up to 1.0 mg cobalt/m3 as cobalt metal for 3 months (Kerfoot 1975).
Dermal Effects.    No studies were located regarding dermal effects in humans or animals after 
inhalation exposure to stable cobalt. 
Endocrine Effects. A group of female workers occupationally exposed to a semisoluble cobalt glaze 
(cobalt-zinc silicate, estimated concentrations of 0.05 mg Co/m3) showed significantly elevated levels of 
serum thyroxine (T4) and free thyroxine, but no change in T3 levels (Prescott et al. 1992).  In contrast to 
this, Swennen et al. (1993) reported no significant change in serum T4 levels, but a significant reduction 
in serum T3 in workers occupationally exposed to cobalt oxides, cobalt salts, and cobalt metal.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COBALT  50 
3. HEALTH EFFECTS 
Ocular Effects.    Congestion of the conjunctiva was observed in a metal worker after occupational 
exposure to an unknown level of cobalt for 4 years (Barborik and Dusek 1972); however, due to the 
nature of the exposure, this effect may also have been the result of direct dermal or ocular contact.  Upon 
autopsy, the cause of death was determined to be cardiomyopathy. 
No histological lesions were reported in the eyes or on the skin of rats or mice exposed to ≤76 mg 
cobalt/m3 as cobalt sulfate for 16 days, up to 11.4 mg cobalt/m3 for 13 weeks, or up to 1.14 mg cobalt/m3 
for 104 weeks (Bucher et al. 1990, 1999; NTP 1991, 1998). 
Body Weight Effects.    Weight loss, measured individually from time of initial examination 
throughout followup, was observed in a group of five diamond polishers suffering from cobalt-induced 
interstitial lung disease (Demedts et al. 1984b), but the exposure level of cobalt was not reported. 
Decreased body weight, relative to controls at study termination, was reported in both rats and mice 
exposed to 19 mg cobalt/m3 as cobalt sulfate over 16 days or to 11.4 mg cobalt/m3 for 13 weeks (Bucher 
et al. 1990; NTP 1991).  A 13-week exposure to 11.4 mg cobalt /m3 resulted in ruffled fur in male rats, 
with no clinical signs reported in female rats or either sex of mice (Bucher et al. 1990; NTP 1991).  
Chronic exposure of rats and mice to up to 1.14 mg cobalt/m3 did not result in decreased body weight 
(Bucher et al. 1999; NTP 1998). 
Weight loss was found in dogs, but not rats or guinea pigs, exposed for 3 months to cobalt at a level of 
9 mg cobalt/m3 as cobalt hydrocarbonyl (Palmes et al. 1959).  Lifetime exposure of hamsters to a similar 
concentration (7.9 mg cobalt/m3 as cobalt oxide) did not result in decreased body weight gain (Wehner et 
al. 1977). 
3.2.1.3 Immunological and Lymphoreticular Effects  
Cobalt is known to function as a hapten, resulting in the generation of antibodies against cobalt-protein 
complexes.  Although the minimum exposure level associated with cobalt sensitization has not been 
determined, sensitization has been demonstrated in hard metal workers with work-related asthma who 
have experienced prolonged occupational exposure (>3 years) to levels ranging from 0.007 to 0.893 mg
cobalt/m3 (Shirakawa et al. 1988, 1989).  The lower end of this range, 0.007 mg/m3, is reported in 
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Table 3-1 and plotted in Figure 3-1 as a LOAEL.  The sensitization phenomenon includes the production
of IgE and IgA antibodies to cobalt (Bencko et al. 1983; Shirakawa et al. 1988, 1989).  Exposure to 
inhaled cobalt chloride aerosols can precipitate an asthmatic attack in sensitized individuals (Shirakawa et 
al. 1989), believed to be the result of an allergic reaction within the lungs. 
Necrosis of the thymus was reported in rats exposed to 19 mg cobalt/m3 as cobalt sulfate over 16 days, 
and hyperplasia of the mediastinal lymph nodes was found in mice exposed to 11.4 mg cobalt/m3 for 
13 weeks (Bucher et al. 1990; NTP 1991).  Tests of immunological function, however, were not 
performed on the rats or mice. 
3.2.1.4 Neurological Effects 
Occupational exposure to cobalt in humans has been reported to cause several effects on the nervous 
system, including memory loss (Wechsler Memory Scale-Revised), nerve deafness, and a decreased 
visual acuity (Jordan et al. 1990; Meecham and Humphrey 1991).  It should be noted, though, that both of 
these studies had small numbers of subjects (n=38 for Jordan et al. 1990, n=1 for Meecham and 
Humphrey 1991), and exposure characterization was not reported. 
Congestion in the vessels of the brain/meninges was reported in rats and mice exposed to 19 mg
cobalt/m3 or greater as cobalt sulfate over 16 days (Bucher et al. 1990; NTP 1991). 
3.2.1.5 Reproductive Effects  
No studies were located regarding reproductive effects in humans after inhalation exposure to cobalt. 
In animals, long-term exposure to cobalt-containing aerosols has resulted in effects on reproductive end 
points. Testicular atrophy was reported in rats, but not in mice, exposed to 19 mg cobalt/m3 as cobalt 
sulfate over 16 days (Bucher et al. 1990; NTP 1991). Following exposure of mice to cobalt (as cobalt 
sulfate) for 13 weeks, a decrease in sperm motility was found at 1.14 mg cobalt/m3, and testicular atrophy
was found at 11.4 mg cobalt/m3. A significant increase in the length of the estrous cycle was reported in 
female mice exposed to 11.4 mg cobalt/m3 for 13 weeks (Bucher et al. 1990; NTP 1991).  No effects on 
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the male or female reproductive systems were observed in rats similarly treated for 13 weeks (Bucher et 
al. 1990; NTP 1991), or in mice or rats exposed to up to 1.14 mg cobalt/m3 for 104 weeks (Bucher et al. 
1999; NTP 1998). 
3.2.1.6 Developmental Effects 
No studies were located regarding developmental effects in humans or animals after inhalation exposure 
to cobalt. 
3.2.1.7 Cancer 
Several studies have evaluated the effects of inhalation of cobalt-containing compounds on possible 
carcinogenicity in humans.  The mortality of a cohort of 1,143 workers in a plant that refined and 
processed cobalt and sodium was analyzed (Mur et al. 1987); the French national population mortality
data were used as a reference population.  An increase in deaths due to lung cancer was found in workers 
exposed only to cobalt (standardized mortality ratio [SMR] of 4.66; four cases in the exposed group 
versus one case in the controls).  In a study within the cohort that controlled for date of birth, age at death, 
and smoking habits, 44% (four workers) in the group exposed to cobalt and 17% (three workers) in the 
group not exposed to cobalt died of lung cancer.  The authors, however, indicated that the difference was 
not statistically significant and that the workers were exposed to both arsenic and nickel as well as cobalt.  
The nonneoplastic lung diseases commonly found in cobalt-exposed workers (see Section 3.2.1.2) were 
not reported in this group. These lung diseases may have been present in these workers, but if they were 
not listed as the cause of death on the death certificate, they would not have been mentioned.  Inhalation 
was probably a prominent route of exposure to cobalt; however, oral and dermal exposure probably
occurred as well. No adjustments were made for smoking habits in the larger study, and the exposure 
levels of cobalt were not reported for either study.  However, a followup study of this cohort (Moulin et 
al. 1993) did not report significant increases in mortality due to respiratory or circulatory diseases.  
Similarly, no increase in the SMR for lung cancer was noted in exposed workers, relative to controls.  
While an elevated SMR for lung cancer was seen in maintenance workers (SMR=1.80, 95% confidence 
interval [CI]=0.78–3.55), it was not statistically significant, since the 95% confidence interval included an 
SMR of 1. 
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Lasfargues et al. (1994) reported on the mortality of a cohort of 709 male workers in a French hard metal 
plant, using the national rates for French males for comparison.  The overall mortality did not differ from
expected, but there was a significant increase in mortality due to cancer of the trachea, bronchus, and lung 
(SMR=2.13, 95% CI=1.02–3.93).  Smoking alone did not account for the lung cancer excesses, although 
the influence of smoking on the observed mortality could not be entirely ruled out. 
A cohort of 5,777 males and 1,682 females who were exposed occupationally to cobalt (concentrations 
ranging from 1 to 515 µg/m3, means of exposure levels ranging from 39.37 to 169.0 µg/m3) and tungsten 
carbide (as hard metal dust) was examined by Moulin et al. (1998).  A significantly increased mortality
rate (SMR=1.30, 95% CI=1.00–1.66) was seen for lung cancer in exposed workers, when compared to the 
national average. Within this study group, 61 cases and 180 controls were selected for a case-control 
study of cancer risk.  When exposures during the last 10 years were ignored, presumably because cancer 
is a late-developing disease, a significant increase in lung cancer mortality (OR=1.93, 95% CI=1.03–3.62) 
relative to controls was seen among workers simultaneously exposed to cobalt and tungsten carbide.  
Significant trends for increasing cancer risk with increasing cumulative exposure and exposure duration 
were noted. Adjustments for smoking and for coexposures to other carcinogens did not change the 
results, though occupational risk was greatest among smokers. 
A later study by the same group (Moulin et al. 2000) examined the lung cancer mortality of 4,288 male 
and 609 female workers employed in the production of stainless and alloyed steel from 1968 to 1992.  No 
significant changes in mortality rate from lung cancer were seen among exposed workers (SMR=1.19, 
95% CI=0.88–1.55), and a concurrent case control study identified no correlation between lung cancer 
excess and for exposure to cobalt (OR=0.64, 95% CI=0.33–1.25). 
Wild et al. (2000) reported on a cohort of 2,216 male hard metal workers who had been employed for at 
least 3 months; this cohort was the same as that in Moulin et al. (2000), with some modifications.  The 
total mortality was not increased in workers, relative to local mortality rates.  However, lung cancer 
mortality was significantly increased (SMR=1.70, 95% CI=1.24–2.26).  The risks increased with 
increasing exposure scores, even after adjustment for smoking and coexposure to other known or 
suspected carcinogens. 
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Inhalation exposure to 7.9 mg cobalt/m3 as cobalt oxide intermittently for a lifetime did not increase the 
incidence of malignant or benign tumors in hamsters (Wehner et al. 1977). 
NTP (1998) exposed groups of rats and mice of both sexes to 0, 0.11, 0.38, or 1.14 mg cobalt/m3 as cobalt 
sulfate for 2 years.  Increased incidence of alveolar/bronchiolar neoplasms was noted following lifetime 
exposure of male rats to 1.14 mg cobalt/m3 and in female rats exposed to 0.38 mg cobalt/m3 (Bucher et al. 
1999; NTP 1998).  Statistical analysis revealed that tumors occurred with significantly positive trends in 
both sexes of rats.  Similarly, mice of both sexes exposed to 1.14 mg cobalt/m3 showed an increase in 
alveolar/bronchiolar neoplasms, again with lung tumors occurring with significantly positive trends. 
3.2.2 Oral Exposure  
3.2.2.1 Death 
In several studies, lethal cardiomyopathy was reported in people who consumed large quantities of beer 
containing cobalt sulfate (Alexander 1969, 1972; Bonenfant et al. 1969; Morin et al. 1967, 1971; Sullivan 
et al. 1969). The deaths occurred during the early to mid 1960s, at which time, breweries in Canada, the 
United States, and Europe were adding cobalt to beer as a foam stabilizer (Alexander 1969, 1972; 
Bonenfant et al. 1969; Morin et al. 1967, 1971; Sullivan et al. 1969); this practice has been discontinued. 
Deaths occurred following ingestion of beer containing 0.04–0.14 mg cobalt/kg/day for a period of years 
(approximately 8–30 pints of beer each day).  “Acute mortality” (death within several days of admission) 
accounted for 18% of the deaths (Alexander 1972).  Approximately 43% of the patients admitted to the 
hospital with cardiomyopathy died within several years of the initial hospital visit.  It should be noted, 
however, that the cardiomyopathy may have also been due to the fact that the beer-drinkers had protein-
poor diets and may have had prior cardiac damage from alcohol abuse.   
Treatment of both pregnant and nonpregnant anemic patients with doses of cobalt (0.6–1 mg/kg/day) that 
were much higher than the doses in the beer did not result in mortality (Davis and Fields 1958; Holly
1955).  A 19-month-old male child who swallowed an unknown amount of a cobalt chloride solution died 
approximately 6.5 hours after ingestion, despite repeated induced vomiting, gastric lavage, and supportive 
therapy (Jacobziner and Raybin 1961). 
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Oral LD50 values for several cobalt compounds have been determined in Wistar rats (FDRL 1984a, 
1984b, 1984c; Singh and Junnarkar 1991; Speijers et al. 1982).  The LD50 values ranged from 42.4 mg
cobalt/kg as cobalt chloride to 317 mg cobalt/kg as cobalt carbonate.  An LD50 of 3,672 mg cobalt/kg was 
also found for tricobalt tetraoxide, a highly insoluble cobalt compound (FDRL 1984c).  The exact cause 
of death in rats is unknown, but effects on the heart, liver, gastrointestinal tract, and kidneys have been 
observed. In Sprague-Dawley rats, death has been reported to occur at 161 mg cobalt/kg given by gavage 
as cobalt chloride (Domingo and Llobet 1984).  In male Swiss mice, the LD50 values for cobalt chloride 
and cobalt sulfate have been reported to be 89.3 and 123 mg cobalt/kg, respectively (Singh and Junnarkar 
1991). 
Following 5 weeks of exposure to 20 mg cobalt/kg/day as cobalt sulfate by gavage, 20–25% of the guinea 
pigs died (Mohiuddin et al. 1970).  The animals were given cobalt sulfate alone or in combination with 
ethanol (as part of a liquid diet) to compare the effects seen in animals to those seen in humans suffering 
from beer-cobalt cardiomyopathy.  Although effects on the heart were found in the treated animals, 
alcohol did not appear to intensify the toxic effect. 
The LD50 and all reliable LOAEL values for each species and duration category are reported in Table 3-2 
and plotted in Figure 3-2. 
3.2.2.2 Systemic Effects  
Oral cobalt exposure in humans and/or animals resulted in respiratory, cardiovascular, gastrointestinal, 
hematological, hepatic, renal, endocrine, dermal, ocular, hypothermic, and body weight effects.  For each 
effect, the highest NOAEL values and all reliable LOAEL values for each species and duration category
are reported in Table 3-2 and plotted in Figure 3-2. 
Respiratory Effects. In 50 patients with beer-cobalt cardiomyopathy, pulmonary rales and 
pulmonary edema were observed and were attributed to cobalt-induced cardiac failure (Morin et al. 1971).
These patients had ingested, over a period of years, an average of 0.04 mg cobalt/kg/day in beer 
containing cobalt sulfate that was added to stabilize the foam.  It should be noted that these patients 
consumed significant quantities of alcohol, and the effect that this may have had on the symptoms seen is 
not known.  
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161.1
61
42.4
62
194
320
91
321
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63
159
Table 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral 
Exposure/ LOAEL
 
Duration/

a
Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
ACUTE EXPOSURE 
Death 
1 Rat 1x Domingo and Llobet 1984161.1 (LD50)

(Sprague- (GW) Chloride
 
Dawley) 
2 Rat 1x Singh and Junnarkar 199142.4 (LD50)

(Wistar) (GW) Chloride
 
3 Rat 1x Singh and Junnarkar 1991194 (LD50)
(Wistar) (GW) Sulfate 
4 Rat 1 x Speijers et al. 198291 (LD50)
(Wistar) (GO) Fluoride 
5 Rat 1 x Speijers et al. 1982187 (LD50)
(Wistar) (GO) Phosphate 
6 Rat 1 x Speijers et al. 1982109 (LD50)
(Wistar) (GW) Bromide 
7 Rat 1 x Speijers et al. 1982159 (LD50)

(Wistar) (GO) Oxide
 
64
168
66
190
67
140
68
161
69
123
70
89.3
73
1
a
Key to 
figure 
Species 
(Strain) 
LOAEL 
Less SeriousNOAEL 
System 
Table 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral 
(mg/kg/day) (mg/kg/day) 
Exposure/ 
Duration/ 
Frequency 
(Specific Route) 
Serious 
(mg/kg/day) 
(continued) 
Reference 
Chemical Form 
8 
(Wistar) 
Rat 1 x 
(GW) 
168 (LD50) 
Speijers et al. 1982 
Acetate 
9 
(Wistar) 
Rat 1 x 
(GW) 
190 (LD50) 
Speijers et al. 1982 
Chloride 
10 
(Wistar) 
Rat 1 x 
(GW) 
140 (LD50) 
Speijers et al. 1982 
Bromide 
11 
(Wistar) 
Rat 1 x 
(GW) 
161 (LD50) 
Speijers et al. 1982 
Sulfate 
12 
(Swiss-
Webster) 
Mouse 1x 
(GW) 
123 (LD50) 
Singh and Junnarkar 1991 
Sulfate 
13 
14 
(Swiss-
Webster) 
Mouse 
Systemic 
Human 
1x 
(GW) 
2 wk 
(C) 
Endocr 1 (decreased Iodine uptake in 
thyroid) 
89.3 (LD50) 
Singh and Junnarkar 1991 
Chloride 
Roche and Layrisse 1958 
Chloride 
74
161.1
110
75
209
59
149
78
19.4
109.6
79
176.6
42.6 68.2
42.6
176.6
109.6
Table 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral (continued) 
a
Key to 
figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Specific Route) System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form 
15 Rat 1x 
(GW) 
Hemato 161.1 
b 
(increased hematocrit 8%) 
Domingo and Llobet 1984 
Chloride 
16 Rat 1 x 
(GW) 
Other 110 209 (Clinical signs, including 
decreased activity, ataxia, 
diarrhea, salivation) 
FDRL 1984a 
Sulfate 
17 
(Sprague-
Dawley) 
Rat 1 x 
(GO) 
Other 149 (Decreased activity, diarrhea) 
FDRL 1984b 
Carbonate 
18 
(Wistar) 
Rat 1x 
(GW) 
Renal 19.4 (Increased urinary output) 
Singh and Junnarkar 1991 
Sulfate 
19 
(Wistar) 
Rat 1 x 
(GO) 
Cardio 109.6 176.6 (proliferative interstitial tissues, 
swollen muscle fibers, focal 
Speijers et al. 1982 
Fluoride 
myocardial degeneration) 
Hepatic 42.6 68.2 (hyperemia) 
Renal 42.6 (swollen proximal tubules) 176.6 (degeneration of proximal 
tubules) 
Other 109.6 (hypothermia) 
Table 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral	 (continued) 
Exposure/	 LOAEL 
Duration/ 
a Frequency NOAEL Less Serious Reference Key to Species Serious
 
(Specific Route) figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day)
 Chemical Form 
20	 Rat 1 x Speijers et al. 1982 
Cardio 794.5 (hemorrhage) 
(Wistar) (GO) 794.5 Oxide 
80
Hepatic 157.3 (hyperemia) 
157.3
Renal 157.3 (hyperemia) 
157.3
Other 157.3 (hypothermia) 
157.3
21	 Mouse 48 hr Bryan and Bright, 1973 
Hemato 76.4 M (Alteration in electrophoretic 
(Swiss- (W) Chloride profile of serum proteins) 
Webster) 76.4
82
22	 Mouse 3 mo Bryan and Bright, 1973 
Hemato 76.4 M 
(Swiss- (W) Chloride 76.4
Webster) 
83
Neurological 
23 Rat 1x Singh and Junnarkar 1991 
19.4 (Mild depression of 
(Wistar) (GW) Sulfate spontaneous activity, muscle 
tone, and respiration) 
19.4
88
89
4.25
24.8
91
81.7
92
98
0.04
99
20
101
0.07
Table 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral (continued) 
Exposure/ LOAEL 
Duration/
a
Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
24 Rat 1x Singh and Junnarkar 1991
4.25 (Mild depression of
(Wistar) (GW) Chloridespontaneous activity, muscle 
tone, and respiration) 
Developmental 
25 Rat Gd 6-15 Paternian et al. 1988 
24.8
(GW) Chloride 
26 Mouse Gd 8-12 
(GW) 
81.7 
Seidenberg 1986 
Chloride 
INTERMEDIATE EXPOSURE 
Death 
27 Human NR 
(W) 
0.04 (death) 
Morin et al. 1971 
Sulfate 
28 Gn Pig 5 wk 
(F) 
20 (death) 
Mohiuddin et al. 1970 
Sulfate 
Systemic 
29 Human NR 
(W) 
Cardio 0.07 (beer-cobalt cardiomyopathy) 
Alexander 1972 
Sulfate 
102
1
103
0.18
0.18
104
0.5
0.6
0.6
106
0.04
0.04
0.04
0.04
Table 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral	 (continued) 
Exposure/ LOAEL
 
Duration/

a
Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
30 Human 1x/d 25 d c Davis and Fields 1958 
Hemato 1 (polycythemia)
(C)	 Chloride 
31 Human 12-32 wk Duckham and Lee 1976b 
Gastro 0.18 (nausea)
(C)	 Chloride 
b 
Hemato 0.18	 (increased hemoglobin,
 
23-102% increase)
 
32 Human 90 d Holly 1955
Gastro 0.5 (gastric intolerance)
(C)	 Chloride 
Hemato 0.6 
Hepatic 0.6 
33 Human NR Morin et al. 1971 
Resp 0.04 (edema)
(W)	 Sulfate 
Cardio	 0.04 (beer-cobalt cardiomyopathy) 
Gastro 0.04	 (vomiting, nausea) 
Hepatic 0.04	 (necrosis) 
107
0.54
108
0.16
109
3.79
110
4.2
a
Key to Species 
figure (Strain) 
34 Human 
35 Human 
36 Rat 
(Sprague-
Dawley) 
37 Rat 
Table 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral (continued) 
Exposure/ 
Duration/ 
Frequency 
(Specific Route) System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
10-25 d 1x/d 
(C) 
Other 0.54 (decreased Iodine uptake) 
12-32 wk 7d/wk 
(C) 
Hemato 0.16 
b 
(increased hemoglobin) 
4 wk 
(F) 
Bd Wt 3.79 M (45-65% reduction in body 
weight gain) 
8 wk 1x/d 
(F) 
Bd Wt 4.2 (33% decrease in body weight 
gain) 
Reference 
Chemical Form 
Paley et al. 1958 
Taylor et al. 1977 
Chloride 
Chetty et al. 1979 
Chloride 
Clyne et al. 1988 
111
30.2
30.2
30.2
30.2
30.2
30.2
30.2
112
26
113
8.4
a
Key to 
figure 
Species 
(Strain) 
LOAEL 
Less SeriousNOAEL 
System 
Table 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral 
(mg/kg/day) (mg/kg/day) 
Exposure/ 
Duration/ 
Frequency 
(Specific Route) 
Serious 
(mg/kg/day) 
(continued) 
Reference 
Chemical Form 
38 Rat 3 mo 
(W) 
Resp 30.2 (increased lung weight 33%) 
Domingo et al. 1984 
Cardio 
Gastro 30.2 
30.2 (increased heart weight 9.4%) 
Hemato 
Musc/skel 
Hepatic 
Renal 
30.2 
30.2 
30.2 
30.2 (increased hematocrit 29%)c 
39 Rat 8 wk 
(F) 
Cardio 26 (degeneration) 
Grice et al. 1969 
40 
(Sprague-
Dawley) 
Rat 24 wk 
(F) 
Cardio 8.4 M (Left ventricular hypertrophy 
and impaired ventricular 
function) 
Haga et al. 1996 
Sulfate 
18
114
18
18
18
18
18
0.05
115
0.5
2.5
116
12.4
12.4
a
Key to 
figure 
Species 
(Strain) 
LOAEL 
Less SeriousNOAEL 
System 
Table 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral 
(mg/kg/day) (mg/kg/day) 
Exposure/ 
Duration/ 
Frequency 
(Specific Route) 
Serious 
(mg/kg/day) 
(continued) 
Reference 
Chemical Form 
41 Rat 4 mo 
(G) 
Resp 18 
Holly 1955 
Chloride 
Cardio 18 
Gastro 
Hemato 
Hepatic 
Renal 
18 
18 
18 
b 
(erythrocytosis) 
18 (tubular necrosis) 
42 Rat 7 mo 6 d/wk 
(GW) 
Hemato 0.05 0.5 (increased RBC, hemoglobin) 
b Krasovskii and Fridlyand 1971 
Hepatic 2.5 
43 
CFY 
Rat 3 wk 
(G) 
Cardio 12.4 M (Incipient, multifocal 
myocytolysis, with degeneration 
of myofibrilles) 
Morvai et al. 1993 
Chloride 
Bd Wt 12.4 M (Decreased body weight 8%) 
117
10
10
10
10
8.4
118
8.4
10.6
119
10.6
Table 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral (continued) 
a
Key to 
figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Specific Route) System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form 
44 Rat 150 d 5 d/wk 
(GW) 
Hemato 10 
b 
(increased hemoglobin) 
Murdock 1959 
Chloride 
Hepatic 10 (increased weight 17%) 
Renal 10 (necrosis of tubular lining cells) 
Bd Wt 10 
45 
(Sprague-
Dawley) 
Rat 8 wk 
Hemato 8.4 M 
Pehrsson et al. 1991 
Sulfate 
Bd Wt 8.4 M (>20% decrease from 
appropriate control) 
46 
(Sprague-
Dawley) 
Rat 12-16 d 
(W) 
Bd Wt 10.6 M 
Saker et al. 1998 
Chloride 
Metab 10.6 M (Decreased serum glucose 
levels in diabetic rats, but not 
control rats) 
0.6
120
2.5
20
121
100
122
26
123
20
20
124
5
109
3.79
Table 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral (continued) 
Exposure/ LOAEL 
Duration/
a
Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
47 Rat 6 wk 7 d/wk b Stanley et al. 1947
Hemato 0.6 2.5 (polycythemia)
(C) Chloride 
48 3 d 
(Long- Evans) (F) 
Rat 
Bd Wt 20 M 100 M (<20% reduction of body 
weights) 
Wellman et al. 1984 
Chloride 
49 
Parkes 
Mouse 45 d 
(W) 
Endocr 26 F (Necrosis and inflammation  of 
thyroid) 
Shrivastava et al. 1996 
Chloride 
50 Gn Pig 5 wk 
(F) 
Cardio 20 (cardiomyopathy) 
Mohiuddin et al. 1970 
Bd Wt 20 
51 Dog 4 wk 7 d/wk 
(F) 
Hemato 5 
b 
(polycythemia) 
Brewer 1940 
Immuno/ Lymphoret 
52 
(Sprague-
Dawley) 
Rat 4 wk 
(F) 
3.79 M (Atrophy of the thymus) 
Chetty et al. 1979 
Chloride 
0.05
125
0.5
126
20
127
20
0.05
128
0.5
2.5
129
4.96
5
130
20
a
Key to 
figure 
Species 
(Strain) 
LOAEL 
Less SeriousNOAEL 
System 
Table 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral 
(mg/kg/day) (mg/kg/day) 
Exposure/ 
Duration/ 
Frequency 
(Specific Route) 
Serious 
(mg/kg/day) 
(continued) 
Reference 
Chemical Form 
53 Rat 7 mo 6 d/wk 
(GW) 
0.05 0.5 (decreased phagocytic ability) 
Krasovskii and Fridlyand 1971 
Chloride 
54 
Neurological 
57 d 
(W)(Sprague-
Dawley) 
Rat 
20 M (Increased latency during 
retention testing) 
Bourg et al. 1985 
Chloride 
55 Rat 57 d 
(W) 
20 (increased reactivity) 
Bourg et al. 1985 
Chloride 
56 Rat 7 mo 6 d/wk 
(GW) 
0.05 0.5 (mildly increased latent reflex) 2.5 (pronounced increase in latent 
reflex) 
Krasovskii and Fridlyand 1971 
Chloride 
57 
(Wistar) 
Rat 30 d 
(W) 
4.96 M (Alterations in 
sympathetically-induced 
contractility of vas deferens) 
Mutafova-Yambolieva et al. 1994 
Chloride 
58 Rat 69 d 
(F) 
5 20 (changes in schedule training, 
conditioned suppression, and 
mixed schedule training tests) 
Nation et al. 1983 
131
6.44
20
132
100
551
20
550
30.2
133
13.25
5
134
20
Table 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral (continued) 
Exposure/ LOAEL 
a
Key to 
figure 
Duration/ 
Frequency 
(Specific Route)
Species 
(Strain) System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
59 30 d 
(W)(Wistar) 
Rat 
6.44 M (Alterations in cholinergic 
sensitivity) 
60 3 d 
(Long- Evans) (F) 
Rat 
20 M 100 M (Saccharin and food aversion) 
Reproductive 
61 98 days 
(F)(Sprague-
Dawley) 
Rat 
62 90 d 
(W)(Sprague-
Dawley) 
Rat 
30.2 M 26% decrease in testicular 
weight 
63 98 d 7 d/wk 
(F) 
Rat 
64 69 d 
(F) 
Rat 
5 
Reference
 
(mg/kg/day) Chemical Form
 
Serious 
Vassilev et al. 1993 
Nitrate 
Wellman et al. 1984 
Chloride 
Corrier et al. 1985
20 M Pronounced histologic alteration
 
of seminiferous tubules Chloride
 
Domingo et al. 1984 
Chloride 
Mollenhauer et al. 1985
13.25 (testicular degeneration) 
Nation et al. 1983
20 M (testicular atrophy)
 
Chloride
 
135
43.4
136
43.4
137
23
138
58.9
0.6
139
Table 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral (continued) 
Exposure/ LOAEL
 
Duration/

a
Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
65 Mouse 13 wk Anderson et al. 199243.4 M (Irreversible testicular
 
(CD-1) (W) Chloride
degeneration) 
66 Mouse 13 wk Anderson et al. 199343.4 M (Testicular degeneration)
 
(CD-1) (W) Chloride
 
67 Mouse 13 wk Pedigo et al. 1988
23 (reversible testicular
(W) Chloridedegeneration) 
68 Mouse 10 wk Pedigo et al. 199358.9 M (Reduced pregnant females and
 
(B6C3F1) (W) pups per litter; reduced fertility) Chloride
 
Developmental 
69 Human 90 d Holly 1955
0.6
(C) Chloride 
   
141
5.4
Table 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral (continued) 
Exposure/ LOAEL
 
Duration/

a
Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
70 Rat Gd 14- Ld 21 Domingo et al. 19855.4 (stunted pup growth)
(G) Chloride 
a The number corresponds to entries in Figure 3-2.
 
b An increase in hemoglobin or red blood cells is not necessarily considered an adverse effect.
 
c Used to derive an intermediate oral MRL; concentration was divided by an uncertainty factor of 100 (10 for use of a LOAEL and 10 for human variability), resulting in an MRL of 0.01 
mg/kg/day. 
Bd Wt = body weight; (C) = capsule; Cardio = cardiovascular; d = day(s); Endocr = endocrine; (F) = feed; F = female; (G) = gavage; Gd = gestation day; (GO) = gavage oil; (GW) = 
gavage-water, Gastro = gastrointestinal; Hemato = hematological; hr = hour(s); Ld = lactation day; LD50 = dose producing 50% death; LOAEL = lowest-observed-adverse-effect 
level; M = male; Metab = metabolism; mo = month(s); NOAEL = no observed-adverse-effect level; NS = not specified; (W) = drinking water; wk = week(s); x = times. 
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Figure 3-2. Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral 
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Figure 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral (Continued) 
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Figure 3-2 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral (Continued) 
Intermediate (15-364 days) 
mg/kg/day 
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A significant increase in the weight of the lungs, without morphological or histological changes, was 
found in rats that received 30.2 mg cobalt/kg/day as cobalt chloride in drinking water for 3 months, as 
compared with controls (Domingo et al. 1984).  No morphological changes were seen in the lungs of rats 
treated with 18 mg cobalt/kg/day for 4 months (Holly 1955). 
Cardiovascular Effects. Beer-cobalt cardiomyopathy was observed in people who heavily 
consumed beer containing cobalt sulfate as a foam stabilizer (Alexander 1969, 1972; Bonenfant et al. 
1969; Kesteloot et al. 1968; Morin et al. 1967, 1971; Sullivan et al. 1969).  The beer drinkers ingested an 
average of 0.04 mg cobalt/kg/day (Morin et al. 1971, n=50) to 0.14 mg cobalt/kg/day for a period of years 
(Alexander 1969, 1972, n=28).  The cardiomyopathy was characterized by sinus tachycardia, left 
ventricular failure, cardiogenic shock, diminished myocardial compliance, absence of a myocardial 
response to exercise or catecholamine, enlarged heart, pericardial effusion, and extensive intracellular 
changes (changes in the myofibers, mitochondria, glycogen, and lipids).  The beer-cobalt cardiomyopathy 
appeared to be similar to alcoholic cardiomyopathy and beriberi, but the onset of beer-cobalt 
cardiomyopathy was very abrupt.  It should be noted, however, that the cardiomyopathy may have also 
been due to the fact that the beer-drinkers had protein-poor diets and may have had prior cardiac damage 
from alcohol abuse.  Treatment of both pregnant and nonpregnant anemic patients for 90 days with doses 
of cobalt (0.6–1 mg/kg/day as cobalt chloride) that were much higher than the doses in the beer did not 
result in effects on the heart (Davis and Fields 1958; Holly 1955). 
Approximately 40–50% of the patients admitted to the hospital with cardiomyopathy died within several 
years of diagnosis.  In a followup study of four different sites, 0–43% of the survivors, depending on the 
site, showed a residual cardiac disability and 23–41% had abnormal electrocardiograms (Alexander 
1972). 
In an experiment designed to simulate conditions leading to beer-cobalt cardiomyopathy in humans, 
guinea pigs were given 20 mg cobalt/kg/day as cobalt sulfate by gavage either alone or in combination 
with ethanol (as part of a liquid diet) for 5 weeks (Mohiuddin et al. 1970).  The experiment resulted in 
cardiomyopathy, which was characterized by abnormal EKGs; increased heart weights; lesions involving 
the pericardium, myocardium, and endocardium; and disfigured mitochondria.  Alcohol did not intensify
the cardiac effects. Myocardia changes (proliferative interstitial tissue, swollen muscle fibers, and focal 
degeneration) were also found in rats following a single dose of 176.6 mg cobalt/kg administered by
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gavage as cobalt fluoride or a single dose of 795 mg cobalt/kg administered as cobalt oxide (Speijers et al. 
1982). 
Three weeks of exposure to 12.4 mg cobalt/kg/day as cobalt chloride in male rats resulted in cardiac 
damage, presenting as incipient, multifocal myocytolysis, with degeneration of myofibrilles (Morvai et al. 
1993).  After longer-term exposure (2–3 months) of rats to 26–30.2 mg cobalt/kg/day as cobalt sulfate in 
the diet or as cobalt chloride in the drinking water, degenerative heart lesions (Grice et al. 1969) and an 
increase in heart weight were found (Domingo et al. 1984).  Exposure of rats to 8.4 mg cobalt/kg/day as 
cobalt sulfate resulted in left ventricular hypertrophy and impaired left ventricular systolic and diastolic 
functions in an isolated working rat heart model (Haga et al. 1996).  Clyne et al. (2001) reported that 
exposure of rats to 8.4 mg cobalt/kg/day, as cobalt sulfate, in the diet for 24 weeks resulted in significant 
reductions in a number of enzymes in cardiac tissues, including manganese-superoxide dismutase, 
succinate-cytochrome c oxidase, NADH-cytochrome c reductase, and cytochrome c oxidase, as well as 
reducing the mitochondrial ATP production rate. 
Gastrointestinal Effects.    The first signs of the beer-cobalt cardiomyopathy syndrome were 
gastrointestinal effects and included nausea, vomiting, and diarrhea (Morin et al. 1971).  Signs of heart 
failure subsequently appeared.  These individuals had ingested an average of 0.04 mg cobalt/kg/day for a 
period of years during which cobalt sulfate was added to beer as a foam stabilizer; however, it is likely
that alcohol consumption was also a factor. 
In pregnant women given cobalt supplements (alone or combined with iron) to prevent the decrease in 
hematocrit and hemoglobin levels commonly found during pregnancy (n=78), a small percentage of those 
treated complained of gastric intolerance (Holly 1955).  The women were treated with 0.5–0.6 mg
cobalt/kg/day as cobalt chloride for 90 days.  Nausea was reported in one anemic patient following 
treatment with 0.18 mg cobalt/kg/day as cobalt chloride (Duckham and Lee 1976b). 
No morphological changes in the gastrointestinal system were observed following exposure of 20 male 
rats for 3 months to 30.2 mg cobalt/kg/day as cobalt chloride in the drinking water (Domingo et al. 1984)
or exposure for 4 months to 18 mg cobalt/kg/day as cobalt chloride by gavage (Holly 1955). 
Hematological Effects. Cobalt has been shown to stimulate the production of red blood cells in 
humans.  Davis and Fields (1958) exposed six apparently normal men, ages 20–47, to a daily dose of 
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cobalt chloride, administered as a 2% solution diluted in either water or milk, for up to 22 days.  Five of 
the six received 150 mg cobalt chloride per day for the entire exposure period, while the sixth was started 
on 120 mg/day and later increased to 150 mg/day.  Blood samples were obtained daily from free-flowing 
punctures of fingertips at least 2 hours after eating, and at least 15 hours after the last dosage of cobalt.  
Blood was analyzed for red blood cell counts, hemoglobin percentage, leukocyte counts, reticulocyte 
percentages, and thrombocyte counts.  Exposure to cobalt resulted in the development of polycythemia in 
all six subjects, with increases in red blood cell numbers ranging from 0.5 to 1.19 million (~16–20% 
increase above pretreatment levels).  Polycythemic erythrocyte counts returned to normal 9–15 days after 
cessation of cobalt administration.  Hemoglobin levels were also increased by cobalt treatment, though to 
a lesser extent than the erythrocyte values, with increases of 6–11% over pretreatment values.  In five of 
the six subjects, reticulocyte levels were elevated, reaching at least twice the pre-experiment values.  
Thrombocyte and total leukocyte counts did not deviate significantly from pretreatment values.  From the 
LOAEL of 1 mg/kg-day identified by this study, an intermediate-duration oral MRL of 1x10-2 mg/kg-day
was derived (for derivation, see Section 2.3 and Appendix A). 
Increased levels of erythrocytes were also found following oral treatment of anephric patients (with 
resulting anemia) with 0.16–1.0 mg cobalt/kg/day daily as cobalt chloride for 3–32 weeks (Duckham and 
Lee 1976b; Taylor et al. 1977).  The increase in hemoglobin resulted in a decreased need for blood 
transfusions. Treatment of pregnant women for 90 days with 0.5–0.6 mg cobalt/kg/day as cobalt chloride, 
however, did not prevent the reduction in hematocrit and hemoglobin levels often found during pregnancy
(Holly 1955).
Significantly increased erythrocyte (polycythemia), hematocrit, and hemoglobin levels were found in
animals treated orally with cobalt chloride as a single dose of 161 mg cobalt/kg (Domingo and Llobet 
1984) or with longer-term exposure (3 weeks to 2 months) to ≥0.5 mg/kg/day (Brewer 1940; Davis 1937; 
Domingo et al. 1984; Holly 1955; Krasovskii and Fridlyand 1971; Murdock 1959; Stanley et al. 1947).  
Of particular note is an 8-week study in rats (Stanley et al. 1947), which reported dose- and time-related 
increases in erythrocyte number following oral administration of cobalt chloride, with an apparent 
NOAEL of 0.6 mg cobalt/kg/day and a LOAEL of 2.5 mg cobalt/kg/day.  Changes in the levels of other 
blood proteins (transferrin, several haptoglobulins, and ceruloplasmin) were noted in male Swiss mice 
following 4, 24, and 48 hours of treatment with 76.4 mg cobalt/kg as cobalt chloride in the drinking water 
(Bryan and Bright 1973). Exposure for 3 weeks or 3 months to 76.4 mg cobalt/kg as cobalt chloride in 
the drinking water resulted in no alterations in serum proteins examined. 
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Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans after 
oral exposure to cobalt. 
No morphological changes were found in the skeletal muscle of rats exposed to 30.2 mg cobalt/kg/day as 
cobalt chloride in the drinking water for 3 months (Domingo et al. 1984).  This NOAEL in rats for 
intermediate-duration exposure is reported in Table 3-2 and plotted in Figure 3-2.
Hepatic Effects. Liver injury was evident in patients with beer-cobalt cardiomyopathy, characterized 
by central hepatic necrosis accompanied by increased levels of serum bilirubin and serum enzymes 
(serum glutamic oxaloacetic transaminase [SGOT], serum glutamic pyruvic transaminase [SGPT], lactate 
dehydrogenase [LDH]), creatine phosphokinase, ornithine carbamyl transferase, isocitric dehydrogenase, 
aldolase) (Alexander 1972; Morin et al. 1971).  The hepatic injury may have resulted from ischemia, 
secondary to the cardiac effects of cobalt, and/or from excessive alcohol consumption. The 
cardiomyopathy resulted from the ingestion of beer containing 0.04 mg cobalt/kg/day as cobalt sulfate 
that had been added as a foam stabilizer (Morin et al. 1971).  Liver function tests were found to be normal 
in pregnant women receiving up to 0.6 mg cobalt/kg/day as cobalt chloride for 90 days for treatment of 
the decreases in hematocrit and hemoglobin levels commonly found during pregnancy (Holly 1955). 
Data from animals have also indicated that cobalt has hepatic effects.  Hyperemia of the liver and 
cytoplasmic changes in hepatocytes (clumpy cytoplasm located along the cell membrane) were found in
rats administered a single dose of 68.2 mg cobalt/kg as cobalt fluoride or a single dose of 157.3 mg
cobalt/kg as cobalt oxide (Speijers et al. 1982). 
Increased liver weight (17%) was found in rats exposed to 10 mg cobalt/kg/day (as cobalt chloride) for 
5 months (Murdock 1959).  No morphological or enzymatic changes were found in the livers of rats 
exposed to 2.5–30.2 mg cobalt/kg as cobalt chloride by gavage or as cobalt chloride in the drinking water 
for 3–7 months (Domingo et al. 1984; Holly 1955; Krasovskii and Fridlyand 1971). 
Renal Effects. No studies were located regarding renal effects in humans after oral exposure to 
cobalt. 
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Acute and prolonged exposure to cobalt results in renal tubular degeneration in rats.  Renal injury, 
evidenced by histologic alteration of the proximal tubules, was observed in rats after a single oral 
exposure to 42 mg cobalt/kg as cobalt fluoride (Speijers et al. 1982) and after exposure to 10–18 mg
cobalt/kg/day as cobalt chloride for 4–5 months (Holly 1955; Murdock 1959).  A slightly decreased 
urinary output was observed in rats exposed to 19.4 mg cobalt/kg as cobalt sulfate, but not in rats exposed 
to 4.25 mg cobalt/kg as cobalt chloride (Singh and Junnarker 1991). 
Endocrine Effects. Roy et al. (1968) reported on 20 Québécois patients who died of beer drinkers’ 
myocardosis.  Of these, 14 thyroids were available for examination.  Three of those were normal, and the 
other 11 formed the basis of the study.  “Abnormal” thyroids did not show gross changes, but upon 
histologic examination, they showed irregular follicle morphology and decreased follicular size. 
Kriss et al. (1955) reported on five patients who had been receiving cobalt therapy for sickle-cell anemia
or renal amyloidosis.  Three of five developed goiter, one severe, while four of five showed microscopic 
alterations of the thyroid gland.  Two of the patients died from non-cobalt-related causes, while the other 
three recovered once cobalt treatment was removed.  A similar study was reported by Gross et al. (1955) 
in which stable cobalt was used therapeutically in four cases of sickle-cell anemia.  Treatment with cobalt 
resulted in an enlargement of the thyroid gland, which was reversible upon cessation of cobalt therapy.
Similar effects on the thyroid, including enlargement, hyperplasia, and an increased firmness, have been 
reported in several other cases where cobalt therapy for anemia was used (Chamberlain 1961; Little and 
Sunico 1958; Soderholm et al. 1968; Washburn and Kaplan 1964).  No other studies examining the 
endocrine effects of stable cobalt in humans were located. 
NTP (1998; Bucher et al. 1999) reported increased incidence of pheochromocytoma, a tumor of the 
adrenal medulla, in female rats exposed to 1.14 mg cobalt/m3 for 2 years, but did not measure any other 
endocrine effects. Female mice exposed to 26 mg cobalt/kg-day in the drinking water for up to 45 days
showed histopathological changes to the thyroid gland (Shrivastava et al. 1996).  Cobalt significantly
stimulated serum testosterone in mice treated orally with 23 mg cobalt/kg as cobalt chloride, though no 
dose-response relationship was present (Pedigo et al. 1988). 
Dermal Effects.    Allergic dermatitis has been reported in some cobalt-sensitized people following oral 
challenge with cobalt. Several patients with eczema of the hands were challenged orally with 1 mg cobalt 
as cobalt sulfate given in tablet form once per week for 3 weeks (0.014 mg/kg/day).  A flaring of the 
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eczema was considered to be a positive allergic response to cobalt (Veien et al. 1987).  No other studies 
were located regarding dermal effects in humans or animals after oral exposure to cobalt. 
Ocular Effects.    Severe visual disturbances (optic atrophy, impaired choroidal perfusion) developed in 
a man who was treated with cobalt chloride for pancytopenia and hypercellular bone marrow (Licht et al. 
1972). He received 1.3 mg cobalt/kg daily for four series of treatments with a total duration of 6 weeks.  
However, no other cases of visual disturbances due to therapeutic administration of cobalt have been 
reported, and no such effects have been observed in animals. 
Body Weight Effects.    No effects on body weight in animals were found following longer-term (1– 
5 months) exposure of rats to 10–30.2 mg cobalt/kg/day as cobalt chloride (Bourg et al. 1985; Domingo et 
al. 1984; Murdock 1959) or of guinea pigs to 20 mg cobalt/kg/day as cobalt sulfate (Mohiuddin et al. 
1970). A significant decrease (33%) in body weight gain was observed following 8 weeks of exposure of 
rats to 4.2 mg cobalt/kg/day as cobalt sulfate (Clyne et al. 1988). 
Metabolic Effects. Treatment of rats with 10.6 mg Co/kg/day as CoCl2 in the drinking water for 12– 
16 days resulted in a significant decrease in serum glucose levels in diabetic rats, but not in control rats 
(Saker et al. 1998). 
Other Systemic Effects.    Hypothermia occurred in rats following a single oral dose of 157 mg
cobalt/kg given as cobalt oxide or a single oral dose of 110 mg cobalt/kg given as cobalt fluoride (Speijers 
et al. 1982). The hypothermia was time- and dose-related.  Hypothermia was reported as an effect during 
LD50 studies with other cobalt compounds, but the exact dose for the onset of hypothermia with these 
compounds was not reported (Speijers et al. 1982). Other physiological signs noted in LD50 studies 
include decreased activity, ataxia, diarrhea, and salivation (FDRL 1984a, 1984b). 
3.2.2.3 Immunological and Lymphoreticular Effects  
Cobalt is known to function as a hapten, resulting in the generation of antibodies against cobalt-protein 
complexes.  Allergic dermatitis has been reported in some cobalt-sensitized people following oral 
challenge with cobalt. Several patients with eczema of the hands were challenged orally with 1 mg cobalt 
as cobalt sulfate given in tablet form once per week for 3 weeks (0.014 mg/kg/day).  A flaring of the 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COBALT  80 
3. HEALTH EFFECTS 
eczema was considered to be a positive allergic response to cobalt (Veien et al. 1987).  Using both the 
oral challenge test and dermal patch tests, it was determined that the cobalt allergy was systemically
induced. The exposure level associated with sensitization to cobalt was not established.  After 
sensitization, allergic reactivity may be independent of dose.  Cobalt has been found to be a sensitizer 
following inhalation exposure (Section 3.2.1.3).  This LOAEL value was not reported in Table 3-2 
because sensitized individuals only represent a small percent of the population. 
A case report of a 6-year-old boy who had ingested approximately 1.7 mg of cobalt chloride reported 
neutropenia by 7 hours post-exposure (Mucklow et al. 1990).   
Thymic atrophy was reported in male Sprague-Dawley rats exposed to 3.79 mg cobalt/kg/day as cobalt 
chloride in the feed for 4 weeks (Chetty et al. 1979).  A deterioration in immunological reactivity, 
manifested by a decline in phagocytic activity, was reported in rats following 6–7 months of treatment 
with 0.5 mg cobalt/kg or greater as cobalt chloride (Krasovskii and Fridlyand 1971).  This value is 
presented in Table 3-2 and Figure 3-2. 
3.2.2.4 Neurological Effects 
No studies were located regarding neurological effects in humans after oral exposure to stable cobalt. 
Several rodent studies have identified neurological effects following cobalt exposure.  In Wistar rats, a 
single gavage dose of 4.25 mg cobalt/kg as cobalt chloride resulted in a moderate reduction in 
spontaneous activity, muscle tone, touch response, and respiration, while 19.4 mg cobalt/kg as cobalt 
sulfate caused a mild reduction the same parameters (Singh and Junnarkar 1991).  In rats exposed to 
4.96 mg cobalt/kg/day as cobalt chloride for 30 days in the drinking water, cobalt led to changes in 
sympathetically mediated contractile activity of isolated rat vas deferens (Mutafova-Yambolieva et al. 
1994). Rats exposed to 6.44 mg cobalt/kg/day as cobalt nitrate in the drinking water showed an increased 
sensitivity and decreased maximal response to a cholinergic agonist (Vassilev et al. 1993).  In rats 
exposed to 20 mg cobalt/kg/day as cobalt chloride for 57 days in the drinking water, cobalt enhanced 
behavioral reactivity to stress (the animals were less likely to descend from a safe platform to an 
electrified grid) (Bourg et al. 1985).  Rats exposed to the same dose in the diet for 69 days showed a 
slower rate of lever pressing than controls, but no change in behavioral reactivity to stress (Nation et al. 
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1983). Longer-term exposure of rats to cobalt chloride (7 months) resulted in a significant increase in the 
latent reflex period at ≥0.5 mg cobalt/kg as cobalt chloride and a pronounced neurotropic effect (disturbed 
conditioned reflexes) at 2.5 mg cobalt/kg (Krasovskii and Fridlyand 1971). 
The NOAEL value and the LOAEL value for rats for intermediate duration are reported in Table 3-2 and 
plotted in Figure 3-2. 
3.2.2.5 Reproductive Effects  
No studies were located regarding reproductive effects in humans after oral exposure to stable cobalt. 
Testicular degeneration and atrophy have been reported in rats exposed to 13.3–58.9 mg cobalt/kg/day as 
cobalt chloride for 2–3 months in the diet or drinking water (Corrier et al. 1985; Domingo et al. 1984;
Mollenhauer et al. 1985; Nation et al. 1983; Pedigo and Vernon 1993; Pedigo et al. 1988), or in mice 
exposed to 43.4 mg cobalt/kg/day as cobalt chloride for 13 weeks in the drinking water (Anderson et al. 
1992, 1993). 
The highest NOAEL and all reliable LOAEL values for rats in the intermediate-duration category are 
reported in Table 3-2 and plotted in Figure 3-2. 
3.2.2.6 Developmental Effects 
No developmental effects on human fetuses were observed following treatment of pregnant women with 
cobalt chloride to raise hematocrit and hemoglobin levels that are often depressed during pregnancy.
Dosages up to 0.6 mg cobalt/kg/day for 90 days were given (Holly 1955).  Examination of the fetuses, 
however, was limited to the reporting of obvious birth defects, and exposure only occurred in the final 
trimester. 
Oral exposure of female rats to cobalt chloride at 5.4 or 21.8 mg cobalt/kg/day from gestation 
day 14 through lactation day 21 has been shown to result in stunted growth and decreased survival, 
respectively, of newborn pups (Domingo et al. 1985b).  The effects on the offspring occurred at levels 
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that also caused maternal toxicity (reduced body weight and food consumption, and altered hematological 
measurements) and might therefore have been an indirect effect of maternal toxicity rather than a direct 
effect of cobalt on the fetus (Domingo et al. 1985b).  Teratogenic effects were not observed. 
Szakmary et al. (2001) reported that exposure of pregnant rats to 0–38 mg Co/kg-day as cobalt sulfate did 
not result in changes in fetal death rates, maternal body weigh gain, average litter size, or average fetal or 
placental weights; however, a dose-related trend was seen for the percent of fetuses with retarded body 
weights. In contrast, no effects on fetal growth or survival were found following exposure of rats to 
24.8 mg cobalt/kg/day as cobalt chloride during gestation days 6–15 (Paternian et al. 1988).  In mice, 
exposure to 81.7 mg cobalt/kg/day as cobalt chloride during gestation days 8–12 was reported to have no 
effect on fetal growth or mortality in mice (Seidenberg et al. 1986).  In a later mouse study that exposed 
pregnant mice to 19 mg Co/kg-day as cobalt sulfate, no changes in litter size, postimplantation loss, or 
average fetal or placental weights were seen; the only difference seen was an increase in the percent of 
fetuses with retarded body weights (Szakmary et al. 2001).  The same study reported that rabbits exposed 
to ≥ 38 mg Co/kg-day, as cobalt sulfate, showed nearly complete maternal lethality, and complete fetal 
loss. Rabbits exposed to 7.6 mg Co/kg, as cobalt sulfate, showed significant increases in mortality and 
fetal resorption, as well as an increase in fetuses with retarded body weight (Szakmary et al. 2001).  The 
highest NOAEL and all reliable LOAEL values for each species and duration category are reported in 
Table 3-2 and plotted in Figure 3-2. 
3.2.2.7 Cancer 
In a survey assessing the correlation between cancer mortality and trace metals in water supplies 
(10 basins) throughout the United States, no correlation was found between cancer mortality and the level 
of cobalt in the water (Berg and Burbank 1972).  Cobalt levels of 1–19 µg/L, with resulting human 
intakes ranging from 0.03 to 0.54 µg/kg/day, were reported. 
No studies were located regarding carcinogenic effects in animals after oral exposure to stable cobalt. 
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3.2.3 Dermal Exposure  
3.2.3.1 Death 
No studies were located regarding lethal effects in humans after dermal exposure to cobalt. 
No mortality was observed in guinea pigs dermally exposed to 51.75 mg cobalt/kg for 5 days/week as 
dicobalt octacarbonyl for a total of 18 applications (Kincaid et al. 1954). 
3.2.3.2 Systemic Effects  
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological,
musculoskeletal, hepatic, renal, or ocular effects in humans or animals after dermal exposure to stable 
cobalt. 
Dermal Effects.    Dermatitis is a common result of dermal exposure to cobalt in humans that has been 
verified in a large number of studies (Alomar et al. 1985; Bedello et al. 1984; Dooms-Goossens et al. 
1980; Fischer and Rystedt 1983; Goossens et al. 2001; Kanerva et al. 1988, 1998; Kiec-Swierczyńska and 
Krecisz 2002; Marcussen 1963; Minamoto et al. 2002; Pryce and King 1990; Swennen et al. 1993; 
Romaguera et al. 1982; Valer et al. 1967).  Using patch tests and intradermal injections, it has been 
demonstrated that the dermatitis is probably caused by an allergic reaction to cobalt.  Contact allergy was 
reported in 22 of 223 (9.9%) nurses who were tested with a patch test of 1.0% cobalt chloride (Kieć­
Świerczyńska and Kręcisz 2000), as well as 16 of 79 (20.3%) of examined dentists (Kieć-Świerczyńska 
and Kręcisz 2002).  Persons with body piercings showed an increased prevalence of allergy to cobalt, 
with the incidence of contact allergy being proportional to number of piercings (Ehrlich et al. 2001).  The 
prevalence of sensitivity to cobalt following exposure to cobalt as a component of metal implants is low, 
with only 3.8% of patients developing a new sensitivity to cobalt following insertion of the implant 
(Swiontkowski et al. 2001). Exposure levels associated with the development of dermatitis have not been 
identified. It appears that the allergic properties of cobalt result mainly from exposure to the metal itself, 
rather than a salt, as Nielsen et al. (2000) demonstrated that daily repeated exposure to aqueous cobalt 
salts did not result in hand eczema in patients known to have cobalt allergy. 
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In animals, scabs and denuded areas were found after six doses of 51.75 mg cobalt/kg (5 days/week) as 
dicobalt octacarbonyl were applied to the shaved abdomens (uncovered area of approximately 50 cm2) of 
guinea pigs (Kincaid et al. 1954).  By the 11th dose, the lesions disappeared.  No adverse effects were 
observed in vehicle controls (methyl ethyl ketone).  It is not known whether or not a similar reaction 
would result from metallic or inorganic forms of cobalt.  This LOAEL value is reported in Table 3-3. 
3.2.3.3 Immunological and Lymphoreticular Effects  
Cobalt-induced dermatitis is well documented in the literature, and the studies indicate that cobalt is a 
sensitizer (Alomar et al. 1985; Dooms-Goossens et al. 1980; Fischer and Rystedt 1983; Goh et al. 1986;
Kanerva et al. 1988; Marcussen 1963; Valer et al. 1967).  Patch testing and intradermal injections were 
performed, but exposure levels of cobalt were not reported.  Interrelationships exist between nickel and 
cobalt sensitization (Bencko et al. 1983; Rystedt and Fisher 1983); however, the extent of any potential 
interactions between the two metals on immunologic end points is not well understood.  In guinea pigs, 
nickel and cobalt sensitization appear to be interrelated and mutually enhancing (Lammintausta et al. 
1985), though cross-reactivity was not reported to occur. 
Single or multiple dermal exposures of BALB/c mice to CoCl2 in dimethylsulfoxide or in ethanol resulted 
in an increased cellular proliferation in the local lymph node assay in a concentration-dependant manner 
(Ikarashi et al. 1992a).  The effect of three consecutive exposures to varying concentrations of CoCl2 in 
DMSO on lymph node proliferation was measured in rats, mice, and guinea pigs (Ikarashi et al. 1992b).  
Stimulation Indices of 3 or greater, indicated by the authors as a significant response, were reported for 
mice exposed to 1, 2.5, or 5% CoCl2, rats exposed to 2.5 or 5% CoCl2, and guinea pigs exposed to 5%
CoCl2; these treatments resulted in dose levels of 10.8, 27, or 54.1 mg cobalt/kg/day for mice, 9.60 or 
19.2 mg cobalt/kg/day for rats, and 14.7 mg cobalt/kg/day for guinea pigs.  
No studies were located regarding the following health effects in humans or animals after dermal 
exposure to stable cobalt: 
mg/kg/day
mg/kg/day
142
mg/kg/day
143
mg/kg/day
mg/kg/day
144
mg/kg/day
mg/kg/day
145
mg/kg/day
146
LOAEL 
Table 3-3 Levels of Significant Exposure to Cobalt - Chemical Toxicity - Dermal 
Species 
(Strain) System NOAEL Less Serious 
Exposure/ 
Duration/ 
Frequency 
(Specific Route) 
ACUTE EXPOSURE 
Immuno/ Lymphoret 
(Fischer- 344) 
Rat 3.84 F 
mg/kg/day 
F 
(Increased proliferation of 
lymphatic cells) 
9.6 
mg/kg/day 
1x/d 3d 
Serious 
Reference 
Chemical Form 
Ikarashi et al. 1992b 
Chloride 
(BALB/c) 
Mouse 1x or 1x/d for 3 d F10.8 
mg/kg/day (Increased proliferation of lymphatic cells) 
Ikarashi et al. 1992a 
Chloride 
CBA/N 
Mouse 1x/d 3 d 5.4 F 
mg/kg/day 
F10.8 
mg/kg/day (Increased proliferation of lymphatic cells) 
Ikarashi et al. 1992b 
Chloride 
(Hartley) 
Gn Pig 1x/d 3 d 7.39 F 
mg/kg/day 
F14.7 
mg/kg/day (Increased proliferation of lymphatic cells) 
Ikarashi et al. 1992b 
Chloride 
INTERMEDIATE EXPOSURE 
Systemic 
(NS) 
Gn Pig 18 d 5 d/wk Dermal 51.75 
mg/kg/day (skin lesions (scabs and denuded areas) at 
application site) 
Kincaid et al. 1954 
d =day(s); F = female; LOAEL = lowest-observed-adverse-effect level; NOAEL = no observed-adverse-effect level; wk = week(s); x = times. 
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3.2.3.4 Neurological Effects 
3.2.3.5 Reproductive Effects  
3.2.3.6 Developmental Effects 
3.2.3.7 Cancer 
No studies were located regarding carcinogenic effects in humans or animals after dermal exposure to 
cobalt. 
3.2.4 Other Routes of Exposure 
Endocrine Effects. Patients (n=12) injected with a single diagnostic dose of radioactive iodine, and 
then treated 48 hours later with 1 mg cobalt/kg/day as cobalt chloride for 2 weeks, resulted in a greatly
reduced uptake of radioactive iodine by the thyroid in 1 week, with uptake nearing 0 by the second week 
(Roche and Layrisse 1956).  When the cobalt treatment ended, the uptake values returned to normal.  The 
decrease of radioactive iodine uptake found in patients administered 0.54 mg cobalt/kg/day for 10– 
25 days prior to iodine injection was found to result from cobalt blocking the organic binding of iodine 
(Paley et al. 1958).   
In various species of animals, parenteral administration of cobalt resulted in cytotoxic effects on the alpha 
cells of the pancreas (Beskid 1963; Goldner et al. 1952; Hakanson et al. 1974; Lacy and Cardeza 1958; 
Lazarus et al. 1953; Van Campenhout 1955).  Because this effect has never been reported in humans or 
animals following inhalation, oral, or dermal exposure to cobalt, the relevance of the effect to humans is 
not known.   
Moger (1983) exposed primary cultures of mouse Leydig cells to 0–2.5 mM cobalt as cobalt for 3 hours, 
and measured the effects on androgen production.  Cobalt exposure caused a dose-related decrease in both 
basal and LH-stimulated androgen production, with no effects on protein synthesis.  The author suggested 
that these effects are the result of cobalt inhibition of calcium influx across the plasma membrane. 
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3.3 	 DISCUSSION OF HEALTH EFFECTS OF RADIOACTIVE COBALT BY ROUTE OF 
EXPOSURE
Section 3.3 discusses radiation toxicity associated with exposure to radionuclides of cobalt and is 
organized in the same manner as that of Section 3.2, first by route of exposure (inhalation, oral, and 
external) and then by health effect  (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing NOAELs or LOAELs reflect the actual dose (levels of 
exposure) used in the studies.  Refer to Section 3.2 for detailed discussion of the classification of 
endpoints as a NOAEL, less serious LOAEL, or serious LOAEL. 
Refer to Appendix B for a User's Guide, which should aid in the interpretation of the tables and figures 
for Levels of Significant Exposure. 
3.3.1 Inhalation Exposure 
No studies were located regarding the following health effects in humans or animals after inhalation 
exposure to radioactive cobalt: 
3.3.1.1 Death 
3.3.1.2 Systemic Effects 
3.3.1.3 Immunological and Lymphoreticular Effects 
3.3.1.4 Neurological Effects 
3.3.1.5 Reproductive Effects 
3.3.1.6 Developmental Effects 
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3.3.1.7 Cancer 
3.3.2 Oral Exposure  
No studies were located regarding the following health effects in humans or animals after oral exposure to 
radioactive cobalt: 
3.3.2.1 Death 
3.3.2.2 Systemic Effects 
3.3.2.3 Immunological and Lymphoreticular Effects 
3.3.2.4 Neurological Effects 
3.3.2.5 Reproductive Effects 
3.3.2.6 Developmental Effects 
3.3.2.7 Cancer 
3.3.3 External Exposure 
This section contains information regarding health effects related to external exposure to radioactive 
cobalt sources. Radionuclides of cobalt may emit beta particles and/or gamma rays, which may be a 
health hazard in living organisms because they ionize the atoms that they hit while passing through the 
tissues of the body (see Table 3-4 and Figure 3-3).  Beta particles can travel appreciable distances in air, 
but travel only a few millimeters in solids.  External exposure to beta particles may result in damage to 
skin and superficial body tissues at sufficiently high doses.  Beta radiation is only a threat to internal 
organs if the radiation source is internalized.  Gamma radiation, on the other hand, can easily pass 
completely through the human body and cause ionization of atoms in its path.  For most radionuclides of 
public interest, the fraction of gamma rays that actually deposits energy and contributes to the radiation  
152
2250
155
627
156
1420
12.7
166
12.7
168
159
159
a
Key to 
figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Specific Route) System 
NOAEL 
(rad) 
Less Serious 
(rad) 
LOAEL 
Serious 
(rad) 
Reference 
Chemical Form 
ACUTE EXPOSURE 
Death 
1 Human 2250 M (Death) 
Stavem et al. 1985 
Table 3-4 Levels of Significant Exposure to Cobalt - Radiation Toxicity - External Radiation 
2 Mouse Darwezah et al. 1988627 (30-day LD50 value, single
(BALB/c) exposure) 
3 Mouse 1x Down et al. 19861420 M (Death) 
CBA/Ca.Lac.C 
Systemic 
4 Human (occup) House et al. 1992 
Gastro 12.7 
Hemato 12.7 
5 Human Klener et al. 1986 
Dermal 159 M (Severe alterations to skin of left 
hand) 
Ocular 159 M (Progressive occlusion of vision 
of left eye) 
171
2250
2250
2250
2250
172
1000
174
10000
176
2500
Table 3-4 Levels of Significant Exposure to Cobalt - Radiation Toxicity - External Radiation (continued) 
Exposure/ LOAEL
 
Duration/

a
Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (rad) (rad) (rad) Chemical Form 
6 Human Stavem et al. 1985 
Cardio 2250 M (left ventricular hypertrophy) 
Gastro 2250 M (Pronounced atrophy in 
intestines; less severe in 
stomach) 
Hemato 2250 M (>35% decrease in hemogolbin 
and >90% decrease in 
thrombocytes) 
Renal 2250 M (Enlarged kidneys) 
7 Monkey 30 min Bruner 1977 
Cardio 1000 M (Minor changes: increased heart 
(Rhesus) rate; decreased blood pressure; 
variable cardiac output and total 
peripheral resistance) 
8 Monkey 1 hr Cockerham et al. 1986 
Cardio 10000 M (Pronounced decreases in
 
(Rhesus) mean arterial blood pressure
 
and blood flow to the brain)
 
9 Rat Bezek et al. 1990 
Cardio 2500 M (Increased brain uptake index) 
(Wistar) 
178
1500
180
1000
182
1330
1800
186
1000
193
4355
195
800
a
Key to Species 
figure (Strain) 
10	 Rat 
(Sprague-
Dawley) 
11	 Mouse 
(Swiss-
Webster) 
12	 Mouse 
CBA/Ca.Lac.C 
13	 Mouse 
(Swiss-
Webster) 
14	 Dog 
(Mongrel) 
15	 Dog 
(Beagle) 
Table 3-4 Levels of Significant Exposure to Cobalt - Radiation Toxicity - External Radiation	 (continued) 
Exposure/ 
Duration/ 
Frequency 
(Specific Route) System 
NOAEL 
(rad) 
Less Serious 
(rad) 
LOAEL 
Serious 
(rad) 
1x 
Resp 1500 M (Severe inflammation, 
pulmonary histopathology, 
fibrosis) 
Gastro 1000 M (Intestinal crypt cell damage, 
including necrosis and altered 
mitotic figures) 
1x 
Resp 1330 M (Increased breathing rate) 
Dermal 1800 M (Mild epilation) 
24 hr 
Hepatic 1000 M (Transient decrease in total liver 
protein) 
198 d 
Cardio 4355 (Cardiac arrhythmia) 
10.44 min 
Gastro 800 (Repeated emesis) 
Reference 
Chemical Form 
Lafuma et al. 1987 
Devi et al. 1979 
Down et al. 1986 
Mazur et al. 1991 
Dick et al. 1979 
Gomez-de-Segura et al. 1998 
198
1730
200
900
1090
201
874
202
780 1190
780 980
203
557
a
Key to Species 
figure (Strain) 
16	 Rabbit 
(New 
Zealand) 
17	 Pig 
Large White 
18	 Pig 
Large White 
19	 Pig 
Large White 
20	 Pig 
Large White 
Table 3-4 Levels of Significant Exposure to Cobalt - Radiation Toxicity - External Radiation	 (continued) 
Exposure/	 LOAEL 
Reference 
Chemical Form 
Cox et al. 1981 
Rezvani et al. 1989 
Robbins et al. 1989a 
Robbins et al. 1989b 
Robbins et al. 1989c 
Duration/ 
Frequency 
(Specific Route) System 
NOAEL 
(rad) 
Less Serious 
(rad) 
1x 
Dermal 1730 M (Alopecia) 
1x 
Resp 900 F (Reversible decrease in 
ventilation capacity) 
1x 
Renal 
1x 
Hemato 780 F (Slight decreases in 
erythrocytes, hemoglobin, and 
hematocrit) 
Renal 780 F (Reversible changes in effective 
renal plasma flow and 
glomerular filtration rate) 
1x 
Renal 
Serious 
(rad) 
1090 F (Irreversible decrease in 
ventilation capacity, 
histopathology, pulmonary 
atrophy) 
874 F (50% loss in effective renal
 
plasma flow)
 
1190 F (Severe decreases in 
erythrocytes, hemoglobin, and 
hematocrit) 
980 F (Persistent changes in effective 
renal plasma flow and 
glomerular filtration rate) 
557 F (50% loss in effective renal
 
plasma flow)
 
204
980
206
3000
49
205
77
12.7
207
208
159
209
2250
Table 3-4 Levels of Significant Exposure to Cobalt - Radiation Toxicity - External Radiation (continued) 
Exposure/ LOAEL
 
Duration/

a
Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (rad) (rad) (rad) Chemical Form 
21 Pig 1x Robbins et al. 1991 
Renal 980 F (Progressive inflammatory and
 
Large White
 degenerative changes in the 
glomerulus) 
22 Baboon 3-4 wk, 1x/wk Collins et al. 1978 
Resp 3000 (Severe pulmonary fibrosis) 
23 Ferret 2 hr King 1988
Gastro 49 M 77 M (Emesis with wretching) 
Immuno/ Lymphoret 
24 Human (occup) House et al. 1992 
12.7 
25 Human Klener et al. 1986 
159 M (Minor reduction in white cell 
counts) 
26 Human Stavem et al. 19852250 M (Pronounced decrease in 
lymphocytes and granulocytes) 
210
1000
150
212
450
300
214
500
217
450
218
330
220
80
a
Key to 
figure 
Species 
(Strain) 
Less SeriousNOAEL 
System 
Table 3-4 Levels of Significant Exposure to Cobalt - Radiation Toxicity 
(rad) (rad) 
Exposure/ 
Duration/ 
Frequency 
(Specific Route) 
LOAEL 
Serious 
- External Radiation 
(rad) 
(continued) 
Reference 
Chemical Form 
27 
(Swiss-
Webster) 
Mouse 24 hr 
1000 M (>50% decrease in spleen 
weight and protein; increased 
spleen acid phosphatase) 
Mazur et al. 1991 
28 
Neurological 
140 d 
(CD) 
Rat 
150 M 450 M (Reversible deficits in fixed-ratio 
behavior parameters) 
Mele et al. 1988 
29 
(Swiss-
Webster) 
Mouse 97 d 
300 M 500 M (Reversible decreases in 
aggressive behavior) 
Maier and Landauer 1989 
30 
31 
12 hr 
Burgundy 
fawn 
Rabbit 
Reproductive 
1x 
(Sprague-
Dawley) 
Rat 
450 M (Altered firing rates and patterns 
of hippocampal neurons) 
330 M (Decreased testis weight and 
altered spermatogenesis, with 
some evidence of recovery) 
Bassant and Court 1978 
Cunningham and Huckins 1978 
32 
(Wistar) 
Rat 1x 
80 M (Reversible decrease in 
testicular weight) 
Laporte et al. 1985 
224
100
225
50
226
260
227
260
11
228
16 560
229
210
Table 3-4 Levels of Significant Exposure to Cobalt - Radiation Toxicity - External Radiation	 (continued) 
Exposure/ LOAEL
 
Duration/

a
Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (rad) (rad)	 (rad) Chemical Form 
Developmental 
33 Monkey 1x Brizzee et al. 1978100 (Developmental retardation,

Squirrel
 neurobehavioral deficits) 
34	 Rat 1x Bruni et al. 199450 F (Defective eye development and
 
(Sprague- spinal curvature)

Dawley)
 
35	 Rat 1x Inano et al. 1989260	 (Testicular trophy; adrenal 
atrophy) 
36 Rat 1x Inano et al. 1990 
260 M (Reduced NADPH cytochrome 
(Wistar) p450 reductase) 
37 Rat 4d or 6d Reyners et al. 1992
11 16 (slightly decreased (2.6%) brain 560 (decreased (13.1%) brain
(Wistar) weight in offspring)	 weight in offspring) 
38	 Rat 1x Suzuki et al. 1990210 M (Testicular atrophy)
 
(Wistar)
 
5230
10
50
231
25
234
100
236
200
237
20
Table 3-4 Levels of Significant Exposure to Cobalt - Radiation Toxicity - External Radiation (continued) 
Exposure/ LOAEL
 
Duration/

a
Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (rad) (rad) (rad) Chemical Form 
39 Mouse 1x Devi et al. 1994 
5 10 (Decreased brain weight 3-4%, 50 (Increased fetal mortality and
(Swiss- significantly increased growth retardation)
Webster) microphthalmia) 
40 Mouse 1x Devi et al. 1998 
25 (Decreased body weight 5%,
(Swiss- liver weight 5%, and spleen
Webster) weight 12%. Decreased spleen 
cellularity.) 
41 Mouse 1x Nitta et al. 1992100 M (Increased number of
 
(B6C3F1) tumor-bearing animals after in
 
utero exposure)
 
42 Mouse 1x Schmidt and Lent 1987200 (Atrophy or lack of development

(Swiss- of corpus callosum)

Webster)
 
43 Mouse 6d Want et al. 199320 F (Altered neurobehavioral 
parameters, growth retardation) 
238
50
239
200
240
83
242
15.6
16
245
83
247
96
Table 3-4 Levels of Significant Exposure to Cobalt - Radiation Toxicity - External Radiation (continued) 
Exposure/ LOAEL 
a
Key to 
figure 
Species 
(Strain) 
Duration/ 
Frequency 
(Specific Route) System 
NOAEL 
(rad) 
Less Serious 
(rad) 
44 
LACA 
Mouse 1x 
45 
(Golden 
Syrian) 
Hamster 1x 
46 
(Beagle) 
Dog 1x 
47 
(Beagle) 
Dog 1x 
48 
(Beagle) 
Dog 1x 
16 83 (Hypodontia) 
49 
(Beagle) 
Dog 1x 
ReferenceSerious 
(rad)	 Chemical Form 
Zhong et al. 1996
50	 (Delayed development, altered
 
hindlimb splay)
 
Harvey et al. 1962
200 F (Severe developmental 
abnormalities of multiple organ 
systems, embryo death) 
Benjamin et al. 1997
83	 (Increased risk of thyroid
 
neoplasia)
 
Benjamin et al. 1998b
15.6	 (Increased cancer-related 
mortality - multiple tumor types) 
Lee et al. 1989 
Schweitzer et al. 1987
96	 (Optic atrophy/degeneration) 
260
15.6
263
7500
272
4800
277
4623
278
3600
279
4056
Table 3-4 Levels of Significant Exposure to Cobalt - Radiation Toxicity - External Radiation (continued) 
a 
System 
Key to 
figure 
Exposure/ 
Duration/ 
Frequency 
(Specific Route)
Species 
(Strain) 
NOAEL 
(rad) 
LOAEL 
Less Serious Serious 
(rad) (rad) 
Cancer 
50 1x 
(Beagle) 
Dog 
15.6 (Increased cancer-related 
mortality) 
INTERMEDIATE EXPOSURE 
Death 
51 Human 7500 F (Death) 
Systemic 
52 
Ocular
Human 
4800 F (Progressive visual impairment 
and blindness) 
53 
Cardio 
22 - 35 d 
teletherapy 
Human 
4623 (Persistent pericarditis) 
54 
Gastro 
18 dHuman 
3600 (Loose bowel movements, 
impaired absorption of vitamin 
B12) 
55 
Dermal 
17 dHuman 
4056 F (Comedones, which were 
resolved with treatment) 
Reference 
Chemical Form 
Benjamin et al. 1998b 
Roscher and Woodard 1969 
Fishman et al. 1976 
Martin et al. 1975 
McBrien 1973 
Myskowski and Safai 1981 
282
7500
2400
283
284
4700
2400
289
4800 7200
292
1125
293
1125
Table 3-4 Levels of Significant Exposure to Cobalt - Radiation Toxicity - External Radiation (continued) 
a
Key to 
figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Specific Route) System 
NOAEL 
(rad) 
Less Serious 
(rad) 
LOAEL 
Serious 
(rad) 
56 Human 
Gastro 7500 F (Severe gastrointestinal 
necrosis and fibrosis) 
57 Human 3 yr 
Other 2400 
58 Human 7 wk 
Dermal 4700 (Reversible changes in skin 
pigmentation) 
59 
(albino) 
Rat 10 wk 
Other 2400 M 4800 M (Transient alterations in incisor 
histopathology) 
7200 M (Lasting alterations in incisor 
histopathology) 
60 
61 
150-300 d 
(Beagle) 
Dog 
Immuno/ Lymphoret 
150-300 d 
(Beagle) 
Dog 
Hemato 1125 M (Aplastic anemia) 
1125 M (Dose- and time-related 
reduction in granulocytes, 
monocytes, and lymphocytes) 
Reference 
Chemical Form 
Roscher and Woodard 1969 
Thibadoux et al. 1980 
van Oort et al. 1984 
Sweeney et al. 1977 
Seed et al. 1989 
Seed et al. 1989 
294
4800
295
13150
296
5500
5000
298
6600
299
1282
304
1800
305
25150
Table 3-4 Levels of Significant Exposure to Cobalt - Radiation Toxicity - External Radiation (continued) 
a
Key to 
figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Specific Route) System 
NOAEL 
(rad) 
Less Serious 
(rad) 
LOAEL 
Serious 
(rad) 
Reference 
Chemical Form 
Neurological 
62 Human Fishman et al. 19764800 F (Optic nerve damage, resulting 
in visual impairment and 
blindness) 
63 Human 9 mo Llena et al. 197613150 F (Neural necrosis and gliosis) 
64 Human Sanyal et al. 19795500 M (Partial paralysis secondary to 
radiation myelopathy) 
b 
5000 F (Partial paralysis secondary to 
radiation myelopathy) 
Reproductive 
65 Human 47 d Keys and Reed 19806600 M (Calcification of the prostate) 
66 Mouse 32 wk Searle et al. 19801282 F (Decreased offspring per litter 
and sterility) 
Cancer 
67 Human NS Garcia-Silva et al. 19961800 F (Basal cell carcinoma) 
68 Human 8 mo Wollenberg et al. 199525150 M (Multiple basal cell carcinomas) 
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Table 3-4 Levels of Significant Exposure to Cobalt - Radiation Toxicity - External Radiation (continued) 
a
Key to 
figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Specific Route) System 
NOAEL 
(rad) 
Less Serious 
(rad) 
LOAEL 
Serious 
(rad) 
Reference 
Chemical Form 
CHRONIC EXPOSURE 
69 
Systemic 
Human 3 yr 
Cardio 13150 F (Endothelial hyperplasia, 
dysplasia, and fibrosis) 
Llena et al. 1976 
a The number corresponds to entries in Figure 3-3. 
b Differences in levels of health and cancer effects between males and females are not indicated in Figure 3-3. Where such differences exits, only the levels of effect for the most 
sensitive gender are represented. 
Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; F = female; Gastro = gastrointestinal; Hemato = hematological; hr = hour(s); LOAEL = 
lowest-observed-adverse-effect level; M = male; Metab = metabolism; min = minute(s); mo = month(s); NOAEL = no observed-adverse-effect level;  NS = not specified; (occup) = 
occupational; Resp = respiratory; wk = week(s); yr = year(s). 
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Figure 3-3. Levels of Significant Exposure to Cobalt - Radiation Toxicity - External Radiation 
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Figure 3-3. Levels of Significant Exposure to Cobalt - Radiation Toxicity - External Radiation (Continued) 
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Figure 3-3. Levels of Significant Exposure to Cobalt - Radiation Toxicity - External Radiation (Continued) 
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Figure 3-3. Levels of Significant Exposure to Cobalt - Radiation Toxicity - External Radiation (Continued) 
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dose increases with tissue density (resulting in a higher dose to bone than soft tissue) and decreases with 
energy.  Several feet of concrete or a few inches of lead are typical shield thicknesses for protection from
gamma rays.  Because it is so highly penetrating, gamma radiation released by radionuclides such as 
cobalt may be a radiation hazard to internal organs (Agency for Toxic Substances and Disease Registry
1999; EPA 1997b). 60Co gamma rays are commonly used for human radiotherapy.  The purpose of this 
section is to provide information regarding health effects associated with external exposure to a 
radioactive cobalt source. These health effects are not specific to cobalt, but apply to any radionuclide 
delivering the same beta and gamma radiation dose at a comparable dose rate.  Refer to Agency for Toxic 
Substances and Disease Registry (1999) for a detailed description of health effects from external exposure 
to ionizing radiation in general. 
3.3.3.1 Death 
Exposure to high levels of external radiation, including radiation from cobalt radionuclides, may result in
mortality when the whole body dose exceeds 300 rads.  Stavem et al. (1985) reported a case in which a 
worker was exposed to 2,250 rad (22.5 Gy) within a few minutes time, resulting in death due to acute 
radiation sickness (depressed leukocyte counts, vomiting, diarrhea, etc.).  Complications resulting from
cobalt radiotherapy resulted in the death of a patient from severe gastrointestinal complications (Roschler 
and Woodard 1969). 
Norris and Poole (1969) reported on the mortality of dogs exposed to 60Co gamma rays at a rate of 35 rad 
(0.35 Gy) per day for 40 days, resulting in a cumulative exposure of 1,400 rad (14 Gy).  Twelve of 
40 animals died prior to termination of the 40-day exposure period, 13 of 40 died within the 23-day post-
exposure observation period, and 15 survived to the end of the study period, indicating an LD50 of 
<1,400 rad at 35 rad/day. Darwezah et al. (1988) reported single, whole-body exposure LD50 values in 
mice of 913 rad (9.13 Gy) and 627 rad (6.27 Gy) at 6 and 30 days post-irradiation, respectfully.  Down et 
al. (1986) reported a slightly higher LD50 of 1,400–1,450 rad (14–14.5 Gy) for 60Co thoracic irradiation in 
mice at 26 days postirradiation.  Several studies have demonstrated that decreasing the dose rate or the 
portion of the body exposed will increase the LD50 for 60Co gamma rays (Darwezah et al. 1988; Down et 
al. 1986; Hanks et al. 1966; Page et al. 1968). 
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3.3.3.2 Systemic Effects 
Respiratory Effects. Ionizing radiation is known to exert dramatic effects on the tissue of the lung
(Agency for Toxic Substances and Disease Registry 1999; Davis et al. 1992; Libshitz 1993; Roswit and 
White 1977), particularly at the high doses used in radiotherapy.  The first phase of damage usually
consists of radiation pneumonitis, which occurs between 3 and 13 weeks after irradiation and is 
characterized by low-grade fever, mild exertional dyspnea, congestion, and unproductive cough.  The 
second phase is characterized by radiation-induced lung fibrosis, emphysema, and pleural thickening.  
Patients receiving radiotherapy treatment regimens of ≥4,000 rad (40 Gy) to the chest region almost 
always develop radiographic changes in the lung (Davis et al. 1992), whereas lower therapeutic doses 
(2,500–3,000 rad, 25–30 Gy) generally result in a lower risk of adverse pulmonary symptoms (Davis et 
al. 1992; Roswit and White 1977).  Prophylactic protective measures may be taken, and these symptoms 
may be treated later if detected early enough in their progression (Roswit and White 1977). 
At similar doses, studies in animals, including rats, mice, baboons, and pigs, using 60Co radiation have 
also shown radiation pneumonitis and fibrosis, similar to effects seen in humans (Collins et al. 1978; 
Down et al. 1986; Lafuma et al. 1987; Rezvani et al. 1989).  Other respiratory changes seen in animal 
experiments included an increased breathing rate, effects on the surfactant system, edema, increased 
pleural fluid content, pulmonary atrophy, and histologic alterations of the lung parenchyma (Bellet-
Barthas et al. 1980; Collins et al. 1978; Down et al. 1986; Lafuma et al. 1987). 
Cardiovascular Effects. Martin et al. (1975) reported that 24 of 81 patients who underwent 60Co 
teletherapy for Hodgkin’s disease, using an upper mantle treatment regimen of 4,000 rad (40 Gy) over 
22–35 days, developed radiation-related pericarditis.  In 14 of these patients, the condition was transient, 
while it persisted in the other 10 patients.  Llena et al. (1976) presented a case wherein a 51-year-old 
woman who had received a localized dose of 13,150 rad (131.5 Gy) of 60Co radiation between the 
nasopharynx and cervical lymph nodes as part of radiotherapy developed severe alterations in the 
endothelial cells of the brain, including proliferation, increased cytoplasmic organelles, and infoldings of 
the plasma membrane.   
Whole-body exposure of Rhesus monkeys to 10,000 rad (100 Gy) over a 90-second period resulted in 
dramatic decreases in mean systemic arterial blood pressure, as well as in mean blood flow in the pons 
and pre-central gyrus, beginning at 10 minutes post-irradiation and persisting throughout the 60-minute 
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observation period (Cockerham et al. 1986).  Bruner (1977) examined cardiovascular parameters in 
Rhesus monkeys exposed to 1,000 rad (10 Gy) at rates of 129–164 rad/minute (1.29–1.64 Gy/minute).  
Heart rate was elevated post-exposure, blood pressure was reduced near the end of exposure and 
thereafter, cardiac output increased at the end of exposure, but thereafter fell to below control levels, and 
total peripheral resistance to blood flow decreased at early times post-exposure, but thereafter rose to 
above control levels.  Ten of 12 dogs irradiated with 4,355–5,655 rad (43.6–56.6 Gy), focused on the 
interatrial septum of the heart, developed cardiac arrhythmias (Dick et al. 1979).  The permeability of the 
blood-brain barrier was significantly increased, particularly for hydrophillic compounds, in rats exposed 
to 2,500 rad (25 Gy) from a 60Co source (Bezek et al. 1990). 
Gastrointestinal Effects.    A worker accidentally exposed to an acute whole-body dose of 2,250 rad 
(22.5 Gy) showed slight atrophy of the stomach glands, marked atrophy in the small intestine, and total 
atrophy of the glands in the large intestine (Stavem et al. 1985).  Two years after a woman received 60Co 
radiation therapy amounting to 4,000 rad (40 Gy) anteriorly and 3,500 rad (35 Gy) posteriorly over a 
6-week period, she reported severe gastrointestinal difficulties, including epigastric pain, vomiting, 
bloody stools, and weight loss (Roschler and Woodard 1969), eventually resulting in death.  Autopsy
revealed dense fibrous layers around the sacrum, with severe fibrosis confirmed by microscopic 
examination.  Cobalt radiotherapy for carcinoma of the bladder (~3,100–3,600 rad, 31–36 Gy, over 
18 days) resulted in loose bowel movements and a decreased absorption of vitamin B12 following oral 
exposure in 8 of 14 patients (McBrien 1973).  No gastrointestinal symptoms were reported in three 
workers who were accidentally exposed to much lower exposure levels, ranging from 2.24 to 12.7 rad 
(0.022–0.127 Gy) (House et al. 1992). 
Exposure of male Sprague-Dawley rats to 850 rad (8.5 Gy) of 60Co gamma radiation resulted in marked 
alterations in drug absorption, primarily due to a decrease in gastric emptying rate (Brady and Hayton 
1977b).  Exposure of young adult beagle dogs to 800 rad (8 Gy) of 60Co radiation at a rate of 
177.5 rad/minute (1.775 Gy/minute) resulted in a 100% emesis rate within 10 hours post-irradiation, with 
an average of 2.4 episodes per animal and an average time to emesis of 82 minutes (Gomez-d-Segura et 
al. 1998).  King (1988a) reported a NOAEL of 49 rad (0.49 Gy) and an EC50 of 77 rad (0.77 Gy) for 
emesis and wretching following exposure of male ferrets to 60Co gamma radiation.  Exposure of male 
Swiss mice to 1,000 rad (10 Gy) of 60Co radiation resulted in necrosis of the intestinal crypt cells (Devi et 
al. 1979). 
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Hematological Effects. No changes in hematologic parameters were reported in three workers who 
were accidentally exposed to levels ranging from 2.24 to 12.7 rad (0.022–0.127 Gy) (House et al. 1992).  
Hashimoto and Mitsuyasu (1967) reported that in 50 of 58 patients receiving local radiotherapy, irradiated 
bone marrow was more hypoplastic in the hematopoietic elements than in non-irradiated marrow in the 
same individual.  A male worker exposed to 159 rad (1.59 Gy) showed minor reductions in leukocytes, 
neutrophils, and lymphocytes (Klener et al. 1986).  Stavem et al. (1985) reported that a male worker 
exposed to 2,250 rad (22.5 Gy) showed a progressive decrease in hemoglobin and circulating 
thrombocytes prior to death.  Autopsy showed a pronounced hypocellularity of the bone marrow.   
Seed et al. (1989) exposed male Beagle dogs to 7.5 rad/day (0.075 Gy/day) gamma radiation for  
150–700 days from a 60Co source.  The irradiated dogs initially showed a significant suppression, 
compared with levels from the control animals, of the five circulating types of cells studied (granulocytes, 
monocytes, platelets, erythrocytes, and lymphocytes), which lasted ~250 days; this was followed by a 
recovery phase for the remainder of the study period.  Hashimoto and Mitsuyasu (1967) exposed guinea 
pigs to whole-body 60Co radiation, and reported an initial hypoplasia of the bone marrow followed by 
recovery of hematopoietic activity by 3 weeks post-irradiation.  Robbins et al. (1989b) reported 
significant reductions in erythrocyte count, hematocrit, and hemoglobin levels within 6–8 weeks of 
irradiation of the kidneys of female pigs with 980–1,400 rad (9.8–14 Gy) of 60Co gamma rays. 
Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans or 
animals following external exposure to 60Co radiation. These tissues are among the most radioresistant in 
both humans and animals. 
Hepatic Effects. No studies were located regarding hepatic effects in humans following external 
exposure to 60Co radiation.
No changes in liver weight were seen in male Swiss mice exposed to 1,000 rad (10 Gy) of 60Co radiation 
and examined every 4 hours for 24 hours post-irradiation (Mazur et al. 1991).  Andrzejewski et al. (1980) 
reported increased respiration rates in rat liver mitochondria after whole-body exposure to 1,000 or 
3,000 rad (10 or 30 Gy) of 60Co radiation; the increase was greater and more persistent at the higher dose 
level. 
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Renal Effects. Stavem et al. (1985) reported that a 64-year-old man who accidentally received a fatal 
dose (2,250 rad) of cobalt radiation developed enlarged kidneys.  No other studies were located regarding 
renal effects in humans after external exposure to cobalt radiation. 
Robbins et al. (1989a, 1989b, 1989c, 1991a, 1991b) performed a series of studies in female White pigs 
wherein the kidneys of the animals were exposed to single doses of 780–1,400 rad (7.8–14 Gy) of 60Co 
radiation and examined for periods up to 24 weeks postirradiation.  Irradiation resulted in an initial 
increase in glomerular filtration rate (GFR), followed by a dose-related decrease in the GFR, beginning at 
4 weeks postexposure. Effective renal plasma flow (ERPF) was also decreased in a dose-related manner 
beginning at 4 weeks postexposure, but did not show the initial increase seen in GFR.  Some recovery of 
GFR and ERPF occurred by 24 weeks postirradiation, though values were still significantly reduced 
below controls in all groups but the 780 rad (7.8 Gy) group.  Histology was performed on animals 
exposed to 980 rad (9.8 Gy) and killed between 2 and 24 weeks after exposure.  Beginning at 2 weeks 
postirradiation, increased numbers of inflammatory cells were present within the glomerulus, and there 
was an increase in mesangial matrix and number of mesangial cells.  The glomerular changes continued 
to progress in severity throughout the observation period, with generalized thickening of the capillary 
walls, extensive duplication of the basement membrane, and progressive inflammation.  Tubular changes 
appeared to be maximal at 6 weeks, including focal degeneration and necrosis, with partial recovery at 
later timepoints. 
Endocrine Effects. Prager et al. (1972) reported that 5 of 23 patients receiving cobalt radiotherapy
(3,900–4,600 rad, 39–46 Gy) for Hodgkin’s disease developed hypothyroidism, with substantial decreases 
in levels of T4 relative to patients with normal thyroids.  Chang et al. (2001) examined the residents of 
60Co-contaminated buildings for effects on the thyroid.  There was an increased prevalence of goiter in 
males of all ages and females <15 years of age, as well as a dose-related increase in the prevalence of 
thyroid cysts in females of all ages, and elevated tri-iodothyronine levels in males <15 years of age.  No 
other studies examining the endocrine effects of radioactive cobalt exposure, either internal or external, in 
humans were located. 
Whole-body acute exposure of rats to 330 rad (3.3 Gy) did not affect FSH, LH, or testosterone levels 
(Cunningham and Huckins 1978).  Similarly, male Wistar rats exposed to a single dose of 80 rad (0.8 Gy) 
of testicular radiation showed no changes in FSH, LH, prolactin, or testosterone (Laporte et al. 1985).  No 
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other studies examining the endocrine effects of radioactive cobalt exposure, either internal or external, in 
animals were located. 
Dermal Effects.    Several studies in humans have demonstrated that high-dose exposure to cobalt 
radiation can result in damage to the skin.  Klener et al. (1986) described the accidental irradiation of a 
worker who was attempting to bring under control a sealed 60Co source. The patient’s left palm (the 
patient was left-handed) developed an irregular oval defect 3x4 cm with whitish edges and bleeding, as 
well as superficial lesions on the third and fourth finger.  Considerable spontaneous pain required the 
administration of analgesics.  The lesions showed no tendency to heal, instead spreading to the adjacent 
digits. After several failed skin graft attempts, the condition worsened, necessitating the amputation of 
fingers five through two.  Walter (1980) reported that a patient who had undergone 60Co radiotherapy
(dose not reported) of the forehead and scalp developed a pronounced acneform reaction, characterized 
primarily by alopecia with multiple open comedones on the scalp and forehead, and hair loss. With 
treatment, the comedones were 80% cleared at 9 months post-diagnosis (13 months post-treatment), but 
no hair regrowth was noted.  Myskowski and Safai (1981) have likewise reported localized comedones in 
a patient following 4,056 rad (40.6 Gy) of 60Co radiotherapy.  Van Oort et al. (1984) reported that patients 
receiving 4,700–6,000 rad (47–60 Gy) of 60Co radiotherapy over a 7-week period showed significant 
differences in baseline color of the skin, primarily erythema, and pigmentation, beginning the third week 
of exposure and persisting throughout the fifth week postirradiation (study week 12).  Johansson et al. 
(2000) reported that 86% of women who had been treated with 5,400–5,700 rad (54–57 Gy) after a 
radical mastectomy developed fibrosis of the skin of the treated area. 
Cox et al. (1981) reported a dose-related loss of hair in rabbits exposed to 1,730–3,210 rad  
(17.3–32.1 Gy) 60Co gamma rays, targeted at the skin near the eyes or of the ears, with recovery initially
noted in animals exposed to 2,140 rad (<21.4 Gy) by day 200 postirradiation.  Beginning at day
500 postirradiation, a substantial loss of hair again was seen, persisting throughout the end of the study.
Mice exposed to 1,800 rad (18 Gy) of 60Co radiation showed a slight increase in epilation score (Down et 
al. 1986). 
Ocular Effects.    Exposure to high-dose radiation from cobalt sources has been shown to result in 
effects on the eye, in particular the development of cataracts.  Augsburger and Shields (1985) described 
13 patients who developed cataracts following 60Co plaque radiotherapy; estimated doses to the eyes 
ranged from 2,000 to 10,000 rad (20–100 Gy).  Fishman et al. (1976) reported on two patients who 
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received head-only 60Co radiotherapy, in combination with chemotherapy, for the treatment of acute 
lymphocytic leukemia.  Both patients, who received 2,400 rad (24 Gy) over an initial 16-day course of 
treatment followed later by either 2,400 or 2,500 rad (24 or 25 Gy) in followup therapy, developed 
progressively severe vision disorders, resulting in partial or total blindness.  Exposure of a male worker to 
a whole-body dose of 159 rad (1.59 Gy) of 60Co radiation resulted in a progressive deterioration of visual 
acuity, due to cataract development, in the left eye (which was more exposed than the right) over time 
(Klener et al. 1986).  Chen et al. (2001) evaluated subjects that had been exposed to 120–194 mSv (range:  
1.11–1493.4 mSv) for an undisclosed period of time for lenticular opacities.  Subjects <20 years old 
showed a dose-dependent increase in the numbers of focal lens defects, while for those aged 20–40 and
>40, no such statistical correlation was seen. 
Other Systemic Effects.    Thibadoux et al. (1980) reported that of 61 children receiving a course of 
2,400 rad (24 Gy) of cranial radiotherapy, none developed significant reductions in hearing levels by the 
end of the third year after irradiation. 
Taiwanese children (48 boys, 37 girls) who were raised in apartments contaminated with 60Co were
compared to 21,898 age- and sex-matched nonexposed children from a nationwide surveillance program
(Wang et al. 2001).  After adjusting for effects from parental heights and body mass index, clear dose-
related decreases in height percentile (HP) and age-specific relative height differences (RHD) were seen 
in exposed boys, but not in exposed girls.  Average cumulative doses were 120.8 and 129.9 mSv for the 
boys and girls, respectively. 
Sweeney et al. (1977) examined the effects of 60Co radiation on the teeth of rats exposed to 0, 2,400, 
4,800, or 7,200 rad (0, 24, 48, or 72 Gy).  Animals exposed to 4,800 rad (48 Gy) showed transient effects 
on the incisors only, while at 7,200 rad (72 Gy), the effects lasted throughout the 10-week study period.
3.3.3.3 Immunological and Lymphoreticular Effects 
A worker accidentally exposed to an acute dose of 2,250 rad (22.5 Gy) showed a rapid fall in circulating 
lymphocytes and granulocytes prior to death (Stavem et al. 1985). Chronic exposure to low amounts of 
60Co radiation in people living in a contaminated building significantly reduced the numbers of circulating 
CD4+ lymphocytes in the blood (Chang et al. 1997, 1999b); mean total radiation dose was estimated to be 
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0.169 Gy (16.9 rad) over a 2–13-year period.  Similarly, children chronically-exposed to low levels 
(estimated dose of 0.002–0.085 Gy [0.2–8.5 rad]) of 60Co radiation in a contaminated kindergarten 
building showed significant decreases in total leucocytes and neutrophils, but an increase in eosinophils, 
5–7 years after exposure had ceased (Chang et al. 1999a). 
In male Swiss mice exposed to 1,000 rad (10 Gy) of 60Co radiation, significant decreases in weight of the 
spleen were seen as early as 1 hour post-exposure and persisted throughout the following 24 hours (Mazur 
et al. 1991). Spleen acid phosphatase activity, expressed as activity per gram of protein, was significantly
increased in irradiated animals beginning at 13 hours post-exposure. 
3.3.3.4 Neurological Effects 
Exposure of both humans and animals to high doses of cobalt radiation has been shown to result in 
damage to nervous tissue, particularly peripheral nerves.  Llena et al. (1976) presented a case wherein a 
51-year-old woman who had received 13,150 rad (131.5 Gy) of 60Co radiation between the nasopharynx 
and cervical lymph nodes as part of radiotherapy developed focal necrosis of the brain in the frontal lobe, 
as confirmed by gross and microscopic examination. Fishman et al. (1976) reported on two patients who 
received head-only 60Co radiotherapy, in combination with chemotherapy, for the treatment of acute 
lymphocytic leukemia.  Both patients, who received 2,400 rad (24 Gy) over an initial 16-day course of 
treatment followed later by either 2,400 or 2,500 rad (24 or 25 Gy) in followup therapy, developed 
progressively severe vision disorders, resulting in partial or total blindness.  Histopathology from one 
patient demonstrated severe alterations in the optic nerve, including severe atrophy, terminal beading, 
lack of myelin, and calcification.  Sanyal et al. (1979) reported on five patients who received doses of 
4,500–6,000 rad (45–60 Gy) 60Co radiation as radiotherapy, who developed varying degrees of 
myelopathy, resulting in minimal to mild paralysis.  In patients that had been treated with 60Co radiation 
(total dose of 54–57 Gy, or 5,400–5,700 rad) following mastectomy, 63% developed brachial plexus 
neuropathy and 5% developed vocal chord paresis over the 30-year period reported by the study
(Johansson et al. 2000). 
Mele et al. (1988) exposed male rats to 50, 150, or 450 rad (0.5, 1.5, or 4.5 Gy) 3 times, at 43-day
intervals, and examined them for changes in behavior daily for 30 days following each exposure.  Rats 
exposed to 450 rad (4.5 Gy), but not those exposed to 150 rad (1.5 Gy) or 50 rad (0.5 Gy), showed 
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significant deficits in fixed-ratio response rates and running rates after each exposure, beginning the day 
after exposure and persisting for 4–5 days, after which both rates returned to normal.  After the third 
exposure, all rats were exposed to 650 rad (6.5 Gy), which resulted in similar performance decrements as 
were seen in the 450 rad (4.5 Gy) animals, again beginning 24 hours after exposure, with previous 
exposure resulting in no differences in behavioral parameters.  Maier and Landauer (1989) reported 
significant decreases in offensive behavior in mice acutely exposed to whole-body doses of 500 or 
700 rad (5 or 7 Gy), but not those exposed to 300 rad (3 Gy), with changes occurring in the second week 
postirradiation and responses returning to normal by day 19 postirradiation.  Rabin et al. (1998) reported 
that exposure of rats to 60Co radiation (up to 30 Gy or 3,000 rad) showed a dose-related decrease in the 
acquisition of controlled taste aversion behavior.  Bassant and Court (1978) reported that rabbits exposed 
to 450 rad (4.5 Gy) of 60Co radiation whole-body showed an altered activity of hippocampal cells, with a 
slowed mean discharge rate and increased interspike variability persisting for at least 12 hours 
postirradiation. 
3.3.3.5 Reproductive Effects 
Ionizing radiation in general, and gamma-emitting isotopes in particular, is known to have profound 
effects on reproductive tissues, with effects seen primarily in rapidly-dividing germ cells resulting in
temporary or permanent sterility in both sexes, as well as other effects (Agency for Toxic Substances and 
Disease Registry 1999).  These effects are usually observed only at high radiation doses.  Keys and Reed 
(1980) reported a case of a man who, as treatment for a prostate tumor, received an estimated dose of 
6,600 rad (66 Gy) to the prostate over a 47-day period, and who later developed a severe prostatic 
calcification necessitating surgical correction. 
60Co radiation at high doses has been shown to elicit profound decrements in reproductive ability in 
animal species.  Whole-body acute exposure of rats to 330 rad (3.3 Gy) decreased testicular weights 
beginning at 22 days postirradiation, with recovery of testicular weight beginning about day
65 (Cunningham and Huckins 1978).  Histologic examination of the testes revealed destruction of the 
spermatogonial population, with a slow recovery as the spermatogonial population was rebuilt from the 
surviving stem cells.  Searl et al. (1976) reported that exposure of male mice to 1,128 rad (11.3 Gy) over a 
28-week period resulted in significant reductions of testis mass and epididymal sperm count.  Male Wistar 
rats exposed to a single dose of 80 rad (0.8 Gy) to the testes showed increased tubular fluid production 
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and decreased testicular weight at 30 and 45 days postirradiation, but not at later time points (Laporte et 
al. 1985).  Single doses of >100 rad (1 Gy) of 60Co radiation caused decreased fertility in exposed female 
mice (Philippe 1975).  Continuous exposure of female mice to an average daily dose of 8 or 16 rad/day 
(0.08 or 0.16 Gy/day) caused a decreased number of offspring per litter and decreased reproductive 
performance, with 100% sterility occurring at 32 weeks of exposure at 8 rad/day (0.08 Gy/day) or 
20 weeks of exposure at 16 rad/day (0.16 Gy/day) (Searl et al. 1980).  Female rabbits exposed to 400 rad 
(4 Gy) prior to implantation showed dramatic decreases in implantation (Chang et al. 1963). 
3.3.3.6 Developmental Effects 
No studies were located regarding developmental effects in humans after external exposure to cobalt 
radiation. 
In utero exposure to cobalt radiation has been extensively studied in animal species, and may elicit 
substantial effects across many organ systems of the developing organism.  Effects have been noted 
following single-dose exposures as low as 10 rad (0.10 Gy) in mice (Devi et al. 1994; Wang et al. 1993), 
50 rad (0.5 Gy) in rats (Bruni et al. 1994), 200 rad (2 Gy) in hamsters (Harvey and Chang 1962), 250 rad 
in rabbits (Chang et al. 1963), 15.6 rad (0.16 Gy) in dogs (Benjamin et al. 1998a, 1998b), and 100 rad 
(1 Gy) in monkeys (Brizzee et al. 1978).  Organs known to be affected include the brain (Brizzee et al. 
1978; Bruni et al. 1994; Devi et al. 1994; Hamilton et al. 1989; Reyners et al. 1992; Schmidt and Lent 
1987), eyes (Brizzee et al. 1978; Bruni et al. 1994; Schweitzer et al. 1987), hair (Hirobe 1994; Hirobe and 
Zhou 1990), kidney (Benjamin et al. 1998a; Brizzee et al. 1978), liver (Devi et al. 1998), ovaries (Inano et 
al. 1989), pituitary (Brizzee et al. 1978), skeleton (including cleft palate, shortened digits, fused digits, 
and other gross abnormalities) (Bruni et al. 1994; Chang et al. 1963; Harvey and Chang 1962), spleen 
(Devi et al. 1998), teeth (Lee et al. 1989), testes (Inano et al. 1989; Suzuki et al. 1990), and thyroid 
(Benjamin et al. 1997).  60Co radiation in utero has also shown to cause functional alterations, including
postnatal growth retardation (Wang et al. 1993; Zhong et al. 1996), neurobehavioral changes (Brizzee et 
al. 1978; Wang et al. 1993), hormonal production (Brizzee et al. 1978; Inano et al. 1989; Suzuki et al. 
1990), alterations in hepatic enzymes (Inano et al. 1990), and diabetes mellitus (Benjamin et al. 1998a).  
In utero irradiation with cobalt also leads to increased tumor incidence later in life (Benjamin et al. 1991, 
1997, 1998b; Nitta et al. 1992). 
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Devi et al. (1994) exposed pregnant mice to a single dose of 0–50 rad (0–0.50 Gy) of 60Co radiation on
day 11.5 of gestation.  A significant decrease in pup brain weight and an increase in the incidence of 
microphthalmia was seen at 10 rad (0.10 Gy), with decreases in head width, head length, body length, and 
body weight occurring at higher doses.  A later study (Devi et al. 1998) found decreases in body weight, 
liver weight, and spleen weight in pups 72 hours after irradiation with 25 rad (0.25 Gy) of 60Co radiation 
on day 17 of gestation.  Male offspring, but not female offspring, of mice exposed to 50 rad (0.5 Gy) on
gestation day 9 showed decreased body weights on postnatal days 0, 3, and 7, while offspring of both 
sexes showed delays in pinna detachment, incisor eruption, eye opening, and testes descent (Zhong et al. 
1996).  Wang et al. (1993) reported that mice exposed to a cumulative in utero dose of 10 rad (0.10 Gy) 
showed alterations in visual placing reflex tests, while those exposed to 20 or 40 rad (0.20 or 0.40 Gy) 
showed decreased mean body weight, delayed eye opening, and alterations in the air righting reflex. 
Rats exposed to 50 rad (0.50 Gy) of 60Co radiation on gestational day 9.5 showed histologic damage to 
the neuro-epithelium 4 hours post-exposure, with abnormal flexion of the embryo and abnormal flexion 
of the head at 48 hours post-exposure (Bruni et al. 1994).  At birth, rats showed increased incidence of 
defective eye development, spinal curvature, and visceral anomalies.  Reyners et al. (1992) reported 
decreased brain weight in 3-month-old rats that had been exposed to cumulative doses of 160 rad (1.6 Gy)
over gestation days 12–16 or 170 rad (1.7 Gy) over gestation days 14–20.  Male rats exposed to 210 rad 
(2.1 Gy) on day 20 of gestation showed atrophy of the testes, prostates, and seminal vesicles, as well as a 
complete disappearance of germinal cells within the testes, on postnatal day 70 (Suzuki et al. 1990).
Inano et al. (1989) exposed rats on gestation day 20 to 260 rad (2.6 Gy) of 60Co radiation.  Seminiferous 
tubules of male offspring and ovaries of female offspring showed pronounced atrophy, and steroid 
hormone production was significantly altered. 
Benjamin et al. (1997, 1998a, 1998b) exposed groups of pregnant Beagle dogs to 15.6–17.5 or 
80.8–88.3 rad (0.15–0.175 or 0.8–0.88 Gy) of 60Co radiation on day 8, 28, or 55 post-breeding. Animals 
were allowed to live their full life span and were observed for radiation-related illnesses and cause of 
death. No change in the mean age at death was seen as a result of exposure.  Males exposed to either 
exposure level at day 55 post-breeding, but not females at any time or males exposed at days 8 or 28, 
showed an increase in deaths due to renal disease.  High-dose females exposed on days 28 or 55 showed 
an increase in the frequency of diabetes mellitus.  Both sexes showed an increase in malignant neoplasias 
in general when exposed to radiation at 8 or 55 days postcoitus, but not at 28 days, while females exposed 
on day 55 also showed an increase in lymphoid neoplasia.  A similar exposure on day 28 or 55 postcoitus 
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also resulted in a dose-dependent decrease in brain weight (Hamilton et al. 1989).  In utero radiation of 
dogs to higher doses (100–380 rad [1–3.8 Gy]) resulted in retinal dysplasia and atrophy (Schweitzer et al. 
1987). 
3.3.3.7 Cancer 
The carcinogenic effects of high doses of ionizing radiation have been well documented (Agency for
Toxic Substances and Disease Registry 1999), though the effects of lower doses are less clearly defined.  
Duncan et al. (1977) reported on a cohort of patients who had received radiotherapy for carcinoma of the 
cervix. Eight of 2,674 patients developed bladder tumors within 6 months to 20 years following 
irradiation; the incidence rate was over 57 times greater than the general female population.  All eight 
patients had received high (therapeutic) doses of 60Co irradiation, though five of the eight also received 
radium therapy in conjunction with 60Co irradiation.  Wollenberg et al. (1995) presented a case of a 
55-year-old farmer who received a total of 25,150 rad (251.5 Gy) distributed over six areas of the body 
over an 8-month period as a 60Co teletherapy treatment regimen.  Twenty years after irradiation, the 
patient developed a total of 43 basal cell carcinomas of the skin over the treated areas, all of which were 
successfully removed with cryosurgery.  A 2-year-old girl exposed to 1,800 rad (18 Gy) of 60Co radiation 
as part of a treatment regimen for acute lymphoblastic leukemia L1 developed, at age 12, a basal cell 
carcinoma of the scalp (Garcia-Silva et al. 1996).  Three patients receiving cobalt irradiation as part of a 
chemotherapy/radiation treatment developed basal cell carcinoma of the scalp 8–15 years after treatment 
in the area of radiation treatment (Dinehart et al. 1991). 
3.3.4 Other Routes of Exposure 
This section includes injection and in vitro studies that provide evidence for the biological basis of 
toxicity of stable and radioactive cobalt in humans and animals.  Since these studies are not directly
relevant to general population exposure conditions, no LSE tables have been created for this section. 
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3.4 GENOTOXICITY  
Stable Cobalt.  No studies were located regarding genotoxic effects in humans following oral or dermal 
exposure to cobalt.  No studies were located regarding genotoxic effects in animals following inhalation 
exposure to cobalt. 
Gennart et al. (1993) examined a cohort of 26 male workers who had been occupationally-exposed to 
cobalt, chromium, nickel, and iron.  Analysis of variance on sister-chromatid exchange rank values 
revealed that exposure status (exposed vs. controls) and smoking habits had statistically significant 
effects. De Boeck et al. (2000) reported no significant change in the comet assay on lymphocytes from
nonsmoking workers who had been occupationally exposed to cobalt or hard metal dusts; a positive 
association was found between hard metal exposure and increased micronucleus formation in smokers
only.
Single oral exposure of male Swiss mice to 0, 4.96, 9.92, or 19.8 mg cobalt/kg as cobalt chloride resulted 
in significantly increased percentages of both chromosomal breaks and chromosomal aberrations in bone 
marrow cells, with significant linear trends toward increasing aberrations with increased exposure (Palit et 
al. 1991a, 1991b, 1991c, 1991d). 
Results of genetic testing of cobalt are presented in Table 3-5.  Several different forms of cobalt, 
including cobalt chloride and cobalt sulfide, were tested.  No profound differences were found among the 
various forms.   
Cobalt was found to be generally nonmutagenic in bacteria (Salmonella typhimurium, Escherichia coli) 
and yeast when compounds with a valence state of II were tested (Arlauskas et al. 1985; Fukunaga et al. 
1982; Kanematsu et al. 1980; Kharab and Singh 1985; Ogawa et al. 1986; Singh 1983; Tso and Fung
1981).  A very weak mutagenic response was found with Bacillus subtilis (Kanematsu et al. 1980).  A 
mutagenic response to cobalt was found, however, when compounds with a valence state of III were 
tested in S. typhimurium and E. coli (Schultz et al. 1982).  The authors suggested that this may be due to
the formation of cobalt(III) complexes that are inert to ligand substitution, allowing optimal interaction of 
cobalt with genetic material (Schultz et al. 1982).  Other studies have shown cobalt to be a comutagen in 
combination with 4-substituted pyridines in S. typhimurium (Ogawa et al. 1988).  It has been reported that 
cobalt acts as an antimutagen in bacterial (S. typhimurium, B. subtilis, E. coli) and yeast test systems  
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Table 3-5. Genotoxicity of Cobalt In Vitro 
Results
With Without Valence 
Species (test system) End point activation activation Reference state
Stable Cobalt
Prokaryotic organisms: 
Salmonella typhimurium
(plate incorporation) 
Gene mutations No data – Tso and Fung 
1981 
II 
S. typhimurium (plate 
incorporation) 
Gene mutations No data – Arlauskas et al. 
1985 
II 
S. typhimurium (plate 
incorporation) 
Gene mutations No data – Ogawa et al. 1986 II 
S. typhimurium (plate 
incorporation) 
Gene mutations No data + Schultz et al. 1982 III 
Bacillus subtilis (rec assay) Gene mutations No data (+) Kanematsu et al. 
1980 
II 
Escherichia coli (reversion 
assay) 
Gene mutations No data – Kanematsu et al. 
1980 
II 
E. coli (repair assay) DNA damage No data + Schultz et al. 1982 III 
Eukaryotic organisms: 
Fungi: 
Saccharomyces cerevisiae
(plate assay) 
Reversion No data – Kharab and Singh 
1985 
II 
S. cerevisiae (plate assay) Reversion No data – Fukunaga et al. 
1982 
II 
S. cerevisiae (plate assay) Reversion No data – Singh 1983 II 
S. cerevisiae (plate assay) Conversion No data + Kharab and Singh 
1985 
II 
S. cerevisiae (plate assay) Conversion No data + Fukunaga et al. 
1982 
II 
S. cerevisiae (plate assay) Conversion No data + Singh 1983 II 
Mammalian cells: 
Hamster ovary cells Clastogenic 
effects 
No data + Hamilton-Koch et 
al. 1986 
II 
Hamster embryo cells Transformation No data + Costa et al. 1982 II 
Human lymphocytes Sister chromatid 
exchange 
No data + Andersen 1983 II 
Human HeLa cells Inhibition of DNA No data + Painter and II 
synthesis Howard 1982
Human diploid fibroblasts DNA damage No data + Hamilton-Koch et 
al. 1986 
II 
  
 
 
 
 
 
 
 
 
 
     
      
      
     
 
 
 
   
  
  
 
 
 
 
 
  
  
 
  
 
 
COBALT 120 
3. HEALTH EFFECTS 
Table 3-5. Genotoxicity of Cobalt In Vitro 
Results
With Without Valence 
Species (test system) End point activation activation Reference state
Radioactive Cobalt
Mammalian cells: 
Chinese hamster ovary DNA amplification No data + Luecke-Huhle et N/A 
cells al. 1986 
Hamster embryo cells DNA amplification No data + Luecke-Huhle et N/A 
al. 1990 
 Mouse lymphosarcoma Chromosomal No data + Juraskova and N/A 
cells aberrations Drasil 1987 
 Mouse lymphosarcoma Sister-chromatid No data + Juraskova and N/A 
cells exchanges Drasil 1987 
 Human lymphocytes Chromosomal No data + Koksal et al. 1995 N/A 
aberrations 
 Human lymphocytes Micronucleus No data + Koksal et al. 1996 N/A 
formation 
Human leukocytes DNA strand No data + Rueff et al. 1993 N/A 
breaks 
 Human leukocytes Chromosomal No data + Rueff et al. 1993 N/A 
aberrations 
 Human leukocytes Chromosome No data + Lindahl-Kiessling N/A 
breaks et al. 1970 
Human fibroblasts Transformation No data + Namba et al. 1981 N/A 
Human fibroblasts Transformation No data + Namba et al. 1985 N/A 
Human fibroblasts DNA strand No data + Coquerelle et al. N/A 
breaks 1987 
Human fibroblasts Transformation No data + Namba et al. 1988 N/A 
 Human fibroblasts Retinoblastoma No data + Endo et al. 1993 N/A 
gene alterations 
Human fibroblasts DNA strand No data + Dolling et al. 1998 N/A 
breaks 
Human kidney cells DNA strand No data + Feinendegen et al. N/A 
breaks 1977 
Human kidney cells DNA strand No data + Feinendegen et al. N/A 
breaks 1978 
DNA = deoxyribonucleic acid; + = positive results; – = negative results; (+) = weakly positive results 
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(Saccharomyces cerevisiae) (Inoue et al. 1981; Kada et al. 1986; Kuroda and Inoue 1988).  A possible 
explanation was that cobalt acts by correcting the error-proneness of deoxyribonucleic acid (DNA) 
replicating enzymes by improving their performance in DNA synthesis (Inoue et al. 1981; Kada et al. 
1986; Kuroda and Inoue 1988).  However, cobalt has also been shown to increase the frequency of
genetic conversions in S. cerevisiae (Kharab and Singh 1985; Singh 1983).  The reasons for this apparent 
dichotomy in yeast cells is not known. 
In contrast to the results seen in bacteria, stable cobalt compounds were generally found to be genotoxic 
or mutagenic in mammalian assay systems.  Exposure to cobalt compounds (metal, salts, or hard metal) 
has been shown to produce clastogenic effects in mammalian cells, including human lymphocytes (Anard 
et al. 1997; Hamilton-Koch et al. 1986; Painter and Howard 1982); transformation in hamster cells (Costa 
et al. 1982); sister chromatid exchanges in human lymphocytes (Andersen 1983); and micronucleus 
formation in mouse bone marrow cells (Suzuki et al. 1993) and human lymphocytes (Capomazza and 
Botta 1991; Olivero et al. 1995; Van Goethem et al. 1997).  Hard metal is generally more genotoxic in in 
vitro tests than other cobalt compounds.  Cobalt ions are also thought to inhibit DNA repair in
mammalian cells by interaction with zinc-finger proteins involved in DNA excision repair (Asmuß et al. 
2000; De Boeck et al. 1998; Hartwig et al. 1991; Kasten et al. 1997; Sarkar 1995).
Thirty hours following single intraperitoneal injection of cobalt(II) chloride in BALB/c mice, an increase 
in micronucleus formation was seen at 12.4 or 22.3 mg cobalt/kg (as cobalt chloride), but not at 
6.19 mg/kg (Suzuki et al. 1993).  Single injection of mg cobalt/kg (as cobalt chloride) resulted in 
significantly increased micronucleus formation at 24 hours post-injection, but not at 12, 48, 72, or 
96 hours.  Two or 10 days following intraperitoneal injection of male and female F344 rats with 3 or 6 mg
cobalt/kg, increased levels of oxidatively-damaged DNA bases were noted in the liver, kidney, and to a 
lesser extent, the lung (Kasprzak et al. 1994). 
Radioactive Cobalt. The ability of ionizing radiation to induce genotoxic damage is well-documented 
(Agency for Toxic Substances and Disease Registry 1999).  Chang et al. (1999c) reported increased 
micronucleus frequency, both of single and multiple nucleates, in 48 people who had been exposed to  
12–1,600 rad (0.12–16 Gy) over a 2–10-year period as a result of a building contaminated with 60Co­
containing steel.  Subjects who had left the building showed a decrease in micronucleus formation that 
correlated with time since cessation of exposure.  Three workers accidentally exposed to 2.2–12.7 rad 
(0.022–0.127 Gy) showed no elevation in frequency of chromosome alterations (House et al. 1992).  Ten
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children who received chemotherapy and 1,725–2,405 rad (17.25–24.05 Gy) as cobalt radiotherapy for 
acute lymphatic leukemia showed no clastogenic changes after chemotherapy but before irradiation.  
After radiotherapy, significant dose-related increases in chromosomal aberrations were seen (Rauscher 
and Bauchinger 1983). 
Radiation from cobalt isotopes has been shown to induce numerous genetic changes, including
translocations (Gilot-Delhalle et al. 1988; Grahn and Carnes 1988; Grahn et al. 1983; Searl et al. 1976), 
decreased DNA synthesis (Lohmann et al. 1966), dominant lethal mutations (Grahn et al. 1988; Searl et 
al. 1976; Zhou et al. 1986), chromosome deletions (Brooks et al. 1971b, 1974), polycentrics (Brooks et al. 
1971a, 1974), and aberrations (Brooks et al. 1971a, 1971b) in exposed animals. 
Radiation from cobalt isotopes was genotoxic in several assay systems in mammalian cells: DNA 
amplification in hamster cells (Lucke-Huhle et al. 1986, 1990); chromosomal aberrations and sister-
chromatid exchanges in mouse lymphosarcoma cells (Juraskova and Drasil 1987); chromosomal 
aberrations and micronucleus formation in human lymphocytes (Koksal et al. 1995, 1996; Schmid et al. 
2002); DNA breakage in human leukocytes (Lindahl-Kiessling et al. 1970; Reuff et al. 1993), kidney cells 
(Feinendegen et al. 1977), and fibroblasts (Coquerelle et al. 1987; Dolling et al. 1998); chromosomal 
aberrations in human leukocytes (Reuff et al. 1993); transformation of human fibroblasts (Namba et al. 
1981, 1985, 1988); and retinoblastoma gene alterations in human fibroblasts (Endo et al. 1993). 
3.5 TOXICOKINETICS 
3.5.1 Absorption
3.5.1.1 Inhalation Exposure 
Inhaled cobalt particles are deposited in the upper and lower respiratory tract and cobalt is subsequently
absorbed by several mechanisms (Casarett and Doull 1986); however, two of these mechanisms in 
particular appear to be most relevant.  The deposition pattern in the respiratory tract is related to particle 
size, which determines the degree to which particles are affected by inertial impaction, sedimentation, 
diffusion, and electrostatic precipitation.  Large particles (diameter >2 µm) tend to deposit in the upper 
respiratory tract where high airstream velocities and airway geometry promote inertial impaction of larger 
particles. Smaller particles escape inertial impaction and enter the lower respiratory tract where lower 
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airstream velocities and airway geometry favor the process of sedimentation, diffusion, and electrostatic 
precipitation of small particles.  Fractional deposition can be expected to vary considerably with age, 
particle size, and breathing patterns (see Table 3-10).  Fractional deposition of inhaled cobalt oxide 
particles in humans varied from approximately 50% of the inhaled dose for particles with a geometric 
mean diameter of 0.8 µm to approximately 75% of the inhaled dose for particles with a geometric mean 
diameter of 1.7 µm (Foster et al. 1989). 
The transfer pathways of cobalt oxide (57Co used as a tracer) from the lungs in humans and animals are 
shown in Figure 3-4.  Particles of cobalt deposited in the respiratory tract can be absorbed into the blood 
after dissolution (S(t)) or mechanically transferred to the gastrointestinal tract by mucociliary action of the 
respiratory tract and swallowing action (M(t)).  Only a portion (probably <50%) of the cobalt that enters 
the gastrointestinal tract will be absorbed into the body.  The relative magnitude of the translocation and 
mechanical clearance pathways depends on the size and solubility of the cobalt particles that are inhaled.  
Large particles (>2 µm) will tend to deposit in the middle and upper airways where mechanical clearance
mechanisms predominate over translocation.  Smaller particles that enter the lower respiratory tract will 
tend to remain until dissolved or phagocytized by macrophages and translocation occurs.  The sum of the 
activities of translocation and mechanical clearance determine the kinetics of absorption of inhaled cobalt.  
In humans, the ratio of translocation (S(t)) to mechanical clearance (M(t)) is approximately 5–1 for 
particle sizes ranging from 0.8 to 1.7 µm (mean geometric diameter) (Foster et al. 1989). 
Data on retention of cobalt oxide (57Co used as a tracer) in the respiratory tracts of humans and several 
animal species are summarized in Table 3-6.  Considerable variability exists among species.  In humans, 
almost one-half of the original lung burden persisted 6 months after exposure; in rats, clearance of cobalt 
from the lungs was nearly complete after 6 months.  The elimination half-time for cobalt in the human 
lung increased with increasing time after exposure (Foster et al. 1989; Sedlet et al. 1958).  This may
reflect slower clearance of cobalt that is bound to cellular components in the lung (Kreyling et al. 1985, 
1986). 
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Figure 3-4. Transfer Parameters for Cobalt Following Inhalation of Cobalt Oxide*
(CO3O4) Particles, Showing the Fractions of the Lung Content, L(t), and Time, t, 
Cleared Per Day by Each Route** 
 
 
 
GI tract = gastrointestinal tract; 

bfS(t) = fraction of cobalt excreted in the feces after translocation; 

buS(t) = fraction of cobalt excreted in the urine after translocation; 

F(t) = fecal excretion rate; 

gfM(t) = fraction of cobalt excreted in the feces after mechanic clearance to the gastrointestinal tract; 

guM(t) = fraction of cobalt excreted in the urine after mechanic clearance to the gastrointestinal tract; 

M(t) = rate of mechanical transport of cobalt particles from the lungs to the gastrointestinal tract; 

S(t) = rate of translocation of cobalt from the lungs to the blood; 

U(t) = urinary excretion rate 

*Cobalt-57 tracer used 

**Derived from Bailey et al. 1989 
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Table 3-6. Initial (Day 3) Lung Deposits of Cobalt Oxide and Summary of Lung 

Retention at 90 and 180 Daysa,b
 
Mean initial 57Co activity in Lung retention Lung retention 
lung L(3) (kBq) L(90)/L(3) (%) L(180)/L(3) (%)
Species (strain) 0.8 µm 1.7 µm 0.8 µm 1.7 µm 0.8 µm 1.7 µm 
Human 53 42 64 75 45 56 
Baboon 2,100 1,700 55 55 26 37 
Beagle dog 1,150 1,450 27 45 5.5 12 
Guinea pig (Harwell) 8.4 1.4 49 46 8.3 15 
Rat (HMT, 1985) 10.8 4.7 5.2 20 1.3 8.0 
Rat (HMT, 1986) 3.2 0.7 5.3 18 1.2 9.2 
Rat (F344, SPF) 8.8 4.4 14 25 4.7 9.2 
Rat (Sprague-Dawley) 0.9 0.10 8 39 1 15 
Syrian hamster 4.0 1.2 21 35 3.4 12 
Mouse (CBA/H) 1.8 No data 15 No data 2.8 No data 
aDerived from Bailey et al. 1989 
bCobalt-57 used as tracer
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3.5.1.2 Oral Exposure 
Gastrointestinal absorption of cobalt in humans varies considerably (18–97% of the given dose) based on 
the type and dose of cobalt compound given and the nutritional status of the subjects (Harp and Scoular 
1952; Smith et al. 1972; Sorbie et al. 1971; Valberg et al. 1969).  More cobalt was absorbed through the 
gastrointestinal tract of humans when the body was deficient in iron (31–71% in iron deficiency; 18–44%
in controls) (Sorbie et al. 1971; Valberg et al. 1969). One study in humans has shown that oral exposure 
to cobalt chloride resulted in significantly higher urinary excretion in females relative to males
(Christensen et al. 1993). 
In animal studies, many factors have been shown to influence the absorption of cobalt compounds 
following oral exposure.  In several studies in rats (Ayala-Fierro et al. 1999; Barnaby et al. 1968; Hollins 
and McCullough 1971; Kirchgessner et al. 1994; Schade et al. 1970; Taylor 1962), soluble cobalt chloride 
was absorbed in the range of 13–34%, whereas physiologically insoluble cobalt oxide particles have been 
shown to be poorly absorbed, in the range of 1–3% (Bailey et al. 1989; Collier et al. 1989; Patrick et al. 
1989).  The particle size of the given dose of cobalt oxide had no significant effect on gastrointestinal 
absorption (Table 3-7).  Administration of cobalt chloride labeled with radioactive 58Co and complexed 
with histidine, lysine, glycylglycine, ethylenediaminetetraacetic acid (EDTA), casein, or glycine resulted 
in decreased gastrointestinal absorption of cobalt; administration of cobalt chloride (with 58Co tracer) in 
cows' milk permitted a significantly greater (about 40%) absorption through the gastrointestinal tract 
(Taylor 1962).  The same study found that while there was no difference in the chlorides of cobalt(II) and 
cobalt(III), a cobalt(II) glycine complex was absorbed in greater quantities than a cobalt(III) glycine 
complex.  Other studies have also demonstrated that the chemical form of the cobalt compound can affect 
the absorption of cobalt following oral exposure (Deka et al. 1981; Firriolo et al. 1999; Inaba et al. 1980; 
Kinoshita and Fujita 1972), with more water-soluble compounds generally showing greater absorption. 
Iron deficiency led to increased absorption of cobalt from the gastrointestinal tract, and simultaneous 
administration of cobalt and iron reduced the amount of cobalt absorbed (Reuber et al. 1994; Schade et al. 
1970). Increasing oral doses of cobalt resulted in decreased fractional absorption (Houk et al. 1946; 
Kirchgessner et al. 1994; Taylor 1962), and more soluble forms of cobalt were better absorbed than less 
soluble compounds (Kreyling et al. 1986).  Absorption is 3- to 15-fold greater in younger animals (rats 
and guinea pigs examined from days 1–60 of life) than in adult (200 days of age) animals (Naylor and  
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Table 3-7. Summary of Measurements of Retention and Excretion After 

Intragastric Administration of Cobalt Oxide (Co3O4) Particles (Mean 

Percentage of Recovered Activity at 7 Days After Administration)a,b
 
Cumulative fecal Whole body Cumulative urinary 
Species excretion retention excretion Absorption
(strain) 0.8 µm 1.7 µm 0.8 µm 1.7 µm 0.8 µm 1.7 µm 0.8 µm 1.7 µm 
Baboon 97.8 98.4 0.12 0.20 2.0 1.4 2.6 1.9 
Guinea pig 98.7 97.6 0.16 0.66 1.1 1.9 1.3 2.3 
Rat (HMT) 96.3 99.4 0.09 0.02 2.8 0.6 3.9 1.0 
Rat 99.6 99.7 0.04 0.03 0.4 0.3 0.4 0.3 
(F-344) 
Hamster 96.0 96.3 0.50 0.18  3.5 3.5 5.1 5.1 
Mouse 99.1 No data 0.3 No data 0.6 No data 0.8 No data 
(CBA/H) 
aDerived from Bailey et al. 1989 
bCobalt-57 used as tracer
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Harrison 1995).  Species differences in absorption of cobalt oxide do not appear to exist (Bailey et al. 
1989), but absorption of soluble cobalt compounds is greater in rats (13–34%) than in dairy cows (1–2%) 
and guinea pigs (4–5%) following oral exposure (Ayala-Fierro et al. 1999; Barnaby et al. 1968; Hollins 
and McCullough 1971; Kirchgessner et al. 1994; Naylor and Harrison 1995; Schade et al. 1970; Taylor 
1962; van Bruwaene et al. 1984). 
3.5.1.3 Dermal Exposure  
Four humans who placed their right hands into a box filled with hard metal dust (~5–15% cobalt metal, 
95–85% tungsten carbide) for 90 minutes showed an increase in urinary cobalt levels by an order of 
magnitude in the post-exposure samples, remaining elevated for as long as 48–60 hours (Scansetti et al. 
1994). Similarly, cobalt was detected in the fingernails of three volunteers who placed their fingers in 
cobalt solution 10 minutes/day for 7 days (Nielsen et al. 2000), even after the cessation of exposure.  
These findings demonstrate that cobalt from these metal dusts can be absorbed through the skin.  The 
absorption of 2.2x10-5 mg 60Co/kg as cobalt chloride in 1.4N HCl through 1 cm2 of intact or abraded skin 
of guinea pigs was examined by Inaba and Suzuki-Yasumoto (1979).  Absorption through intact skin was 
very small (<1%), while absorption through abraded skin was almost 80% 3 hours after exposure.  A 
study in hamsters (Lacy et al. 1996) also reported a low amount of absorption of cobalt through
unabraded skin. 
3.5.1.4 Other Routes of Exposure 
No studies were located regarding absorption of cobalt in humans or animals after other routes of 
exposure. 
3.5.2 Distribution 
As a component of vitamin B12, cobalt is an essential element and, therefore, is found in most body 
tissues. It has been identified in liver, muscle, lung, lymph nodes, heart, skin, bone, hair, stomach, brain, 
pancreatic juice, kidneys, plasma, and urinary bladder of nonexposed subjects, with the highest cobalt 
concentration found in the liver (Collecchi et al. 1986; Forbes et al. 1954; Hewitt 1988; Ishihara et al. 
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1987; Muramatsu and Parr 1988; Teraoka 1981; Yamagata et al. 1962; Yukawa et al. 1980) (see 
Chapter 6 for more information).  Tissue levels reflected exposure from all routes.  The total body content 
of cobalt has been estimated at 1.1–1.5 mg (ICRP 1979; Yamagata et al. 1962); about 0.11 mg was found 
in the liver (ICRP 1979). 
In patients with laryngeal carcinoma, levels of cobalt in the tumor were significantly higher (p<0.001) 
than levels in the nonmalignant tissues around the tumor (68.7 ng/g tissue versus 39.6 ng/g) (Collecchi et 
al. 1986).  The mean cobalt concentrations in plasma (18.3 ng/mL) were also significantly higher in these 
patients than in the comparison population (0.73 ng/mL).  The clinical significance of these findings is 
not known. 
3.5.2.1 Inhalation Exposure 
In workers occupationally exposed to airborne cobalt, increased cobalt levels were found in tissues at 
death. Significant increases in cobalt in the lung have been found in copper smelter and metal workers 
and coal miners occupationally exposed to cobalt (Gerhardsson et al. 1984; Hewitt 1988; Hillerdal and 
Hartung 1983; Teraoka 1981). No increase in liver or kidney cobalt levels were found in the copper 
smelter workers as compared to controls (Gerhardsson et al. 1984).  In metal workers, increased cobalt 
levels were also found in the lymph nodes, liver, spleen, and kidneys (Hillerdal and Hartung 1983; 
Teraoka 1981). 
The tissue distribution of cobalt in animals is similar to that in humans, with marked increases in the 
concentration of cobalt in the lungs following inhalation exposure (Barnes et al. 1976; Brune et al. 1980; 
Collier et al. 1991; Kreyling et al. 1986; Kyono et al. 1992; Patrick et al. 1989; Talbot and Morgan 1989).  
Histologically, the particles of cobalt in the lung are found in macrophages within the bronchial wall or in 
the interstitium close to the terminal bronchioli (Brune et al. 1980).  Significant concentrations of cobalt 
have been found in the liver, kidney, trachea, spleen, bones, and heart (Barnes et al. 1976; Brune et al. 
1980; Kerfoot 1975; Kreyling et al. 1986; Wehner and Craig 1972), with the greatest concentrations in the 
liver and the kidney (Kerfoot 1975; Wehner and Craig 1972). 
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3.5.2.2 Oral Exposure 
No studies were located regarding distribution in humans after oral exposure to cobalt. 
In animals, the cobalt absorbed through the gastrointestinal tract was primarily retained in the liver 
(Ayala-Fierro et al. 1999; Greenberg et al. 1943; Simesen 1939).  Appreciable levels were also found in 
the kidneys, heart, stomach, and intestines (Ayala-Fierro et al. 1999; Persson et al. 1992; Simesen 1939).  
Following a single oral dose of cobalt napthenate, appreciable levels of cobalt were found in the heart, 
liver, and kidney, but not in the spleen or testes (Firriolo et al. 1999).  Following oral exposure to 
pregnant rats, a dose-dependent increase in cobalt levels in fetal blood and amniotic fluid was seen 
(Szakmary et al. 2001). 
Following longer-term exposure (8 weeks) to cobalt sulfate in the diet, exposed rats showed a 30-fold 
increase in the cobalt concentration in the myocardium, a 26-fold increase in the concentration in the 
soleus muscle, and a 100-fold increase in the concentration in serum compared with nonexposed controls 
(Clyne et al. 1988; Pehrsson et al. 1991).  Long-term oral exposure of rats to cobalt chloride resulted in 
significantly increased levels of cobalt in the liver, kidney, muscle, brain, and testes of treated rats 
(Barnaby et al. 1968; Bourg et al. 1985; Thomas et al. 1976). 
3.5.2.3 Dermal Exposure 
No studies were located regarding distribution in humans or animals after dermal exposure to cobalt. 
3.5.2.4 Other Routes of Exposure 
Following intravenous injection of cobalt chloride (as a combination of radioactive 55CoCl2 and 56CoCl2) 
in two humans, the liver and bladder contained the highest portions of cobalt (Jansen et al. 1996). 
Distribution in animals after an intravenous dose appears to be similar to what we know of cobalt 
distribution in humans following injection of cobalt compounds.  Two hours after intravenous injection of 
cobalt chloride (with a radioactive 57Co tracer) in rats, accumulation was found in the liver (22.8% of the 
dose), kidneys (10.2%), and intestines (3.16%) (Gregus and Klaassen 1986).  Similar results (29% liver, 
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10% kidneys, 4.6% intestines) were found following intracardiac injection of cobalt nitrate in rats (Patrick 
et al. 1989) or intravenous injection of a combination of radioactive 55CoCl2 and 56CoCl2 in rats (exact 
percentages were not provided) (Jansen et al. 1996). One hundred days after intravenous injection of 
60CoCl2 in rats, the greatest concentrations were found in spleen>heart>bone, while liver and kidney, 
initially the highest in cobalt, contained comparatively low amounts of cobalt (Thomas et al. 1976).  
Similar results were seen 132 days following an intraperitoneal injection of 60CoCl2 in rats (Barnaby et al. 
1968).  Intramuscular injection of cobalt mesoporphyrin in rats yielded the greatest levels of cobalt in 
liver and blood, followed by kidney, lung, spleen, adrenal glands, and heart at 7 days post-injection and 
later (Feng et al. 1998).  Four weeks after subcutaneous administration of cobalt protoporphyrin, the 
greatest tissue levels of cobalt occurred in the kidney, followed by spleen, liver, lung, thymus, and gonads 
(Rosenberg 1993). When cobalt (with a 57Co tracer) encapsulated in liposomes was intravenously 
injected into rats, decreased distribution to the heart (40% less than animals receiving cobalt chloride), 
kidneys, and carcass, and increased distribution to the spleen and bones were found (Szebeni et al. 1989). 
3.5.3 Metabolism 
Cobalt is essential in the body because it is a component of cyanocobalamin (vitamin B12) (Vouk 1986). 
Vitamin B12 acts as coenzyme in many enzymatic reactions, most notably a methyl transfer reaction that 
converts homocysteine to methionine and for a separate reaction that converts L-methylmalonylcoenzyme 
A (CoA) to succinyl-CoA (Institute of Medicine 2000).  Vitamin B12 is also a part of some enzymes 
involved in hematopoiesis; deficiency can lead to pernicious anemia (Domingo 1989).  No other essential 
function of cobalt has been reported.  The Recommended Dietary Allowance (RDA) for vitamin B12 for
adults is 2.4 µg/day, which contains 0.1 µg of cobalt (Institute of Medicine 2000). 
3.5.4 Elimination and Excretion 
3.5.4.1 Inhalation Exposure 
No data are available on the clearance of soluble cobalt particles in humans.  Following exposure of 
humans to physiologically insoluble cobalt compounds (cobalt metal, cobalt oxides), clearance from the 
body, assessed by both urinary/fecal clearance and a reduction in whole-body retention, appears to follow 
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three-phase kinetics. The first phase, likely representing mucociliary clearance of particles deposited in 
the tracheobronchial region, has a half-time on the order of 2–44 hours (Apostoli et al. 1994; Mosconi et 
al. 1994b). The second phase, with a half-time on the order of 10–78 days, may represent macrophage-
mediated clearance of cobalt particles from the lung (Beleznay and Osvay 1994; Mosconi et al. 1994b). 
The third clearance phase, representing long-term clearance from the lungs, has a half-time on the order 
of years (Bailey et al. 1989; Beleznay and Osvay 1994; Mosconi et al. 1994b; Newton and Rundo 1971).  
Following a controlled aerosol exposure in humans, about 40% of the initial lung burden of inhaled cobalt 
oxide (with a 57Co tracer) was retained for a period of 6 months after exposure (Foster et al. 1989).  
Within the first week, about 17% of the initial lung burden was eliminated, with the majority (about 90%) 
mechanically cleared to the gastrointestinal tract and excreted in the feces (Foster et al. 1989).  Six 
months after exposure, a cumulative elimination of 33% of the initial lung burden was found in the urine 
and 28% was found in the feces (Foster et al. 1989).  The ratio of peak absorption rate to average 
mechanical clearance rate (Figure 3-4 and Table 3-8) was about 5 to 1.  The elimination of cobalt 
following inhalation exposure was affected by the time after exposure (urinary excretion increases as time 
increases) and particle size (more cobalt is initially mechanically cleared to the gastrointestinal tract when 
the aerosol consists of bigger particles) (Bailey et al. 1989; Foster et al. 1989). 
In animals, the solubility of the cobalt compound appears to greatly affect its long-term clearance.  
Studies with cobalt oxides have shown that the more soluble CoO is cleared from the lungs at a greater 
rate than the less soluble Co3O4 (Barnes et al. 1976; Kreyling 1984a).  More soluble cobalt compounds 
are absorbed into the blood at a greater rate, and excreted in the urine and, to a lesser extent, the feces 
(Barnes et al. 1976).  The rate of urinary excretion appears to correlate with the rate of translocation of 
cobalt from the lungs to the blood, and the rate of fecal clearance with the rate of mechanical clearance of 
cobalt from the lungs to the gastrointestinal tract (Andre et al. 1989; Bailey et al. 1989; Collier et al. 1989; 
Kreyling et al. 1986, 1989; Patrick et al. 1989; Talbot and Morgan 1989).  Following an initial high rate 
of fecal clearance, urinary excretion was the primary route of cobalt elimination after a single inhalation 
exposure (2 weeks of observation) (Palmes et al. 1959) or 3 months of exposure (Kerfoot 1975; Palmes et 
al. 1959).  In several species of animals, most of the inhaled Co3O4 (with a 57Co tracer) following a single 
exposure was cleared from the lungs by 6 months after exposure (Table 3-6) (Andre et al. 1989; Bailey et 
al. 1989; Collier et al. 1989; Kreyling et al. 1989; Patrick et al. 1989; Talbot and Morgan 1989).  The 
peak translocation and average mechanical clearance of cobalt from the lungs for different species are 
reported in Table 3-8, with the rate (high to low) following as mouse > rat > hamster > guinea pig > 
baboon, human > beagle dog. 
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Table 3-8. Peak Translocation and Average Mechanical Clearance Rates After 

Inhalation of Cobalt Oxidea,b
 
Percent of lung content cleared per day
Species (strain) 0.8 µm
Translocation at peak
Peak day 1.7 µm Peak day
Average mechanical 
clearancec 
Human 0.45 180 0.5 180 0.1 
Baboon 0.6 180 0.2 d 0.1 
Beagle dog 2.1 85 1.7 180 0.03 
Guinea pig 2.1 180 1.0 75 0.3 
Rat HMT 2.4 40 0.6 d 0.9 
Rat (F-344) 1.1 10 0.4 d 1.0 
Hamster 1.8 180 0.7 180 0.8 
Mouse 1.7 180 No data No data 1.05 
aDerived from Bailey et al. 1989 
bCobalt-57 used as tracer 
cClearance rates were virtually identical in both particle size groups 
dConstant value over 180 days
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3.5.4.2 Oral Exposure 
In humans orally exposed to cobalt, fecal elimination, which is the primary route of elimination, varies 
considerably (3–99% of the dose) and depends on the amount and type of cobalt given and on the 
nutritional status of the subjects (Section 3.5.1.2) (Harp and Scoular 1952; Paley et al. 1958; Smith et al. 
1972; Sorbie et al. 1971; Valberg et al. 1969).  Within days after oral exposure, 10 times more cobalt was 
excreted in feces than in the urine (Paley et al. 1958).  Less cobalt was eliminated in the feces (more was 
absorbed) in subjects with an iron deficiency (Sorbie et al. 1971; Valberg et al. 1969). 
Fecal elimination of cobalt is the primary route of elimination in animals following oral exposure and 
depends mainly upon the particle solubility (decreasing fecal clearance with increasing solubility) of the 
cobalt compound.  The cumulative urinary and fecal elimination in several species following oral 
administration of Co3O4 (with a 57Co tracer) is reported in Table 3-7 (Bailey et al. 1989).  Following oral 
administration in several species, very little Co3O4 was absorbed through the gastrointestinal tract and 
most (>96%) was quickly eliminated in the feces.  No significant differences in elimination of 
Co3O4 were found among species of animals (Andre et al. 1989; Bailey et al. 1989; Collier et al. 1989;
Patrick et al. 1989; Talbot and Morgan 1989).  For the more soluble cobalt(II) chloride, reported fecal 
elimination levels have ranged from 70 to 83% of the administered dose for rats, with urinary excretion 
accounting for the majority of the remainder of the dose (Ayala-Fierro et al. 1999; Barnaby et al. 1968; 
Hollins and McCullough 1971).  In lactating dairy cows, about 97% of an oral dose of cobalt chloride was 
recovered in the feces by day 70 post-exposure, while the urine and milk contained 0.26 and 0.012% of 
the dose, respectively (van Bruwaene et al. 1984).  Following a single exposure in beagle dogs, more 
Co3O4 (physiologically insoluble) was eliminated in the feces (90% in the feces and 5% in the urine) than 
following an exposure to cobalt nitrate (soluble) (70% in the feces and 25% in the urine) (Kreyling et al. 
1986). 
As is the case for absorption of cobalt compounds, the iron status of the animal also appears to affect the 
elimination of cobalt compounds.  Following oral exposure, iron-deficient rats eliminated less of a given 
dose in the feces than normal rats, while co-administration of iron compounds resulted in an increased 
fecal excretion of cobalt compounds (Reuber et al. 1994; Schade et al. 1970). 
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3.5.4.3 Dermal Exposure  
No studies were located regarding excretion in humans after dermal exposure to cobalt. 
Lacy et al. (1996) reported that the majority of the absorbed dose of CoCl2 was excreted in the urine 
48 hours after a single dermal exposure in Syrian hamsters.  No other studies were located regarding 
excretion in animals after dermal exposure to cobalt. 
3.5.4.4 Other Routes of Exposure 
Following intravenous injection of cobalt chloride in humans, about 30% of the dose was excreted in the 
urine within 24 hours (Smith et al. 1972), 56–73% was excreted within 48 hours (Paley et al. 1958), and 
57% was excreted within 2 weeks (Kent and McCance 1941). 
Following intravenous injection of cobalt nitrate (with a 57Co tracer) in various species of animals, most 
of the injected dose was excreted in the urine; about 80% of the given dose was excreted in the urine 
within 21 days (Table 3-9) (Andre et al. 1989; Bailey et al. 1989; Collier et al. 1989; Patrick et al. 1989;
Talbot and Morgan 1989).  Other investigators have also found that the urine is the primary route of 
cobalt excretion following intravenous administration (Ayala-Fierro et al. 1999; Barnaby et al. 1968; 
Gregus and Klaassen 1986; Kreyling et al. 1986; Onkelinx 1976; Thomas et al. 1976).  Most of the 
remaining cobalt (5–30% of the total dose) after intravenous exposure was excreted in the feces, with the 
majority of studies reporting very little long-term retention.  Excretion of cobalt (about 2–7% of the 
injected dose) in the bile was also reported (Cikrt and Tich 1981; Gregus and Klaasen 1986; Sheline et al. 
1945). Elimination following intraperitoneal injection is similar to that seen following intravenous 
exposure, with urinary excretion being the major route of elimination, and fecal excretion accounting for 
the majority of the remainder of the dose (Barnaby et al. 1968; Hollins and McCullough 1971; Talbot and 
Morgan 1989), though long-term clearance may be more balanced between the two (Hollins and 
McCullough 1971).  Following subcutaneous injection, both CoCl2 and Co(NO3)2 were cleared rapidly
from the body (Rosenberg 1993; Talbot and Morgan 1989), with the urine being the major route of 
clearance (Talbot and Morgan 1989). 
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Table 3-9. Summary of Measurements of Retention and Excretion of Cobalt 

Following Injection of Cobalt Nitrate Co(NO3)2 Solution (Mean Percent 

Recovery)a,b 

Whole body retention on Cumulative urinary Cumulative fecal 
Species day excretion on day excretion on day
(strain) 1 7 21 1 7 21 1 7 21
Baboon No data No data No data 57 74 80 5 17 20 
Beagle dog No data No data No data 71 86 87 3.4 4.4 4.9 
Guinea pig 34 8 3.5 64 82 85 2.2 10 12 
Rat (HMT) 18 4.2 1.9 64 72 74 18 24 24 
Rat (F-344) No data No data 2.9 No data No data 80 No data No data 18 
Hamster 27 4.3 1.9 55 68 69 17 28 29 
Mouse 23 2.9 1.1 59 71 72 18 26 27 
aDerived from Bailey et al. 1989 
bCobalt-57 used as tracer
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Following injection, studies have shown that the chemical form of the cobalt compound can affect its 
elimination.  Subcutaneous injection of cobalt protoporphyrin in rats, in which the cobalt atom is chelated 
within the porphyrin ring, resulted in a slower elimination from the body than cobalt chloride, with 
significant cobalt levels (~20% of initial injection) still present in the body 14 days after exposure 
(Rosenberg 1993). Likewise, intramuscular injection of cobalt mesoporphyrin resulted in primarily in
fecal excretion, with a high systemic retention (Feng et al. 1998).  It therefore appears that a greater 
solubility leads to fast elimination, mainly in the urine, while a less soluble compound will be retained for 
longer periods and eliminated to a greater extent in the feces. 
3.5.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points. 
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen et al. 
1987; Andersen and Krishnan 1994).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors. 
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of 
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toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these 
solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) is 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
Similar models have been developed for radionuclides.  These PBPK models provide a scientifically
sound means to predict the target tissue dose of chemicals in humans who are exposed to environmental 
levels (for example, levels that might occur at hazardous waste sites) based on the results of studies where 
doses were higher or were administered in different species.  Figure 3-5 shows a conceptualized 
representation of a PBPK model.  Figures 3-6 through 3-9 show models for radionuclides in general or 
specifically for cobalt.   
The ICRP (1995) developed a Human Respiratory Tract Model for Radiological Protection, which 
contains respiratory tract deposition and clearance compartmental models for inhalation exposure that 
may be applied to particulate aerosols of cobalt compounds.  The ICRP (1993) also developed a 
3-compartment biokinetic model for human oral exposure that applies to cobalt.  EPA (1998) has adopted 
the ICRP (1993, 1995) models for assessment of radiologic cancer risks from cobalt exposures.  The 
National Council on Radiation Protection and Measurement (NCRP) has also developed a respiratory
tract model for inhaled radionuclides (NCRP 1997).  At this time, the NCRP recommends the use of the  
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Figure 3-5. Conceptual Representation of a Physiologically Based 

Pharmacokinetic (PBPK) Model for a Hypothetical  

Chemical Substance 

Source: adapted from Krishnan et al. 1994 
Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a hypothetical 
chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by ingestion, 
metabolized in the liver, and excreted in the urine or by exhalation. 
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ICRP model for calculating doses for radiation workers and the general public.  Readers interested in this 
topic are referred to NCRP Report No. 125; Deposition, Retention and Dosimetry of Inhaled Radioactive 
Substances (NCRP 1997).  In the appendix to the report, NCRP provides the animal testing clearance data 
and equations fitting the data which supported the development of the human model for cobalt
Human Respiratory Tract Model for Radiological Protection (ICRP 1994). 
Respiratory Tract Deposition. The ICRP (1994) has developed a physiologically-based 
pharmacokinetic model for behavior of aerosols and vapors in the respiratory tract.  ICRP (1994) provides
inhalation dose coefficients that can be used to estimate the committed equivalent and the effective doses 
to organs and tissues throughout the body based on a unit intake of radioactive material and the 
anticipated distribution and retention of the material, its radioactive decay, and the energy of the 
radiationemitted from the material and absorbed by tissues.  The model applies to three levels of particle 
solubility, a wide range of particle sizes (approximately 0.0005–100 µm in diameter), and parameter 
values that can be adjusted for various segments of the population (e.g., sex, age, level of physical 
exertion). This model also allows one to evaluate the bounds of uncertainty in deposition estimates.  
Uncertainties arise from natural biological variability among individuals and the need to interpret some
experimental evidence that remains inconclusive.  It is applicable to particulate aerosols containing 
cobalt, and was developed for a wide variety of radionuclides and their chemical forms. 
The ICRP deposition model estimates the fraction of inhaled particle mass that initially deposits in each 
compartment (Figure 3-6).  The model was developed with 5 compartments:  (1) the anterior nasal 
passages (ET1); (2) all other extrathoracic airways (ET2) (posterior nasal passages, the naso- and 
oropharynx, and the larynx); (3) the bronchi (BB); (4) the bronchioles (bb); and (5) the alveolar 
interstitium (AI).  Particles deposited in each of the regions may be removed from each region and 
redistributed either upward into the respiratory tree or to the lymphatic system and blood by different 
particle removal mechanisms. 
For extrathoracic deposition of particles, the model uses experimental data, where deposition is related to 
particle size and airflow parameters, and scales deposition for women and children from adult male data.   
Similarly to the extrathoracic region, experimental data served as the basis for lung (bronchi, bronchioles, 
and alveoli) aerosol transport and deposition.  A theoretical model of gas transport and particle deposition 
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Figure 3-6. Compartment Model to Represent Particle Deposition and 

Time-Dependent Particle Transport in the Respiratory Tract* 

*Compartment numbers shown in lower right corners are used to define clearance pathways. The clearance rates, 
half-lives, and fractions by compartment, as well as the compartment abbreviations are presented in Table 3-11. 
Source: ICRP 1994b 
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was used to interpret data and to predict deposition for compartments and subpopulations other than adult 
males. Table 3-10 provides reference respiratory values for the general Caucasian population under 
several levels of activity.
Deposition of inhaled gases and vapors is modeled as a partitioning process, which depends on the 
physiological parameters noted above as well as the solubility and reactivity of compound in the 
respiratory tract (Figure 3-7).  The ICRP (1994) model defines three categories of solubility and 
reactivity: SR-0, SR-1, and SR-2: 
•	 Type SR-0 compounds include insoluble and nonreactive gases (e.g., inert gases such as H2, He).  
These compounds do not significantly interact with the respiratory tract tissues and essentially all 
compound inhaled is exhaled.  Radiation doses from inhalation of SR-0 compounds are assumed 
to result from the irradiation of the respiratory tract from the air spaces. 
•	 Type SR-1 compounds include soluble or reactive gases and vapors that are expected to be taken 
up by the respiratory tract tissues and may deposit in any or all of the regions of the respiratory 
tract, depending on the dynamics of the airways and properties of the surface mucous and airway 
tissues, as well as the solubility and reactivity of the compound. 
•	 Type SR-2 compounds include soluble and reactive gases and vapors that are completely retained 
in the extrathoracic regions of the respiratory tract.  SR-2 type compounds include sulfur dioxide 
(SO2) and hydrogen fluoride (HF). 
Respiratory Tract Mechanical (Particle) Clearance.    This portion of the model identifies the 
principal clearance pathways within the respiratory tract.  The model was developed to predict the 
retention of various chemical materials.  The compartmental model is linked to the deposition model (see 
Figure 3-6) and to reference values presented in Table 3-11.  This table provides deposition fractions and 
clearance rates for each compartment for insoluble particles.  The table provides rates of insoluble particle 
transport for each of the compartments, expressed as a fraction of the deposit per day and also as 
clearance half-time.  ICRP (1994) also developed modifying factors for some of the parameters, such as 
age, smoking, and disease status.  Parameters of the clearance model are based on human evidence for the 
most part, although particle retention in airway walls is based on experimental data from animal 
experiments. 
The clearance of deposited particles from the respiratory tract is a dynamic process.  The rate of clearance 
generally changes with time from each region and by each route.  Following deposition of large numbers  
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Table 3-10. Reference Respiratory Values for a General Caucasian Population at 

Different Levels of Activitya
 
Activity: Resting (sleeping) Sitting awake Light exercise Heavy exercise
Maximal 
workload: 8% 12% 32% 64% 
Breathing 
parametersb 
VT 
(L)
B
(m3h-1)
fR 
(min-1)
VT 
(L)
B
(m3h-1)
fR 
(min-1)
VT 
(L)
B
(m3h-1)
fR 
(min-1)
VT 
(L)
B fR 
(m3h-1) (min-1)
Age Sex 
3 months 0.04 0.09 38 N/A N/A N/A 0.07 0.19 48 N/A N/A N/A 
1 year 0.07 0.15 34 0.1 0.22 36 0.13 0.35 46 N/A N/A N/A 
5 years 0.17 0.24 23 0.21 0.32 25 0.24 0.57 39 N/A N/A N/A 
10 years Male: 0.841 2.22 44 
 Female: 0.667 1.84 46 
Both: 0.3 0.31 17 0.33 0.38 19 0.58 1.12 32 
15 years Male: 0.50 0.42 14 0.533 0.48 15 1.0 1.38 23 1.352 2.92 36 
 Female: 0.42 0.35 14 0.417 0.40 16 0.903 1.30 24 1.127 2.57 38 
Adult Male: 0.63 0.45 12 0.750 0.54 12 1.25 1.5 20 1.923 3.0 26 
 Female: 0.44 0.32 12 0.464 0.39 14 0.992 1.25 21 1.364 2.7 33 
aSee Annex B (ICRP 1994) for data from which these reference values were derived. 
bVT = Tidal volume, B = ventilation rate, fR = respiration frequency 
h = hour; L = liter(s); min = minute(s); N/A = not applicable 
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Figure 3-7. Reaction of Gases or Vapors at Various Levels of the Gas-Blood 

Interface 
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Table 3-11. Reference Values of Parameters for the Compartment Model to 

Represent Time-dependent Particle Transport from the  

Human Respiratory Tract 

Part A 
Clearance rates for insoluble particles
Pathway From To Rate (d-1) Half-timea 
m1,4 AI1 bb1 0.02 35 days 
m2,4 AI2 bb1 0.001 700 days 
m3,4 AI3 bb1 0.0001 7,000 days 
m3,10 AI3 LNTH 0.00002 — 
m4,7 bb1 BB1 2 8 hours 
m5,7 bb2 BB1 0.03 23 days 
m6,10 bbseq LNTH 0.01 70 days 
m7,11 BB1 ET2 10 100 minutes
m8,11 BB2 ET2 0.03 23 days 
m9,10 BBseq LNTH 0.01 70 days 
m11,15 ET2 GI tract 100 10 minutes
m12,13 ETseq LNET 0.001 700 days 
m14,16 ET1 Environment 1 17 hours 
See next page for Part B 
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Table 3-11. Reference Values of Parameters for the Compartment Model to 

Represent Time-dependent Particle Transport from the  

Human Respiratory Tract 

Part B 
Partition of deposit in each region between compartmentsb 
Fraction of deposit in region assigned to 
Region or deposition site Compartment compartmentc 
ET2 ET2 0.9995 
ETseq 0.0005 
BB 	BB1 0.993-fs
 BB2  fs
 BBseq 0.007 
bb 	bb1 0.993-fs
 bb2  fs
 bbseq 0.007 
AI 	AI1 0.3 
AI2 0.6 
AI3 0.1 
aThe half-times are approximate since the reference values are specified for the particle transport rates and are 

rounded in units of day-1. A half-time is not given for the transport rate from Al3 to LNTH, since this rate was chosen 

to direct the required amount of material to the lymph nodes.  The clearance half-time of compartment Al3 is 

determined by the sum of the clearance rates from it. 

bSee paragraph 181, Chapter 5 (ICRP 1994) for default values used for relating fs to dae. 

cIt is assumed that fs is size-dependent.  For modeling purposes, fs is taken to be: 

f s = 05. for d ae  ≤ . ρ χ µ  2 5  / m and 
0 63  d / − . )  . (  ρ χ 2 5aef s = 05. e  for  d  ae > . ρ χ µ  2 5  / m
where: 

fs = fraction subject to slow clearance 

dae = aerodynamic particle diameter/(µm) 

ρ = particle density (g/cm3) 

χ = particle shape factor 

AI = alveolar-interstitial region; BB = bronchial region; bb = bronchiolar region; BBseq = compartment representing 

prolonged retention in airway walls of small fraction of particles deposited in the bronchial region; 

bbseq = compartment representing prolonged retention in airway walls of small fraction of particles deposited in the 

bronchiolar region; ET = extrathoracic region; Etseq = compartment representing prolonged retention in airway tissue 

of small fraction of particles deposited in the nasal passages; LNET = lymphatics and lymph nodes that drain the 

extrathoracic region; LNTH = lymphatics and lymph nodes that drain the thoracic region 

Source: ICRP 1994 
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of particles (acute exposure), transport rates change as particles are cleared from the various regions.  
Physical and chemical properties of deposited material determine the rate of dissolution and as particles 
dissolve; absorption rates tend to change over time.  By creating a model with sub-compartments of 
different clearance rates within each region (e.g., BB1, BB2, BBseq), the ICRP model overcomes 
problems associated with time-dependent functions.  Each compartment clears to other compartments by
constant rates for each pathway.
Particle transport from all regions is toward both the lymph nodes and the pharynx, and a majority of 
deposited particles end up being swallowed.  In the front part of the nasal passages (ET1), nose blowing, 
sneezing, and wiping remove most of the deposited particles.  Particles remain here for about a day.  For 
particles with AMADs a few micrometers or greater, the ET1 compartment is probably the largest 
deposition site. The majority of particles deposited at the back of the nasal passages and in the larynx 
(ET2) are removed quickly by the fluids that cover the airways.  In this region, particle clearance is 
completed within 15 minutes.  Ciliary action removes deposited particles from both the bronchi and 
bronchioles. Though it is generally thought that mucocilliary action rapidly transports most particles 
deposited here toward the pharynx, a fraction of these particles are cleared more slowly. Evidence for 
this is found in human studies.  For humans, retention of particles deposited in the lungs (BB and bb) is 
apparently biphasic.  The “slow” action of the cilia may remove as many as half of the bronchi- and 
bronchiole-deposited particles.  In human bronchi and bronchiole regions, mucus moves more slowly the 
closer to the alveoli it is. For the faster compartment, it has been estimated that it takes about 2 days for 
particles to travel from the bronchioles to the bronchi and 10 days from the bronchi to the pharynx.  The 
second (slower) compartment (BB2 and bb2) is assumed to have fractions of the inhaled particles, 
depending on the particle size, deposited in BB2 and bb2; both have clearance half-times estimated at 
20 days.  A small fraction of particles deposited in the BB and bb regions is retained in the airway wall 
for even longer periods (BBseq and bbseq). 
If particles reach and become deposited in the alveoli, they tend to stay imbedded in the fluid on the 
alveolar surface or move into the lymph nodes.  The one mechanism by which particles are physically
resuspended and removed from the AI region is coughing.  For modeling purposes, the AI region is 
divided into three subcompartments to represent different clearance rates, all of which are slow. 
Particle clearance from the alveolar-interstitial region has been measured in human subjects.  The ICRP 
model uses 2 half-times to represent clearance: about 30% of the particles have a 30-day half-time, and 
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the remaining 70% are given a half-time of several hundred days.  Over time, the AI particle transport rate 
falls and some compounds have been found in lungs 10–50 years after exposure. 
Absorption into Blood.  The ICRP model assumes that absorption into blood occurs at equivalent rates in 
all parts of the respiratory tract, except in the anterior nasal passages (ET1), where no absorption occurs. 
It is essentially a 2-stage process, as shown in Figure 3-8.  First, there is a dissociation (dissolution) of 
particles; then, the dissolved molecules or ions diffuse across capillary walls and are taken up by the 
blood.  Immediately following dissolution, rapid absorption is observed.  For some elements, rapid 
absorption does not occur because of binding to respiratory-tract components.  In the absence of data for 
specific compounds, the model uses the following default absorption rate values for those compounds that 
are classified as Types F (fast), M (medium), S (slow), and V (instantaneous): 
•	 For Type F, there is rapid 100% absorption within 10 minutes of the material deposited in the BB, 
bb, and AI regions, and 50% of material deposited in ET2. Thus, for nose breathing, there is rapid 
absorption of approximately 25% of the deposit in ET and 50% for mouth breathing. 
•	 For Type M, about 70% of the deposit in AI reaches the blood eventually.  There is rapid 
absorption of about 10% of the deposit in BB and bb, and 5% of material deposited in ET2. Thus, 
there is rapid absorption of approximately 2.5% of the deposit in ET for nose breathing, and 5%
for mouth breathing. 
•	 For Type S, 0.1% is absorbed within 10 minutes and 99.9% is absorbed within 7,000 days, so
there is little absorption from ET, BB, or bb, and about 10% of the deposit in AI reaches the 
blood eventually. 
•	 For Type V, complete absorption (100%) is considered to occur instantaneously.  
ICRP (1995) considers the experimental and human data to support the following classifications: cobalt 
chloride and nitrate, Type F; cobalt oxides, Type M or S; cobalt in fused aluminosilicate or polystyrene, 
Type S; cobalt in mineral dusts such as fly ash and volcanic ash, Type M; cobalt metal and metal alloys, 
M or S. ICRP (1995) recommends assigning all cobalt aerosols to Type M in the absence of specific 
information supporting an alternative classification. 
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Figure 3-8. The Human Respiratory Tract Model: Absorption into Blood 
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ICRP (1993) Cobalt Biokinetics Model. 
Description of the model. 
ICRP (1979, 1993) developed a 3-compartment model of the kinetics of ingested cobalt in humans that is 
applicable to infants, children, adolescents, and adults.  Absorption of ingested cobalt is assumed to be  
60% in infants up to 3 months of age, 30% from 3 months to 15 years of age, and 10% after age 15 years.  
Absorbed cobalt is assumed to distribute as follows: 50% is excreted (urine and feces combined in a 
6:1 ratio), 5% is transferred to the liver, and 45% is transferred to other tissues (Figure 3-9).  Elimination 
from tissue compartments is described by three first order rate constants representing slow, medium, and 
fast elimination pools with half-times of 6, 60, and 800 days, respectively.  The elimination half-times are 
assumed to be independent of age. 
Validation of the model. 
The extent to which the ICRP model has been validated is not described in ICRP (1993). 
Risk assessment. 
The model has been used to establish radiation dose equivalents (Sv/Bq) of ingested 57Co, 58Co, and 60Co
for ages 3 months to 70 years (ICRP 1993). 
Target tissues. 
The model can be used to estimate the radiation dose from cobalt radionuclides to all major organs and 
can be applied to environmental and occupational exposures. 
Species extrapolation. 
The model is designed for applications to human dosimetry and cannot be applied to other species without
modification. 
Interroute extrapolation. 
The model is designed to simulate oral exposures to cobalt and cannot be applied to other routes of 
exposure without modification. 
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Absorbed cobalt enters a virtual transfer compartment from which unidirectional transfer to tissues is assumed to 
occur. Percentages shown are of the initial amounts absorbed.  Numbers in parentheses are elimination half-times to 
urine and feces combined (d=days.  Liver other tissues are assumed to have fast, medium, and slow elimination 
pools. 
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3.6 MECHANISMS OF ACTION  
3.6.1 Pharmacokinetic Mechanisms 
Absorption.    Following inhalation exposure, the absorption of deposited cobalt compounds seems to 
be related to their biological solubility.  Cobalt compounds deposit in the lungs based on their aerosol 
characteristics. Physiologically insoluble cobalt particles are generally cleared by phagocytosis and/or 
mucociliary transport, and thus, have a low systemic absorption.  To some extent, cobalt particles may be 
dissolved within alveolar macrophages (Kreyling et al. 1990).  More soluble forms of cobalt may enter 
the bloodstream through the alveolar or bronchial walls. 
Following oral exposure, the absorption of cobalt varies with the amount given, with a greater dose 
leading to 4- to 20-fold greater fractional absorption (Smith et al. 1972).  Nutritional status also seems to 
be an important factor in cobalt absorption, with both overnight fasting and iron deficiency resulting in
increased cobalt absorption (Smith et al. 1972; Sorbie et al. 1971; Valberg et al. 1969).  It has been 
suggested that cobalt and iron share a common absorptive pathway in the intestines, though the cobalt 
absorption takes place without ferritin (Reuber et al. 1994; Schade et al. 1970; Thomson et al. 1971).  
Solubility of the cobalt compound is also an important factor regarding the absorption following oral 
exposure, with increasing solubility resulting in increasing absorption (Christensen et al. 1993).  One 
study in humans showed that oral exposure to cobalt resulted in significantly higher urinary excretion in 
females relative to males (Christensen et al. 1993), but these results have not been verified by other 
studies. A complex, specific pathway exists for the absorption of vitamin B12, whereby the molecule 
interacts with several factors in the stomach and intestine to facilitate absorption (for review, see Russel-
Jones and Alpers 1999). 
Dermal absorption of cobalt compounds depends greatly on whether the skin is intact or damaged.  
Absorption through intact skin is comparatively low, while absorption through damaged skin is much 
higher (Inaba and Suzuki-Yasumoto 1979; Lacy et al. 1996). 
Distribution.    As a component of vitamin B12, cobalt is found in most body tissues.  Absorbed cobalt is 
transported throughout the body in the blood, with greatest levels found in the liver, followed by the 
kidney (Ayala-Fierro et al. 1999; Greenberg et al. 1943; Gregus and Klaassen 1986; Patrick et al. 1989).  
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Following inhalation exposure, significant levels of cobalt are found in the lungs of exposed humans and 
animals (Barnes et al. 1976; Brune et al. 1980; Collier et al. 1991; Gerhardsson et al. 1984; Hewitt 1988; 
Hillerdal and Hartung 1983; Kreyling et al. 1986; Kyono et al. 1992; Patrick et al. 1989; Talbot and 
Morgan 1989; Teraoka 1981).  Within the lung, physiologically insoluble cobalt particles tend to be 
located within macrophages within the bronchial wall or in the interstitium close to the terminal 
bronchioli (Brune et al. 1980). 
Excretion. Following inhalation exposure, the rate of urinary excretion appears to correlate with the 
rate of translocation of cobalt from the lungs to the blood, and the rate of fecal clearance with the rate of 
mechanical clearance of cobalt from the lungs to the gastrointestinal tract (Andre et al. 1989; Bailey et al. 
1989; Collier et al. 1989; Kerfoot 1975; Kreyling et al. 1986, 1989; Palmes et al. 1959; Patrick et al. 
1989; Talbot and Morgan 1989).  Likewise, the majority of absorbed cobalt following oral exposure is 
rapidly removed from the body by excretion in the urine, and to a lesser extent in the bile and feces, with 
fecal elimination being the primary method of excretion for physiologically insoluble cobalt compounds 
in both humans and animals (Andre et al. 1989; Bailey et al. 1989; Collier et al. 1989; Harp and Scoular 
1952; Paley et al. 1958; Patrick et al. 1989; Smith et al. 1972; Sorbie et al. 1971; Talbot and Morgan 
1989; Valberg et al. 1969).  The primary route for excretion following dermal exposure is the urine (Lacy
et al. 1996; Scansetti et al. 1994). 
3.6.2 Mechanisms of Toxicity
Stable Cobalt.  The exact mechanisms by which cobalt exerts its effects on cells are not completely
understood. However, a number of potential mechanisms have been identified. Several studies have 
demonstrated that hard metal, a metal alloy with a tungsten carbide and cobalt matrix, is considerably
more toxic than either cobalt or tungsten carbide alone.  A mechanism by which hard metal may exert its 
effects has been proposed by a group of Belgian researchers (Lasfargues et al. 1995; Lison et al. 1995, 
1996).  In this proposed mechanism, tungsten carbide, which is a very good conductor of electrons, 
facilitates the oxidation of cobalt metal to ionic cobalt (presumably Co2+) by transferring electrons from
the cobalt atom to molecular oxygen adjacent to the tungsten carbide molecule.  The result is an increased 
solubility of cobalt, relative to cobalt metal alone, and the generation of active oxygen species.  The 
cobalt ions formed may be absorbed into the blood and transported throughout the body, where they may
elicit effects by the above mechanisms. In vitro evidence for this mechanism includes the ability of hard 
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metal particles, but neither cobalt nor tungsten carbide alone, to generate substantial levels of oxidant 
species and cause significant lipid peroxidation (Lison et al. 1995; Zanetti and Fubini 1997).  Hard metal 
particles have also been shown to increase the levels of inducible nitric oxide synthase (iNOS), a gene 
responsive to oxidant stress (Rengasamy et al. 1999). 
Another potential mechanism for cobalt toxicity is through oxidant-based and free radical-based 
processes. Exposure to soluble cobalt increases indices of oxidative stress, including diminished levels of 
reduced glutathione, increased levels of oxidized glutathione, activation of the hexose monophosphate 
shunt, and free-radical-induced DNA damage (Hoet et al. 2002; Kasprzak et al. 1994; Lewis et al. 1991; 
Zhang et al. 1998a); hydrogen peroxide appears to be a necessary cofactor for cobalt-induced oxidative 
DNA damage (Ivancsits et al. 2002).  Cobalt has been shown to generate oxygen radicals, including 
superoxide, both in vitro and in vivo (Kadiiska et al. 1989; Kawanishi et al. 1994; Moorhouse et al. 1985),
through what may be a Fenton-type mechanism (Lloyd et al. 1997). In vivo exposure to cobalt in rats and 
guinea pigs resulted in increased lipid peroxidation in the liver (Christova et al. 2001, 2002; Sunderman 
and Zaharia 1988), as well as changes in reduced glutathione and hepatic levels of superoxide dismutase, 
catalase, heme oxygenase, and glutathione peroxidase (Christova et al. 2001, 2002).  Exposure to cobalt 
results in accumulation in cardiac tissues, and is thought to stimulate carotid-body chemoreceptors, 
mimicking the action of hypoxia (Di Giulio et al. 1990, 1991; Hatori et al. 1993; Morelli et al. 1994).
Cobalt administration to a neuroblastoma/glioma cell line resulted in an upregulation of opioid delta 
receptors, through a mechanism similar to that of hypoxia (Mayfield et al. 1994).  Exposure to cobalt also 
elicits effects on a number of genes known to be sensitive to oxidant status, including hypoxia-inducible 
factor 1, erythropoietin, vascular endothelial growth factor, catalase, and monooxygenase enzymes (Bunn 
et al. 1998; Daghman et al. 1999; Dalvi and Robbins 1978; Di Giulio et al. 1991; Goldberg et al. 1988, 
1994; Ho and Bunn 1996; Hoet et al. 2002; Ladoux and Frelin 1994; Legrum et al. 1979; Semenza et al. 
1994; Yasukochi et al. 1974), and may also lead, through these genes or other pathways, to the induction 
of apoptosis (Zou et al. 2001). 
Soluble cobalt has also been shown to alter calcium influx into cells, functioning as a blocker of inorganic 
calcium channels (Henquin et al. 1983; Moger 1983; Yamatani et al. 1998).  This mechanism has been 
linked to a reduction of steroidogenesis in isolated mouse Leydig cells (Moger 1983).  Additionally, 
soluble cobalt has been shown to alter the inorganic calcium influx in liver cells after exposure to 
glucagon (Yamatani et al. 1998), and calcium influx into pancreatic β cells (Henquin et al. 1983) and 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COBALT 155 
3. HEALTH EFFECTS 
isolated rat islets (Henquin and Lambert 1975).  Cobalt may also affect neuromuscular transmission 
though antagonism with calcium (Weakly 1973). 
Another potential mechanism of cobalt toxicity is relevant to cobalt cardiomyopathy.  As mentioned 
previously, cobalt accumulated in the heart of beer drinkers.  Microscopic analysis revealed fragmentation 
and degeneration of myofibers and aggregates of abnormal mitochondria (Ferrans et al. 1964).  These 
mitochondrial changes are indicative of disturbances in energy production or utilization possibly related 
to cobalt effects on lipoic acid.  Cobalt irreversibly chelates lipoic acids under aerobic conditions (Webb 
1982). Lipoic acid is a required cofactor for oxidative decarboxylation of pyruvate to acetyl CoA and of 
α-ketoglutarate to succinate (Lehninger 1982).  In the myocadrium of rats treated with cobalt, oxidation of 
pyruvate or fatty acids is impaired (Wiberg 1968). 
A number of investigators have reported that cobalt ions can result in increased damage to DNA when co­
exposed with oxidants in vitro, such as UV radiation or H2O2 (De Boeck et al. 1998; Hartwig et al. 1991; 
Nackerdien et al. 1991).  It is believed that cobalt acts by inhibition of DNA repair, particularly the 
incision and polymerization steps (Asmuß et al. 2000; Kasten et al. 1997), accomplishing this through 
interaction with zinc finger DNA repair proteins (Asmuß et al. 2000; Sarkar 1995). 
Another potentially important mechanism by which cobalt may exert effects is through its effects on 
heme and heme-containing enzymes.  Cobalt is thought to inhibit heme synthesis in vivo by acting upon 
at least two different sites in the biosynthetic pathway: synthesis of 5-aminolevulinate and conversion of 
5-aminolevulinate into heme (de Matteis and Gibbs 1977).  This inhibitory activity might result in the 
formation of cobalt protoporphyrin rather than heme (Sinclair et al. 1979).  Cobalt treatment also 
stimulates heme oxidation in many organs, due to the induction of heme oxygenase (for review, see 
Sunderman 1987).  Effects on heme synthesis may potentially affect a wide variety of heme-containing 
proteins, including monooxygenase enzymes (i.e., cytochromes P450) and catalase (Legrum et al. 1979; 
Yasukochi et al. 1974).  Conversely, cobalt acts, through a mechanism believed to involve a heme-
containing protein, to increase erythropoietin, which stimulates the production of red blood cells 
(Di Giulio et al. 1991; Goldberg et al. 1988; Smith and Fisher 1973).  The regulatory mechanisms behind 
this apparent dichotomy have not been fully elucidated. 
Another potential mechanism by which cobalt may exert its effects is through interactions with the 
immune system.  Exposure of humans to cobalt by the inhalation and dermal routes have resulted in 
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sensitization to cobalt (Alomar et al. 1985; Bencko et al. 1983; Dooms-Goossens et al. 1980; Fischer and 
Rystedt 1983; Goh et al. 1986; Kanerva et al. 1988; Marcussen 1963; Shirakawa et al. 1988, 1989; Valer 
et al. 1967). Exposure to inhaled cobalt chloride aerosols can precipitate an asthmatic attack in sensitized 
individuals (Shirakawa et al. 1989), suggesting cobalt sensitization as one mechanism by which cobalt-
induced asthma may be produced.  IgE and IgA antibodies specific to cobalt have been reported in 
humans (Bencko et al. 1983; Shirakawa et al. 1988, 1989).  There is evidence that cobalt sensitivity in
humans may to be regulated by T-lymphocytes (Katsarou et al. 1997).  A human helper T-lymphocyte 
cell line specific for cobalt (CoCl2) has been established (Löfström and Wigzell 1986).  Cobalt may also 
interact directly with immunologic proteins, such as antibodies or Fc receptors, to result in 
immunosensitization (Cirla 1994).  In vitro, cobalt(II) has been shown to reduce the proliferation of both 
B and T lymphocytes, as well as the release of the cytokines IL-2, IL-6, and IFN-Gamma (Wang et al. 
1996).  Interrelationships exist between nickel and cobalt sensitization (Bencko et al. 1983; Rystedt and 
Fisher 1983); however, the extent of any potential interactions between the two metals on immunologic 
end points is not well understood.  In guinea pigs, nickel and cobalt sensitization appear to be interrelated 
and mutually enhancing (Lammintausta et al. 1985), though cross-reactivity was not reported to occur. 
Cobalt has been shown to have a number of effects on glucose metabolism.  Treatment of animals with 
cobalt results in a depression of serum (Eaton and Pommer 1973; Ybarra et al. 1997) or tissue (Wiberg 
1968) glucose levels.  In rats made diabetic by pretreatment with streptozotocin, this depression was 
persistent, whereas it was transient in normal rats (Ybarra et al. 1997).  Many of the effects of cobalt on 
glucose metabolism are thought to result from alterations in the expression of the glut family of glucose 
transport proteins, a family of facilitative Na+-independent transport proteins thought to mediate non-
insulin-dependent transport of glucose.  Exposure to soluble cobalt results in increased expression of 
these genes, particularly GLUT1, in cells of the liver, kidney cortex, myocardium, skeletal muscle, and 
cerebrum (Behrooz and Ismail-Beigi 1997; Ybarra et al. 1997).  Cobalt also reduces the amount of 
glucose produced in liver cells following stimulation with glucagon (Eaton and Pommer 1973; Yamatani 
et al. 1998), as well as reducing insulin release in isolated rat islets (Henquin and Lambert 1975). 
Radioactive Cobalt. Due to the nature of its ionizing radiation, radioactive cobalt can present a health 
hazard. Highly-penetrating gamma emissions are the major source of damage to tissues and internal 
organs following external exposure to radioactive cobalt isotopes.  If radioactive cobalt is internalized, 
nearby tissues are at highest risk for damage due to the release of beta particles.  In either case, exposure 
to ionizing radiation results in an increased risk of cellular damage.  Both beta and gamma radiations are 
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capable of producing ionization events when they hit cellular molecules, including DNA, RNA, or lipids.  
Ionized molecules within irradiated cells may be repaired quickly to prevent further damage.  On the 
other hand, irreparable damage may be imposed on cellular materials, such as DNA, which might 
ultimately result in either cell death or the formation of cancerous tumors.  Very large acute radiation 
doses can damage or kill enough cells to cause the disruption of organ systems, resulting in acute 
radiation syndrome or even death.  Human and animal data indicate that sufficiently high exposures to 
cobalt radiation can result in adverse effects such as reduced fertility, abnormal development, 
genotoxicity, pulmonary fibrosis, gastrointestinal atrophy and fibrosis, hematological and lymphoreticular 
disorders, cancer, and death (Chang et al. 1999b; Davis et al. 1992; Dinehart et al. 1991; Hashimoto and 
Mitsuyasu 1967; Klener et al. 1986; Libshitz 1993; Myskowski and Safai 1981; Rauscher and Bauchinger 
1983; Roschler and Woodard 1969; Roswit and White 1977; Stavem et al. 1985; Van Oort et al. 1984).  
For a more complete discussion of the mechanisms associated with the toxic effects of ionizing radiation, 
refer to Chapter 5 of the Toxicological Profile for Ionizing Radiation (Agency for Toxic Substances and 
Disease Registry 1999). 
3.6.3 Animal-to-Human Extrapolations 
Bailey et al. (1989) reported a wide variation across species, including man, in the retention and clearance 
of inhaled physiologically insoluble 57Co particles (see Table 3-8), noting that this variation illustrates 
the potential difficulty of extrapolating the results of animal lung retention experiments to human even 
qualitatively.  Species differences in absorption of physiologically insoluble cobalt oxide following oral 
exposure do not appear to exist (Bailey et al. 1989), although humans were not examined.  Absorption of 
soluble cobalt compounds is greater in rats (13–34%) than in dairy cows (1–2%) and guinea pigs (4–5%) 
following oral exposure (Ayala-Fierro et al. 1999; Barnaby et al. 1968; Hollins and McCullough 1971; 
Kirchgessner et al. 1994; Naylor and Harrison 1995; Schade et al. 1970; Taylor 1962; van Bruwaene et al. 
1984). 
3.7 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS  
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors.  However, appropriate 
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terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Colborn and Clement (1992), was also used in 1996 when Congress mandated the 
Environmental Protection Agency (EPA) to develop a screening program for “...certain substances 
[which] may have an effect produced by a naturally occurring estrogen, or other such endocrine
effect[s]...”.  To meet this mandate, EPA convened a panel called the Endocrine Disruptors Screening and 
Testing Advisory Committee (EDSTAC), which in 1998 completed its deliberations and made 
recommendations to EPA concerning endocrine disruptors. In 1999, the National Academy of Sciences 
released a report that referred to these same types of chemicals as hormonally active agents. The 
terminology endocrine modulators has also been used to convey the fact that effects caused by such 
chemicals may not necessarily be adverse.  Many scientists agree that chemicals with the ability to disrupt 
or modulate the endocrine system are a potential threat to the health of humans, aquatic animals, and 
wildlife. However, others think that endocrine-active chemicals do not pose a significant health risk, 
particularly in view of the fact that hormone mimics exist in the natural environment.  Examples of 
natural hormone mimics are the isoflavinoid phytoestrogens (Adlercreutz 1995; Livingston 1978; Mayr et 
al. 1992).  These chemicals are derived from plants and are similar in structure and action to endogenous 
estrogen. Although the public health significance and descriptive terminology of substances capable of 
affecting the endocrine system remains controversial, scientists agree that these chemicals may affect the 
synthesis, secretion, transport, binding, action, or elimination of natural hormones in the body responsible 
for maintaining homeostasis, reproduction, development, and/or behavior (EPA 1997c).  Stated 
differently, such compounds may cause toxicities that are mediated through the neuroendocrine axis.  As 
a result, these chemicals may play a role in altering, for example, metabolic, sexual, immune, and 
neurobehavioral function. Such chemicals are also thought to be involved in inducing breast, testicular, 
and prostate cancers, as well as endometriosis (Berger 1994; Giwercman et al. 1993; Hoel et al. 1992). 
The available human and animal data suggest that the endocrine system, particularly the thyroid gland,
may be a target of stable and radioactive cobalt toxicity.  These effects are discussed in Sections 3.2 and 
3.3 under Systemic Effects. 
3.8 CHILDREN’S SUSCEPTIBILITY  
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential 
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effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed. 
Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure.  Exposures of children are discussed in Section 6.6 Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life and a 
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
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have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer. 
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
Though human data are lacking, animal studies have suggested several differences in pharmacokinetic 
behavior of cobalt compounds between children and adults.  Following inhalation exposure to Co3O4, 
deposition tended to increase with age, though no significant differences were reported (Collier et al. 
1991).  The youngest animals exposed (3 weeks postnatal) had the lowest fractional retention 182 days
postexposure, though no differences were seen at day 7 or 83.  The authors attributed this to a faster rate
of translocation of cobalt from the lung to the blood, which could enhance subsequent excretion.  Naylor 
and Harrison (1995) reported that in rats and guinea pigs, fractional absorption of cobalt following oral 
exposure was highest at 1 day after birth, and diminished rapidly with time thereafter.  Collier et al. 
(1991) reported no difference in absorption of cobalt nitrate following oral exposure to animals aged 3– 
46 weeks, which is in agreement with the results of the later portion of the Naylor and Harrison (1995) 
study.  No PBPK models specific for cobalt exposures to children were located.  However, the ICRP 
Human Respiratory Tract Model is applicable to children, and may be used for children if the appropriate 
values for the parameters are used. 
Once in the bloodstream, soluble cobalt compounds have been shown, in animal studies, to cross the 
placenta and enter the fetus. Twenty-four hours after intravenous injection of cobalt chloride in rats, 
0.14% of the dose was found in the fetus, 0.19% in the chorioallantoic placenta, and 0.22% in the yolk sac 
(Zylicz et al. 1975).  Several other rat studies (Nishimura et al. 1978; Zylicz et al. 1975, 1976) have 
demonstrated that the amount of cobalt crossing the placenta following intravenous injection is greater in 
later gestation stages, though the percent of the maternal dose reaching the fetus is still relatively low (in 
<1% of the maternal dose).  The fetal uptake of cobalt following intravenous administration to the mother 
was increased when the cobalt was given as cyanocobalmin, relative to cobalt chloride (~5% of the 
maternal dose for cyanocobalmin, compared to <1% for cobalt chloride) (Nishimura et al. 1978), 
indicating that the form of the cobalt compound may affect its availability to the fetus. 
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Cobalt has been detected in human breast milk (Byczkowski et al. 1994; Kratchler et al. 1998).  In 
general, physiological concentrations of cobalt in breast milk are very low, on the order of parts per 
billion (Byczkowski et al. 1994).  Animal studies are in agreement with this observation.  By day 70 post-
exposure in lactating dairy cows orally exposed to cobalt chloride, the milk contained 0.012% of the dose 
(van Bruwaene et al. 1984).  One to two percent of cobalt given intravenously to mother rats as 
cyanocobalmin was transferred to offspring via the breast milk (Nishimura et al. 1978). 
Health Effects from Exposure to Stable Cobalt.  Available data have not clearly defined whether 
children are at greater risk from exposure to stable cobalt than adults.  Studies in adult humans have 
identified several health effects of cobalt compounds following inhalation, oral, or dermal exposure.  Data 
on effects of cobalt in children following inhalation exposures are lacking.  Jacobziner and Raybin (1961) 
reported on two cases of children who had accidentally ingested unknown amounts of cobalt chloride; a 
19-month-old male died approximately 6.5 hours after ingestion, whereas a 3-year-old male was given 
medical treatment and showed no symptoms after ingestion.  Several studies (Chamberlain 1961; Little 
and Sunico 1958; Sederholm et al. 1968; Washburn and Kaplan 1964) have reported enlarged thyroid
glands in children given cobalt chloride for treatment of anemia; removal of cobalt therapy resulted in a 
return to normal thyroid size.  Patch testing of children aged 4–14 years revealed a 13.3% dermal 
sensitization rate to cobalt chloride (Romaguera and Vilaplana 1998).  More girls reacted positively than 
boys, which the authors attributed to the wearing of costume jewelry, which often contains cobalt, and the 
resulting exposure. 
Offspring of mice intravenously injected with approximately 1.2 mg cobalt/kg at day 8 of gestation, but 
not at day 3, showed a significant increase in the number of skeletons with delayed ossification (Wilde 
1984).  Other studies, however, have not shown developmental effects of stable cobalt compounds, or 
have shown effects only at maternally toxic doses (Domingo et al. 1985b; Paternian et al. 1988; 
Seidenberg 1986). 
Health Effects from Exposure to Radioactive Cobalt.  Taiwanese children (48 boys, 37 girls) who were 
raised in apartments contaminated with 60Co were compared to 21,898 age- and sex-matched non-exposed 
children from a nationwide surveillance program (Wang et al. 2001).  After adjusting for effects from
parental heights and body mass index, clear dose-related decreases in height percentile (HP) and age-
specific relative height differences (RHD) were seen in exposed boys, but not in exposed girls.  Average 
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cumulative exposures were 120.8 and 129.9 mSv (equivalent to ~12.1 or 13 rad) for the boys and girls, 
respectively.
No other studies of human children exposed to radioactive cobalt or cobalt radiation were located.  As 
rapidly-dividing cells are more sensitive to radiation, the developing fetus and growing children are 
expected to be more sensitive to cobalt radiation than adults. 
Animal studies have shown that exposures to external radiation from cobalt isotopes (as low as 10 rad 
[0.1 Gy] in mice) may have a dramatic effect on the developing fetus (see Section 3.2.4.6 and Agency for 
Toxic Substances and Disease Registry 1999).  Exposure duration, gestational day, and dose all influence 
the effect of cobalt radiation on the developing organism.  Radiation exposure to very young dogs (80 rad 
[0.8 Gy] on day 2 or 70 postpartum) has resulted in an increased incidence of diabetes mellitus, renal 
disease, and cancer (Benjamin et al. 1998a, 1998b). 
3.9 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989).  The 
preferred biomarkers of exposure are generally the substance itself or substance-specific metabolites in 
readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures 
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic 
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental 
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the 
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous 
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substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as 
copper, zinc, and selenium).  Biomarkers of exposure to cobalt are discussed in Section 3.9.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused 
by cobalt are discussed in Section 3.9.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.11 “Populations That Are Unusually Susceptible”. 
3.9.1 Biomarkers Used to Identify or Quantify Exposure to Cobalt  
Biomonitoring data exist that demonstrate a positive correlation between occupational exposure levels of 
cobalt and the levels of cobalt in both the urine and blood (Table 3-12) (Alexandersson 1988; Ichikawa et 
al. 1985; Lison et al. 1994; Nemery et al. 1992; Scansetti et al. 1985).  Available studies of unexposed 
humans have reported cobalt blood levels of 0.05–0.19 µg/dL and urinary cobalt levels of 0.04–2 µg/dL 
(Alexandersson 1988; Ichikawa et al. 1985).  Figure 3-10 graphically presents the cobalt exposure data 
and cobalt in blood data presented in Table 3-12 (Ichikawa et al. 1985).  The highest excretion rate of 
cobalt in urine occurs during the first 24 hours after short-term exposure; therefore, subjects should be 
tested quickly to assess whether cobalt exposure has occurred (Alexandersson 1988).  Occupational 
exposure to 0.1 mg/m3 cobalt resulted in blood levels of cobalt ranging (95% CI) from 0.57 to 0.79 µg/dL, 
compared to 0.19 µg/dL in unexposed workers, and urinary levels from 59 to 78 µg/L, compared to 
2 µg/L in unexposed workers (Ichikawa et al. 1985). Correlations between recent exposure and cobalt 
levels in the blood or urine are more consistent for soluble cobalt compounds (metal, salts, and hard  
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Table 3-12. Cobalt Exposure Concentrations and Amounts in the Blood and 

Urine of Subjects Examineda
 
Cobalt in airb Cobalt in bloodb Cobalt in urineb 
Subjects Number mean±SD µg/m3 mean±SD µg/dL mean±SD µg/L 
Powder handlers 2 186±108 (110–262) 1.08±0.28 (0.88–1.28) 148±13 (138–158) 
Rubber press 6 367±324 (92–859) 1.87±1.96 (0.40–5.30) 235±182 (41–392) 
operators 
Automatic press 11 56±60 (9–210) 0.57±0.53 (0.10–0.95) 34±43 (4–73) 
operators 
Shapers (lathing) 7 33±15 (15–62) 0.67±0.44 (0.14–1.34) 33±30 (11–95) 
Shapers (sawing) 21 50±35 (8–144) 0.52±0.31 (0.15–1.15) 41±60 (6–266) 
Sintering workers 21 28±30 (4–145) 0.26±0.10 (0.09–0.45) 10±10 (2–46) 
Wet grinders 
A 27 44±48 (4–227) 0.42±0.31 (0.10–1.30) 35±34 (2–180) 
B 18 45±50 (3–161) 0.33±0.10 (0.16–0.52) 19±15 (2–67) 
C 12 92±92 (15–291) 0.43±0.39 (0.12–1.90) 68±87 (3–265) 
D 25 44±54 (3–205) 0.35±0.20 (0.10–1.00) 17±16 (1–69) 
Workers using 25 317±307 (7–1,203) 0.65±0.86 (0.20–3.90) 26±30 (1–119) 
respirators 
Office workers 20 No data 0.19±0.11 (0.08–0.40) 2±1 (1–4) 
aAdapted from Ichikawa et al. 1985 

bThe range of each value is given in parentheses. 

SD = standard deviation 
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Figure 3-10. Relation Between Mean Cobalt Exposure and Mean Blood 

Concentration of Cobalt in Exposed Workers* 
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metals), while blood and/or urinary cobalt levels are less reflective of recent exposure for less soluble 
compounds (cobalt oxides) (Lison et al. 1994). 
Sensitive serum protein responses were found in animals exposed to cobalt at levels below those 
necessary to produce hematopoietic effects (Stokinger and Wagner 1958).  These serum protein responses 
included an increase in alpha globulin fractions of serum proteins and associated serum neuraminic acid.  
The responses were observed in rabbits and dogs following both inhalation and injection of cobalt.  The 
authors indicated that this increase was a unique response to cobalt exposure.  The characteristics of the 
response were similar to those of the erythropoietic response found following exposure to higher levels of 
cobalt; the response is delayed, does not occur in all animals within a given exposure group, is not of
great magnitude, and is not persistent (Stokinger and Wagner 1958). 
Biomarkers specific for exposure to cobalt radioisotopes have not been reported. 
3.9.2 Biomarkers Used to Characterize Effects Caused by Cobalt  
Sensitization to cobalt results in cobalt-specific changes in serum antibodies (IgE and IgA) that may be 
monitored to determine if sensitization, or additional exposure, to cobalt has occurred (Bencko et al. 
1983; Shirakawa et al. 1988, 1989). 
No biomarkers specific for effects of radioactive cobalt isotopes have been reported.  Biomarkers for 
response to ionizing radiation are discussed in Agency for Toxic Substances and Disease Registry (1999). 
3.10 INTERACTIONS WITH OTHER CHEMICALS  
A major medical use of cobalt is in combination with bleomycin, an antineoplastic antibiotic, as a tumor-
localizing and therapeutic agent (Goodwin and Meares 1976; Hansen et al. 1976; Kapstad 1978, 1979).
The anti-tumor effects of the two agents are amplified when given in combination with each other.  The 
complex, wherein cobalt is coordinately bound to the bleomycin molecule, is intravenously injected and 
acts by binding to and cleaving the DNA in the tumor cells (Kakinuma and Orii 1982). 
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The interaction of cobalt with various chelators has been investigated in animals for mitigation of the 
toxicity of cobalt (Baker et al. 1987; Domingo et al. 1983; Llobet et al. 1988).  Glutathione, N-acetyl­
L-cysteine (NAC) and diethylenetriaminepentaacetic acid (DTPA), administered to rats previously 
exposed to cobalt, significantly increased urinary excretion of cobalt, while EDTA, NAC, and 2,3-di­
mercaptosuccinic acid (DMSA) increased fecal excretion.  NAC was the most effective chelator because 
it increased both urinary and fecal excretion of cobalt while decreasing its levels in liver and spleen 
(Llobet et al. 1988).  Cysteine, also acting as a chelator, mitigated the toxicity of cobalt when both 
chemicals were given to chicks in the feed (Baker et al. 1987). 
A number of studies have suggested an association between cobalt ions and calcium ions.  Soluble cobalt 
has also been shown to alter calcium influx into cells, functioning as a blocker of inorganic calcium
channels (Henquin et al. 1983; Moger 1983; Yamatani et al. 1998).  This mechanism has been linked to a 
reduction of steroidogenesis in isolated mouse Leydig cells (Moger 1983).  Additionally, soluble cobalt 
has been shown to alter the inorganic calcium influx in liver cells after exposure to glucagon (Yamatani et 
al. 1998), and calcium influx into pancreatic β cells (Henquin et al. 1983) and isolated rat islets (Henquin 
and Lambert 1975).  Cobalt may also affect neuromuscular transmission through antagonism with 
calcium (Weakly 1973). 
Hard metal, consisting of 5–10% cobalt with the balance being tungsten carbide, has been shown to be 
considerably more toxic than cobalt alone, resulting from interactions between particles of cobalt metal 
and tungsten carbide particles.  The mechanisms responsible for this interaction are discussed in 
Section 3.6.2.
An interrelationship between cobalt and nickel sensitization has been reported in individuals exposed to 
the two metals (Rystedt and Fisher 1983; Veien et al. 1987), as well as in animal studies (Wahlberg and 
Lidén 2000).  It was concluded that the combination of nickel sensitivity and irritant eczema resulted in a 
high risk for developing an allergy to cobalt.  Studies of cultured alveolar type II cells showed a 
synergistic (greater than additive) response to co-exposure to cobalt and nickel chlorides (Cross et al. 
2001).
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3.11 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
A susceptible population will exhibit a different or enhanced response to cobalt than will most persons 
exposed to the same level of cobalt in the environment.  Reasons may include genetic makeup, age, health 
and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  These parameters 
result in reduced detoxification or excretion of cobalt, or compromised function of organs affected by
cobalt. Populations who are at greater risk due to their unusually high exposure to cobalt are discussed in 
Section 6.7, Populations With Potentially High Exposures. 
Individuals who are already sensitized to cobalt may be unusually susceptible because cobalt exposure 
may trigger asthmatic attacks (Shirakawa et al. 1988, 1989).  Sensitization to cobalt results in cobalt-
specific changes in serum antibodies (IgE and IgA) (Bencko et al. 1983; Shirakawa et al. 1988, 1989).  
Potolicchio et al. (1997, 1999) have suggested that individuals with a polymorphism in the HLA-DP gene 
(presence of glutamate 69 in the β chain) may be more susceptible to hard metal lung disease.  Individuals 
with ongoing respiratory illness may also be more susceptible to the effects of inhaled cobalt.  Following 
oral exposure, individuals with iron deficiency may at greater risk, as animal studies have shown an 
increased absorption of cobalt compounds in iron-deficient animals (Reuber et al. 1994; Schade et al. 
1970).  Studies of beer-cobalt cardiomyopathy have suggested that individuals with high alcohol 
consumption may be more susceptible to health effects of cobalt (Alexander 1969, 1972; Morin et al. 
1971). 
Ionizing radiation has greater effects on rapidly-dividing cells than on those that divide at a slower rate.  
The most sensitive population to exposure to cobalt radiation is likely to be the developing fetus, as even 
moderate exposures to cobalt radiation have been shown to cause dramatic effects on the developing fetus 
in animal studies (see Section 3.2.4.6),  Likewise, growing children are likely to be more susceptible to 
cobalt radiation than adults, and people who are immunocompromised, have existing lung diseases, or 
who have defects in genetic repair enzymes would be expected to show an increased susceptibility to 
cobalt radiation. A detailed discussion on the effects of ionizing radiation in children can be found in 
Agency for Toxic Substances and Disease Registry (1999). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COBALT 169 
3. HEALTH EFFECTS 
3.12 METHODS FOR REDUCING TOXIC EFFECTS  
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to cobalt.  However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to cobalt.  When specific 
exposures have occurred, poison control centers and medical toxicologists should be consulted for 
medical advice. The following texts provide specific information about treatment following exposures to 
cobalt: 
Ellenhorn MJ, Schonwald S, Ordog G, et al., eds.  1997.  Medical toxicology:  Diagnosis and treatment of 
human poisoning. 2nd edition.  Baltimore, MD:  Williams & Wilkins, 1682–1723. 
Goldfrank, LR, Flomenbaum, NE, Lewin, NA, et al., eds.  1998. Toxicological emergencies.  6th edition.  
Connecticut: Appleton & Lange, 481t, 489, 490t, 1338–1339. 
REAC/TS. Radiation Emergency Assistance Center/Training Site.  www.orau.gov/reacts/. 
3.12.1 Reducing Peak Absorption Following Exposure  
Methods for reducing peak absorption are similar for both the stable and radioactive forms of cobalt.  
General management and treatment of patients following acute exposure to cobalt includes removal of the 
victim from the contaminated area, and removal and isolation of contaminated clothing, jewelry, and 
shoes (Bronstein and Currance 1988; Stutz and Janusz 1988).  The excess solid contaminant is gently
brushed away, and excess liquids are blotted with absorbent material.  If the victim is in respiratory
distress, ventilation assistance is provided and oxygen is administered.  Measures that are appropriate to 
the route of exposure are then taken to remove cobalt from the body.  Following ocular exposure, the eyes 
are immediately flushed thoroughly with water.  Skin is washed immediately with soap or mild detergent 
and water. Some evidence has been presented that the use of cheating creams on the skin can reduce the 
occurrence of symptoms in allergic persons (Wöhrl et al. 2001).  Following ingestion of cobalt, two 
conflicting forms of treatment have been recommended.  Stutz and Janusz (1988) recommend that victims 
over 1 year old be given ipecac, followed by activated charcoal (after vomiting).  A cathartic, such as 
magnesium sulfate in water, is then administered to adults and children.  Bronstein and Currance (1988) 
recommend that the victim be given water for dilution of the cobalt; however, they recommend that 
emetics not be administered.  Following all routes of exposure, victims are monitored for pulmonary
edema, circulatory collapse, and shock, and treated as necessary.
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3.12.2 Reducing Body Burden  
Chelation therapy with EDTA or dimercaprol can be effectively used if necessary (Goldfrank et al. 1990; 
Haddad and Winchester 1990; Stutz and Janusz 1988).  Animal studies have investigated the 
effectiveness of various chelating agents for mitigating the toxicity of cobalt (Baker et al. 1987; Domingo 
et al. 1983; Llobet et al. 1988).  NAC was found to be the most effective chelator because it increased 
both urinary and fecal excretion of cobalt as well as decreased the levels of cobalt in the liver and spleen 
(Llobet et al. 1988). These chelators react chemically with cobalt, so they are effective for both stable 
and radioactive cobalt isotopes. For more complete information on treatment of specific symptoms, refer 
to Bronstein and Currance (1988) and Stutz and Janusz (1988). 
3.12.3 Interfering with the Mechanism of Action for Toxic Effects  
No studies were located in humans or animals regarding interfering with the mechanism of action of 
stable or radioactive cobalt compounds. 
3.13 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of cobalt is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of cobalt. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
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3.13.1 Existing Information on Health Effects of Cobalt 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals are 
summarized in Figure 3-11 for stable cobalt and in Figure 3-12 for radioactive cobalt.  The purpose of 
these figures is to illustrate the existing information concerning the health effects of cobalt.  Each dot in 
the figure indicates that one or more studies provide information associated with that particular effect.  
The dot does not necessarily imply anything about the quality of the study or studies, nor should missing 
information in this figure be interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision 
Guide for Identifying Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic 
Substances and Disease Registry 1989), is substance-specific information necessary to conduct 
comprehensive public health assessments.  Generally, ATSDR defines a data gap more broadly as any 
substance-specific information missing from the scientific literature.
Figures 3-11 and 3-12 represent studies conducted with all forms of cobalt.  The effects of cobalt have 
been studied in humans following both inhalation and oral exposure.  Human dermal studies designed to 
investigate nondermal systemic effects of cobalt have been reported.  Similarly, the effects of cobalt in 
animals have been studied following inhalation and oral exposure.  Few dermal studies are available. 
3.13.2 Identification of Data Needs 
Stable Cobalt.  Effects in humans following acute inhalation, oral, and dermal exposures to cobalt have 
been reported. In humans, the primary targets following acute exposure to cobalt include the respiratory
system following inhalation exposure (Kusaka et al. 1986a), the thymus following oral exposure (Roche 
and Layrisse 1956), and the immunological system following dermal exposure (Alomar et al. 1985;
Fischer and Rystedt 1983; Kanerva et al. 1988).  Acute oral studies in animals have also identified the 
cardiovascular and hematopoietic systems as targets of cobalt toxicity (Domingo and Llobet 1984;
Speijers et al. 1982).  Although acute exposure levels associated with some of these effects in humans 
have been reported, the minimal acute exposure levels required to produce these effects are not known 
because few acute human studies exist.  The results of animal studies of the acute toxicity of cobalt have 
been used to determine dose levels that produce death and respiratory effects following inhalation 
exposure, death and various systemic effects following oral exposure, and dermal and immunological 
effects following dermal exposure.   
   
 
 
 
 
Figure 3-11. Existing Information on Health Effects of Stable Cobalt 
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Figure 3-12. Existing Information on Health Effects of Radioactive Cobalt 
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There were insufficient data for derivation of inhalation or oral acute MRLs because reported effects were 
severe and occurred at levels above those reported in the few human studies.  Animal studies that identify
minimally effective inhalation and oral exposure levels for the various cobalt compounds would be useful 
in estimating acute MRLs for each cobalt compound.  Acute dermal studies would enable the 
determination of hazardous levels for this route of exposure.  Because a small portion of the cobalt taken 
into the body is retained for a relatively long time, studies on the long-term consequences of acute 
exposure on the heart, respiratory tract, hematological system, and immune response could provide 
information about the potential for chronic effects of acute exposures in humans.  Knowledge about the 
acute toxicity of cobalt is important because people living near hazardous waste sites might be exposed 
for brief periods. 
Radioactive Cobalt. Data on health effects following acute exposure to radioactive cobalt by the 
inhalation, oral, or dermal routes are lacking. Because all cobalt radioisotopes are man-made (see 
Chapter 5), only low-level exposure to radioactive cobalt in the environment by these routes is likely to 
occur. A number of health effects have been seen following cases of accidental acute exposure to high 
levels of external cobalt radiation in humans, including death, gastrointestinal disorders, hematological 
alterations, and dermal lesions (Klener et al. 1986; Stavem et al. 1985).  Acute-exposure animal studies 
have shown pronounced effects, including death, cardiovascular changes, gastrointestinal effects, kidney
effects, and neurobehavioral changes (Brady and Hayton 1977b; Bruner 1977; Cockerham et al. 1986;
Darwezah et al. 1988; Down et al. 1986; Gomez-d-Segura et al. 1998; Hanks et al. 1966; King 1988a; 
Mele et al. 1988; Page et al. 1968; Robbins 1989a, 1989b, 1989c, 1991a).  The most pronounced effects 
in animals following acute exposure to cobalt radiation have been reproductive and developmental effects 
(see Sections 3.2.4.5 and 3.2.4.6).  Agency for Toxic Substances and Disease Registry (1999) has derived 
an acute MRL for external exposure to ionizing radiation, which is applicable to external exposures to 
cobalt radiation, so additional data for the derivation of an MRL are not needed. 
Intermediate-Duration Exposure.     
Stable Cobalt.  Information on oral exposure of humans to cobalt, in the form of cobalt chloride added to 
beer as a foam stabilizer, provides the only human data available for exposure of intermediate duration 
(Alexander 1969, 1972; Morin et al. 1971).  Inhalation and dermal data in humans were not located for 
this duration of exposure.  The cardiac and hematopoietic systems are the primary targets in humans 
following oral exposure to cobalt.  Some exposure levels associated with cardiomyopathy have been 
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reported following oral exposure, but the minimal exposure level required to produce this effect in 
humans is not known (Alexander 1969, 1972; Morin et al. 1971).  Oral studies in animals reported dose 
levels associated with death, various systemic and neurological effects, and effects on reproduction and 
development (Domingo et al. 1984, 1985b; Krasovskii and Fridlyand 1971; Mohiuddin 1970; 
Mollenhauer et al. 1985; Pedigo et al. 1988).  Intermediate-duration inhalation studies in animals reported
that the respiratory tract is the target of the toxicity of inhaled cobalt (Bucher et al. 1990; Johansson et al. 
1987; Kerfoot 1975; NTP 1991; Palmes et al. 1959).  Animal studies were insufficient for derivation of an
intermediate-duration MRL for oral exposure, since the reported effects were severe and the effects 
occurred at levels above those reported in the few human studies.  Dermal data in animals were not 
located. Animal studies that investigate the possible toxic interaction between cobalt and alcohol may be 
helpful in understanding the role of cobalt in the cardiomyopathy reported in the heavy beer drinkers 
(Alexander 1969, 1972; Morin et al. 1971).  One such study in guinea pigs already exists (Mohiuddin et 
al. 1970), but this study used a single, high dose of cobalt.  Studies using a series of lower doses, both 
with and without alcohol preexposure, would be helpful in determining the threshold for the cardiac 
effects. Intermediate-duration dermal studies would enable determination of hazardous levels for this 
route of exposure.  Intermediate-duration toxicity information is important because people living near 
hazardous waste sites might be exposed for corresponding time periods. 
Radioactive Cobalt. Data on health effects following acute exposure to radioactive cobalt by the 
inhalation, oral, or dermal routes are lacking.  Because cobalt radioisotopes are man-made (see 
Chapter 5), only low-level exposure to radioactive cobalt in the environment by these routes is likely to 
occur. Substantial human data exist concerning intermediate-duration exposure to external radiation, as 
radiotherapy treatment regimens fall into this duration category.  Animal data from intermediate-duration 
external exposure also exist, but are less numerous.  Additional intermediate-duration studies are not 
likely to provide substantial additions to our knowledge of radiation-induced toxic effects. 
Chronic-Duration Exposure and Cancer.     
Stable Cobalt.  Chronic inhalation exposure levels in humans associated with respiratory effects have 
been reported (Gennart and Lauwerys 1990; Nemery et al. 1992; Shirakawa et al. 1988; Sprince et al. 
1988).  In humans, the respiratory system is the primary target following chronic inhalation exposure.  A 
chronic-duration inhalation MRL was derived from a NOAEL for decreased ventilatory function in 
exposed workers (Nemery et al. 1992). Wehner et al. (1977) reported no adverse effects in hamsters 
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exposed chronically to cobalt oxide.  NTP (1998; Bucher et al. 1999) exposed rats and mice to cobalt 
sulfate for 2 years, reporting pronounced effects on the respiratory tract, including hyperplasia,
inflammation, fibrosis, and metaplasia; an increased incidence of cancer was also reported.  Chronic oral 
or dermal studies have not been reported in either humans or animals.  Animal studies that identify 
minimally effective chronic oral exposure levels would be useful for estimating a chronic MRL.  Chronic 
dermal studies would enable determination of hazardous levels for this route of exposure.  Chronic 
toxicity information is important because people living near hazardous waste sites might be exposed to 
cobalt for many years. 
Several studies of hard metal exposure in humans have reported increases in lung cancer mortality from
occupational inhalation exposure to hard metal (Lasfargues et al. 1994; Moulin et al. 1998; Wild et al. 
2000).  In humans, cancer has not been reported following exposure to cobalt by the oral or dermal routes.  
An increased incidence of alveolar/bronchiolar neoplasms was noted following lifetime exposure of male 
rats to 1.14 mg cobalt/m3 and in female rats to 0.38 mg cobalt/m3 as cobalt sulfate, with tumors occurring 
in both sexes with significantly positive trends (Bucher et al. 1999; NTP 1998). Similarly, mice of both 
sexes exposed to 1.14 mg cobalt/m3 showed an increase in alveolar/bronchiolar neoplasms, again with 
lung tumors occurring with significantly positive trends.  Parenteral exposure to cobalt has been found to 
induce tumors (Gilman 1962; Gilman and Ruckerbauer 1962; Heath 1956, 1969; Heath and Daniel 1962; 
Shabaan et al. 1977).  Further chronic exposure studies by the oral and dermal routes may determine the 
actual carcinogenic potential of cobalt.  Also, studies examining the effect of cobalt speciation (i.e., cobalt 
metal vs. cobalt sulfate) would add to our understanding of the carcinogenic potential of cobalt. 
Radioactive Cobalt. Data on health effects following chronic exposure to radioactive cobalt by the 
inhalation, oral, or dermal routes are lacking.  Because cobalt radioisotopes are man-made (see 
Chapter 5), only low-level exposure to radioactive cobalt in the environment by these routes is likely to 
occur. Limited data exist on chronic exposure to cobalt radiation in humans, with genotoxicity, 
immunologic effects, and cancer being the primary end points examined.  Animal data are similarly
limited.  Additional human or animal data following chronic exposure to external cobalt radiation would 
be useful in further identifying possible long-term health effects or susceptible populations.  Agency for 
Toxic Substances and Disease Registry (1999) has derived a chronic-duration MRL for external radiation 
exposure, which is applicable to external exposures to cobalt radiation, so additional data for the 
derivation of an MRL are not needed. 
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Genotoxicity.     
Stable Cobalt.  Gennart et al. (1993) reported an increase in sister-chromatid exchanges in workers 
exposed to a mixture of cobalt, chromium, nickel, and iron.  De Boeck et al. (2000) reported no 
significant change in the comet assay on lymphocytes from nonsmoking workers who were 
occupationally exposed to cobalt or hard metal dusts; a positive association was found between hard 
metal exposure and increased micronucleus formation in smokers only. 
Data regarding the mutagenic action of cobalt in bacterial cell lines and mammalian cell lines have been 
reported in the literature (Hamilton-Koch et al. 1986; Kharab and Singh 1985; Ogawa et al. 1986). In 
vivo mutagenicity studies in animals following inhalation, oral, or dermal exposure to cobalt would be 
helpful in ascertaining its true mutagenic potential.  Further studies examining the differences in 
genotoxicity between different valence states of cobalt would also be useful. 
Radioactive Cobalt. Data on genotoxic effects following exposure to radioactive cobalt by the inhalation,
oral, or dermal routes are lacking.  Because cobalt radioisotopes are man-made (see Chapter 5), only low-
level exposure to radioactive cobalt in the environment by these routes is likely to occur.  Several studies 
have demonstrated genotoxic effects in humans exposed to external cobalt radiation (Chang et al.1999c; 
House et al. 1992; Rauscher and Bauchinger 1983).  Numerous data from animal studies exist 
demonstrating the genotoxic effects of ionizing radiation, including cobalt radiation. 
Reproductive Toxicity.
Stable Cobalt.  No studies were located regarding the reproductive effects of cobalt in humans following 
exposure by any route.  Inhalation and oral studies in male animals have demonstrated adverse effects on 
reproductive organs (Anderson et al. 1992, 1993; Bucher et al. 1990; Corrier et al. 1985; Domingo et al. 
1985b; Mollenhauer et al. 1985; NTP 1991; Pedigo et al. 1988).  One study also reported effects on the 
estrous cycle in mice following inhalation exposure (Bucher et al. 1990; NTP 1991).  Multigenerational 
studies would be helpful in assessing the significance of these effects on reproductive performance.  
Radioactive Cobalt. Data on reproductive effects following exposure to radioactive cobalt by the 
inhalation, oral, or dermal routes are lacking.  Because cobalt radioisotopes are man-made (see 
Chapter 5), only low-level exposure to radioactive cobalt in the environment by these routes is likely to 
occur. Human data on reproductive effects following external exposure to cobalt radiation are lacking, 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COBALT 178 
3. HEALTH EFFECTS 
but are sufficiently understood for gamma radiation.  Available animal studies are limited, but have 
demonstrated radiation-induced deficits on reproductive ability in both genders (Cunningham and 
Huckins 1978; Laporte et al. 1985; Searl et al. 1976, 1980).  Additional data in humans and animals 
would be helpful in refining minimal effective doses for radiation effects on reproduction. 
Developmental Toxicity.     
Stable Cobalt.  No developmental effects were observed in the children of 78 women given cobalt 
chloride orally during pregnancy for treatment of anemia (Holly 1955); however, only a limited 
examination of offspring was reported, and details of examined end points were not reported.  No studies 
of developmental effects by other routes of exposure in humans were located.  Developmental effects in 
animals following oral exposure during gestation, however, have been observed (Domingo et al. 1985b).  
Further developmental studies in animals by all relevant routes of exposure (inhalation, oral, dermal) may
clarify the potential developmental effects of cobalt in humans. 
Radioactive Cobalt. Data on developmental effects following exposure to radioactive cobalt by the 
inhalation, oral, or dermal routes are lacking.  Because cobalt radioisotopes are man-made (see 
Chapter 5), only low-level exposure to radioactive cobalt in the environment by these routes is likely to 
occur. No human studies describing developmental effects of exposure to external cobalt radiation were 
located. Extensive data from animal studies have shown that even acute exposures to small amounts of 
cobalt radiation may elicit profound effects on the developing organism (see Section 3.2.4.6).  The effects 
of ionizing radiation on the developing organism are also described in the Agency for Toxic Substances 
and Disease Registry Toxicological Profile for Ionizing Radiation (1999). 
Immunotoxicity.     
Stable Cobalt.  Humans have been shown to develop sensitivity to cobalt following occupational 
exposure (Bencko et al. 1983; Shirakawa et al. 1988, 1989).  No immunological effects were observed 
following oral exposure of humans to cobalt.  Similar evidence of sensitization has been reported in 
animals (Lammintausta et al. 1985).  Studies examining the mechanism of sensitization might be helpful 
in fully understanding and treating this effect in humans.  A battery of immune function tests would 
further assess the immunotoxicity of cobalt in humans and animals. 
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Radioactive Cobalt. Data on immunotoxic effects following exposure to radioactive cobalt by the 
inhalation, oral, or dermal routes are lacking.  Because cobalt radioisotopes are man-made (see 
Chapter 5), only low-level exposure to radioactive cobalt in the environment by these routes is likely to 
occur. Following external exposure to cobalt radiation, above levels normally encountered except for 
medical procedures, decreases in white blood cell counts have been seen in both humans and animals.  
Further studies on the immunotoxic effects of external cobalt radiation would be useful in refining the 
minimum effective dose. 
Neurotoxicity.     
Stable Cobalt.  No studies were located regarding neurotoxic effects of cobalt in humans following oral 
or dermal exposure. Two occupational inhalation exposure studies have reported memory deficits, optic 
atrophy, or nerve deafness in humans exposed to cobalt (Jordan et al. 1990; Meecham and Humphrey
1991).  In animals, alterations in several neurologic parameters were found following oral exposure 
(Bourg et al. 1985; Krasovskii and Fridlyand 1971; Mutafova-Yambolieva et al. 1994; Nation et al. 1983; 
Singh and Junnarkar 1991; Vassilev et al. 1993; Wellman et al. 1984).  Additional studies in animals 
would assist in determining whether these neurological effects have any relevance to potential effects in 
humans. 
Radioactive Cobalt. Data on neurotoxic effects following exposure to radioactive cobalt by the 
inhalation, oral, or dermal routes are lacking.  Because cobalt radioisotopes are man-made (see 
Chapter 5), only low-level exposure to radioactive cobalt in the environment by these routes is likely to 
occur. Human data following cobalt radiotherapy have demonstrated effects believed to result from
neurological damage, but data are limited, doses were extreme, and effects have not been well-
characterized.  Several animal studies have shown neurobehavioral or neurophysiological changes 
following exposure to cobalt radiation (Bassant and Court 1978; Maier and Landauer 1989; Mele et al. 
1988). 
Epidemiological and Human Dosimetry Studies.     
Stable Cobalt.  Epidemiological studies relating to cobalt exposure are available in the literature.  Studies 
of persons exposed to cobalt occupationally are available (Kusaka et al. 1986a, 1986b; Shirakawa et al. 
1988, 1989; Sprince et al. 1988), dietetically (beer drinkers) (Alexander 1969, 1972; Morin et al. 1971), 
and medically (cobalt given to alleviate anemia) (Davis and Fields 1958; Holly 1955; Taylor et al. 1977).  
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Further studies assessing the cause/effect relationship between cobalt exposure and human health effects 
would be helpful in monitoring individuals living near a hazardous waste site to verify that documented 
exposure levels are not associated with adverse health effects. 
Radioactive Cobalt. Epidemiological data on exposure to radioactive cobalt by the inhalation, oral, or 
dermal routes are lacking.  Because cobalt radioisotopes are man-made (see Chapter 5), only low-level 
exposure to radioactive cobalt in the environment by these routes is likely to occur.  Human external 
exposures to cobalt radiation have been documented in the literature.  Radiotherapy exposures, though to 
extremely high radiation doses, are generally well-controlled and documented, whereas environmental 
and accidental workplace exposures are less frequent and less well-documented. 
Biomarkers of Exposure and Effect.     
Exposure. 
Stable Cobalt.  Information is available on the monitoring of cobalt exposure by the quantification of 
cobalt in urine and blood (Alexandersson 1988; Ichikawa et al. 1985; Scansetti et al. 1985).  A portion of 
inhaled cobalt is rapidly excreted in the feces, and the amount retained in the body tends to be steadily
excreted over time. Levels in body fluids, therefore, can be monitored up to several days after exposure.  
Many different methods for the detection of cobalt in body fluids have been reported (Section 7.1). 
Radioactive Cobalt. No information is available regarding biomarkers specific for exposure to cobalt 
radionuclides by the inhalation, oral, dermal, or external exposure routes.  Biomarkers for exposure to 
ionizing radiation are discussed in Agency for Toxic Substances and Disease Registry (1999).  Personal 
dosimeters (film or luminescent) are an artificial surrogate to measure the amount of exposure to external 
beta or gamma radiation, though these are not specific for radiation from cobalt radionuclides. 
Effect. 
Stable Cobalt.  Alterations in serum proteins and changes in serum antibodies have been found that are 
specific for cobalt exposure (Stokinger and Wagner 1958).  These changes may be the earliest indication 
of the effects of cobalt exposure.  Further studies may reveal other cobalt-specific biomarkers that, in 
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combination with these changes, may alert health professionals to cobalt exposure before serious 
toxicological effects occur. 
Radioactive Cobalt. While in many cases radioactive cobalt itself can be measured following exposure, 
no information is available regarding biomarkers specific for effects of cobalt radionuclides following 
exposure by the inhalation, oral, dermal, or external exposure routes.  Biomarkers for effects of ionizing
radiation are discussed in Agency for Toxic Substances and Disease Registry (1999), and include changes 
in levels of formed elements of the blood as some of the most sensitive indicators.  These biomarkers are 
believed to be suitable for monitoring exposure to cobalt radiation.
Absorption, Distribution, Metabolism, and Excretion.  Pharmacokinetic data in humans indicate 
that cobalt is absorbed through the lungs (Foster et al. 1989) and the gastrointestinal tract (Harp and 
Scoular 1952; Sorbie et al. 1971; Valberg et al. 1969), that cobalt is well distributed in the body with the 
highest concentration being found in the lungs following inhalation (Gerhardsson et al. 1984; Hewitt 
1988; Hillerdal and Hartung 1983; Teraoka 1981), and that some of the inhaled or ingested cobalt is 
rapidly excreted in the feces, with the amount retained in the body being excreted slowly, primarily in the 
urine (Foster et al. 1989; Paley et al. 1958; Smith et al. 1972).  Pharmacokinetic studies in animals 
following inhalation and oral exposure have demonstrated similar responses (Andre et al. 1989; Bailey et 
al. 1989; Collier et al. 1989; Foster et al. 1989; Patrick et al. 1989; Talbot and Morgan 1989).  Few data 
exist regarding the pharmacokinetics of cobalt following dermal exposure, though what data are available 
demonstrate that cobalt can be absorbed in small quantities through human (Scansetti et al. 1994) and 
animal (Inaba and Suzuki-Yasumoto 1979; Lacy et al. 1996) skin, with greater absorption occurring 
through damaged than intact skin. 
Comparative Toxicokinetics.  Several inhalation and oral studies have compared the toxicokinetics 
of cobalt in several different species of animals, including humans (Andre et al. 1989; Bailey et al. 1989; 
Collier et al. 1989; Foster et al. 1989; Patrick et al. 1989; Talbot and Morgan 1989).  No comparative 
pharmacokinetic studies following dermal exposure were located.  These studies would be useful because 
humans are exposed via the skin in the workplace and may potentially be exposed via this route at waste 
sites. 
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Methods for Reducing Toxic Effects.   
Stable and Radioactive Cobalt.  Chelation therapy is expected to apply equally well to stable and 
radioactive cobalt isotopes.  EDTA or British anti-lewisite (BAL) has been shown to effectively mitigate 
the toxicity of cobalt in humans (Goldfrank et al. 1990; Haddad and Winchester 1990; Stutz and Janusz 
1988).  In animal studies examining the effectiveness of various chelators, n-acetyl cysteine (NAC) was 
shown to be the most effective (Llobet et al. 1988).  It would be useful to determine the effective dose of 
NAC in humans. Studies examining the effectiveness of other chelating agents may be helpful in 
determining the most effective chelation therapy for humans. 
Children’s Susceptibility.     
Stable Cobalt.  Data comparing the susceptibility of children to cobalt compounds are limited.  Animal 
studies have suggested that absorption following inhalation or oral exposure may be greater in very young 
animals, resulting in increased systemic dose.  Data are not available on the differences between children 
and adults following dermal exposure.  Further studies on the susceptibility of young animals relative to 
adult animals may be useful in determining whether children are at greater risk from exposure to cobalt in 
the environment than adults. 
Radioactive Cobalt. No data are available on whether children are more susceptible to the effects of 
radioactive cobalt compounds than adults.  Animal studies have shown that exposure in utero to even 
moderate amounts of cobalt radiation can cause dramatic effects in the developing organism.  It would be 
expected that children would be more susceptible to the effects of external cobalt radiation, due to the 
greater percentage of rapidly-dividing cells during growth. 
Child health data needs relating to exposure are discussed in 6.8.1 Identification of Data Needs: 
Exposures of Children. 
3.13.3 Ongoing Studies 
Relevant ongoing studies were not located for cobalt.
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4.1 CHEMICAL IDENTITY  
Cobalt is a naturally-occurring element that appears in the first transition series of Group 9 (VIII) of the 
periodic table along with iron and nickel.  There is only one stable isotope of cobalt, 59Co. There are 
about 26 known radioactive isotopes of cobalt, of which only two are of commercial importance, 60Co and 
57Co. 60Co, a commonly-used source of gamma radiation, is the most important radionuclide.  It may be a 
low-level contaminant of cooling water released by nuclear reactors.  Table 4-1 summarizes information 
on the chemical identity of elemental cobalt and some common cobalt compounds.  
4.2 PHYSICAL, CHEMICAL, AND RADIOLOGICAL PROPERTIES  
Cobalt commonly occurs in the 0, +2, and +3 valence states.  Compounds containing cobalt in the -1, +1,
+4, and +5 oxidation state are few and uncommon (Cotton and Wilkinson 1980). Cobalt (II) is much 
more stable than Co(III), and Co3+ is a sufficiently powerful oxidizing agent to oxidize water, liberating 
oxygen.  Table 4-2 summarizes important physical and chemical properties of elemental cobalt and some
common cobalt compounds.  These properties are similar to those of its neighbors in Group 9 of the 
periodic table, iron and nickel.  Metallic cobalt, Co(0), occurs as two allotropic forms, hexagonal and 
cubic; the hexagonal form is stable at room temperature.  A biochemically important cobalt compound is 
vitamin B12, or cyanocobalamin, in which cobalt is complexed with four pyrrole nuclei joined in a ring 
called the corrinoid ligand system (similar to porphyrin).   
The Chemical Abstract Service (CAS) registry numbers, decay modes, half-lives, and specific activity of 
the three principal radioactive cobalt isotopes, 57Co, 58Co, and 60Co, are presented in Table 4-3.  60Co 
(half-life of 5.27 years) decays by beta decay to nickel-60, a stable isotope (ICRP 1983; Lide 1998). 
60 60 0 
27 Co→28Ni+−1e + γ 
  
 
 
 
 
 
 
 
 
 
Table 4-1. Chemical Identity of Cobalt and Selected Compounds 
 
Characteristic Cobalt Cobalt(II) acetate Cobalt(III) acetate Cobalt(II) carbonate 
Synonym(s) Cobalt-59, Cobaltous acetate, Cobaltic acetate, 
cobalt metal cobalt diacetate cobalt triacetate 
Registered trade No data No data No data 
name(s) 
Chemical formula Co Co(C2H4O2)2 Co(C2H4O2)3
O O Chemical structure Co 
C C O O Co O Co O
C CO 
O O C O  
 
Identification numbers: 
  CAS registry 7440-48-4 71-48-7 917-69-1 
 NIOSH RTECS GF8750000 AG3150000 No data 
  EPA hazardous No data No data No data 
waste 

 OHM/TADS No data No data No data 
 DOT/UN/NA/IMCO UN1318 No data No data 

  shippinga
 HSDB 519 997 No data 
 NCI C60311 No data No data 
 
Cobaltous carbonate; 
carbonic acid; cobalt (+2) 
 salt
No data 
  CoCO3 
O 
O Co
O  
513-79-10 
FF9450050 
No data 
No data 

No data 

No data 

No data 
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Table 4-1. Chemical Identity of Cobalt and Selected Compounds 
 
Characteristic Cobalt carbonyl Cobalt(II) chloride 
Cobalt(II) 
hydroxide 
Cobalt(II) meso-
porphyrin 
Synonym(s) 	Dicobalt octa-
carbonyl; cobalt 
 tetracarbonyl
Registered trade No data 
name(s) 
Chemical formula  Co2(CO)8
Chemical structure O	 O 
OCC C 
O C Co Co C O 
C CC
 
O
 O
O  
Identification numbers: 
  CAS registry 10210-68-1 
 NIOSH RTECS GG0300000 
  EPA hazardous No data 
waste 
 OHM/TADS No data 
 DOT/UN/NA/IMCO No data 
shipping 
 HSDB 6345 
 NCI No data 
 
Cobalt dichloride; 
cobaltous chloride 
No data 
 CoCl2
C l  
C o  
C l  
7646-79-9 
GF9800000 
No data 
7217328 
No data 
1000 
No data 
Cobaltous hydr-
oxide; cobalt 
dihydroxide 
No data 
 Co(OH)2
HO Co OH  
21041-93-0 
No data 
No data 
No data 
No data 
No data 
No data 
Cobalt meso­
porphyrin IX Cobalt­
iprotoporphyrin 
No data 
  C34H34CoN4O4 
No data
21158-51-0 
No data 
No data 
No data 
No data 
No data 
No data 
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Table 4-1. Chemical Identity of Cobalt and Selected Compounds 
 
Cobalt(II) Cobalt(II) 

Characteristic  naphthenate nitrate Cobalt(II) oxide Cobalt(III) oxide 

Synonym(s) 	Naftolite; Cobaltous Black 13; C.I. 77322; Cobalt black; cobaltic 
naphthenic acid, nitrate cobalt monoxide; oxide; cobalt sesquioxide; 
 cobalt salt cobaltous oxide cobalt trioxide; C.I. 77323 
Registered trade No data No data C.I. Pigment No data 
name(s) Black 13; Zaffre 
Chemical formula Co(C11H10O2)2 Co(No3)2•6H20 CoO  Co2O3 
Chemical structure O  Co  O Co OCo O  
O O  
C Co O NO Co 
O O  2C  
O 
 
Identification numbers: 
  CAS registry 10210-68-1 7646-79-9 21041-93-0 21158-51-0 
 NIOSH RTECS GG0300000 GF9800000 No data No data 
  EPA hazardous No data No data No data No data 
waste 

 OHM/TADS No data 7217328 No data No data 

 DOT/UN/NA/IMCO No data No data No data No data 

shipping 

 HSDB 6345 1000 No data No data 

 NCI No data No data No data No data 
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Table 4-1. Chemical Identity of Cobalt and Selected Compounds 
 
Characteristic Cobalt(II, III) oxide Cobalt(II) sulfate   
Synonym(s) 
Registered trade name(s) 
Chemical formula  
Chemical structure 
Identification numbers: 
  CAS registry
 NIOSH RTECS 
 EPA hazardous waste 
 OHM/TADS 
 DOT/UN/NA/IMCO 
shipping 
HSDB 
 NCI 
Cobaltic-cobaltous oxide; cobalt tetra-
 oxide, tricobalt tetraoxide, cobaltosic
 oxide; cobalt black; C.I. Pigment Black 13 
No data 
Co3O4
Co=OO=Co–O–Co=O 
1308-06-1 
No data 
No data 
No data 
No data 
No data 
No data 
 Cobalt sulfate; cobaltous   
sulfate 
No data   
  CoSO4 
O O   
S Co 
O O  
10124-43-3   
GG3100000   
No data   
7217330   
No data   
240   
No data   
 
 aThe identification number for radioactive materials is UN2910
 
CAS = Chemical Abstract Service; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
  America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for 
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; 
RTECS = Registry of Toxic Effects of Chemical Substances 
 
Source: Budavari 1996; HSDB 2001; RTECS 1987 
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Table 4-2. Physical and Chemical Properties of Cobalt and Selected Compounds 
Property Cobalt Cobalt(II) acetate Cobalt(III) acetate Cobalt(II) carbonate 
Molecular weight 58.93 177.03 236.07 118.94 
Color Silvery gray Light pink Dark green Red 
Physical state Solid Solid Solid Solid 
Melting point, °C 1,495 No data Decomposes at 
100 °C
Decomposes 
Boiling point, °C 
Density, g/cm3 
2,870 
8.9 (20 °C) 
No data 
No data 
Not relevant 
No data 
Not relevant 
4.13 
Odor No data No data No data No data 
Odor threshold: 
 Water No data No data No data No data 
Air No data No data No data No data 
Solubility: 
 Water Insoluble Soluble Soluble 0.18 g/100 g H2O at 
15 °C 
 Organic 
solvent(s) 
Insoluble  2.1 g/100 g 
methanol at 15 °C 
soluble in alcohol, 
acetic acid 
Insoluble in ethanol 
Partition coefficients: 
 Log Kow
 Log Koc 
No data 
No data 
No data 
No data 
No data 
No data 
No data 
No data 
Vapor pressure 1 mmHg at 
1,910 °C
No data No data No data 
Henry’s law constant No data No data No data No data 
Autoignition 
temperature 
760 °C for dust 
cloud 
No data No data No data 
Flashpoint No data No data No data No data 
Flammability limits 
Conversion factors 
No data 
Not relevanta
No data 
 Not relevanta
No data 
 Not relevanta
No data 
 Not relevanta 
Explosive limits No data No data No data No data 
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Table 4-2. Physical and Chemical Properties of Cobalt and Selected Compounds 
Cobalt(II) 
Property Cobalt carbonyl Cobalt(II) chloride Cobalt(II) hydroxide mesoporphyrin 
Molecular weight 341.9 129.84 92.95 621.2b 
Color Orange (white Blue Rose red or blue No data 
when pure) green 
Physical state Solid Solid Solid No data 
Melting point, °C 51 724 No data No data 
Boiling point, °C Decomposes 1,049 No data No data 
Density, g/cm3 1.73 at 18 °C 3.356 (36 °C)  3.597 at 15 °C No data 
Odor No data No data No data No data 
Odor threshold: 
 Water No data No data No data No data 
Air No data No data No data No data 
Solubility: 
 Water Insoluble 450 g/L at 7 °C 0.0032 g/L No data 
 Organic Soluble in ether; 544 g/L in ethanol; No data No data 
solvent(s) insoluble in 86 g/L in acetone 
naphtha
Partition coefficients: 
 Log Kow No data No data No data No data 
 Log Koc No data No data No data No data 
Vapor pressure 199.5 at 25 °C No data No data No data 
Henry’s law constant No data No data No data No data 
Autoignition No data No data No data No data 
temperature, °C 
Flashpoint, °C No data No data No data No data 
Flammability limits No data No data No data No data 
Conversion factors Not relevanta Not relevanta Not relevanta Not relevanta 
Explosive limits No data No data No data No data 
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Table 4-2. Physical and Chemical Properties of Cobalt and Selected Compounds 
Cobalt(II) 
Property naphthenate Cobalt(II) nitrate Cobalt(II) oxide Cobalt(III) oxide 
Molecular weight 407 182.94 74.93 165.86 
Color No data Red Pink Black-gray 
Physical state Solid Solid Solid Solid 
Melting point, °C 140 Decomposes at 100– 
105b 
1,795 895 
(decomposes) 
Boiling point, °C No data Not relevant No data Not relevant 
Density g/cm3 0.9 2.49b 6.45 5.18 
Odor No data No data No data No data 
Odor threshold: 
 Water No data No data No data No data 
Air No data No data No data No data 
Solubility: 
 Water Insoluble 133.8 at 0 °Cc Insoluble Insoluble 
 Organic No data Soluble in ethanol, Insoluble in Insoluble in 
solvent(s) acetone alcohol ethanol 
Partition coefficients: 
 Log Kow No data No data No data No data 
Log Kow No data No data No data No data 
Vapor pressure No data No data No data No data 
Henry’s law constant No data No data No data No data 
Autoignition No data No data No data No data 
temperature 
Flashpoint No data No data No data No data 
Flammability limits No data No data No data No data 
Conversion factors Not relevanta Not relevanta Not relevanta Not relevanta 
Explosive limits No data No data No data No data 
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Table 4-2. Physical and Chemical Properties of Cobalt and Selected Compounds 
Property Cobalt(II, III) oxide Cobalt(II) sulfate 
Molecular weight 250.80 154.99 
Color Black Dark blue 
Physical state Solid Solid 
Melting point, °C -O2 at 900–950 Decomposes at 735 °C 
Boiling point, °C 
Density g/cm3
Not relevant 
6.07 
Not relevant 
3.71 
Odor No data No data 
Odor threshold: 
 Water No data No data 
Air No data No data 
Solubility: 
 Water 
 Organic solvent(s) 
Insoluble 
No data 
3.83 g/100 mL H2O at 25 °C
1.04 g/100 mL methanol at 18 °C 
Partition coefficients: 
 Log Kow
Log Kow 
No data 
No data 
No data 
No data 
Vapor pressure No data No data 
Henry’s law constant No data No data 
Autoignition temperature No data No data 
Flashpoint No data No data 
Flammability limits 
Conversion factors 
No data 
Not relevanta
No data 
 Not relevanta 
Explosive limits No data No data 
aSubstances exist in the atmosphere in the particulate state, and the concentration is expressed in weight per cubic 
meter 
bCAS Online 
cHexahydrate 
Source: Budavari 1996; HSDB 2001, 2004; Lide 1994; Stockinger 1981; Weast 1985 
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Table 4-3. Principal Radioactive Cobalt Isotopes 
 Beta radiation Gamma radiation 
Isotope 
CAS 
registry no. 
Decay mode 
(product) 
Decay mode 
energy (MeV) 
55Co 13982-25-7 E.C. β+ 
(55Fe) 
3.452 
Energy 
(MeV) 
1.498 
1.021 
Intensity 
(percent) 
46 
25.6 
Energy 
(MeV) 
0.9312 
0.4772 
Intensity 
(percent) Half-life 
75 
20 
17.53 
hours 
2.043 10.7 1.408 16.88 
57Co 13981-50-5 E.C. (57Fe) 0.836 0.700 99.8 0.1221 
0.1365 
85.6 
10.7 
271.8 
days 
0.014 9.2 
58Co 13981-38-9 E.C. β+ 
(58Fe) 
2.30 1.4966 
0.4746 
83.9 
14.9 
0.811 99 70.86 
days 
60Co 10198-40-0 β- (60Ni) 2.824 0.3181 99.9 1.173 
1.332 
100 
100 
5.271 
years 
Β– = negative beta emission; β+ = positron emission; E.C. = orbital electron capture 
Source: ICRP 1983; LBNL 2000; Lide 1998 
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The decay is accompanied by the emission of 1.173 and 1.332 MeV gamma rays.  57Co (half-life of 
271.8 days) and 58Co (half-life of 70.9 days) decay by electron capture and electron capture/position (β+) 
emission to 57Fe and 58Fe, respectively. These decay processes are also accompanied by gamma 
emissions (Table 4-3). 
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5.1 PRODUCTION  
Cobalt is the 33rd most abundant element, comprising approximately 0.0025% of the weight of the earth’s 
crust. It is often found in association with nickel, silver, lead, copper, and iron ores and occurs in mineral 
form as arsenides, sulfides, and oxides.  The most import cobalt minerals are: linnaeite, Co3S4; carrolite, 
CuCo2S4; safflorite, CoAs2; skutterudite, CoAs3; erythrite, Co3(AsO4)2•8H2O; and glaucodot, CoAsS 
(Hodge 1993; IARC 1991; Merian 1985; Smith and Carson 1981).  The largest cobalt reserves are in the 
Congo (Kinshasa), Cuba, Australia, New Caledonia, United States, and Zambia.  Most of the U.S. cobalt 
deposits are in Minnesota, but other important deposits are in Alaska, California, Idaho, Missouri, 
Montana, and Oregon. Cobalt production from these deposits, with the exception of Idaho and Missouri, 
would be as a byproduct of another metal (USGS 2004).  Cobalt is also found in meteorites and deep sea 
nodules. 
The production of pure metal from these ores depends on the nature of the ore.  Sulfide ores are first 
finely ground (i.e., milled) and the sulfides are separated by a floatation process with the aid of frothers 
(i.e., C5–C8 alcohols, glycols, or polyethylene or polypropylene glycol ethers).  The concentrated product 
is subjected to heating in air (roasting) to form oxides or sulfates from the sulfide, which are more easily
reduced. The resulting matte is leached with water and the cobalt sulfate leachate is precipitated as its 
hydroxide by the addition of lime.  The hydroxide is dissolved in sulfuric acid, and the resulting cobalt 
sulfate is electrolyzed to yield metallic cobalt.  For the cobalt-rich mineral cobaltite, a leaching process 
with either ammonia or acid under pressure and elevated temperatures has been used to extract cobalt.  
The solution is purified to remove iron and is subsequently reduced by hydrogen in the presence of a 
catalyst under elevated temperature and pressure to obtain fine cobalt powder (Duby 1995; Nagaraj 1995; 
Planinsek and Newkirk 1979). 
Except for a negligible amount of byproduct cobalt produced from some mining operations, no cobalt is 
presently mined or refined in the United States.  In addition to byproduct production, U.S. production is 
derived from scrap (secondary production).  In 2003, an estimated 2,200 metric tons of cobalt were 
recycled from scrap (USGS 2004).  Since 1993, production has been supplemented by sales of excess 
cobalt from the National Defense Stockpile (NDS), which the government maintains for military, 
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industrial, and essential civilian use during national emergencies.  In fiscal year 2002, 2,720 metric tons 
of cobalt were released from the NDS.  In 2001, the United States did not mine or refine cobalt, with the 
exception of small amounts of byproduct cobalt produced from mining operations in Missouri and 
Montana. The 2002 U.S. consumption of cobalt metal, organic and inorganic cobalt compounds, and 
purchased scrap (in terms of cobalt content) was 3,870, 1,270, and 2,800 metric tons, respectively (USGS 
2002).
Current U.S. manufacturers of selected cobalt compounds are given in Table 5-1.  Table 5-2 lists facilities 
in each state that manufacture, process, or use cobalt or cobalt compounds, the intended use, and the 
range of maximum amounts of these substances that are stored on site.  In 2000, there were 618 reporting 
facilities that produced, processed, or used cobalt or cobalt compounds in the United States.  The data 
listed in Table 5-2 are derived from the Toxics Chemicals Release Inventory (TRI) (TRI01 2004).  Only
certain types of facilities were required to report.  Therefore, this is not an exhaustive list. 
60Co is produced by irradiating stable cobalt, 59Co, with thermal neutrons in a nuclear reactor: 
59Co(n,γ)60Co.  The neutron flux employed is 1012–1015 n/cm2-sec and the conversion is 99%. The 
maximum specific activity obtained is 3.7x1013 Bq/g (1,000 Ci/g). Commercial 60Co sources used for 
bacterial sterilization are made into rods with double metal shielding.  The individual sources have an 
activity of about 2x1014–6x1014 Bq (6–15 kCi).  The annual output of 60Co was about 2x1018–3x1018 Bq 
(50–80 MCi) in the early 1990s.  In 1991, there were 170 gamma irradiation systems operating in 
45 countries having a total activity of about 6x1018 Bq (160 MCi) (Zyball 1993).  Producers of 60Co 
include MDS Nordion in Canada, AEA Technology (formerly Amersham QSA) in the United Kingdom, 
and Neutron Products in Dickerson, Maryland.   
58Co is not produced commercially.  It can be produced by irradiating 58Ni, a stable isotope, with 
neutrons, followed by positron decay:  58Ni(n,γ)58Co.  It can be produced in a nuclear reactor or a 
cyclotron.  Both 60Co and 58Co may be produced unintentionally in reactors.  These are the dominant 
sources of residual radiation in the primary circuit outside the reactor core of nuclear plants and are 
formed by neutron absorption of 59Co and 58Ni, both stable isotopes commonly used in plant construction 
materials (Taylor 1996). 60Co is commonly found as one of the radionuclides present in the low-level 
radioactive waste discharges from many nuclear power plants; however, amounts rarely make a 
significant contribution to the radiation exposure of the public (Leonard et al. 1993a).  The geometric 
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Table 5-1. Current U.S. Manufacturers of Cobalt Metal and Selected Cobalt 

Compoundsa 

Company Location 
Cobalt metalb: 
 Kennametal, Inc. Latrobe, Pennsylvania 
OM Group, Inc. Cleveland, Ohio 
Cobalt (II) acetate: 
The IMC Group  Shelby, North Carolina  
McGean-Rohco, Inc., McGean Specialty Chemicals Division Cleveland, Ohio 
OM Group, Inc. Franklin, Pennsylvania 
The Shepard Chemical Company Cincinnati, Ohio
Cobalt (II) carbonate: 
The IMC Group Shelby, North Carolina 
McGean-Rohco, Inc., McGean Specialty Chemicals Division Cleveland, Ohio 
 OMG Apex St. George, Utah 
OM Group, Inc. Franklin, Pennsylvania 
The Shepherd Chemical Co. Cincinnati, Ohio
Cobalt (II) chloride: 
The IMC Group Shelby, North Carolina 
Johson Matthey, Inc., Alfa Aesar Ward Hill, Massachusetts 
McGean-Rohco, Inc., McGean Specialty Chemicals Division Cleveland, Ohio 
OM Group. Inc. Franklin, Pennsylvania 
The Shepard Chemical Company Cincinnati, Ohio
Cobalt (II) hydroxide: 
McGean-Rohco, Inc., McGean Specialty Chemicals Division Cleveland, Ohio 
OM Group, Inc. Franklin, Pennsylvania 
The Shepard Chemical Company Cincinnati, Ohio
Cobalt (II) nitrate: 
The IMC Group Shelby, North Carolina 
Johnson Matthey, Inc., Alfa Aesar Ward Hill, Massachusetts 
McGean-Rohco, Inc., McGean Specialty Chemicals Division Cleveland, Ohio 
 OMG Apex St. George, Utah 
OM Group, Inc. Franklin, Pennsylvania 
The Shepard Chemical Company Cincinnati, Ohio
Umicore USA, Inc., Cobalt Products Laurinburg, North Carolina
Cobalt (II) oxide: 
 OMG Apex St. George, Utah 
The Shepard Chemical Company Cincinnati, Ohio
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Table 5-1. Current U.S. Manufacturers of Cobalt Metal and Selected Cobalt 

Compoundsa 

Cobalt (III) oxide: 
Johnson Matthey, Inc., Alfa Aesar Ward Hill, Massachusetts 
 Mallinckrodt Baker, Inc. Phillipsburg, New Jersey 
McGean-Rohco, Inc., McGean Specialty Chemicals Division Cleveland, Ohio 
OM Group, Inc. Franklin, Pennsylvania 
Osram Sylvania Inc. Towanda, Pennsylvania 
Cobalt (II) sulfate: 
The IMC Group Shelby, North Carolina 
McGean-Rohco, Inc., McGean Specialty Chemicals Division Cleveland, Ohio 
 OMG Apex St. George, Utah 
OM Group, Inc. Franklin, Pennsylvania 
The Shepard Chemical Company Cincinnati, Ohio
aDerived from Stanford Research Institute (SRI) 2003, except where otherwise noted.  SRI reports production of 
chemicals produced in commercial quantities (defined as exceeding 5,000 pounds or $10,000 in value annually) by
the companies listed 
bU.S. members of The Cobalt Development Institute that are listed as producers of cobalt powder or hard metal 
products
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Table 5-2. Facilities that Produce, Process, or Use Cobalt and Cobalt 

Compounds 

Number of Minimum amount Maximum amount 
Statea facilities on site in poundsb on site in poundsb Activities and usesc 
AK 2 10,000 999,999 1, 5, 7, 12 
AL 22 100 999,999 1, 2, 3, 4, 5, 6, 7, 8,9, 10, 12, 13 
AR 9 100 99,999 1, 5, 7, 8,9 
AZ 12 1,000 49,999,999 1, 2, 3, 5, 7, 8,9, 10, 12, 13, 14 
CA 28 0 9,999,999 1, 2, 3, 5, 6, 7, 8,9, 10, 11, 12 
CO 1 10,000 99,999 12 
CT 9 0 999,999 2, 3, 7, 8 
DE 2 1,000 9,999 1, 5,9, 13 
FL 11 0 99,999 1, 2, 3, 4, 5, 6, 7, 8,9, 12, 13, 14 
GA 17 100 999,999 1, 2, 3, 4, 5, 6, 7, 8,9, 11, 12, 13 
IA 6 100 99,999 3, 4, 7, 8, 12 
ID 2 100,000 999,999 1, 3, 5, 12 
IL 24 100 9,999,999 1, 2, 3, 4, 5, 6, 7, 8,9, 10, 11, 12, 13, 14 
IN 42 100 999,999 1, 2, 3, 4, 5, 6, 7, 8,9, 10, 11, 12, 13, 14 
KS 5 10,000 99,999 1, 3, 5, 6, 7, 8,9, 10, 11, 12, 13 
KY 22 100 999,999 1, 2, 3, 4, 5, 6, 7, 8,9, 12, 13, 14 
LA 15 1,000 999,999 1, 2, 3, 4, 5, 6, 8, 10, 12, 13, 14 
MA 11 100 99,999 1, 5, 8,9, 12 
MD 6 1,000 99,999 1, 2, 3, 4, 5, 6, 7,9, 13 
ME 2 100 99,999 1, 5, 8 
MI 24 0 999,999 1, 2, 3, 4, 5, 7, 8,9, 11, 12, 13, 14 
MN 6 100 99,999 1, 2, 5, 7, 8,9, 10, 12, 13, 14 
MO 5 1,000 999,999 1, 2, 3, 4, 5, 6, 8,9, 12, 13, 14 
MS 7 100 99,999 1, 5, 6, 7, 8, 10
MT 1 10,000 99,999 1, 5, 12, 14 
NC 24 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8,9, 10, 12, 13, 14 
ND 4 1,000 99,999 1, 5, 7, 12, 13, 14 
NE 1 1,000 9,999 8, 11 
NH 1 100 999 8 
NJ 14 1,000 9,999,999 1, 3, 4, 5, 6, 7, 8, 10, 12, 14 
NM 6 1,000 9,999,999 1, 3, 4, 5, 7, 8,9, 11, 12, 13 
NV 8 1,000 10,000,000,000 1, 5, 6, 8, 12, 13, 14 
NY 12 1,000 99,999 1, 2, 3, 4, 5, 7, 8,9, 11, 12 
OH 44 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8,9, 11, 12, 13, 14 
OK 14 100 999,999 1, 2, 3, 5, 6, 7, 8,9, 10, 11, 12 
OR 6 1,000 99,999 1, 5, 7, 8, 12 
PA 44 100 9,999,999 1, 2, 3, 4, 5, 6, 7, 8,9, 10, 11, 12, 13, 14 
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Table 5-2. Facilities that Produce, Process, or Use Cobalt and Cobalt 

Compounds 

Number of Minimum amount Maximum amount 
Statea facilities on site in poundsb on site in poundsb Activities and usesc 
PR 2 1,000 99,999 8,9 
RI 1 100,000 999,999 8 
SC 26 100 9,999,999 1, 2, 3, 4, 5, 6, 7, 8,9, 10, 11, 12, 13 
SD 1 10,000 99,999 7 
TN 18 0 999,999 1, 2, 3, 4, 5, 6, 7, 8,9, 10, 12, 13 
TX 45 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8,9, 10, 11, 12, 13, 14 
UT 6 1,000 9,999,999 1, 3, 4, 5, 7, 8,9, 12, 13 
VA 9 10,000 999,999 1, 2, 3, 4, 5, 6, 7, 8 
VI 1 10,000 99,999 10 
WA 2 10,000 99,999 1, 3, 4, 5,9, 10, 11, 12, 13 
WI 20 100 999,999 1, 3, 4, 5, 7, 8,9, 11, 12, 13, 14 
WV 13 100 999,999 1, 2, 3, 4, 5, 7, 8,9, 11, 12, 13, 14 
WY 2 0 99,999 1, 5,9, 12, 13 
Source: TRI01 2004 
aPost office state abbreviations used 
bAmounts on site reported by facilities in each state 
cActivities/Uses:
1. Produce 6. Impurity 11. Chemical Processing Aid
2. Import 7. Reactant 12. Manufacturing Aid  
3. Onsite use/processing 8. Formulation Component 13. Ancillary/Other Uses 
4. Sale/Distribution 9. Article Component 14. Process Impurity 
5. Byproduct 10. Repackaging 
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mean release of 60Co in liquid effluents of light-water nuclear power stations was reported as in the early
1970s as 0.0805 Ci/year (3.0 GBq) (Morgan 1976). 
The 60Co activities for a representative pressurized-water reactor (PWR) and boiling water reactor (BWR) 
fuel assemblies are 1,100 and 170 Ci (41 and 6.3 TBq), respectively.  There are 78 PWR and 40 BWR 
reactors in the United States, several of which have ceased operation.  The postirradiation cobalt content 
of typical PWR and BWR reactor fuel assemblies are 38 g (0.01%) and 26 g (0.01%), respectively (DOE 
2002).
55Co may be produced by applying 12 MeV indirect deuteron energy to 54Fe (54Fe(d,n)55Co), 40 MeV 
protons to natural iron (56Fe(p,2n)55Co), or 20 MeV protons to natural nickel foil (58Ni(p,α)55Co) followed 
by separation of the 55Co on an ion exchange column (Wolf 1955).  Due to the short half-life (17.5 hours), 
however, 55Co would not be persistent in the environment or in waste sites.  57Co (half-life of 270 days) is 
produced by AEA Technology (formerly Amersham QSA) in the United Kingdom (Web Research Co. 
1999). 
5.2 IMPORT/EXPORT 
In 2002, 8,450 metric tons of cobalt were imported into the United States compared with 7,670, 8,150,
8,770, and 9,410 metric tons in 1998, 1999, 2000, and 2001 (USGS 2002).  Between 1999 and 2002, 
Finland, Norway, Russia, and Canada supplied 24, 18, 13, and 10% of cobalt, respectively (USGS 2004).
Imports for 2002 by form included (form, metric tons cobalt content): metal, 6,800; oxides and 
hydroxides, 936; acetates, 84; carbonates, 60; chlorides, 22; and sulfates 545.  Cobalt exports for 1999, 
2000, 2001, and 2002 were 1,550, 2,630, 3,210, and 2,080 metric tons, respectively; exports estimated in 
2002 are 2,500 metric tons (USGS 2002; 2004).   
60Co and 57Co are produced in Canada and in the United Kingdom and are imported from these countries.  
No import and export quantities for cobalt radioisotopes were available. 
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5.3 USE 
The United States is the world’s largest consumer of cobalt.  Cobalt is used in a number of essential 
military and industrial applications.  The largest use of metallic cobalt is in superalloys that are used in 
gas turbines aircraft engines. Superalloys are alloys developed for applications where elevated
temperatures and high mechanical stress are encountered.  It is also used in magnetic alloys and alloys
that are required for purposes requiring hardness, wear resistance, and corrosion resistance.  Cobalt is 
used as a binder for tungsten carbide (cemented carbides) cutting tools to increase impact strength. 
Cobalt compounds are used as pigments in glass, ceramics, and paints; as catalysts in the petroleum
industry; as paint driers; and as trace element additives in agriculture and medicine.   
Over 40% of nonmetallic cobalt is used in catalysis, and most cobalt catalysts are used in 
hydrotreating/desulfurization in the oil and gas industry, the production of terephthalic acid and 
dimethylterephthalate, and the production of aldehydes using the high pressure oxo process 
(hydroformylation).  Cobalt chemicals primarily used as catalysts include cobalt(III) acetate, cobalt(II) 
bromide, carbonate, manganate, oxalate, and sulfide, cobalt carbonyl, and cobalt naphthenate.  Cobalt 
carbonate and chromate are mainly used as pigments and cobalt(II) acetate, 2-ethylhexanoate, linoleate, 
naphthenate, nitrate, oleate, and stearate are mainly used as driers.  Cobalt has been used for hundreds of 
years as a blue colorant in glass, ceramics, and paints (Richardson 1993).   
A growing use for cobalt is as an addition to the Ni/Cd, Ni-metal hydride battery or as the main 
component of the lithium ion cell (LiCoO2). In 2002, the reported U.S. cobalt consumption was 
7,930 metric tons with a use pattern of (end use, metric tons cobalt content, percent): superalloys, 3,700,
46.7%; steel alloys, 555, 7.0%; other alloys, including magnetic alloys, 1,050, 13.2%; cemented carbides, 
617, 7.8%; chemical and ceramic use, 1,950, 24.6%; and miscellany, 63, 0.8%.  Cobalt is also used a 
target material in electrical x-ray generators (Cobalt Development Institute 2004; Donaldson 1986; Hodge 
1993; IARC 1991; Richardson 1993; USGS 2002). 
Gamma rays from 60Co are used medically to treat cancer and industrially to sterilize medical and 
consumer products, to crosslink, graft and degrade plastics, and as an external source in radiography and 
radiotherapy.  60Co, along with iridium 192 (192Ir), are the most commonly used isotopes in industrial 
radiography. In this application, 60Co is used for nondestructive testing of high-stress alloy parts, such as 
pipeline weld joints, steel structures, boilers, and aircraft and ship parts.  Radiography may be conducted 
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at permanent, specially shielded facilities or temporary sites in the field (USNRC 1999). 60Co is used in 
chemical and metallurgical analysis and as a tracer in biological studies.  In 1990, about 95% of installed 
60Co activity was used for the sterilization of medical devices; about 45% of medical devices were 
sterilized using radiation. 60Co is also a source of gamma rays used for food irradiation; depending on the
dose levels, irradiation may be used to sterilize food, destroy pathogens, extend the shelf-life of food, 
disinfest fruits and grain, delay ripening, and retard sprouting (e.g., potatoes and onions).  Sludge, waste 
water, and wood may also be treated with gamma rays to kill harmful organisms. 
57Co decays to an excited state of 57Fe, the most widely used x-ray source in Mössbauer spectroscopy
(Hodge 1993; Richardson 1993).  It is also made into standards and sources for dose calibrators, gamma 
cameras, and gauges, and is used as markers and rulers to help estimate organ size/location.  It is also 
used in in vitro diagnostic kits for the study of anemia related to vitamin B12 deficiency/malabsorption 
(MDS Nordion 2000). 55Co-bleomycin has been used for scanning malignant tumors (e.g., lung and brain
cancer) and is a practical isotope for positron emission tomography (PET) studies because it mainly 
(81%) decays by positron emission. 
5.4 DISPOSAL 
There is a paucity of data on the methods of disposal of cobalt and its compounds.  Due to the lack of 
natural sources of economically extractable ores in the United States, cobalt is entirely imported in the 
United States, and it is considered a strategic mineral.  It is economical to recycle certain cobalt wastes 
rather than to dispose of them.  Recycling of superalloy scrap is an important method for the recovery of 
cobalt. About 2,200 metric tons of cobalt were recycled from purchased scrap in 2003.  This was about 
28% of reported consumption for the year (USGS 2004).  According to TRI (TRI01 2004), 7.14 and 
1.42 million pounds of cobalt and cobalt compounds combined were recycled onsite and offsite, 
respectively, in 2001.  Waste containing cobalt dust and, presumably, waste containing cobalt in the solid 
state may be placed in sealed containers and disposed of in a secured sanitary landfill (HSDB 1989).  
Waste water containing cobalt can be treated before disposal, for instance, by precipitation of carbonate 
or hydroxide of cobalt or by passage through an ion-exchange resin (Clifford et al. 1986).  According to 
TRI (TRI01 2004), 1,619,874 pounds of cobalt and cobalt compounds, were transferred offsite for 
disposal, in processes such as solidification/stabilization and waste water treatment, including publicly
operated treatment plants (POTWs). The amount of cobalt so transferred by state is shown in Table 6-1.  
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In August 1998, EPA issued a final rule listing spent hydrotreated and hydrorefined catalysts as hazardous 
waste under the Resource Conservation and Recovery Act (USGS 1998).  Listing under this act requires 
that releases of these substances will be subject to certain management and treatment standards and 
emergency notification requirements.  Information regarding effluent guidelines and standards for cobalt 
may be found in Title 40 of the Code of Federal Regulations, Parts 421.230, 421.310, and 471.30. 
60Co sources used for irradiation purposes are valuable and are not to be discarded.  However, some
radioactive cobalt isotopes may occur in waste material from nuclear reactors.  Radioactive waste is
categorized according to origin, type of waste present, and level of activity.  Radioactive cobalt isotopes 
may be commingled with other radioactive isotopes.  The first distinction in radioactive waste is between 
defense waste and commercial waste, the former being generated during and after World War II 
principally at the Department of Energy (DOE) facilities at Hanford, Washington; Savannah River, South 
Carolina; and Idaho Falls, Idaho, where plutonium and other isotopes were separated from production 
reactor spent fuel or nuclear-powered naval vessels. Commercial wastes are produced predominantly by
nuclear power plants as well as the long defunct commercial reprocessing facility at West Valley, New 
York and manufacturers of radioisotopes used in nuclear medicine for the treatment and diagnosis of 
disease. Nuclear waste is also classified as high-level waste (HLW), transuranic waste (TRU), and low-
level waste (LLW).  LLW is further differentiated into three classes, A, B, and C, according to increasing 
of the level of activity. A fourth category, commercial greater-than-class-C LLW (listed in 10 CFR 
61.55 Tables 1 and 2 for long and short half-life radionuclides, respectively) is not generally suitable for 
near-surface disposal.  This could include operating and decommissioning waste from nuclear power 
plant and sealed radioisotope sources. The final disposition for this waste has not been determined.  If 
LLW also contains nonradioactive hazardous material (i.e., that which is toxic, corrosive, inflammable, or 
explosive), it is termed mixed waste.  Mine tailings from uranium mining is yet another category of 
radioactive waste (DOE 1999; Murray 1994).  While radioactive cobalt would not ordinarily be found in 
HLW or TRU, the definitions of these are included below for completion. 
TRUs are those containing isotopes, like plutonium, that are above uranium in the periodic table and 
whose half-lives are >20 years. If their level of activity is <100 nanocuries (nCi) (<3,700 becquerels[Bq]) 
of alpha-emitters per gram of waste material (up from 10 nCi/g in 1982), the waste could be disposed of 
by shallow burial.  Otherwise, the waste must be placed in retrievable storage for eventual transfer to a 
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permanent repository.  The level of radioactivity in TRUs is generally low; they generate very little heat 
and can be handled by ordinary means without remote control (Eisenbud 1987, Murray 1994).  
HLW includes spent fuels that are contained in fuel rods that have been used in a nuclear reactor.  These 
may contain small amounts of transuranic elements.  After removal from the reactor, these rods are placed 
into pools adjacent to the commercial nuclear power plants and DOE facilities where they were produced.  
It was originally intended that the fuel rods remain in these pools for only about 6 months to allow for a 
reduction in short-lived radioactivity and rate of heat production temperature and then be transferred to a 
reprocessing or storage facility.  There is no commercial reprocessing facility or permanent disposal 
facility for HLW operating in the United States.  The U.S. Nuclear Regulatory Commission (USNRC) has 
issued standards for the disposal of HLW (10 CFR 60), and the DOE is pursuing the establishment of an 
HLW facility in Yucca Mountain, Nevada. Efforts to establish an HLW facility, which began over 
2 decades ago, have experienced many delays (Eisenbud 1987; Murray 1994).  However, in July, 2002, 
the U.S. Congress and the President selected Yucca Mountain, Nevada as the nation’s first long-term
repository for HLW.  The facility is projected to begin operation in 2010, and efforts are underway to 
consider establishing a nearby interim facility (DOE 2002b). 
LLWs are officially defined as wastes other than those previously defined.  These wastes come from
certain reactor operations and from manufacturers of radioisotopes used in nuclear medicine and 
institutions such as hospitals, universities, and research centers.  Most LLW contain very little 
radioactivity and contain practically no transuranic elements.  It requires little or no shielding or special 
handling and may be disposed of by shallow burial.  However, some LLW contains sufficient 
radioactivity as to require special treatment.  Although USNRC regulations for LLW disposal (10 CFR 
61) permit shallow land burial, many states have enacted more stringent regulations that require artificial 
containment of the waste in addition to natural containment (Eisenbud 1987; Murray 1994).  The EPA has 
the authority to set generally acceptable environmental standards for LLW that would be implemented by
the US NRC and DOE (EPA 2004).  The Manifest Information Management System (MIMS), maintained 
by the Idaho National Engineering and Environmental Laboratory (INEEL), contains information on low-
level radioactive waste shipments received at commercial low-level radioactive waste disposal facilities at 
Barnwell, South Carolina (1/1/86–present), Beaty, Nevada (4/1/86–12/31/92), Richland, 
Washington(1/1/86–present), and Envirocare, Utah (1/1/98–12/31/99).  In 1999, 17 Ci (0.63 TBq) of 
57Co, 1,300 Ci (48 TBq) of 58Co, and 1.08x106 Ci (4.00x104 TBq) of 60Co contained in LLW was received 
at these facilities from academic, industrial, government, and utility generators throughout the United 
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States (INEL 2000).  In addition, 4.26 Ci (0.158 TBq) of 57Co of NARM (“naturally occurring and 
accelerator-related waste”) was received.
At present, DOE stores most of its spent fuel at three primary locations:  the Hanford site, Washington, 
the Idaho National Engineering and Environmental Laboratory (INEEL), Idaho, and the Savannah River 
site, South Carolina.  Some spent fuel is also stored at the dry storage facility at Fort St. Vrain in 
Colorado. Much smaller amounts of spent nuclear fuel stored at other sites were to be shipped to the 
three prime sites for storage and preparation for ultimate disposal (DOE 1999).  The DOE National Spent 
Fuel Program maintains a spent nuclear fuel database that lists the total volume, mass, and metric tons 
heavy metal (MTHM) of 16 DOE categories of spent nuclear fuel stored in each of the three locations.  
The categories having the highest 60Co activities per spent nuclear fuel canister (decayed to 2030) are 
‘naval surface ship fuel’ and ‘naval submarine fuel’.  The 58Co and 60Co solid wastes stored on the 
Hanford site in 1998 as LLW were 2,600 and 6,900 Ci (96 and 260 TBq), respectively (Hanford 1999). 
In addition, 40 Ci (1.5 TBq) of 60Co was included in TRU. 
In commercial irradiators, additional quantities of 60Co are added, usually once a year to maintain
preferred radiation levels of the source (MDS Nordion 2000).  60Co sources are removed from the facility
at the end of their useful life, which is typically 20 years.  In general, manufacturers of 60Co sources 
guarantee to accept the sources they originally supplied.  These old sources may be reencapsulated, 
reprocessed, or recycled when technically, environmentally, and economically feasible. 
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6.1 OVERVIEW
Stable cobalt has been identified in at least 426 of the 1,636 hazardous waste sites that have been 
proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2004).  Radioactive cobalt as 
60Co has been identified in at least 13 of the 1,636 hazardous waste sites that have been proposed for 
inclusion on the EPA NPL (HazDat 2004).  However, the number of sites evaluated for stable cobalt and 
60Co is not known.  The frequency of these sites can be seen in Figures 6-1 and 6-2, respectively.  Of the 
cobalt sites, 421 are located within the United States, 1 is located in Guam (not shown), 3 are located in 
the Commonwealth of Puerto Rico (not shown), and 1 is located in the Virgin Islands (not shown).  All of 
the sites at which 60Co has been identified are located within the United States. 
Cobalt occurs naturally in the earth's crust, and therefore, in soil.  Low levels of cobalt also occur 
naturally in seawater and in some surface water and groundwater (Smith and Carson 1981).  However, 
elevated levels of cobalt in soil and water may result from anthropogenic activities such as the mining and 
processing of cobalt-bearing ores, the application of cobalt-containing sludge or phosphate fertilizers to 
soil, the disposal of cobalt-containing wastes, and atmospheric deposition from activities such as the 
burning of fossil fuels and smelting and refining of metals (Smith and Carson 1981).  Cobalt is released 
into the atmosphere from both anthropogenic and natural sources.  However, emissions from natural 
sources are estimated to slightly exceed those from manufactured sources.  Natural sources include 
windblown soil, seawater spray, volcanic eruptions, and forest fires.  Primary anthropogenic sources 
include fossil fuel and waste combustion, vehicular and aircraft exhausts, processing of cobalt and cobalt-
containing alloys, copper and nickel smelting and refining, and the manufacture and use of cobalt 
chemicals and fertilizers derived from phosphate rocks (Barceloux 1999; Lantzy and Mackenzie 1979; 
Nriagu 1989; Smith and Carson 1981).  60Co and 58Co, both radioactive forms of cobalt, may be released 
to the environment as a result of nuclear research and development, nuclear accidents, operation of 
nuclear power plants, and radioactive waste dumping in the sea or in radioactive waste landfills. 
Cobalt compounds are nonvolatile and cobalt will be emitted to the atmosphere only in particulate form.  
Their transport in air depends on their form, particle size and density, and meteorological conditions.  
Cobalt so released will return to land or surface water as wet or dry deposition.  Coarse particles, those  
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Figure 6-1.  Frequency of NPL Sites with Cobalt Contamination 
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Figure 6-2.  Frequency of NPL Sites with 60Cobalt Contamination 
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with aerodynamic diameters >2 µm (such as those obtained during ore processing), may deposit within 
10 km from the point of emission; finer particles (such as is obtained from thermal processes) may travel 
longer distances. It is generally assumed that anthropogenic cobalt originating from combustion sources 
exists primarily as the oxide; arsenides or sulfides may be released during mining and ore processing 
(Schroeder et al. 1987). Frequently, sediment and soil are the ultimate sinks for cobalt; however, this 
process is dynamic, and cobalt can be released into the water depending upon conditions.  Soluble cobalt 
released into waterways will sorb to particles and may settle into the sediment or be sorbed directly by 
sediment.  It may precipitate out as carbonates and hydroxides or with mineral oxides.  It may also sorb to 
or complex with humic acid substances in the water.  These processes are sensitive to environmental 
factors such as pH and the proportion of dissolved cobalt will be higher at low pH.  In the case of 60Co 
released into an experimental lake in northwestern Ontario, cobalt’s half-life in the water column was 
11 days; 5% of added 60Co remained in the water after 100 days (Bird et al. 1998a).  Cobalt can also be 
transported in dissolved form or as suspended sediment by rivers to lakes and the sea or by ocean 
currents. The proportion of cobalt transported in each form is highly variable (Smith and Carson 1981).  
In deep sediment where water is anoxic and hydrogen sulfide is present, some mobilization of cobalt from
sediment may occur, probably due to the formation of bisulfides and polysulfides (Bargagli 2000; 
Brügmann 1988; Finney and Huh 1989; Glooschenko et al. 1981; Knauer et al. 1982; Nriagu and Coker 
1980; Shine et al. 1995; Smith and Carson 1981; Szefer et al. 1996; Windom et al. 1989).  Cobalt adsorbs 
rapidly and strongly to soil and sediment in which it is retained by metal oxides, crystalline minerals, and 
natural organic matter.  The mobility of cobalt sediment depends on the nature of the soil or sediment; it 
increases with decreasing pH and redox potential (Eh) and in the presence of chelating/complexing agents 
(Brooks et al. 1998; Buchter et al. 1989; King 1988b; McLaren et al. 1986; Schnitzer 1969; Smith and 
Carson 1981; Swanson 1984; Yashuda et al. 1995).
While cobalt may be taken up from soil by plants, the translocation of cobalt from roots to above-ground 
parts of plants is not significant in most soils; the transfer coefficient (concentration in plant/concentration 
in soil) for cobalt is generally 0.01–0.3 (Mascanzoni 1989; Mermut et al. 1996, Smith and Carson 1981).  
However, in highly acidic soils (pH as low as 3.3) and in some higher plants (plants excluding algae), 
significantly higher transfer has been observed (Boikat et al. 1985; Francis et al. 1985; Jenkins 1980; 
Kloke et al. 1984; Mejstrik and Svacha 1988; Palko and Yli-Hala 1988; Tolle et al.1983; Watabe et al. 
1984). The bioaccumulation factors (dry weight basis) for cobalt in marine fish and freshwater fish are 
~100–4,000 and <10–1,000, respectively; accumulation is largely in the viscera and on the skin, as 
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opposed to the edible parts of the fish.  Cobalt does not biomagnify up the food chain (Barceloux 1999; 
Evans et al. 1988; Freitas et al. 1988; Smith and Carson 1981). 
Atmospheric cobalt is associated with particulate matter.  Mean cobalt levels in air at unpolluted sites are 
generally <1–2 ng/m3. In several open-ocean environments, geometric mean concentrations ranged from
0.0004 to 0.08 ng/m3 (Chester et al. 1991). However, in source areas, cobalt levels may exceed 10 ng/m3; 
the highest average cobalt concentration recorded was 48 ng/m3 at the site of a nickel refinery in Wales 
(Hamilton 1994; Smith and Carson 1981).  By comparison, the Occupational Safety and Health 
Administration (OSHA) limit for airborne stable cobalt is 100,000 ng/m3. While 60Co has been detected 
in some air samples at the Hanford, Washington site and Oak Ridge National Laboratories, Tennessee, 
levels were not reported (HazDat 2004; PNNL 1996).  
The concentrations of stable cobalt in surface and groundwater in the United States are generally low; 
<1 µg/L in pristine areas and 1–10 µg/L in populated areas (Hamilton 1994; Smith and Carson 1981).  
However, cobalt levels may be considerably higher in mining or agricultural areas.  Cobalt concentrations 
in surface water and groundwater samples collected in 1992 from area creeks near the Blackbird Mine in 
Idaho, one of the large deposits of cobalt in North America where mining occurred from the late 1800s to 
1982, were reported to range from <1 to 625,000 µg/L, and from not detected to 315,000 µg/L, 
respectively (ATSDR 1995).  Cobalt levels in most drinking water is <1–2 µg/L although levels as high as 
107 µg/L have been recorded (Greathouse and Craun 1978; Meranger et al. 1981; NAS 1977; Smith and 
Carson 1981). 
Little data are available on the levels of 60Co in water.  In 1989, subsequent to the largest effluent 
discharge from the Steam Generating Heavy Water Reactor at Winfrith on the south coast of England, 
60Co levels in offshore seawater from 18 sites contained 0.06–2.22 mBq/L (1.6–69 fCi) of particulate 
60Co, 0.30–10.3 mBq/L (8–280 fCi) of soluble 60Co(II), and 0.12–1.55 mBq/L (3.2–42 fCi) of soluble 
60Co(III) (Leonard et al. 1993a).  The U.S. NRC discharge limit is 111,000 mBq/L (3x106 fCi/L) (USNRC 
1991). 
The average concentrations of cobalt in the earth's crust are 20–25 mg/kg (Abbasi et al. 1989; Merian 
1985; Smith and Carson 1981).  Most soils contain 1–40 mg cobalt/kg; the average cobalt concentration 
in U.S. soils is 7.2 mg/kg (Smith and Carson 1981). Soils containing <0.5–3 mg cobalt/kg are considered 
cobalt-deficient because plants growing on them have insufficient cobalt (<0.08–0.1 mg/kg) to meet the 
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dietary requirements of cattle and sheep.  Cobalt-deficient soils are found in some areas of the 
southeastern and northeastern United States.  Soils near ore deposits, phosphate rocks, or ore smelting 
facilities, and soils contaminated by airport traffic, highway traffic, or other industrial pollution may
contain high concentrations of cobalt; concentrations up to 800 mg/kg have been detected in such areas 
(Kloke et al. 1984; Smith and Carson 1981).  Cobalt concentrations in 28 samples collected from surface 
deposits in the Big Deer and Blackbird Creek drainage basins near a site of former cobalt mining in Idaho
ranged from 26.5 to 7,410 mg/kg (ATSDR 1995).  
The level of cobalt in most foods is low.  However, food is the largest source of exposure to cobalt in the 
general population.  The estimated average daily dietary intake of cobalt in Canada was 11 µg/day.  Food 
groups contributing most heavily to this intake were bakery goods and cereals (29.8%) and vegetables 
(21.9%) (Dabeka and McKenzie 1995).  No estimates of the average dietary input of cobalt in the United 
States were located. People living near mining and smelting facilities or metal shops where cobalt is used 
in grinding tools may be exposed to higher levels of cobalt in air or soil.  Similarly, people living near 
hazardous waste sites may be exposed to higher levels of cobalt in these media.  Contaminated soils pose 
a hazardous exposure pathway to children because of both hand-to-mouth behavior and intentional 
ingestion of soil (pica) that contain metals and other contaminants (Hamel et al. 1998).  However, much 
of the cobalt in soil may not be in a form that is available for uptake by the body.  People who work in the 
hard metal industry, metal mining, smelting, and refining or other industries that produce or use cobalt 
and cobalt compounds may be exposed to substantially higher levels of cobalt, mainly from dusts or 
aerosols in air. Workers at nuclear facilities, irradiation facilities, or nuclear waste storage sites may be 
exposed to radioisotopes of cobalt.  Exposure would generally be to radiation produced by these isotopes 
(e.g., gamma radiation from 60Co). 
6.2 RELEASES TO THE ENVIRONMENT 
Stable cobalt has been identified in a variety of environmental media (air, surface water, leachate, 
groundwater, soil, and sediment) collected at 426 of 1,636 current or former NPL hazardous waste sites 
(HazDat 2004). 60Co has been identified in a variety of environmental media (air, surface water, leachate, 
groundwater, soil, and sediment) collected at 13 of 1,636 current or former NPL hazardous waste sites 
(HazDat 2004). 
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According to the Toxic Chemical Release Inventory (TRI), in 2001, total releases of cobalt and cobalt 
compounds to the environment (including air, water, soil, and underground injection) from 605 reporting 
facilities that produced, processed, or used cobalt or cobalt compounds were 16,443,429 pounds (TRI01 
2004). Table 6-1 lists amounts released from these facilities grouped by state.  In addition, 
1,619,874 pounds of cobalt and cobalt compounds were transferred offsite by these facilities (TRI01 
2004).  Starting in 1998, metal mining, coal mining, electric utilities, and Resource Conservation and 
Recovery Act (RCRA)/solvent recovery industries are required to report, to the TRI, industries with 
potentially large releases of cobalt and cobalt compounds.  Industrial sectors producing, processing, or 
using cobalt that contributed the greatest environmental releases in 2001 were primary metals and 
RCRA/solvent recovery with 141,554 and 531,427 pounds, respectively.  Industrial sectors producing, 
processing, or using cobalt compounds that contributed the greatest environmental releases in 2001 were 
metal mining and electrical utilities with 10,228,193 and 3,652,398, pounds, respectively.  The TRI data 
should be used with caution because only certain types of facilities are required to report.  This is not an 
exhaustive list. 
6.2.1 Air 
The sources of cobalt in the atmosphere are both natural and anthropogenic (Barceloux 1999).  Natural 
sources include wind-blown continental dust, seawater spray, volcanoes, forest fires, and continental and 
marine biogenic emissions.  The worldwide emission of cobalt from natural sources has been estimated to
range from 13 to 15 million pounds/year (Lantzy and Mackenzie 1979; Nriagu 1989).  The global 
atmospheric emission of cobalt from anthropogenic sources is an estimated 9.7 million pounds/year.  
Therefore, natural sources contribute slightly more to cobalt emissions in the atmosphere than
anthropogenic sources (Lantzy and Mackenzie 1979).  The primary anthropogenic sources of cobalt in the 
atmosphere are the burning of fossil fuels and sewage sludge, phosphate fertilizers, mining and smelting 
of cobalt-containing ores, processing of cobalt-containing alloys, and industries that use or process cobalt 
compounds.  Small amounts of cobalt are found in coal, crude oils, and oil shales.  Therefore, burning of 
these fossil fuels for power generation will emit cobalt into the atmosphere.  The cobalt contents of the fly
ash and flue gases of a coal-burning power plant are approximately 25 mg/kg and 100–700 µg/L, 
respectively. Gasoline contains <0.1 mg cobalt/kg, but catalytic converters may contain cobalt; therefore, 
emissions from vehicular exhaust are also a source of atmospheric cobalt (Abbasi et al. 1989; Holcombe  
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Table 6-1. Releases to the Environment from Facilities that Produce, Process, or 

Use Cobalt and Cobalt Compoundsa
 
Reported amounts released in pounds per yearb 
Number Under- Total on and
of ground Total on-site Total off- off-site 
Statec facilities Aird Water injection Land releasee site releasef release 
AK 2 23 0 16,000 546,463 562,486 0 562,486 
AL 21 5,893 8,612 0 315,853 330,358 30,040 360,398 
AR 9 921 142 0 8,301 9,364 2,015 11,379 
AZ 12 1,029 0 0 1,061,035 1,062,064 2,266 1,064,330 
CA 26 646 20 0 307,654 308,320 7,463 315,783 
CO 1 3 1 0 12,026 12,030 0 12,030 
CT 9 632 65 0 0 697 4,133 4,830 
DE 2 1,265 52 0 52 1,369 27,444 28,813 
FL 11 2,397 345 0 93,049 95,791 15,464 111,255 
GA 17 3,508 268 0 282,610 286,386 12,461 298,847 
IA 6 566 0 0 0 566 2,123 2,689 
ID 2 74 5 0 395,424 395,503 0 395,503 
IL 23 1,630 1,278 0 16,999 19,907 102,088 121,995 
IN 42 7,005 351 0 279,122 286,478 64,293 350,771 
KS 5 4,269 0 0 10,200 14,469 3,859 18,328 
KY 22 3,184 542 0 478,855 482,581 13,269 495,850 
LA 15 385 8,477 2,700 66,858 78,420 91,274 169,694 
MA 11 794 780 0 5 1,579 17,403 18,982 
MD 6 2,472 15 0 6,629 9,116 45,382 54,498 
ME 2 66 0 0 0 66 700 766 
MI 24 4,699 559 0 125,405 130,663 33,737 164,400 
MN 5 255 No data 0 0 255 7,666 7,921 
MO 5 1,457 8 0 559,401 560,866 0 560,866 
MS 7 386 120 12,000 44 12,550 3,044 15,594 
MT 1 250 No data 0 31,000 31,250 505 31,755 
NC 24 6,593 8,257 0 194,974 209,824 216,849 426,673 
ND 4 1,165 21 0 108,300 109,486 39,842 149,328 
NE 1 0 27 0 0 27 3,982 4,009 
NH 1 0 No data 0 0 0 No data 0 
NJ 12 1,191 26 0 413 1,630 26,894 28,524 
NM 6 498 1 0 4,257,140 4,257,639 69 4,257,708 
NV 8 678 0 0 4,099,136 4,099,814 9,950 4,109,764 
NY 12 755 44 0 11,843 12,642 14,322 26,964 
OH 44 4,977 771 1,100 310,653 317,501 96,116 413,617 
OK 13 1,357 158 0 5,677 7,192 20,760 27,952 
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Table 6-1. Releases to the Environment from Facilities that Produce, Process, or 

Use Cobalt and Cobalt Compoundsa
 
Reported amounts released in pounds per yearb 
Number Under- Total on and
of ground Total on-site Total off- off-site 
Statec facilities Aird Water injection Land releasee site releasef release 
OR 6 1,262 20 0 16,487 17,769 2,862 20,631 
PA 44 6,169 3,176 0 51,350 60,695 221,662 282,357 
PR 2 2 No data 0 0 2 2,871 2,873 
RI 1 1 1 0 0 2 50 52 
SC 25 1,579 10,970 0 43,488 56,037 70,316 126,353 
SD 1 0 No data 0 0 0 0 0 
TN 18 5,560 4,013 0 330,615 340,188 36,520 376,708 
TX 44 8,126 784 3,730 150,470 163,110 95,840 258,950 
UT 6 278 No data 0 23,350 23,628 126,502 150,130 
VA 9 1,451 518 0 89,388 91,357 9,683 101,040 
VI 1 0 0 0 0 0 0 0 
WA 2 72 91 0 106,618 106,781 5,112 111,893 
WI 20 1,098 5 0 8 1,111 95,996 97,107 
WV 13 1,341 566 0 212,254 214,161 37,047 251,208 
WY 2 898 No data 0 38,927 39,825 0 39,825 
Total 605 88,860 51,089 35,530 14,648,076 14,823,555 1,619,874 16,443,429 
Source: TRI01 2004 
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used. 

dThe sum of fugitive and stack releases are included in releases to air by a given facility.
 
eThe sum of all releases of the chemical to air, land, water, and underground injection wells. 

fTotal amount of chemical transferred off-site, including to publicly owned treatment works (POTW). 
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et al. 1985; Ondov et al. 1982; Smith and Carson 1981).  Cobalt has been detected in cigarette tobacco 
and therefore, smoking is a potential source of atmospheric cobalt that could impact on indoor air quality
(Munita and Mazzilli 1986). 
Stable cobalt has been identified in air samples collected at 5 of the 426 current or former NPL hazardous 
waste sites where it was detected in some environmental media (i.e., air, soil, sediment, or water) (HazDat 
2004). 60Co has been identified in air samples collected at 2 of the 13 current or former NPL hazardous 
waste sites where it was detected in some environmental media (HazDat 2004). 
Air sampling data were used to estimate 60Co release from the Savannah River Site (SRS) from the plant’s 
start up in 1954 to 1989 (DOE 1991).  From this monitoring, it was estimated that 0.092 Ci (3.4 GBq) of 
60Co was released to the atmosphere between 1968 and 1986.  Total releases of 60Co to the atmosphere 
from the SRS between 1968 and 1996 were 0.092 Ci (3.4 GBq) (DOE 1998). Data were not reported for 
all years in this interval.  In 1999, atmospheric releases of 57Co, 58Co, and 60Co as particulates were 
4.71x10-8, 1.27x10-4, and 1.30x10-4 Ci (0.00174, 4.70, and 4.81 MBq), respectively (DOE 1999).  The 
SRS was a major production facility to the U.S. defense program and included five nuclear reactors, a fuel
fabrication plant, a naval fuel materials facility, two chemical separation plants, a heavy water production 
plant, and a laboratory.  60Co has also been detected in air samples at the Hanford site and Oak Ridge 
National Laboratories (HazDat 2004; PNNL 1996).  
According to the TRI, in 2001, releases of 88,860 pounds of cobalt and cobalt compounds to air from
605 reporting facilities accounted for 0.5% of the total onsite environmental releases of these substances 
(TRI01 2004).  The industrial sectors contributing the largest release of cobalt and cobalt compounds to 
air were electrical utilities, chemicals, and primary metals.  Table 6-1 lists the amounts of cobalt and 
cobalt compounds released to air from these facilities grouped by state.  The TRI data should be used with 
caution, however, since only certain types of facilities are required to report. This is not an exhaustive 
list. 
6.2.2 Water 
Compounds of cobalt occur naturally in seawater and in some surface, spring, and groundwater (Smith 
and Carson 1981).  Cobalt is also released into water from anthropogenic sources.  While there has been 
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no mine production of cobalt in the United States in recent years, cobalt is a byproduct or coproduct of the 
refining of other mined metals such as copper and nickel.  Historic mining operations that processed 
cobalt containing ores may continue to release cobalt into surface water and groundwater.  Waste water 
from the recovery of cobalt from imported matte or scrap metal, refining of copper and nickel, or during 
the manufacture of cobalt chemicals are sources of cobalt in water (Smith and Carson 1981).  Process 
water and effluent from coal gasification and residue from solvent-refined coal contain cobalt.  The 
accidental discharge of activated sludge and sewage may be important sources of cobalamins in 
waterways, together with bioconcentration by benthic organisms (Smith and Carson 1981).  The 
discharge of waste water by user industries, such as paint and pigment manufacture, also contributes to 
the release of cobalt into water.  In one case, manufacturers of nickel-cadmium batteries operating 
between 1953 and 1979 discharged cobalt from a battery factory to the Hudson River in Foundry Cove, 
New York, of which 1.2 metric tons are estimated to be present in the eastern cove (Knutson et al. 1987).  
Atmospheric deposition is an additional source of cobalt in water.  Lake Huron receives an estimated 76% 
of its cobalt input from natural sources and 24% from anthropogenic sources.  The corresponding 
estimated values for Lake Superior are 85.4 and 14.6% (Smith and Carson 1981).  In these Great Lakes, it 
therefore appears that natural inputs of cobalt far exceed anthropogenic ones. 
Cobalt has been identified in groundwater and surface water at 255 and 106 sites, respectively, of the 
426 NPL hazardous waste sites, where it was detected in some environmental media (i.e., air, soil, 
sediment, or water) (HazDat 2004). 60Co has been identified in groundwater and surface water at 4 and 
2 sites, respectively, of the 13 NPL hazardous waste sites, where it was detected in some environmental 
media (HazDat 2004). 
According to the TRI, in 2001, the reported releases of 51,089 pounds of cobalt and cobalt compounds to 
water from 605 reporting facilities accounted for 0.3% of the total onsite environmental releases of these 
substances (TRI01 2004).  Table 6-1 lists the amounts of cobalt and cobalt compounds released to water 
from these facilities grouped by state.  As of 1998, TRI no longer separately collects data on substances 
released indirectly to Publicly-Owned Treatment Works (POTWs), part of which may ultimately be 
released to surface waters.  The TRI data should be used with caution, however, since only certain types 
of facilities are required to report.  This is not an exhaustive list. 
60Co is present in the low-level aqueous radioactive waste discharges from many nuclear power plants.  
Alloys that contain stable cobalt (59Co), such as stellite, used in piping of nuclear reactors corrode and 
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may be activated, producing 60Co, which accumulates in the reactor and must be periodically
decontaminated.  A common decontaminating agent includes a reducing metal ion (e.g., vanadium(II)) 
and a chelating agent (e.g., picolinate) resulting in low-level discharges of uncomplexed 60Co(II) and 
complexed 60Co(III). While soluble ionic and particulate forms predominate, at some sites stable, 
nonionic trivalent complexes of cobalt are present (Leonard et al. 1993a, 1993b; USNRC 2000d).  For 
example, in 1987–1989 samples of treated effluent from the Steam Generating Heavy Water Reactor at 
Winfrith on the south coast of England, the percent of 60Co as Co(III) picolinate ranged from 6.2 to 
75.4%.  Between 1978 and 1988, 12 TBq (320 Ci) of 60Co was released into the Irish Sea by the British 
Nuclear Fuels reprocessing plant at Sellafield, United Kingdom (McCartney et al. 1994).  These 
discharges are believed to be Co(II) (Leonard et al. 1993a).  Both 58Co and 60Co are discharged into the 
Rhone River by the nuclear power plant at Bugey, France.  This facility, which consists of a natural 
Uranium-Graphite-Gas unit and four pressurized water reactor (PWR) units, two of which are cooled by
Rhone River water, discharged about 406 and 280 GBq (11.0 and 7.56 Ci) of 58Co and 60Co, respectively,
in liquid waste during 1986–1990 (Beaugelin-Seiler et al. 1994). 
Water sampling data were used to estimate effluent release from the SRS from the plant’s start up in 
1954 to 1989 (DOE 1991).  From this monitoring, it was estimated that 17.8 Ci (659 GBq) of 60Co were
released into seepage basins and 66.4 Ci (2,460 GBq) were released into streams between 1955 and 1988.  
In addition, 2.7 Ci (100 GBq) of 58Co were released into seepage basins between 1971 and 1988; no 58Co 
was released into streams.  Total releases of 60Co to streams from the SRS for 1954–1995 were 66 Ci 
(2,400 GBq) (DOE 1998).  No data were reported from 1985 to 1994.  In 1999, 4.94x10-4 Ci 
(0.0183 GBq) of 60Co was released to surface waters at the SRS (DOE 1999).  60Co has also been reported 
in surface water at, Hanford, Washington, and Oak Ridge National Laboratories, and groundwater at 
Brook Industrial Park, New Jersey, the Hanford site and Oak Ridge National Laboratories, Tennessee 
(HazDat 2004). The Columbia River receives discharges from the unconfined aquifer underlying the 
Hanford Site via subsurface and surface (riverbank springs) discharges.  This aquifer is contaminated by
leachate from past waste-disposal practices at the site.
6.2.3 Soil 
Cobalt occurs naturally in the earth's crust, and therefore, in soil.  However, elevated levels of cobalt in 
soil may result from anthropogenic activities such as the mining and processing of cobalt-bearing ores, 
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the application of cobalt-containing sludge or phosphate fertilizers to soil, the disposal of cobalt-
containing wastes, and atmospheric deposition from activities such as burning of fossil fuels, smelting, 
and metal refining (Smith and Carson 1981).  
Cobalt has been identified in soil at 219 sites and sediment at 143 sites collected from 426 NPL hazardous 
waste sites, where it was detected in some environmental media (i.e., air, soil, sediment, or water) 
(HazDat 2004). 60Co has been identified in soil at 8 sites and sediment at 2 sites collected from 13 NPL 
hazardous waste sites, where it was detected in some environmental media (HazDat 2004).  60Co has been 
detected onsite in soils at the Hanford Site, Washington; INEEL, Idaho; Lawrence Livermore National 
Laboratory, Main Site, California; and Robins Air Force Base, Georgia at maximum concentrations of 
87.7, 570, 0.21, and 0.07 pCi/g (3.24, 21, 0.0078, and 0.003 Bq/g) (HazDat 2004).   
According to the TRI, in 2001, reported releases of 14,646,076 pounds of cobalt and cobalt compounds to 
land from 605 reporting facilities accounted for 98.8% of the total onsite environmental releases of these 
substances (TRI01 2004).  An additional 35,530 pounds, accounting for 0.2% of the total onsite 
environmental releases were injected underground (TRI01 2004).  Industrial sectors contributing the 
largest releases of cobalt and cobalt compounds to land were metal mining and electrical utilities with 
10,210,508 and 3,197,209 pounds, respectively. Table 6-1 lists the amounts of cobalt and cobalt 
compounds released on land from these facilities grouped by state.  The TRI data should be used with 
caution, however, since only certain types of facilities are required to report. This is not an exhaustive 
list. 
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
Cobalt compounds are nonvolatile, and thus, cobalt is emitted to the atmosphere in particulate form.  The 
transport of cobalt in air depends on its particle size and density, and meteorological conditions; it can be 
returned to land or surface water by rain or it may settle to the ground by dry deposition.  In nonarid 
areas, wet deposition may exceed dry deposition (Arimoto et al. 1985; Erlandsson et al. 1983).  Coarse 
particles, with aerodynamic diameters >2 µm (such as those obtained during ore processing), may deposit 
within 10 km from the point of emission; finer particles may travel longer distances.  It is the larger 
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particles that may be responsible for elevated local concentrations around emission sources.  The mass 
median diameter for cobalt particles emitted from a power generator with a stack emission controlled by 
an electrostatic precipitator or scrubber ranged from <2 to 12 µm.  The mass median diameter of cobalt in 
the ambient atmosphere is about 2.6 µm (Milford and Davidson 1985).  Golomb et al. (1997) report 
average total (wet+dry) deposition rates of cobalt to Massachusetts Bay during the period September 15, 
1992 to September 16, 1993.  The total deposition rate was 58 µg/m2-year, of which 47 µg/m2-year was 
dry deposition and 12 µg/m2-year was wet deposition.  Total cobalt deposition flux at a site in the Rhone 
delta in southern France in 1988–1989 was 0.42±0.23 kg/km2-year with 0.15 kg/km2-year in the form of 
wet deposition (Guieu et al. 1991). 
As with most metals, sediment and soil are frequently the final repository for cobalt released into the 
environment, although the process is dynamic, and cobalt can be released into the water depending upon 
conditions. Cobalt released into waterways may sorb to particles and settle into the sediment or be sorbed 
directly into the sediment.  However, complexation cobalt to dissolved organic substances can
significantly reduce sorption to sediment particles (Albrecht 2003).  Studies by Jackman et al. (2001) 
suggest that interparticle migration of cobalt can influence the transport of metal ions, including cobalt, in 
sediments.  For example, migration of a metal ion from a highly mobile sediment particle, such as clay, to
less mobile gravels will slow the transport of that metal.  Cobalt can also be transported in dissolved form
or as suspended sediment by rivers to lakes and the sea or by ocean currents.  Sediment in areas of active 
sedimentation would receive a large portion of the suspended sediment.  In the case of the Peach Bottom
Atomic Power Plant where 60Co is released into the Conowingo Reservoir, an impoundment of the lower 
Susquehanna River, <20% of the radionuclide is trapped in the reservoir sediment, the rest being 
transported downstream and into the Chesapeake Bay (McLean and Summers 1990).  It is often assumed 
that the primary mode of transport of heavy metals in aquatic systems is as suspended solids (Beijer and 
Jernelov 1986). However, in the case of cobalt, the percent that is transported by suspended solids is 
highly variable.  Examples of the percentage of cobalt transported in suspended solids include (water 
body, percent): Main River (Germany), 33.4–42.2%; Susquehanna River (near its source in New York), 
9%; New Hope River (North Carolina), 92%; Yukon River, >98%; Danube Rive (1961–1970), 27.4– 
85.9%; Columbia River (60Co, downstream of the Hanford site), 95–98%; Strait of Juan de Fuca (Puget 
Sound, Washington), 11–15%; North Sea, 34%; and Lake Washington (Washington), 0% (Smith and 
Carson 1981). 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
COBALT 221 
6. POTENTIAL FOR HUMAN EXPOSURE 
In the oxic zones of many surface waters, dissolved cobalt levels decrease with increasing depth.  This 
may be due to cobalt’s continuous input into surface water from discharges or to increased adsorption and 
precipitation of the soluble forms with increasing depth.  The fact that cobalt concentration profiles in 
deep water follow manganese and aluminum profiles strongly suggests that dissolved cobalt is 
precipitated in the adsorbed state with oxides of iron and manganese and with crystalline sediments such 
as aluminosilicate and goethite.  A part of the cobalt may also precipitate out as carbonate and hydroxide 
in water. The higher concentration of organic pollutants in polluted water probably results in the 
formation of higher concentrations of soluble organic complexes.  In a deep sediment where the water 
was anoxic and contained hydrogen sulfide, some mobilization of cobalt was observed, probably due to 
the formation of bisulfide and polysulfide complexes (Bargagli 2000; Brügmann 1988; Finney and Huh 
1989; Glooschenko et al. 1981; Knauer et al. 1982; Nriagu and Coker 1980; Shine et al. 1995; Smith and 
Carson 1981; Szefer et al. 1996; Windom et al. 1989). 
Cobalt strongly binds to humic substances naturally present in aquatic environments.  Humic acids can be 
modified by UV light and bacterial decomposition, which may change their binding characteristics over 
time. The lability of the complexes is strongly influenced by pH, the nature of the humic material, and 
the metal-to-humic substance ratio.  The lability of cobalt-humate complexes decreases in time (“aging 
effect”) (Burba et al. 1994).  The “aging effect” indicates that after a period of time (~12 hours), 
complexes that were initially formed are transformed into stronger ones from which the metal ion is less 
readily dislodged.  In the Scheldt Estuary and the Irish Sea, between 45 and 100% of dissolved cobalt was 
found to occur in these very strong complexes (Zhang et al. 1990).  Aquifer material from the 
contaminated aquifer at a low-level infiltration pit at the Chalk River Nuclear Laboratories in Canada was 
analyzed to assess the nature of the adsorbed 60Co using sequential leaching techniques (Killey et al. 
1984).  Of the sediment-bound 60Co, <10% was exchangeable, 5–35% was retained by iron oxide, and 
55–>90% was fixed.  Over 80% of the dissolved 60Co was present as weakly anionic hydrophilic organic 
complexes.  The average Kd for 60Co between particulate matter and Po River (Italy) water was 451 m3/kg 
over a 2-year monitoring period (Pettine et al. (1994).  The mean Kd for 60Co in Arctic surface sediment 
(Kara Sea) where large quantities of radioactive waste by the former Soviet Union was disposed was 
1x105 L/kg (range 1x103–7x105), which is comparable to that in temperate coastal regions, 2x105 L/kg 
(range, 2x104–1x106) (Fisher et al. 1999).  
The distribution coefficient of cobalt may vary considerably in the same sediment in response to 
conditions affecting the pH, redox conditions, ionic strength, and amount of dissolved organic matter 
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(Mahara and Kudo 1981b).  Uptake of 60Co from the water by sediment increased rapidly as the pH was 
increased from 5 to 7–7.5 and then slightly decrease (Benes et al. 1989a, 1989b).  Therefore, pH would be 
an important factor affecting the migration of cobalt in surface water.  Uptake was little affected by
changes in liquid-to-solids ratio and ionic strength.  60Co is more mobile in anaerobic marine aquatic 
environments than in freshwater aerobic ones (Mahara and Kudo 1981b).  Therefore, 60Co waste is most 
suitably stored underground in aerated zones away from possible seawater intrusions.  In seawater-
sediment systems under anaerobic conditions 60Co was 250 times more mobile than 60Co in freshwater-
sediment systems under aerobic conditions.  Under anaerobic conditions, 30% of the 60Co added to a 
sediment-freshwater system was ‘exchangeable’ and therefore potentially mobile, while under aerobic 
conditions, 98% of the 60Co was permanently fixed.  Most of the mobile 60Co produced under anaerobic 
conditions in seawater consisted of nonionic cobalt associated with low molecular weight organic 
substances that were stable to changes in pH; the exchangeable 60Co appeared to be mostly ionic.   
Bird et al. (1998b) added 60Co to the anoxic hypolimnion of a Canadian Shield lake to simulate a nuclear 
waste scenario where radionuclides entered the bottom waters of a lake, and evaluated its behavior over 
5 years.  This situation was considered to be a likely pathway by which nuclear fuel waste stored deep 
underground in the plutonic (igneous) rock of this region would reach the surface environment via deep 
groundwater flow into the bottom waters of a lake.  It was felt that adding a redox sensitive element such 
as cobalt to the anoxic hypolimnion might be different from adding it to the epilimnion.  Monitoring 
vertical profiles in the lake established that the cobalt remained confined to the anoxic hypolimnion prior 
to the fall turnover (first 72 days) when mixing occurred throughout the water column.  After 358 days, 
only about 4% of the 60Co remained in the water.  After the second year, approximately 2% of the 60Co 
remained and after 5 years, only 0.4%.  These results mirror previous experiments in which the 60Co was 
added to the epilimnion, therefore establishing that there is little difference in the overall behavior of 
cobalt when added to the epilimnion or hypolimnion.  The loss rate coefficient of 60Co was 0.036/day
(half-life=19 days) between days 90 and 131 (lake mixing) during which time, the cobalt sorbed to the 
suspended sediment and bottom sediment under anoxic conditions.  Loss was to the sediment as there was 
no hydrological loss from the lake.  In the previous experiment in which 60Co was added to the 
epilimnion, the initial loss rate coefficient was somewhat higher, 0.056/day (half-life=12 days).  
Following the initial loss, 60Co continued to be slowly removed from the water (loss rate coefficient 
0.002/day; half-life=347 days); after 328 days, 60Co was no longer detectable in the epilimnion.  The half-
life of 60Co in the water column of an experimental lake in northwestern Ontario was 11 days; 5% of 
added 60Co remained in the water after 100 days (Bird et al. 1998b).  The redox potential also affects the 
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behavior of cobalt in sediment.  Under moderately reducing conditions, cobalt is released from sediment 
as Co2+ and forms CoS in the presence of sulfide.  The concentration of cobalt in the bottom water 
increases as the water becomes more anoxic (Brügmann 1988; Smith and Carson 1981).   
The mobility of cobalt in soil is inversely related to how strongly it is adsorbed by soil constituents.  
Cobalt may be retained by mineral oxides such as iron and manganese oxide, crystalline materials such as 
aluminosilicate and goethite, and natural organic substances in soil.  Sorption of cobalt to soil occurs 
rapidly (within 1–2 hours).  Soil-derived oxide materials were found to adsorb greater amounts of cobalt 
than other materials examined, although substantial amounts were also adsorbed by organic materials.  
Clay minerals sorbed relatively smaller amounts of cobalt (McLaren et al. 1986).  In addition, little cobalt 
was desorbed from soil oxides while substantial amounts desorbed from humic acids and montorillonite.  
In clay soil, adsorption may be due to ion exchange at the cationic sites on clay with either simple ionic 
cobalt or hydrolyzed ionic species such as CoOH+. Adsorption of cobalt onto iron and manganese 
increases with pH (Brooks et al. 1998).  In addition, as pH increases, insoluble hydroxides or carbonates 
may form, which would also reduce cobalt mobility. Conversely, sorption onto mobile colloids would 
enhance its mobility.  In most soils, cobalt is more mobile than lead, chromium (II), zinc, and nickel, but 
less mobile than cadmium (Baes and Sharp 1983; King 1988b; Mahara and Kudo 1981b; Smith and 
Carson 1981).  In several studies, the Kd of cobalt in a variety of soils ranged from 0.2 to 3,800.  The 
geometric mean, minimum, median, and maximum Kds of 60Co in 36 Japanese agricultural soils were 
1,840, 130, 1,735, and 104,000 L/kg, respectively (Yasuda et al. 1995).  The soil properties showing the 
highest correlation with Kd were exchangeable calcium, pH, water content, and cation exchange capacity
(CEC). In 11 U.S. soils, the mean Freundlich KF and n values were 37 L/kg and 0.754, respectively; KF 
values ranged from 2.6 to 363 L/kg and correlated with soil pH and CEC (Buchter et al. 1989).  In 
13 soils from the southeastern United States whose soil pH ranged from 3.9 to 6.5, cobalt sorption ranged 
from 15 to 93%; soil pH accounted for 84–95% of the variation in sorption (King 1988b).  
Organic complexing agents such as ethylenediaminetetraacetic acid (EDTA), which are used for 
decontamination operations at nuclear facilities, greatly enhance the mobility of cobalt in soil.  Other 
organic complexing agents, such as those obtained from plant decay, may also increase cobalt mobility in 
soil. However, both types of complexes decrease cobalt uptake by plants (Killey et al. 1984; McLaren et 
al. 1986; Toste et al. 1984).  Addition of sewage sludge to soil also increases the mobility of cobalt, 
perhaps due to organic complexation of cobalt (Gerritse et al. 1982; Williams et al. 1985). 
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Leaching of cobalt has been observed from municipal and low-level radioactive waste sites (Cyr et al. 
1987; Czyscinski et al. 1982; Friedman and Kelmers 1988).  The mobility of cobalt was assessed in two 
soils from the Cabriolet and Little Feller event sites at the Nevada Test site as a function of various 
parameters such as pH, ionic strength, cobalt concentrations, soil solids concentrations, and particle size 
distribution (DOE 1996).  Cobalt was quantitatively sorbed on these soils (at least 90% sorbed) when the 
pH was above 7 and the solid concentration was at least 20 g/L.  The experiments suggest that binding is 
principally on amphoteric surface-hydroxyl surfaces.  Since the pH of these soils is around 8, cobalt 
would bind strongly under normal environmental conditions.  Migration would be severely retarded under 
all but the most extreme conditions, e.g., pH of 4 or below and high ionic strength soil solutions 
(approximately 0.1 M).  In addition, unrealistically large quantities of water would be needed to displace 
cobalt from the upper layers of the soil profile.  
Cobalt may be taken up from soil by plants.  Surface deposition of cobalt on leaves of plants from
airborne particles may also occur.  Elevated levels of cobalt have been found in the roots of sugar beets 
and potato tubers in soils with high cobalt concentrations (e.g., fly ash-amended soil) due to absorption of 
cobalt from soil.  However, the translocation of cobalt from roots to above-ground parts of plants is not 
significant in most soils, as indicated by the lack of cobalt in seeds of barley, oats, and wheat grown in 
high-cobalt soil (Mermut et al. 1996; Smith and Carson 1981).  Mermut et al. (1996) found 0.01– 
0.02 mg/kg in 10 samples of durum wheat grain from different areas of Saskatchewan where surface soil 
cobalt levels ranged from 3.7 to 16.4 mg/kg.  The enrichment ratio, defined as the concentration in a plant
grown in amended soil (fly ash) over the concentration in unamended soil, was about 1.  Other authors 
have determined the transfer coefficient (concentration in plant/concentration in soil) for cobalt to be 
0.01–0.3.  The mean 57Co soil-plant transfer factors obtained for clover from eight soils over a 4-year 
period ranged from 0.02 to 0.35, in good agreement with results of other investigators (Mascanzoni 
1989).  However, in highly acidic soil (pH as low as 3.3), significantly higher than normal concentrations 
of cobalt were found in rye grass foliage, oats, and barley.  For example, cobalt concentrations in rye 
grass grown in unlimed soil (pH<5.0) was 19.7 mg/kg compared with 1.1 mg/kg in rye grass grown in 
limed soil (pH>5.0) (Boikat et al. 1985; Francis et al. 1985; Kloke et al. 1984; Mejstrik and Svacha 1988;
Palko and Yli-Hala 1988; Tolle et al. 1983; Watabe et al. 1984).  Soil and plant samples taken in the 
30-km zone around Chernobyl indicated that 60Co was not accumulated by plants and mushrooms (Lux et 
al. 1995).  Transfer factors obtained in 1992 ranged from 0.005 to 0.16 and those obtained in 1993 ranged
from <0.001 to 0.008.  Studies investigating the uptake of 60Co by tomato plants watered with 60Co­
contaminated water showed that tomato plants absorbed <2% of the activity available from the soil.  The 
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absorption was 6 times higher if the plants were watered aerially rather than ground watering.  Using 
either watering method, >90% of the activity was absorbed by the stems and leaves (Sabbarese et al. 
2002).  Soil to plant transfer factors for 60Co were determined for plants grown in containers with soil 
contaminated with 65Zn and 60Co over a 3-year period under outdoor tropical conditions.  Average transfer 
factors for 60Co over the 3-year period ranged from a high for spinach (1.030) to a low for rice (0.087) 
(Mollah and Begum 2001). 
60Co is taken up by phytoplankton and unicellular algae (Senenastrum capricornutum) with concentration 
factors (dry weight) ranging from 15,000 to 40,000 and 2,300 to 18,000, respectively (Corisco and 
Carreiro 1999).  Elimination experiments with the algae indicate a two component biological half-life, 
1 hour and 11 days, respectively, and suggest that the cobalt might be absorbed not only on the surface, 
but also intracellularly.  Since these organisms are at the bottom of the food chain, they could play an 
important role in the trophic transfer of 60Co released into waterways by nuclear facilities.  However, 
cobalt levels generally diminish with increasing trophic levels in a food chain (Smith and Carson 1981).   
The low levels of cobalt in fish may also reflect cobalt’s strong binding to particles and sediment.  The 
bioaccumulation factors (dry weight basis) for cobalt in marine and freshwater fish are ~100–4,000 and 
<10–1,000, respectively; accumulation in the muscle of marine fish is 5–500 (Smith and Carson 1981).  
Cobalt largely accumulates in the viscera and on the skin, as opposed to the edible parts of the fish.  In 
carp, accumulation from water accounted for 75% of 60Co accumulated from both water and food; 
accumulation from water and food was additive (Baudin and Fritsch 1989).  Depuration half-lives were
53 and 87 days for fish contaminated from food and water, respectively.  In the case of an accidental 
release of 60Co into waterways, the implication is that effects would manifest themselves rapidly since the 
primary route of exposure is from water rather than food.  Uptake of 60Co by biota in lakes in 
northwestern Ontario was not affected by the tropic status of the lakes (Bird et al. 1998a).  Uptake of 60Co 
was very low in whitefish, with concentrations being highest in kidney and undetectable in muscle.  
Similarly, while accumulation of 60Co by carp from food was dependent on food type, the transfer factor 
was very low, approximately 0.01, and no long-term bioaccumulation of the radionuclide occurred 
(Baudin and Fritsch 1987; Baudin et al. 1990).  Accumulation of 60Co from food for rainbow trout 
showed that after the 42-day exposure period, the highest concentrations of 60Co were found in the 
kidneys, secondary gut, and viscera, and the trophic transfer factor was 0.0186.  After 73 days of 
depuration, residual 60Co concentrations were the highest in the kidneys, viscera, and fins (Baudin et al. 
2000). In the experiment described above in which Bird et al. (1998a) added 60Co to the anoxic 
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hypolimnion of a Canadian Shield lake to simulate a nuclear waste scenario where radionuclides entered 
the bottom waters of a lake, 60Co levels in biota were low because of the rapid loss of cobalt to the 
sediment.  Levels in forage fish, minnows, and sculpins were low, <0.3 Bq/g (8 pCi/g) dry weight; an 
occasional high level, ~4 Bq/g (110 pCi/g) dry weight, in slimy sculpin was thought to reflect the 
presence of detritus in the gut of the fish.  Epilimnion additions of 60Co in an earlier study resulted in 
lower maximum concentrations in fish, 0.07, 0.11, and 0.01 Bq/g (2, 3.0, and 0.3 pCi/g) dry weight in 
pearl dace, fathead minnows, and slimy sculpins, respectively, when similar quantities of radioactive 
cobalt were added to the lake.  
Concentration factors have also been reported for various other aquatic organisms.  Freshwater mollusks 
have concentration factors of 100–14,000 (~1–300 in soft tissue).  Much of the cobalt taken up by
mollusks and crustacae from water or sediment is adsorbed to the shell or exoskeleton; very little cobalt is 
generally accumulated in the edible parts (Amiard and Amiard-Triquet 1979; Smith and Carson 1981).  A
concentration factor for 60Co of 265 mL/g (wet weight) was determined for Daphnia magna in laboratory
studies. The rapid decrease in radioactivity during the depuration phase indicated that adsorption to the 
surface was the major contamination process (Adam et al. 2001).  However, the digestive glands of 
crustaceans, which are sometimes eaten by humans, may accumulate high levels of 60Co. Five different 
species of marine mollusks had whole-body 60Co concentration factors between 6.3 and 84 after 1-month 
exposure to 60Co in seawater (Carvalho 1987).  The shell accounted for more than half of the body-
burden. Among the soft tissue, the gills and viscera had the highest concentrations factors and the muscle 
had the lowest. Fisher et al. (1996) studied the release of 60Co accumulated in mussels from water and 
ingested phytoplankton.  In each case, there was a slow and fast component to the release; the rapid 
release was in the form of fecal pellets if uptake was from food and from desorption from the shell if 
uptake was from the dissolved phase.  Biological half-lives obtained in laboratory studies were about 12– 
21 days from both the shell and soft parts.  Higher absorption efficiencies and lower efflux rates were
obtained for cobalamins than for inorganic cobalt, suggesting that it is a more bioavailable form of cobalt 
for mussels.  Cobalt from fecal pellets is rapidly released into the overlying water and may play a role in 
its geochemical cycling (Fisher et al. 1996).  The concentration of cobalt in clams in the Indian River 
Lagoon, Florida did not correlate with levels found in either water or sediment (Trocine and Trefry 1996).  
Kinetics of bioaccumulation of 57Co from water and depuration by starfish (Asterias rubens) were carried 
out in laboratory studies.  After 32 days of exposure to seawater containing 57Co, whole body uptake from
seawater reached a concentration factor of 23 (wet weight).  57Co was released with a half-life of 27 days
after removal to uncontaminated water.  Comparison of the kinetics of loss of 57Co following exposure to 
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57Co-contaminated food versus exposure from 57Co-contaminated water indicate that A. rubens
accumulates 57Co predominately from seawater rather than from food (Warnau et al. 1999). 
6.3.2 Transformation and Degradation  
6.3.2.1 Air 
There is a paucity of data in the literature regarding the chemical forms of cobalt in air and their 
transformations in the atmosphere.  It is generally assumed that anthropogenic cobalt originating from
combustion sources exists primarily as the oxide (Schroeder et al. 1987).  In addition, cobalt may be 
released into the atmosphere as its arsenide or sulfide during ore extraction processes.  It is not clear if 
these species are transformed in the atmosphere.  Should a relatively insoluble species such as the oxide 
be transformed into a more soluble form such as the sulfate, one would expect greater quantities to be 
washed out of the atmosphere in rain. 
6.3.2.2 Water 
Many factors control the speciation and fate of cobalt in natural waters and sediments.  These include the 
presence of organic ligands (e.g., humic acids, EDTA), the presence and concentration of anions (Cl-, 
OH-, CO3-2, HCO3-, SO4-2), pH, and redox potential (Eh).  Modeling the chemical speciation of a metal in 
water depends upon the environmental factors assumed and the stability constants of the various 
complexes.  Mantoura et al. (1978) predicted the equilibrium levels of Co2+ species in fresh water to 
follow the order: free Co+2≥ CoCO3>CoHCO3+>>CoSO4≥Co•humic acid.  However, the mole percent of 
various cobalt species in a Welsh lake was found to be: free Co+2, 76%; CoCO3, 9.8%; CoHCO3+, 9.6%; 
humate complexes, 4.0%; and CoSO4, 0.4%.  The rank order of species concentration in seawater was 
estimated to be: CoCO3>free Co+2>CoSO4≥CoHCO3+. In another model, the speciation of cobalt was 
completely different with CoCl+>free Co+2>CoCO3>CoSO4 (Smith and Carson 1981).  More recently, 
Tipping et al. (1998) estimated the equilibrium speciation of cobalt in riverine, estuarine, and marine 
surface water of the Humber system (England).  In all but seawater, cobalt complexes with carbonate 
-(HCO3 and CO32-) constituted about 70% of dissolved cobalt while the free Co2+ ion, was a major 
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species, ~25%, which is much lower than the 61% predicted by Mantoura et al. (1978).  As the alkalinity
of the water increases, the proportion of cobalt complexed with carbonate increases at the expense of free 
Co2+. The proportion, but not the concentration, of cobalt that exists as the free ion and the carbonate 
complexes in river water is independent of the level of fulvic acid in the water.  In seawater, the carbonate 
species and the free aqua species assume roughly equal importance.  The proportion of dissolved cobalt 
complexed with fulvic acid decreased with increasing salinity.  About 20% of cobalt in seawater was 
estimated to be present as complexes with sulfate.  In a bioconcentration study in which CoCl2 was 
initially added to the seawater, at month’s end, the cationic form of cobalt was progressively converted 
into anionic and neutral forms, possibly as a result of complexation with organic ligands (Carvalho 1987).  
Addition of humic acid to natural waters may merely increase the concentration of colloidal dispersed 
metal rather than form truly soluble humic complexes.  In water that contains high organic wastes such as 
was the case in the Rhone River in France, cobalt was almost completely complexed.  A recent study
determined that the distribution of 60Co in the Rhone River sampled at Arles, France was 45% in the 
particulate phase, 30% in the dissolved phase, and 25% in the colloidal phase (Eyrolle and Charmasson 
2001).  Cobalt forms complexes with EDTA that are very stable environmentally.  EDTA is often used in 
agriculture, food and drug processing, photography, and textile and paper manufacturing, and therefore, it 
is a likely constituent of industrial discharges. 
Acidity and redox potential have an effect on the behavior of cobalt in water.  The adsorption of cobalt by
particulate matter decreases with decreasing pH, since the increasing H+ concentration competes with 
metal binding sites. This may lead to increased concentrations of dissolved cobalt at low pH.  The effect
of Eh (redox potential) on the speciation of cobalt has been shown by the increase in the concentration of 
dissolved cobalt by orders of magnitude with increasing depth in certain parts of Baltic waters.  The 
increase in the concentration of dissolved cobalt may be due to the formation of soluble bisulfide and 
polysulfide complexes in the anoxic zones.  The residence time of soluble cobalt in seawater has been 
estimated to range from <1 to 52 years (Brugmann 1988; Knauer et al. 1982; Smith and Carson 1981). 
Vitamin B12, which contains cobalt, is synthesized by 58 species of seven genuses of bacteria as well as 
blue-green algae and actinomycetes (mold-like bacteria).  Consequently, vitamin B12 levels in marine 
water range from very low levels in some open ocean water to much higher levels in some coastal waters.  
Freshwater environments have comparable levels of vitamin B12. The high level of cobalamins in coastal  
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water appears to be related to the occurrence of macrophytes in these areas with their high concentrations 
of vitamin B12. Cobalamins are released into the water when the organisms die (Smith and Carson 1981).  
Alkaline thermal groundwater in granitic areas have been studied as possible waste disposal sites for 
radioactive waste (Alaux-Negrel et al. 1993).  Water in these areas is characterized by high pH, low CO2 
partial pressure, and generally low redox potential; sulfide concentrations are in the range of 10-4 to 
10-3 mol/L.  The solubility of cobalt is controlled by the solubility of CoS (log K1 and log K2 being 
5.7 and 8.7 at 25°C) and therefore, levels of cobalt are very low, 10-8–10-10 mol/L.  
The 60Co (III) picolinate complex that is released into water by some nuclear reactors does not break 
down immediately on release into seawater, but rather can coexist with the 60Co (II) forms for lengthy
periods in the environment (Leonard et al. 1993a, 1993b).  Studies indicate that several processes occur to 
the Co(III) organic complexes, including reduction to the inorganic form, sorption of both species to 
particulate matter, and transformations of the uncomplexed species.  It is possible that this more soluble 
and uncharged form of radioactive cobalt will increase the dispersion of 60Co from its point of discharge. 
6.3.2.3 Sediment and Soil 
The speciation of cobalt in soil or sediment depends on the nature of the soil or sediment, concentration of 
chelating/complexing agents, pH, and redox potential (Eh) of the soil.  Dissolved cobalt may be absorbed 
by ion exchange and other mechanisms, or may form complexes with fulvic acids, humic acid, or other 
organic ligands in soil.  The humic and fulvic complexes of cobalt are not very stable compared with 
those of copper, lead, iron, and nickel.  The speciation of cobalt in sediment from nine sites in the Red 
Sea, a sea that is unique in that it has no permanent streams flowing into it, was assessed using a 
sequential extraction technique (Hanna 1992).  The mean percentages contained in the various fractions 
were: exchangeable, 5.5%; carbonate, 5%; Fe/Mn oxides, 24%; organic, 30.4%; sulfides, 13%; and 
lithogenous, 22%.  While the mean concentration of cobalt in the sediment increased from 0.003 to 
0.006 ppb between 1934 and 1984, its distribution among the different phases did not change appreciably. 
The reduction of soil Eh, which may occur when soil is flooded or in deeper layers of soil that are 
oxygen-depleted, may change the speciation of cobalt.  This may result in the reduction of soil iron and 
manganese and the subsequent release of adsorbed cobalt from the mineral oxides.  Similarly, a decrease 
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in soil pH may result in the solubilization of precipitated cobalt and desorption of sorbed cobalt, resulting 
in increased cobalt mobility (Smith and Carson 1981).  Co2+ may also be oxidized to Co3+ by manganese 
oxides, a common component of soils and aquifer material, with subsequent surface precipitation 
(Brusseau and Zachara 1993).  This process may affect transport of cobalt in the subsurface environment. 
EDTA complexes of cobalt are very stable and are likely to form in soils containing EDTA.  EDTA is 
widely used as a decontaminating agent at nuclear facilities.  Although cobalt-EDTA complexes are 
adsorbed by some soils, the mobility of cobalt in soil may increase as a result of complex formation 
(Schnitzer 1969; Smith and Carson 1981; Swanson 1984).  60Co that is disposed of in shallow land 
trenches have sometimes been found to migrate more rapidly than expected from the disposal sites.  
Organic chelating agents are frequently present at these sites and would possibly increase the solubility 
and transport of the radionuclide.   
Bacterial action can affect the mobility of a substance by mediating reactions or by participating in 
reactions that lower the pH. Another way of influencing radionuclide mobility is by degrading 
complexing agents used in cleaning reactors (e.g., citric acid), thereby releasing the radionuclide.  
However, experiments on the fate and transport of cobalt released upon the biodegradation of the 
complexing ligand indicate that results are not always predictable; the means of ligand removal and the 
geochemical environment are important factors that must be considered (Brooks et al. 1998).
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT  
Cobalt concentrations in environmental media, including food and human tissue, have been exhaustively 
tabulated by Smith and Carson (1981) and Young (1979).  The International Agency for Research on 
Cancer (IARC 1991) contains reviews of more recent studies, but is primarily focused on occupational 
exposures and body burdens of cobalt. 
6.4.1 Air 
Atmospheric cobalt is associated with particulate matter.  Mean cobalt levels in air at unpolluted sites are 
generally <1–2 ng/m3 (Hamilton 1994; Smith and Carson 1981).  At the South Pole, cobalt levels of 
0.00049±0.00015 ng/m3 were recorded in 1974–1975 (Maenhaut et al. 1979).  Geometric mean cobalt 
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levels in several open-ocean environments ranged from 0.0004 to 0.08 ng/m3 (Chester et al. 1991). The 
average annual PM-10 (particles with diameters ≤10 µm) cobalt concentration at Nahant, Massachusetts 
(near Boston) in 1992–1993 was 1.7 ng/m3 (Golomb et al. 1997). Half of the cobalt was contained in fine 
particles (<2.5 µm) and half in coarse particles (2.5–10 µm).  The mean cobalt level in southern Norway
in 1985–1986 (n=346) was 0.10 ng/m3 with 35% of the samples falling below the detection limit of 
0.04 ng/m3 (Amundsen et al. 1992).  Atmospheric cobalt levels in industrial settings may exceed 
10 ng/m3. The highest recorded average cobalt concentration in air was 48 ng/m3 in Clydach, Wales at 
the site, where nickel and cobalt were refined (Smith and Carson 1981).  Some ambient atmospheric 
levels of cobalt are given in Table 6-2. These data show the contribution of anthropogenic sources in 
increasing the level of cobalt in the ambient air.  Typical occupational cobalt levels are 1.0x104– 
1.7x106 ng/m3 (Barceloux 1999; IARC 1991).  While 60Co has been detected in air samples at the Hanford 
site and Oak Ridge National Laboratories, levels were not reported (HazDat 2004; PNNL 1996).  In 1995, 
the concentration of 60Co in air at the Hanford site was below the detection limit in over 88% of the air 
samples.  
6.4.2 Water 
The concentrations of cobalt in surface water and groundwater in the United States are generally low, 
<1 µg/L in pristine areas and 1–10 µg/L in populated areas (Hamilton 1994; Smith and Carson 1981).  
However, cobalt levels may be considerably higher in mining or agricultural areas.  Levels as high as  
4,500 µg/L were reported in Mineral Creek, Arizona, near a copper mine and smelter; levels of 
6,500 µg/L were reported in the Little St. Francis River, which receives effluent from cobalt mining and 
milling operations (Smith and Carson 1981).  Mining at Blackbird Mine in Idaho, one of the large 
deposits of cobalt in North America, occurred from the late 1800s to 1982.  Cobalt concentration in 
surface water and groundwater samples collected in 1992 from area creeks near this mine were reported 
to range from <1 to 625,000 µg/L, and from not detected to 315,000 µg/L respectively (ATSDR 1995),
Eckel and Jacob (1988) analyzed U.S. Geological Survey (USGS) data for 6,805 ambient surface water 
stations and estimated the geometric mean and median dissolved cobalt concentration as 2.9 and 2.0 µg/L,
respectively. Mean cobalt levels reported in seawater range from 0.078 µg/L in the Caribbean Sea to 
0.39 µg/L in the Indian Ocean (Hamilton 1994). Vitamin B12 is synthesized by bacteria, macrophytes,  
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Table 6-2. Concentration of Cobalt in the Atmosphere 
Possible 
Location source/activity Concentrationa Units Type Reference
Ambient levels—remote
South Pole, 1974–1975 Crustal material 0.00049±0.00015 ng/m3 Mean±SD Maenhaut et 
al. 1979 
Open-ocean  0.0004–0.08 ng/m3 Geomean Chester et al.
range 1991 
North Atlantic 0.006–0.09 ng/m3 Range Smith and 
Carson 1981 
Baltic Sea, 1983 0.09, 0.01–0.43 ng/m3 Mean, range Hasanen etal. 
1990 
Remote sites 0.001–0.9 ng/m3 Range Schroeder et 
al. 1987 
Ambient levels—rural/suburban/urban
Rural sites 0.08–10.1 ng/m3 Range Schroeder et 
al. 1987 
Massachusetts, Nahant, 1.7 ng/m3 Annual Golomb et al.
1992–1993 mean 1997 
Urban sites Schroeder et 
al. 1987 
 United States 0.2–83 ng/m3 Range 
 Canada 1–7.9 
 Europe 0.4–18.3 
Texas state average 2.0 ng/m3 Mean Wiersema et 
(1978–1982) al. 1984 
Illinois, urban air Sweet et al. 
(<2.5 µm; 2.5–10 µm)  1993 
Bondville, Ill (rural) Background 0.2; 0.1 ng/m3 Mean (fine; 
coarse) 
 Southeast Chicago Steel mills 0.4; 0.4 
East St. Louis Smelters 0.5; 0.4 
Washington, DC (1974) Urban area 1.1 ng/m3 Mean Smith and 
Carson 1981 
Ambient levels—industrial
Maryland, Baltimore Ondov et al. 
Harbor Tunnel 1982 
(1973–1974) 
Air outside Vehicular exhaust 0.8–1.9 ng/m3 Range 
Air inside Vehicular exhaust 2.2–5.3 
Ohio, Cleveland Be-Cu alloy and other 610 ng/m3 Maximum Smith and 
industrial activities Carson 1981 
Texas, El Paso Industrial 127 ng/m3 Maximum Wiersema et 
(1978–1982) al. 1984 
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Table 6-2. Concentration of Cobalt in the Atmosphere 
Possible 
Location source/activity Concentrationa Units Type Reference
Texas, Houston (1978– Urban area 81 ng/m3 Maximum Wiersema et 
1982) al. 1984 
Arizona, Tucson Smith and 
Carson 1981 
 Urban Copper smelting 1.9 ng/m3 Mean 
Rural 0.7 
Maryland, Chalk Point Coal-burning power 3.86 ng/m3 Mean Smith and 
Generator plant Carson 1981 
Wales, Clydach Nickel refining 48, 3–300 ng/m3 Mean, range Smith and 
Carson 1981 
Wales, Llausamlet and Towns near Clydach 3.8 Mean Smith and 
Trebanos Carson 1981 
Occupational air levels
Northern Italy, exposure Diamond abrasive Mosconi et al. 
survey, 1991, area mfg. 1994a 
monitoring (n=259) 
Mould-filling 220, 47–960 ng/m3 Median, 
range 
Sintering 101.5, 32–240 
Grinding 22, 15–45 
Mechanical­ 20, 12–44 
working 
 Grinding 5, 2.5–94 
Tool production 6, 5–47 
Hard metal alloy filing 2, 0.8–3 
Other 2.7, 2.3–15 
Northern Italy, exposure Diamond abrasive Mosconi et al. 
survey, 1991, personal mfg. 1994a 
sampling (n=259) 
Mould-filling 382, 76–2,600 ng/m3 Median, 
range 
Sintering 309, 238–413
Grinding 230, 82–690 
Mechanical­ 40, 7.1–65 
working 
 Grinding 9.3, 1.5–178 
Tool production 17, 4–28 
Hard metal alloy 5, 1–107 
filling 
Other 50, 10–290 
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Table 6-2. Concentration of Cobalt in the Atmosphere 
Possible 
Location source/activity Concentrationa Units Type Reference
Japan, personal sampling, Powder preparation Kumagai et al. 
hard metal tool 1996 
manufacture, 8-hour 
TWA, 356 workers 
(n=935) 
Rotation 459, 7–6,390 µg/m3 Mean, range
Full-time 147, 26–378 
Press
Rubber 339, 48–2,910 
Steel 47, 6–248 
Shaping 97, 4–1,160 
Sintering 24, 1–145 
Blasting 2, 1–4 
Electron 3, 1–23 
discharging 
Grinding 45, 1–482 
geomean = geometric mean; SD = standard deviation; TWA = time weighted average
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blue-green algae, and actinomycetes, and cobalt levels in oceans often correlate with biological 
productivity.  In the Baltic Sea, dissolved cobalt levels that are 1.0 ng/L near the surface, increase to 
71.0 ng/L at a depth of 200 m (Brügmann 1988).  The rise in dissolved cobalt is coincident with the onset 
of anoxic conditions and the presence of hydrogen sulfide, indicating that soluble bisulfide and 
polysulfide complexes may be present.  Some cobalt levels reported in water are given in Table 6-3. 
In a 1962–1967 survey, cobalt was detected in 2.8% of 1,577 U.S. raw surface waters from which 
drinking water is derived; the detection limit was 1 µg/L and the maximum concentration was 48 µg/L 
(NAS 1977).  Of 380 U.S. finished drinking waters, only 0.5% contained cobalt levels exceeding 1 µg/L; 
the maximum concentration found was 29 µg/L (NAS 1977).  These values are higher than the respective 
median and maximum levels of <2.0 and 6.0 µg/L found in Canadian finished drinking water (Meranger 
et al. 1981). Meranger et al. (1981) tested source water and drinking water in 71 municipalities across 
Canada and concluded that, in general, both surface water and groundwater used for drinking water 
supplies contain negligible amounts of cobalt.  Greathouse and Craun (1978) analyzed 3,834 grab samples 
of household tap water from 35 geographical areas in the United States for 28 trace elements.  Cobalt was 
found in 9.8% of the samples at concentrations ranging from 2.6 to 107 µg/L.  It is not clear whether these 
higher levels could indicate that cobalt was picked up in the distribution system.  In the earlier National 
Community Water Supply Study (2,500 samples), 62% of the samples contained <1 µg Co/L; the average 
and maximum cobalt concentrations were 2.2 and 19 µg/L, respectively (Smith and Carson 1981).  Cobalt 
was not detected (detection limit 8 µg/L) in a 1982–1983 survey of drinking water in Norway that 
covered 384 waterworks serving 70.9% of the Norwegian population (Flaten 1991). 
The mean concentrations of cobalt in rain is around 0.03–1.7 µg/L, with levels generally ranging from
0.002 µg/L at Enewetak Atoll to about 2.9 µg/L in the Swansea Valley, Wales (Arimoto et al. 1985; 
Dasch and Wolff 1989; Hansson et al. 1988; Heaton et al. 1990; Helmers and Schrems 1995; Nimmo and 
Chester 1993; Nimmo and Fones 1997; Smith and Carson 1981).  The highest recorded level of cobalt in 
precipitation was 68.9 µg/L in the vicinity of a nickel smelter in Monchegorsk in the Russian Arctic 
(Reimann et al. 1997).  An analysis of rain in the Mediterranean and urban and coastal sites in northwest 
England showed that about 33–44% of the cobalt occurred as very stable dissolved organic complexes 
(Nimmo and Chester 1993; Nimmo and Fones 1997). 
As it was pointed out in Section 6.3.2.2, 60Co discharged from the Steam Generating Heavy Water 
Reactor at Winfrith on the south coast of England was shown to be largely in the form of the nonionic 
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Table 6-3. Cobalt Levels in Water 
Nature/location of water Level Units Type Reference
Sea water
Florida (Indian River 
Lagoon) (43 sites) 
0.031, 50 µg/L Mean, range Trocine and Trefry 
1996 
California (Baja) 2–45 km 
offshore (n=11) 
0.022–0.17 nM Range Sañudo-Wilhelmy and 
Flegal 1996 
<100 m off shore (n=11) 0.11–0.59
Agean Sea, 1994; 8 sites 
(dissolved) 
0.168–0.632, 1.917 nM Range of 
means, 
maximum 
Voutsinou-Taliadouri 
1997 
Baltic Sea (Gotland Deep 
site) 
Brügmann 1988 
10 m 1.0 ng/L Mean 
(dissolved Co) 
50 m 1.0 
100 m 3.5 
150 m 4.2 
200 m (anoxic) 71.0 
235 m (anoxic) 49.2 
Seawater background 0.04 µg/L Bargagli 2000 
Seawater 0.27 µg/L Mean Abbasi et al. 1989 
Fresh surface water
Freshwater background 0.05 µg/L Bargagli 2000 
U.S. ambient surface water 
(6,805 stations) 
<2.9, 2.0 µg/L Mean, median Eckel and Jacob 1988 
Five Great Lakes waters ND–0.09 µg/L Range Rossmann and Barres 
1988 
Japan, unpolluted lake <0.004 µg/L Nojiri et al. 1985 
Norway, 11 rivers 0.94 µg/L Maximum Flaten 1991 
Streams near populated
areas 
1–10 µg/L Range Smith and Carson 
1981 
Streams in agricultural and 
mining areas 
11–50 µg/L Range Smith and Carson 
1981 
Suspended solids in rivers 7–94 mg/kg Range Smith and Carson 
1981 
Groundwater
Canada (Chalk River nuclear 
waste site) 
0.0001–0.002 µg/L Cassidy et al. 1982 
 Colorado (Denver)–shallow 
groundwater, (n=30)
<1 (<1–9) µg/L Median, range Bruce and McMahon 
1996 
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Table 6-3. Cobalt Levels in Water 
Nature/location of water Level Units Type Reference
Drinking water
Canadian drinking water Meranger et al. 1981 
(71 municipalities) 
Raw: <2.0 µg/L Median 
Treated: <2.0 
Distributed: ≤2.0 
Precipitation
 Massachusetts, 1984 0.045 (0.008), 0.02– µg/L Mean (SD), Dasch and Wolff 1989 
(12 events) 0.12 range 
Rhode Island (rain/snow), 0.038 (0.067) ppb Median (mean) Heaton et al. 1990 
1985 (n=269) 
0.001–0.80 Range 
 Western Mediterranean, Nimmo and Chester 
1988–1989 1993 
Total cobalt 0.029–0.134, 0.043 µg/L Range, mean
Labile cobalt 0.009–0.104, 0.025 
Organic cobalt ND–0.613, 0.019 
Arctic (7 sites in Finland, <0.02–1.07, 3.32 µg/L Median range, Reimann et al. 1997 
Norway, Russia) maximum 
 Russia (Monchegorsk), 11.8, 68.9 Median, 
nickel smelter maximum 
ND = not detected; SD = standard deviation
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trivalent complex, 60Co(III) picolinate.  The 60Co(III) species is not immediately reduced to the more
particle-reactive divalent form, and both oxidation states may coexist for long periods of time in the 
environment.  The proportion of the more soluble and mobile 60Co(III) would be expected to increase 
with time and distance from the point of discharge.  Shoreline water samples (n=22) taken in 1987–1988 
at two locations in the vicinity of the discharge from the Steam Generating Heavy Water Reactor at 
Winfrith contained 0.3–16.2 mBq/L (8–437 fCi/L) of particulate 60Co, 2.8–44.4 mBq/L (76–1,200 fCi/L) 
of soluble 60Co(II), and 0.2–4.8 mBq/L (5–130 fCi/L) of soluble 60Co(III) (Leonard et al. 1993).  The 
percent of the soluble 60Co present as Co(III) ranged from 4.3 to 18.6%. In 1989, in conjunction with the 
largest discharge of effluent from the plant, offshore seawater samples from 18 sites contained  
0.06–2.22 mBq/L (2–60 fCi/L) of particulate 60Co, 0.30–10.3 mBq/L (8.1–278 fCi/L) of soluble 60Co(II), 
and 0.12–1.55 mBq/L (3.2–41.9 fCi/L) of soluble 60Co(III).  The percent of the soluble 60Co present as 
Co(III) ranged from 6.0 to 28.6%.  
6.4.3 Sediment and Soil 
Cobalt is the 33rd most abundant element in the earth’s crust.  Its average concentrations in the earth's 
crust and in igneous rocks are 20–25 and 18 mg/kg, respectively (Abbasi et al. 1989; Merian 1985; Smith 
and Carson 1981). Trace metals in soils may originate from parent rock or from anthropogenic sources, 
primarily fertilizers, pesticides, and herbicides.  Most soils contain 1–40 mg cobalt/kg.  The average 
cobalt concentration in U.S. soils is 7.2 mg/kg (Smith and Carson 1981).  Soils containing <0.5–3 mg
cobalt/kg are considered cobalt-deficient because plants growing on them have insufficient cobalt  
(<0.08–0.1 mg/kg) to meet the dietary requirements of cattle and sheep.  Cobalt-deficient soils include the 
humus podzols of the southeastern United States, and the podzols, brown podzolic soils, and humus 
groundwater podzols in the northeastern parts of the United States.  (Podzols are generally coarse-
textured soils.) The cobalt content of surface soils from 13 sites in the brown and dark brown soil zones 
of southwestern Saskatchewan ranged from 3.7 to 16.0 mg/kg and only in one case was the soil 
appreciably elevated above the corresponding parent material (Mermut et al. 1996).  Fertilizers used in 
this agricultural area contained 0.12–102 mg Co/kg, with a median of 5.7 mg/kg.
Mean cobalt concentrations in surface soil from nine sites on two active volcanic islands off of Sicily 
ranged from 5.1 to 59.0 mg/kg (Bargagli et al. 1991). Soils near ore deposits, phosphate rocks, or ore  
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smelting facilities, and soils contaminated by airport traffic, highway traffic, or other industrial pollution 
may contain much higher concentrations of cobalt; concentrations up to 800 mg/kg have been detected in 
such areas (Kloke et al. 1984; Smith and Carson 1981).  Cobalt concentrations from 28 samples collected 
from surface deposits in the Big Deer and Blackbird Creek drainage basins in Idaho near the Blackbird 
Mine ranged from 26.5 to 7,410 mg/kg (Agency for Toxic Substances and Disease Registry 1995).  Soils 
around the large copper-nickel smelters in Sudbury, Ontario have been shown to contain high levels of 
cobalt. Fifty kilometers from the smelters, cobalt levels in surface soil were 19 mg/kg.  These levels 
increased to 48 mg/kg at 19 km, 33 mg/kg at 10 km, and 42–154 mg/kg between 0.8 and 1.3 km from the 
smelter (Smith and Carson 1981).  Soils around a cemented tungsten carbide tool grinding factory
contained cobalt levels as high as 12,700 mg/kg, almost 2,000 times the average in U.S. soils (Abraham
and Hunt 1995).  However, neighborhood soils between 30 and 160 meters from the factory only
contained 12–18 mg Co/kg. 
Unpolluted freshwater sediment contains about the same levels of cobalt as does cobalt-sufficient soil, 
generally <20 mg/kg (Smith and Carson 1981).  In the Hudson River Estuary, cobalt levels in suspended 
sediment were an order of magnitude higher than in bottom sediment (Gibbs 1994).  This can be 
attributed to the finer grain size of suspended sediment or local sources.  Cobalt levels in core samples 
(surface to 42 cm deep) from the Upper St. Lawrence Estuary were independent of depth, indicating the 
lack of any recent significant anthropogenic releases (Coakley et al. 1993).  Cobalt levels in sediment are 
shown in Table 6-4. 
No broad-based monitoring studies of 60Co or other radioactive cobalt isotopes in soil or sediment were 
found in the literature.  Soil samples from the O-horizon taken from three sites in the 30-km zone around
Chernobyl in 1992 and again in 1993 contained 14–290 and 4.5–245 Bq/kg (380–7,800 and 120– 
6,620 pCi/kg) dry weight of 60Co, respectively (Lux et al. 1995).  The Columbia River receives 
radiological contaminants along the Hanford Reach primarily through seepage of contaminated
groundwater.  The regional median concentration of 60Co in sediment was highest along the Hanford 
reach, approximately 0.09 pCi/g (0.003 Bq/g) (PNNL 1996).  60Co activity in a sediment cores in water 
off of Southampton in southern England contained up to 28 Bq/kg (760 pCi/kg) in the upper 3 cm; no 
activity was found below 12.5 cm (Croudace and Cundy 1995).  Discharges of treated effluent occurred 
on closing a steam generating heavy water reactor west of where the sampling was done.  The maximum
discharge occurred in 1980–1981; however, no value was reported (Croudace and Cundy 1995). 
  
 
 
 
 
 
 
 
 
 
 
     
 
 
  
 
 
 
 
 
   
   
     
    
   
     
    
     
     
     
 
    
   
     
 
 
 
 
  
 
 
 
 
COBALT 240 
6. POTENTIAL FOR HUMAN EXPOSURE 
Table 6-4. Cobalt Levels in Sediment 
Nature/location of sediment Level Units Type Reference
Freshwater
Polluted lakes and rivers 0.16–133  mg/kg Range Smith and Carson 
1981 
Lake Ontario near Miesissaqua, Canada 4.1–19.8 mg/kg Range Glooschenko et al. 
1981 
Hudson River, Foundry Cove, 1983, Ni-Cd 
battery plant, 1953–1979, surficial (0–5
cm) sediment, 16 sites 
18–700 mg/kg Range Knutson et al. 1987 
Estuaries and Marine
Hudson River Estuary (0–80 km from 
ocean), 1991
Gibbs 1994 
Bottom sediment 1–13 mg/kg Range 
Suspended sediment (near surface) 30–140 
Upper St. Lawrence Estuary, 1989–1990 Coakley et al. 1993 
Core C168 3.1 (0.6) mg/kg Mean (SD) 
Cores LE and LO 2.7 (0.5) 
Massachusetts, New Bedford Harbor- core 
(0–25 cm) 
Shine et al. 1995 
Outer Harbor 7.03, 3.64–9.79, 
range 
Inner Harbor 6.38, 2.62–10.52 
Buzzards Bay (control site) 4.76, 1.64–8.19 
Indian River Lagoon, Florida (43 sites) 2.3, 0.4–6.3 mg/kg Mean, 
range 
Trocine and Trefry 
1996 
Gulf of Mexico Villanueva and 
Botello 1998 
Coastal areas (11 sites) 12.30–36.26 mg/kg Range of 
means 
Continental shelf (3 sites) 6.39–21.00 
Antarctica (Ross Sea) continental shelf 
(n=12)
19, 0.10–13 mg/kg Mean, 
range 
Bargagli 2000 
Northern Arctic Alaska, continental shelf 
(n=136) 
9, 3.3–18 mg/kg Mean, 
range 
Bargagli 2000 
Chukchi Sea, northeast Alaska 
(31 stations, surficial sediment) 
32.7, 19–74 mg/kg Mean, 
range 
Naidu et al. 1997 
Baltic Sea, southern, off Poland (surficial
sediment) 
0.69–18.10 mg/kg Range Szefer et al. 1996 
Baltic Sea (Gotland Deep site) 19, 11–33 mg/kg Mean, Brügmann 1988 
range 
SD = standard deviation
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Sediment samples were analyzed from the Peconic River system on Long Island, New York, downstream
of Brookhaven National Laboratory (BNL).  Near the sewage treatment plant, closest to the BNL, mean 
concentrations of 60Co from three locations at the depth intervals 0.00–0.06, 0.06–0.15, 0.15–0.24, and
0.24–0.37 meters were 9.6, 6.7, 9.6, and 10.5 Bq/kg (0.25, 0.18, 0.25, and 0.28 nCi/kg) dry weight, 
respectively. At one location at the BNL property boundary, mean concentrations of 60Co, using the same 
depth intervals, were 5.8 Bq/kg (0.16 nCi/kg) dry weight for the 0.00–0.06 m depth and <4 Bq/kg 
(<0.11 nCi/kg) dry weight for the remaining depth intervals.  Sediment samples from a control river, 
Connetquot River, were <4 Bq/kg (<0.11 nCi/kg) in two locations at two depths (0.00–0.06 and 0.06– 
0.15 m) (Rapiejko et al. 2001). 
Mururoa and Fangataufa Atolls were used for underground testing of nuclear weapons from 1975 to 1996.
60Co was detected in the particle fraction of water in measurable levels at two of the nine Mururoa Atoll 
sites, Aristee and Ceto, at 0.58 and 1.06 mBq/L (0.016 and 0.029 pCi/L), respectively.  60Co levels were 
found at levels below the detection limit, <0.1 mBq/L (<0.003 pCi/L), at the two Fangataufa Atoll sites 
and at the seven other Muruoa Atoll sites (Mulsow et al. 1999).  Concentrations of 60Co of soil samples 
used for growing onion, potatoes, tomatoes, cabbage, and maize in the Bulgarian village, Ostrov, in the 
vicinity (approximately 25–30 km) of the “Kozloduy” nuclear power plant were <8, 3, 320, 330, and 
180 mBq/kg (2, 8.1, 8.6, 8.9, and 4.9 pCi/kg), respectively (Djingova and Kuleff 2002). 
6.4.4 Other Environmental Media 
The cobalt content of plants depends on the plant, the cobalt content of the soil, and numerous 
environmental factors.  The mean cobalt concentration reported for terrestrial plants was 0.48 µg/g, while 
the mean and median levels for freshwater vascular plants were 0.48 and 0.32 µg/g, respectively 
(Outridge and Noller 1991).  The median cobalt level in freshwater vascular plants from polluted waters 
was about the same as in unpolluted waters, 0.37 µg/g, although extremely high levels of cobalt, up to
860 µg/g, was reported in one species, Myriophyllum verticillatum, from central Ontario lakes.  Grasses 
normally contain 0.2–0.35 µg/g of cobalt, but grasses from cobalt-deficient regions contain only
0.02–0.06 µg/g of cobalt (Hamilton 1994).  Durum wheat grown in southeastern Saskatchewan contained 
0.01–0.02 mg/kg dry weight (Mermut et al. 1996).  In view of the cobalt content of the soil and the fact 
that almost half of the cobalt in fertilizers used in the area was in a readily available form, the uptake of 
cobalt by wheat was negligible. 
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60Co levels in plants and mushrooms in the 30-km zone around Chernobyl were mostly below the 
detection limit in samples obtained in 1992 and 1993; the highest activity recorded was 3.9 Bq/kg 
(110 pCi/kg) dry weight in Athyrium filix femina (Lux et al. 1995). 
Cobalt concentrations have been reported in various aquatic animals and seabirds.  Eel and a freshwater 
fish from three Dutch polder lakes contained 2.5–25.0 and 2.50–5.63 mg cobalt/kg wet weight, 
respectively, (Badsha and Goldspink 1988).  Muscle tissue of ocean fish and rock crabs caught near dump 
sites off New York City, New Haven, Connecticut, and Delaware Bay contained 10–40 and 16.0 µg/kg, 
respectively (Greig and Jones 1976).  In a study of the levels and distribution of 14 elements in oceanic 
seabirds, the concentration of cobalt, an essential element, appeared to be highly regulated, with over 80% 
of the body burden residing in the skeleton.  The mean cobalt concentration in the livers of 11 seabird 
species ranged from 0.048 to 0.078 µg/g dry weight, and cobalt had the lowest coefficient of variation in 
the different species of the elements studied (Kim et al. 1998a).  In another study in Antarctica, mean 
cobalt levels in fish and amphipods were 0.11–0.14 and 1.01 µg/g dry weight, respectively, while those in 
the tissue of penguin and other sea birds ranged from 0.09 to 0.11 µg/g (Szefer et al. 1993).  The 
concentration of cobalt in the tissue of 14 bluefin tuna caught by various commercial fishing vessels off 
Newfoundland was essentially the same, 0.01±0.004 µg/g (Hellou et al. 1992a).  Similarly, in a broad 
survey of contaminant levels in nine species of fish and fiddler crabs from 11 sites in the lower Savannah 
River, Georgia and the Savannah National Wildlife Refuge, mean cobalt levels among different species 
and sites were statistically indistinguishable (Winger et al. 1990).  These and other studies indicate that 
cobalt does not biomagnify up the food chain (Smith and Carson 1981).  While high levels of cobalt were 
found in sediment from the Tigris River in Turkey and low levels in the water, cobalt was not detected in 
two species of fish, Cyprinion macrostomus and Garra rufa (Gümgüm et al. 1994).  Cobalt was detected 
in two other species of fish collect between 1995 and 1996 in the upper Sakarya river basin, Turkey.  
Cobalt concentrations ranged from 0.038 to 0.154 µg/g dry weight for Cyprinus caprio and from 0.045 to 
0.062 µg/g dry weight for Barbus plebejus (Barlas 1999). 
60Co was not detected in fish and mussel samples analyzed from the Peconic River system on Long 
Island, New York, downstream of the BNL.  The lower detection limit for 60Co was 0.4 Bq/kg 
(10 pCi/kg).  60Co had been detected in sediment samples from this area (Section 6.4.3) (Rapiejko et al. 
2001). 
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Some female birds sequester metals into their eggs under certain conditions, a phenomenon that may
jeopardize the developing embryos.  The geometric mean concentrations of cobalt in tern eggs collected 
from coastal New Jersey in 1971 and 1982 were 0.48 and 0.50 mg/kg, respectively.  Unlike the levels of 
seven other common metals (e.g., mercury, cadmium, copper, lead, manganese, nickel, and zinc), the 
level of cobalt in tern eggs (and in the environment) showed no decline over the 11-year period (Burger 
and Gochfeld 1988). 
Table 6-5 shows the levels of cobalt in food items and food categories from different countries.  The level 
of cobalt in most Canadian foods was low; items with the highest concentrations in this study were 
waffles (0.076 µg/g), corn cereal (0.074 µg/g), and potato chips (0.070 µg/g) (Dabeka and McKenzie 
1995). Green leafy vegetables and fresh cereals are the richest sources of cobalt (0.2–0.6 µg/g dry
weight), while dairy products, refined cereals, and sugar contain the least cobalt (0.1–0.3 µg/g dry weight) 
(Barceloux 1999). The levels of cobalt were determined in 50 different food items, mainly meat, fish, 
fruit, vegetables, pulses, and cereals on the Swedish market during the years 1983–1990 (Jorhem and 
Sundström 1993).  Beef liver and seeds were fairly high in cobalt and fish, fruit, and root and leafy
vegetables were under 0.01 µg cobalt/g fresh weight.  The cobalt levels in µg/g fresh weight were highest 
in alfalfa seeds, 0.86; linseed, 0.56; milk chocolate, 0.34; dark chocolate, 0.24; white poppy seeds, 0.30; 
blue poppy seeds, 0.15; soya beans, 0.084; green lentils, 0.054; and beef liver, 0.043.  The cobalt content 
of 20 brands of alcoholic and nonalcoholic beer widely consumed in Spain ranged from 0.16 to 0.56 µg/L 
with a median of 0.39 µg/L (Cameán et al. 1998).  Cobalt, which was at one time added to beer to 
increase the foam head, has been associated with cardiomyopathies (heart disease) in heavy beer drinkers. 
A study of radionuclide levels in various foods and drinks in Hong Kong found that the 60Co content in 
nearly all foods and drinks used in the study were below the minimal detection limit (Yu and Mao 1999).  
Analysis of wild plants in Bulgaria in villages near the “Kozloduy” nuclear power plant showed that the 
concentrations of 60Co were below the detection limit.  Mean activity concentrations of 60Co in edible 
plants in this region were mostly <0.04 Bg/kg (<1 pCi/kg) (Djingova and Kuleff 2002).   
Stable cobalt is present in various consumer products including cleaners, detergents, and soaps, which 
have resulted in dermatitis in sensitive individuals (Kokelj et al. 1994; Vilaplana et al. 1987).  Tobacco 
contains about <0.3–2.3 µg Co/g dry weight and approximately 0.5% of the cobalt appears in mainstream
smoke (Barceloux 1999; Munita and Mazzilli 1986; Ostapczuk et al. 1987; Stebbens et al. 1992). 
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Table 6-5. Cobalt Levels in Food 
Food item Level Unitsa Type Reference
Infant formulas/milk
Evaporated milk (n=21) 0.74, 0.52–2.6 µg/kgb Median, range Dabeka 1989
Ready-to-use formula (n=49) 0.53, 0.21–5.2 µg/kgb Median, range Dabeka 1989
Milk-based (n=33) 0.40, 0.21–0.99 
No added iron (n=6) 0.36, 0.21–0.61 
Added iron (n=27) 0.87, 0.41–0.99 
Soy-based (n=16) 2.27, 1.71–5.2 
Concentrated liquid formula (n=50) 2.27,0.25–11.8 µg/kgb Median, range Dabeka 1989
Milk-based (n=34) 1.57, 0.25–3.11 
No added iron (n=20) 1.06, 0.25–1.77 
Added iron (n=14) 2.59, 2.03–3.11 
Soy-based (n=16) 4.33, 2.7–11.8 
Powdered formula (n=64) 9.54, 2.6–53 µg/kgb Median, range Dabeka 1989
Milk-based (n=36) 4.96, 2.6–10.6 
No added iron (n=23) 4.24, 2.6–9.6
Added iron (n=13) 8.26, 5.1–10.6 
Soy-based (n=28) 20.0, 10.6–53
Agricultural crops
Cabbage, United States 0.2 mg/kgc Typical level NAS 1977 
Corn seed, United States 0.01 mg/kgc Typical level NAS 1977 
Fruits, 12 types, Poland 0.01–0.02 mg/kg Range Bulinski et al. 1986 
Lettuce, Sweden 1983–1990 (n=7) 0.002, 0.006 mg/kg Mean, Jorhem and 
maximum Sundström 1993 
Lettuce, United States 0.2 mg/kgc Typical level NAS 1977 
Onions, 11 Danish sites (n=110) 1.51, 0.119–5.1 µg/kg Median, range Bibak et al. 1998a 
Peas, 10 Danish sites (n=93) 4.6, 0.57–17 µg/kg Median, range Bibak et al. 1998b 
Potatoes, Sweden (n=8) 0.008, 0.017 mg/kg Mean, Jorhem and 
maximum Sundström 1993 
Spinach, United States 0.4–0.6 mg/kgc Typical range NAS 1977 
 Strawberries, Sweden (n=10) 0.004, 0.010 mg/kg Mean, Jorhem and 
maximum Sundström 1993 
Vegetables, 30 types, Poland 0.008–0.032 mg/kg Range Bulinski et al. 1986 
White flour, United States 0.003 mg/kgc Typical level NAS 1977 
Meat, fish, beverages
Beef, Sweden (n=3) 0.001, 0.001 mg/kg Range, Jorhem and 
maximum Sundström 1993 
Beef liver, Sweden (n=3) 0.043, 0.074 mg/kg Range, Jorhem and 
maximum Sundström 1993 
Beef kidney, Sweden (n=3) 0.008, 0.010 mg/kg Range, Jorhem and 
maximum Sundström 1993 
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Table 6-5. Cobalt Levels in Food 
Food item Level Unitsa Type Reference
Beer, Spain, 20 brands  0.39, 0.16–0.56 µg/L Median, range Cameán et al. 1998 
 Cocoa, Germany 1.31 mg/kgc Ostapczuk et al. 
1987 
Coffee (whole), South Africa 0.93 mg/kgc Horwitz and Van der 
Linden 1974 
Coffee (whole), Germany (61% 0.11–0.31 mg/kgc Range Ostapczuk et al. 
water extractable) 1987 
Fish, Sweden, 10 varieties (n=40) <0.001–.008, mg/kg Range of mean, Jorhem and 
0.020 maximum Sundström 1993 
Pork, Sweden (n=36) 0.001, 0.012 mg/kg Range, Jorhem and 
maximum Sundström 1993 
Pork liver, Sweden (n=36) 0.010, 0.023 mg/kg Range, Jorhem and 
maximum Sundström 1993 
Pork kidney, Sweden (n=36) 0.004, 0.011 mg/kg Range, Jorhem and 
maximum Sundström 1993 
Tea (whole), South Africa 0.2 mg/kgc Horwitz and Van der 
Linden 1974 
Tea (whole), Germany (40% water 0.18–6.7 mg/kgc Range Ostapczuk et al. 
extractable) 1987 
Food categories
Bakery good/ cereals, Canada 10.9, 75.7 µg/kg Median, Dakeba and 
(n=24) maximum McKenzie 1995
Beverages, Canada (n=7) 5.9, 9.1 µg/kg Median, Dakeba and 
maximum McKenzie 1995
Fats and oils, Canada (n=3) <2.6, 37.6 µg/kg Median, Dakeba and 
maximum McKenzie 1995
Fish, Canada (n=6) 18.6, 14.3–29.4 µg/kg Median, range Dakeba and 
McKenzie 1995
Fruits and fruit juices, Canada <6.6, 35.7 µg/kg Median, Dakeba and 
(n=25) maximum McKenzie 1995
Meat and poultry, Canada (n=18) <5.5, 38.2 µg/kg Median, Dakeba and 
maximum McKenzie 1995
Milk and milk products, Canada <1.4, 18.9 µg/kg Median, Dakeba and 
(n=13) maximum McKenzie 1995
Soups, Canada (n=4) 5.6, 8.5 µg/kg Median, Dakeba and 
maximum McKenzie 1995
Sugar and candy, Canada (n=7) <0.4, 3.5 µg/kg Median, Dakeba and 
maximum McKenzie 1995
Vegetables, Canada (n=38) 2.4, 18.1 µg/kg Median, Dakeba and 
maximum McKenzie 1995
aProduce on a fresh weight basis, unless otherwise specified 
bAs sold 
cDry weight basis
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
  
COBALT 246 
6. POTENTIAL FOR HUMAN EXPOSURE 
The cobalt content of sewage sludge, incinerator ash, fertilizers, soil amendments, and other substances 
appears in Table 6-6. The concentration of cobalt in U.S. coal averages about 5 mg/kg, levels in crude oil 
and fuel oil are 0.001–10 and 0.03–0.3 mg/kg, respectively, and those in gasoline are <0.1 mg/kg (Smith 
and Carson 1981).  Cobalt levels were below the detection limit of 0.05 ppm dry weight in all but 1 of 
26 samples of composted yard waste, sewage sludge, and municipal solid waste samples nationwide in 
1991. The one positive sample of composted yard waste contained 1.53 ppm of cobalt (Lisk et al. 1992). 
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE  
Exposure of the general population to cobalt occurs through inhalation of ambient air and ingestion of 
food and drinking water.  In general, intake from food is much greater than from drinking water, which in 
turn, is much greater than from air.  From the limited monitoring data available, the average concentration 
of cobalt in ambient air in the United States is approximately 0.4 ng/m3. However, levels may be orders 
of magnitude higher in source areas.  Therefore, intake to cobalt in air will vary substantially from
nonsource areas to areas with cobalt-related industries.  Similarly, the median cobalt concentration in U.S. 
drinking water is <2.0 µg/L; however, values as high as 107 µg/L have been reported in surveys of water 
supplies (Smith and Carson 1981).  Therefore, exposure from drinking water may vary considerably from
one location to another.  In Canada, the daily cobalt intake of the average adult from drinking water is 
≤2.6 µg; this could increase to 10 µg for those living in areas with the highest cobalt levels (Meranger et 
al. 1981).   
General population exposure to cobalt from food is highly variable and normally higher than intake from
drinking water.  Most of the cobalt ingested is inorganic; vitamin B12, which occurs almost entirely in 
food of animal origin, constitutes only a very small fraction of cobalt intake.  The cobalt intake in food 
has been estimated to be 5.0–40.0 µg/day (Jenkins 1980).  The daily cobalt intake, including food, water, 
and beverages of two men that were followed for 50 weeks was much higher, 310 and 470 µg (Smith and 
Carson 1981).  The estimated average daily cobalt intake from diet in Canada was 11 µg/day; the intake 
varied from 4 to 15 µg/day between the various age/sex groups (Table 6-7) (Barceloux 1999; Dabeka and 
McKenzie 1995).  The contributions of various food groups to cobalt intake in this study were (category,
contribution of dietary intake): bakery goods and cereals, 29.8%; vegetables, 21.9%; beverages, 9.8%; 
milk and milk products, 9.4%; meat and poultry, 9.1%; soups, 6.4%; fruit and fruit juices, 5.0%; sugar 
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Table 6-6. Cobalt Content of Miscellaneous Substances 
Substance/source Level Units Type Reference
Bituminous coal used for power 6.4 mg/kg Median Rubin 1999 
generation 
Coal, United States  ~5 mg/kg Mean Smith and Carson 1981 
Fly ash ~25 mg/kg Mean Smith and Carson 1981 
MSW Incinerator ash, Mississippi Buchholz and Landsberger 
1995 
Fly ash (n=30) 11.3–13.5 µg/g Range 
Bottom ash (n=30) 65.2–90.3 
Combined ash (n=30) 24.8–30.5 
MSW Incinerator ash, United States, 1987 Mumma et al. 1990 
Fly ash (n=5) 18.2–54.0 µg/g Range 
Bottom ash (n=7) 13.5–35.1 
Combined ash (n=8) 11.2–43.4 
Compost, Toronto Evans and Tan 1998 
Residential compost 8.1, 3.2–12 mg/kg Median, range 
Greenhouse finished compost 6.1±1.03 Mean ± SD
Sewage sludge
16 large U.S. cities 11.3, 6.08– mg/kg Median, range Gutenmann et al 1994 
29.1 
32 U.S. cities 7.2, 2.4– mg/kg Median, range Mumma et al. 1984 
30.1 
Cow manure (comparison)
Miscellaneous soil amendmentsa 
6.1 mg/kg Mumma et al. 1984 
Raven and Loeppert 1997
 Compost 3.55, 3.57 mg/kg Individual 
means 
Diammonium phosphate 3.24, 0.68 
Dolomite 0.33 
 Manure 2.23 
Monoammonium phosphate 0.78, 3.38 
Rock phosphate, Tilemsi  19.6 
Rock phosphate, North Carolina <0.08 
Sewage sludge, Austinite 4.10 
Sewage sludge, Milorganite 4.07 
 Triple superphosphate 6.61, 2.24 
Street dust, New York City 8.7–12.9 µg/g Range Fergusson and Ryan 1984
aThe rest of the 24 fertilizers and soil amendments tested were below the detection limit (typically <0.07 ppm) 
MSW = municipal solid waste; SD = standard deviation
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Table 6-7. Mean Daily Dietary Intake of Cobalt for Selected Population Groups in 

Canada 

Group Mean daily intake (µg/day) 
1–4 years 7 
5–11 years 10 
12–19 years; male 14 
12–19 years; female 10 
20–39 years; male 15 
20–39 years; female 9 
40–65 years; male 12 
40–65 years; female 9 
65+; male 10 
65+; male 8 
Source: Dabeka and McKenzie 1995 
  
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
   
 
 
COBALT 249 
6. POTENTIAL FOR HUMAN EXPOSURE 
and candies, 2.8%; fish, 2.7%; fats and oils, 2.2%; and miscellaneous, 1.1%.  The average daily intake of 
cobalt in France was estimated to be 29 µg/day (Biego et al. 1998). In this study, foods were divided into
nine categories. The foods accounting for the greatest contributions of cobalt intake were milk and dairy 
products, fish-crustaceans, and condiments-sugar oil, respectively contributing 32, 20, and 16% to the 
daily intake. The U.S. Department of Agriculture (USDA) conducted a special exploratory study in
1985–1986 to determine the concentration of trace metals in tissue of health livestock and poultry 
randomly selected from those slaughtered.  Between 0.6 and 5.9% of samples in the 11 production classes 
had levels of cobalt that exceeded the lowest reliable quantitation level of 0.15 ppm (0.15 mg/kg) and the 
mean of positive samples ranged from 0.20 to 0.23 ppm in all classes but heifer/steer, which had a level of 
1.92 ppm (Coleman et al. 1992).  Cobalt, which has been added to beer to increase the foam head, has 
been associated with cardiomyopathies (heart disease) in heavy beer drinkers.  However, according to a 
recent Spanish study, the low levels of cobalt presently found in beer do not make a significant 
contribution to the total cobalt intake in heavy beer drinkers (Cameán et al. 1998).  Smokers may be 
exposed to cobalt in mainstream smoke, but the level of exposure has not been assessed (Barceloux 
1999). 
Since cobalt and other heavy metals have been used on hand-painted china, a study was conducted to see 
whether these metals are released into food under acidic conditions.  Forty-six samples of porcelain 
dinnerware from Europe or Asia that were manufactured before the mid-1970s and had hand-painted 
designs over the glaze were filled with 4% acetic acid to within 7 mm of the rim and analyzed after 
24 hours (Sheets 1998).  Of these, 36 samples released <0.02 µg/mL of cobalt and 10 released 0.020– 
2.9 µg/mL.  The Food and Drug Administration (FDA) has not established dinnerware extraction limits 
for cobalt. 
Data are lacking on the levels of cobalt in tissues and fluids of the general populations in the United 
States; values from various countries are given in Table 6-8.  This table shows that cobalt concentrations 
are greatest in nail, hair, and bone.  The differences in cobalt levels in similar human tissues (e.g., hair, 
nail) in different countries may be due to differences in dietary and living habits and levels of cobalt in 
food (Takagi et al. 1988). The total amount of cobalt in the body of an adult as vitamin B12 is about 
0.25 mg, of which 50–90% in contained in the liver (IARC 1991).
A recent study in the United States determined the concentrations of trace metals in seminal plasma in 
industrial workers in a petroleum refinery, smelter, and chemical plant as compared with those of hospital  
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Table 6-8. Cobalt Levels in Human Tissues and Fluids 
Tissue or fluid Level Unitsa Type Reference 
Urine, U.S., NHANES, representative 
population (n=1007) 
0.36, 0.11–0.89 µg/L Geomean, 10th– 
90th percentile 
CDC 2001 
Urine, U.S., NHANES 1999–2000, 
Total, age 6 and older (n=2,465) 
0.372, 0.130–1.32 µg/L Geomean, 10th– 
95th percentile 
CDC 2003 
6–11 years (n=340) 0.498, 0.130–1.32 
12–19 years (n=719) 0.517, 0.200–1.52 
20 years and older (n=1,406) 0.339, 0.120–1.28 
 Males (n=1,227) 0.369, 0.150–1.01 
Females (n=1,238) 0.375, 0.120–1.49 
Mexican Americans (n=884) 0.415, 0.130–1.47 
Non-Hispanic blacks (n=568) 0.433, 0.160–1.45 
Non-Hispanic whites (n=822) 0.365, 0.120–1.29 
Urine, The Netherlands <0.2–1.2 µg/L Range Bouman et al. 
1986 
Urine, Sweden 0.5, 0.1–2.2 µg/L  Mean, range Alexandersson 
1988 
Urine, Denmark (3 reference groups) Poulsen et al. 1994 
Unexposed control females (n=46) 1.5, LOD–20.5 nmolb Mean, range
Unexposed males (n=12) 0.9, LOD–2.31 
Unexposed females (n=11) 5.9, LOD–25.02 
Urine, hip arthroplasty patients, 0.9–1.05 µg/L Range IARC 1991 
observed 7–15 years (n=17) 
Urine, hip arthroplasty patients, 3.8 µg/L Mean IARC 1991 
observed 5–15.5 years (n=10) 
Urine, 48 metal sharpening workers in 0–40.3, 86 µg/L Range of means, Imbrogno et al. 
12 Italian factories maximum 1994 
Urine, 12 female cobalt powder Ferdenzi et al. 
sintering workers, Italy 1994 
Monday, before shift 25, 1–51 µg/L Mean, range
Friday, before shift 29, 3–159 
Friday, end-of shift 85, 6–505 
After 3-week holiday 11, 4–34 
Urine, Italian workers wet grinding of Sesana et al. 1994 
hard metal tools (end of shift) 
Factory A no local exhausts (n=3) 138.3 (108), 123.7 µg/L Mean (SD) 
(74) Monday, Friday  
Factory B local exhausts (n=5) 15.3 (7.7), 24.4 
(14.1)
Factory C local exhausts (n=3) 48.2 (7.3), 74.7 
(13)
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Table 6-8. Cobalt Levels in Human Tissues and Fluids 
Tissue or fluid Level Unitsa Type Reference 
Urine, Northern Italy, 1991, Mosconi et al. 
occupational exposure survey, 1994 
314 exposed people 
Diamond abrasive production 

  Mould-filling 320, 587, 39– µg/L Median, mean, 

2,100 range 

Sintering 168, 193, 02–390 

  Grinding 61, 151, 34–520 

  Mechanical-working 50, 67, 143–165 

Grinding 15, 32, 0.8–730 

Tool production 12, 19, 0.8–100 

Hard metal alloy filling 5, 5, 0.8–18 

Other 1, 2.9, 0.8–72
 
Blood, Denmark, porcelain factory Raffn et al. 1988 
Plate painters, off work for 6 weeks 8.05, 1.70–22.1 nmol/L Mean, range
 
(n=46)
 
Plate painters, working 4 weeks 36.7, 3.40–407
 
(n=46)
Top glaze painters (unexposed) 4.04, <1.70–10.2 
(n=51)
Urine, Denmark, porcelain factory Raffn et al. 1988 
Plate painters, off work for 6 weeks 81.8, <1.70–445 nmol/L Mean, range
 
(n=46)
 
Plate painters, working 4 weeks 1,308, 37.4–
 
(n=46) 14,397 
Top glaze painters (unexposed) 16.0, <1.70–234 
(n=51)
Plasma, Sweden 0.1–1.2 µg/L Range Alexandersson 
1988 
Whole Blood, Denmark (3 Reference Poulsen et al. 1994 
groups) 
Unexposed control females (n=46) 4.1, <1.7–10.2 nmol/L Mean, range
Unexposed males (n=12) 3.1, <1.7–6.8
Unexposed females (n=11) 7.6, <1.7–30.5 
Lung, Sweden Gerhardsson et al. 
1988 
Rural 0.007 mg/kg Mean 
 Urban 0.011 
Liver Tissue, United Kingdom, 17.4±11.3 (15.9) ng/g mean±SD Patriarca et al. 
newborns and infants that died from wet (median) 1999 
SIDS (n=157) mass 
Liver, New Zealand (n=96) 0.120 mg/kg Mean IARC 1991 
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Table 6-8. Cobalt Levels in Human Tissues and Fluids 
Tissue or fluid 	 Level Unitsa Type Reference 
Tissue, Japan Yamagata et al. 
1962 
 Pectoral muscle 0.016 mg/kg Mean 
 Rib bone 0.036 
Stomach 0.021 
Liver 0.017 
Brain 0.0055 
 Urinary bladder 0.0055 
Kidney 0.012 
Aorta 0.021 
Nails Takagi et al. 1988 
 Canada (n=40) 0.09 mg/kg Mean 
 India (n=100) 0.06 
 Japan (n=252) 0.17 
 Poland (n=49) 0.04 
U.S. (n=71) 0.06 
Adipose tissue 0.035–0.078 mg/kg Range EPA 1986 
Hair Takagi et al. 1986 
 Canada (n=92) 0.043 mg/kg Mean 

 India (n=255) 0.051 

 Japan (n=457) 0.18 

Poland (n=46) 0.022 

United States (n=55) 0.047 

Hair, Italy Vienna et al. 1995 
Male biology students (n=20) 0.007, 0.001–0.07 mg/kg Geomean, range 
Female biology students (n=20) 0.017, 0.001–0.28 
Hair, Pakistan	 Ashraf et al. 1995 
Rural (n=28) 2.05, 0.10–4.80 mg/kg Mean, range
Urban (n=39) 3.86, 1.10–5.90 
afresh weight, unless otherwise specified 
bcreatinine basis
geomean = geometric mean; LOD = limit of detection; NHANES = Nation Health and Nutrition Examination Survey; 
SD = standard deviation; SIDS = sudden infant death syndrome 
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workers (control group). There were four groups each with 50 adult men.  The mean cobalt 
concentrations (µg/dL), including standard errors, were determined to be 31±2 (hospital workers), 
25±0.8 (metal ore smelter workers), 19±0.6 (petroleum refinery workers), and 22±1 (chemical workers) 
(Dawson et al. 2000).   
Surgical implants for knee and hip replacements often use cobalt-containing alloys, which may lead to 
elevated cobalt levels in body fluids.  Indeed, cobalt levels in serum and urine have been used as an index 
of prosthesis wear. In some cases, significant increases in cobalt levels have been observed, while in 
other cases, elevations were much lower or only sporadic (IARC 1991).  These differences have been 
ascribed to greater release rates from metal to metal than metal to polyethylene articular surfaces as well 
to differences in the cobalt-containing alloys. 
There are several reports of cobalt exposure among occupational groups.  The concentrations of cobalt in 
the air of hard metal manufacturing, welding, and grinding factories may range from 1 to 300 µg/m3, 
compared to normal atmospheric levels of 0.4–2.0 ng/m3 (Burr and Sinks 1989; Haddad and Zikovsky
1985; Koponen et al. 1982; Lichtenstein et al. 1975).  The maximum OSHA permissible level is 
100 µg/m3. The concentration of cobalt in the dust of an electric welding factory was 4.2 µg/g compared 
to its normal dust level of 0.1–1.0 µg/g (Baumgardt et al. 1986).  The higher rate of exposure to cobalt for 
occupational groups is also reflected in the higher cobalt content in tissues and body fluids of living and 
deceased workers in this group.  The levels of cobalt in the urine of workers in the hard metal industry
varied with the levels of cobalt concentration in the working atmosphere.  At a concentration of 
0.09 mg/m3, the urinary excretion of cobalt exceeded normal values by orders of magnitude.  When the 
cobalt concentration in the working atmosphere was 0.01 mg/m3 or lower, urinary cobalt excretion was 
4–10 times higher than normal level (Alexandersson 1988; Scansetti et al. 1985).  At high exposure 
levels, the cobalt concentration in blood was 20 times higher than normal; in the low exposure group, it 
was only slightly higher than in the control group (Alexandersson 1988).
An extensive survey of workers potentially exposed to cobalt in the Bergamo Province in northern Italy in
1991 identified 403 exposed workers in different production areas (Mosconi et al. 1994a).  Significant 
cobalt exposure occurred especially for operators working in diamond abrasive production, and in 
particular, in mold filling and sintering units where environmental limits are regularly exceeded.  
Exposure in tool production, tool sharpening, and hard metal alloy filling is much more restrained.  
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Occupational cobalt air levels and urinary excretion levels recorded in the survey appear in Tables 6-2 
and 6-8. 
Several studies of cobalt concentrations in air in the hard metal industry have been reported.  In the hard 
metal industry in Japan, Kumagai et al. (1996) found that mean 8-hour time weighted averages (TWAs) 
of airborne cobalt were >50 µg/m3 for workers involved in powder preparation (rotation), powder 
preparation (full-time), rubber press, and shaping operations; mean atmospheric concentrations were 459, 
147, 339, and 97 µg/m3, respectively.  Workers involved in the manufacture and maintenance of hard 
metal and stellite blades in Finland were exposed to breathing zone cobalt concentrations ranging from
2 to 240 µg/m3, with a geometric mean of 17 µg/m3 (Linnainmaa et al. 1996).  The average proportion of 
water soluble cobalt in airborne cobalt was 68% (range 14–100%).  Wet grinding was not sufficient to 
adequately control cobalt levels and coolant cobalt levels were high.  In a group of 12 factories in Italy in 
which 48 workers were tested who had been exposed to cobalt in operations such as sharpening with 
diamond grinding stones, the mean concentration of cobalt in air was 21.2 and 137.7 µg/m3 (Permissible 
exposure limit [PEL]-TWA 100 µg/m3) in work places with and without dust ventilation, respectively
(Imbrogno et al. 1994).   
Urine concentrations have been used to monitor workers' exposure to airborne cobalt.  Ferdenzi et al. 
(1994) obtained a correlation between Friday TWA air cobalt levels and Friday end-of-shift urine levels 
among women in the powder sintering industry.  Median urinary cobalt concentrations were 25 (range: 1– 
51) and 29 (3–159) µg/L, on Monday and Friday before the shift, respectively, and 85 (6–505) µg/L on 
Friday after the shift. Imbrogno and Alborghetti (1994) evaluated the levels of occupational exposure to 
cobalt during dry and/or wet hard metal sharpening.  The mean urine cobalt level in the workers in 
12 factories was found to range from 0 to 40.3 µg/L and the maximum was 86 µg/L.  The average urinary
cobalt level among workers using wet/mixed sharpening methods was 4 times higher than those using dry
sharpening methods; 21.38 µg/L as compared to 5 µg/L, respectively.  Gallorini et al. (1994) found that 
the ratio of inorganic to organic cobalt in the urine of hard metal workers was 2.3 compared to 1.01 in 
controls; the ratio was constant over the range of urinary cobalt levels analyzed (180–1,254 µg/L).  
Exposure to cobalt during the wet grinding of hard metal tools (Widia tools) used in the wood industry
produced exposure to cobalt above the PEL-TWA of 100 µg/m3 (Sesana et al. 1994).  However, exhausts 
near the grinding wheels were shown to substantially reduce exposure levels (see Table 6-8). In the 
processing department of a small company producing carbide tip saw blades for the woodworking 
industry, area air sampling showed that exposure levels were low in all departments except tip grinding
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where wet and dry tip grinding areas contained 55 and 21 µg/m3 of cobalt, respectively, for the total 
collection method (Stebbins et al. 1992).  For the method collecting respirable particles, cobalt levels 
ranged from 2 to 28 µg/m3. Wet grinding is a traditional method for controlling dust during grinding.  
However, some coolants may contain significant concentrations of cobalt (in this case, 61–538 mg/mL) 
that can contribute to exposure during grinding (Stebbins et al. 1992).  Among cobalt blue dye plate 
painters in a porcelain factory in Denmark, the blood and urine cobalt levels were, respectively, 2–4 and 
5–15 times higher than in control groups (Raffn et al. 1988).  Similarly, lungs taken from deceased, 
occupationally exposed workers also had higher levels of cobalt than lungs from control groups.  Lungs 
of deceased hard metal industry workers in Sweden contained 2.5–4 times higher levels of cobalt than 
control lungs (Gerhardsson et al. 1988).  Similarly, the lungs of coal miners from England contained 
6 times higher cobalt levels than control lungs (Hewitt 1988). 
Exposure to radioactive cobalt can occur through various means.  Workers at nuclear facilities, irradiation 
facilities, or nuclear waste storage sites may be accidentally exposed to radioisotopes of cobalt.  Also, 
workers using cobalt isotopes in tracer studies, in calibration or other devices, or 57Co in Mössbauer 
spectroscopy, may be exposed to radioactive cobalt.  Exposure would generally be to radiation produced 
by these isotopes (e.g., gamma radiation from 60Co). Patients receiving 60Co radiotherapy will obviously
be exposed to its radiation.  According to the USNRC (1999), the collective intake of 60Co by ingestion 
and inhalation at power reactors in 1998 was 352 µCi (13 MBq) for 25 intake records and 27,000 µCi 
(1,000 MBq) for 281 intake records (USNRC 1999).  The collective intake at fuel fabrication facilities 
was 0.486 µCi (0.180 MBq) for 502 intake records.  The USNRC occupational inhalation annual limits of 
intake (ALIs) for 60Co are 200 µCi (7.4 MBq) for all compounds, except oxides, hydroxides, halides, and 
nitrates, and 30 µCi (1.1 MBq) for compounds of oxides, hydroxides, halides, and nitrates (USNRC 
2001k).   
6.6 EXPOSURES OF CHILDREN  
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in 3.8 Children’s Susceptibility. 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
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larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age: from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993). 
As with adults, most children are exposed to cobalt largely through their diet.  Dabeka and McKenzie 
(1995) estimated that the dietary cobalt intake by Canadian children ages 1–19 ranged from 7 to 
14 mg/day (see Table 6-7).  Milk constitutes a larger part of children’s diets than that of adults, and 
infants may consume infant formula.  Cobalt concentrations ranging from 0.3 to 0.8 ng/g in cow’s milk 
were reported by Iyengar (1982).  The levels of cobalt in human milk from Nigeria, Zaire, Guatemala, 
Hungary, Philippines, and Sweden ranged from 150 (Hungary) to 1,400 ng/g (Philippines), median 
320 ng/g (Nriagru 1992).  Garg et al. (1993) reported much lower cobalt levels in three samples of human 
milk in India, 2.42 ng/g, and reported a cobalt concentration of 5.07 ng/g in cow’s milk in India.  Dakeba 
(1989) determined cobalt levels in various infant formulas (see Table 6-5).  Milk-based infant formulas 
and evaporated milk contained <1 ng/g of cobalt on a “ready-to-use” basis.  Milk-based formulas with 
added iron contained about twice the cobalt as those with no added iron and soy-based formulas contained 
about 5 times more cobalt.  The influence of added iron suggests that the cobalt in formula is not 
primarily from vitamin B12. Using literature values of cobalt in food, Dakeba also estimated that infants 
0–12 months old ingest an average of 0.52 µg Co/kg-day (3.93 µg/day) from food and water and that for
an infant, 0–12 months old, the total dietary cobalt intake would range from 0.42 µg/kg-day (3.39 µg/day) 
for a breast or milk-based formula fed infant to 1.0 µg/kg-day (7.33 µg/day) for an infant fed soy-based 
formula powder.  The recommended dietary allowance for Canadian infants is 0.012 µg/day cobalt as 
vitamin B12. In a 1967 study of the total dietary intake of some trace elements, excluding drinking water, 
of institutionalized children aged 9–12 in 28 U.S. cities, cobalt intake ranged from 0.297 to 1.767 mg/day
with a mean value of 1.024 mg/day (Murthy et al. 1971). 
Exposure to stable cobalt in communities near mining and smelting facilities or metal shops where cobalt 
is used in grinding tools is a public health concern, especially for infants and children.  Since cobalt 
remains in the surface soil indefinitely and long past land uses may be forgotten, people may not realize 
that they are living in areas where high levels of cobalt may occur in soil.  Contaminated soils pose a 
particular hazard to children because of both hand-to-mouth behavior and intentional ingestion of soil that 
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contain metals and other contaminants (Hamel et al. 1998).  In these communities, cobalt may have been 
tracked in from outdoors and contaminate carpeting.  Cobalt-containing dust may be brought home in the 
clothing of parents working in industries where they are exposed to cobalt.  Children may be exposed to 
this cobalt while crawling around or playing on contaminated carpeting.  Exposure may also result from
dermal contact with soil, or by inhaling dust and then swallowing it after mucociliary transport up out of 
the lungs. Because there is little absorption of cobalt through the skin following dermal exposure, and 
because much of the cobalt in soil is embedded in or adsorbed to soil particles or insoluble, it may not be 
in a form accessible for uptake by the body, and therefore may not pose a serious health hazard.   
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
In addition to workers in the hard metal industry (tool production, grinding, etc.) and industries such as 
coal mining, metal mining, smelting and refining, cobalt dye painters, and the cobalt chemical production, 
the general population living near these industrial sites may be exposed to high levels of cobalt in air and 
in soil. Exposure to cobalt during the wet grinding of hard metal tools is especially high when local 
exhausts are not in use (Sesana et al. 1994).  People living near hazardous waste sites may be exposed to 
cobalt by inhaling dust from contaminated sites or through dermal contact with cobalt-contaminated soil.  
In the case of children playing in and around unrestricted landfill sites, exposure via dermal and ingestion 
routes is possible. The general populations in agricultural areas that use sewage sludge or cobalt-
containing fertilizers or other soil amendments may be exposed to higher levels of cobalt via inhalation of 
dust or dermal contact with the soil.  However, no experimental evidence of higher than normal exposures 
for these population groups was found in the literature.  People who live in areas that naturally contain 
higher levels of cobalt minerals may also be exposed to higher levels of cobalt from both the inhalation 
and dermal contact routes. 
The higher exposure of cobalt in patients with cobalt-chromium knee implants has been demonstrated by
the slightly higher levels of cobalt in whole blood, serum, and urine, and by very high levels of cobalt in 
bone of these patients (IARC 1991; Ostapczuk et al. 1985; Sunderman et al. 1989).  Prosthetic devices 
that contain polyethylene components to avoid metal-to-metal contact do not appear to cause elevated 
levels of cobalt in tissues and body fluids (IARC 1991; Ostapczuk et al. 1985; Sunderman et al. 1989).  
People who use cobalt supplements as a treatment for anemia and those who take large amounts of 
vitamin B-12 as a dietary supplement would have higher intakes of cobalt than the general population. 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
    
COBALT 258 
6. POTENTIAL FOR HUMAN EXPOSURE 
Workers at nuclear facilities and nuclear waste storage sites may be exposed to potentially high levels of 
radiation exposure from 60Co and 58Co. Workers at irradiation facilities using 60Co may be exposed to 
potentially high levels of gamma radiation exposure from this isotope.  Patients receiving 60Co 
radiotherapy will intentionally be exposed to high levels of gamma radiation. 
6.8 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of cobalt is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of cobalt.  
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
6.8.1 Identification of Data Needs 
Physical, Chemical and Radiological Properties.    As can be seen from Table 4-2 and 
Section 4.2, the relevant physical and chemical properties of cobalt and its compounds are sufficiently
known to enable prediction of environmental fate and transport of cobalt compounds (Budavari 1996; 
Lide 1994; Stokinger 1981; Weast 1985).  Information on the radiological properties of important cobalt 
isotopes are also well known (see Table 4-3) (ICRP 1983; Lide 1994).  No data needs were identified. 
Production, Import/Export, Use, Release, and Disposal. Information on the production, 
import/export, use, release, and disposal of a chemical is important because it is an indicator of possible 
environmental contamination and human exposure.  Large releases and consumer use would indicate 
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higher general population exposure from environmental sources (e.g., air, drinking water, and food) and 
use of consumer products. Occupational exposure may also increase with increased production and use.  
U.S. production of cobalt is derived primarily from scrap (secondary production).  Information is 
available on cobalt consumption derived from secondary production, import/export, and release of cobalt 
from the National Defense Stockpile (USGS 1998, 1999, 2002).  However, production volumes of 
individual cobalt compounds are not available and information on the production of individual 
compounds would be useful in assessing exposure to specific cobalt compounds.  Radioactive cobalt 
isotopes, primarily 60Co and 57Co, are not commercially produced in the United States, but rather are 
imported from Canada and the United Kingdom; consumption amounts are not available.  Information on 
the uses of cobalt is available (Cobalt Development Institute 2004; Donaldson 1986; Hodge 1993; IARC 
1991; Richardson 1993; USGS 1998, 2002).  Cobalt-containing products are mostly used in the 
workplace, although some consumer products contain cobalt.  
According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C.
Section 11023, industries are required to submit chemical release and offsite transfer information to the 
EPA. The TRI for 2001 is currently available (TRI01 2004).  Starting in 1998, metal mining, coal 
mining, electric utilities, and RCRA/solvent recovery industries were required to report to the TRI.  These 
sectors include those contributing greatest environmental releases of cobalt and cobalt compounds, giving 
us a much more complete picture of cobalt releases to the environment.  The TRI also contains 
information on the onsite and offsite disposal and management of wastes (e.g., recycling, treatment, 
transfer to publicly owned treatment works [POTWs]).  EPA guidelines address the disposal of hazardous 
cobalt wastes. The TRI database will be updated yearly and provides a list of industrial production 
facilities and emissions.  The TRI data should be used with caution since the 1987 data represent first-
time reporting by these facilities.  Only certain types of facilities were required to report.  This is not an 
exhaustive list. 
Environmental Fate. There are data that permit assessment of the environmental fate and transport of 
cobalt in water and soil (Section 6.3).  Frequently, sediment and soil are the ultimate sinks for cobalt; 
however, this process is dynamic, and cobalt can be released into the water depending upon conditions.  
There is a paucity of data in the literature regarding the chemical forms of cobalt released to the 
atmosphere and their transformations in air and this information would facilitate the determination of the 
transport and persistence of cobalt in the atmosphere.  Additional data elucidating the mode of speciation 
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of cobalt in water and soil would also be desirable.  For example, under what circumstances Co(III) 
compounds might be formed in the environment and how long. 
Bioavailability from Environmental Media.    Absorption by the inhalation and oral routes in 
humans has been studied, but the results vary considerably (see Section 3.5.1) (Foster et al. 1989; Harp 
and Scoular 1952; Sedlet et al. 1958; Sorbie et al. 1971; Valberg et al. 1969).  These variations were 
attributed to differences in the types and doses of cobalt compounds given, to the nutritional status of the 
subjects following oral exposure, and to particle size differences following inhalation exposure.  
Additional data assessing the absorption of cobalt following soil ingestion by children may be helpful.  
Data in animals are plentiful for both inhalation and oral routes and correlate well with the human data 
(Andre et al. 1989; Bailey et al. 1989; Collier et al. 1989; Kreyling et al. 1986; Patrick et al. 1989; Talbot 
and Morgan 1989).  Data in animals following dermal exposure suggested that cobalt is not absorbed well 
through intact skin, but is rapidly taken up through damaged skin.  Data regarding the bioavailability of 
cobalt following dermal exposure are important because dermal exposure to cobalt in the workplace is 
probable. 
Food Chain Bioaccumulation. Bioaccumulation in the food chain is important in assessing the 
human exposure to cobalt from the consumption of food.  Data are available that indicate that cobalt is 
not taken up appreciably by plants and does not biomagnify up the food chain (Baudin and Fritsch 1987; 
Baudin et al. 1990; Boikat et al. 1985; Francis et al. 1985; Kloke et al. 1984; Lux et al. 1995; Mascanzoni 
1989; Mejstrik and Svacha 1988; Mermut et al. 1996; Palko and Yli-Hala 1988; Smith and Carson 1981; 
Tolle et al. 1983; Watabe et al. 1984). 
Exposure Levels in Environmental Media. Monitoring data on levels of cobalt in air, water, and 
food permits the estimation of exposure from these sources.  Data are available on the cobalt levels in 
ambient air (Golomb et al. 1997; Hasanen et al. 1990; Schroeder et al. 1987; Smith and Carson 1981; 
Sweet et al. 1993; Wiersema et al. 1984).  However, the data are not sufficiently recent or broad-based for 
estimating the current levels of exposure to cobalt in the general U.S. population and particularly those 
living near cobalt-containing hazardous waste sites.  In addition, in only isolated studies was there an 
assessment of the concentration of cobalt associated with coarse and fine particles (Sweet et al. 1993) or 
an average annual level obtained at a site (Golomb et al. 1997).  Similarly, levels of cobalt in ambient 
water, while generally low, are also not sufficiently broad-based or recent to be satisfactory (Bargagli 
2000; Bruce and McMahon 1996; Cassidy et al. 1982; Eckel and Jacob 1988; Flaten 1991; Nojiri et al. 
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1985; Rossmann and Barres 1988; Smith and Carson 1981). This deficiency may be satisfied when the 
EPA’s improved and updated STORET database becomes available.  Cobalt levels in Canadian drinking 
water are ≤2.0 mg/L (Meranger et al. 1981).  However, U.S. drinking water levels have not been reported 
and would be useful.  The levels of cobalt in sediment are available (Bargagli 2000; Coakley et al. 1993;
Gibbs 1994; Glooschenko et al. 1981; Knutson et al. 1987; Naidu et al. 1997; Shine et al. 1995; Smith and 
Carson 1981; Trocine and Trefry 1996; Villanueva and Botello 1998), but more data on levels in soil and 
in the vicinity of industrial and hazardous waste sites would be useful.  Few data on the levels of cobalt in 
U.S. foods are available, although studies from Canada and Sweden are available that indicate that cobalt 
levels in food items are generally low (Barceloux 1999; Dabeka and McKenzie 1995; Jorhem and 
Sundström 1993).  In particular, total diet studies of cobalt in U.S. food is lacking.  A Canadian total diet 
study estimated average daily cobalt intake to range from 7 to 15 µg/day for different age-sex groups 
(Dabeka and McKenzie 1995). 
Few data are available on levels of 60Co and other cobalt isotopes in environmental media. 
Exposure Levels in Humans. The levels of cobalt in hair, nail, and adipose tissues of the general 
U.S. population are known (EPA 1986; Takagi et al. 1986, 1988).  No reliable data on the levels of this 
substance in blood (or plasma) and urine of the general U.S. population were found, although such data 
are available for certain European populations including occupationally-exposed groups (Table 6-8).  
These data may be important for establishing the background exposure level of cobalt.  No data on the 
levels of cobalt in any body tissue or fluid for populations living near hazardous waste sites are available.  
Such data would be important in assessing the exposure levels of this group of people. 
Exposures of Children.    Dabeka (1989) reported the levels of cobalt in various formulas and milk 
products consumed by children in Canada, and Dabeka and McKenzie (1995) determined the mean 
dietary intake of Canadian children as young as 1–4 years of age.  Nriagru (1992) reported levels of 
cobalt in human milk from several countries.  No analogous U.S. studies were found.  Cobalt levels is the 
tissue and body fluids of children have not been found. 
Child health data needs relating to susceptibility are discussed in 3.13.2 Identification of Data Needs: 
Children’s Susceptibility. 
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Exposure Registries. No exposure registries for cobalt were located. This compound is not 
currently one of the compounds for which a subregistry has been established in the National Exposure 
Registry.  The compound will be considered in the future when chemical selection is made for 
subregistries to be established. The information that is amassed in the National Exposure Registry
facilitates the epidemiological research needed to assess adverse health outcomes that may be related to 
the exposure to cobalt and its compounds. 
6.8.2 Ongoing Studies 
The Federal Research in Progress (FEDRIP 2002, 2004) database provides additional information 
obtainable from a few ongoing studies that may fill in some of the data needs identified in Section 6.8.1.
These studies are summarized in Table 6-9. 
Remedial investigations and feasibility studies conducted at the NPL sites known to be contaminated with 
cobalt, such as the Blackbird Mine in Idaho, will add to the available database on exposure levels in 
environmental media, exposure levels in humans, and exposure registries, and will increase the current 
knowledge regarding the transport and transformation of cobalt in the environment.   
The Cobalt Development Institute (CDI) is implementing a research program to assess environmental 
risks posed by the manufacture and use of cobalt and cobalt compounds.  Studies that are underway
include the assessment of seasonal and background variability of cobalt compounds in aquatic 
environment and a literature survey for existing data on the effects of cobalt and cobalt compounds in 
soils and sediment. Environmental studies proposed for 2002 included the assessment of seasonal and 
background variability of cobalt compounds in soils and sediments and a literature survey for existing 
data on the effects of cobalt and cobalt compounds on marine environments. 
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Table 6-9. Ongoing Studies on Cobalt 
Investigator Affiliation Research description Sponsor
Hamilton, JW Dartmouth College, 
Hanover, New 
Hampshire 
The overall goal of the Dartmouth Superfund Basic 
Research Program (SBRP) Project, Toxic Metals in 
the Northeast: From Biological to Environmental 
Implications is to determine the impact of toxic metals 
found at waste sites, including Superfund sites on 
human health and the environment.  The program-
wide focus of this research program is on toxic 
metals, particularly on arsenic, and also chromium, 
nickel, cadmium, mercury, cobalt, and lead.  
NIH 
Jones, BT Wake Forest
University, Winston-
Salem, North 
The investigators developing a novel, low-cost, 
portable instrument for the simultaneous 
determination of trace radioactive elements in nuclear 
NSF 
Carolina forensic samples.  At issue is the routine, inexpensive 
sampling for radioactivity that could be released on 
transport or storage of potential "dirty bomb" material.  
The instrument to be developed is expected to 
provide analytical figures comparable to inductively 
coupled plasma mass spectrometry, but the 
instrument is much lower cost and more portable.  
The specific objectives of the project include 
determination of the analytical figures of merit for 
elements including cobalt, cesium, and strontium, and 
analysis of real samples such as soil, urban dust, 
water and agricultural materials. 
Kpomblekou-
Ademawou, K 
Ankumah, RO
Tuskegee University, 
Tuskegee, Alabama 
This project will investigate if excessive accumulation 
of some trace elements, added to poultry diet and 
excreted through feces, affects nitrogen 
transformation in broiler (chicken) litter amended soils 
and if this compromises safe food and feed 
production.  The goals of this work are (1) to study 
the effects of concentrations of key trace elements 
(e.g., As, Cd, Co, Cr, Cu, Mn, Ni, Pb, Se, and Zn) 
found in broiler litter on nitrogen transformation in 
litter amended soils, (2) to assess the effects of
temperature on the nitrogen transformation in the 
presence of trace elements and (3) to assess the fate 
of trace elements in sudax (Sorghum bicolor) grown 
in trace element-enriched broiler litter amended soils.  
USDA 
Longnecker, M NIEHS, NIH Evaluate the use of toenail levels as a measure of 
exposure by analyzing toenail and whole-diet 
homogenates by neutron activation analysis.  
Toenails reflect exposure over a longer period of time 
than do blood or urine measures, and are less likely 
to be influenced by contamination than hair. 
NIEHS 
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Table 6-9. Ongoing Studies on Cobalt 
Investigator Affiliation Research description Sponsor
Saito, MA Woods Hole This research will examine the influence of cobalt and NSF 
Oceanographic 
Institution, Woods 
Hole, MA 
cadmium speciation on Synechococcus and 
Crocosphaera at two sites in the Pacific Ocean.  In 
addition, the distribution of cobalt across transects in
the Eastern Equatorial Pacific will be determined to 
improve understanding of the global biogeochemical 
cycle of cobalt.   
Tavlarides, LL Syracuse University, 
Syracuse, New York
This work will be towards the development of sol-gel 
synthesis methods for organo-ceramic adsorbants for 
the extraction of toxic and valuable metal ions, such 
NSF 
as cobalt, chromium, and arsenic ions from aqueous 
streams.
NIEHS = National Institute of Environmental Health Sciences; NIH = National Institute of Health; NSF = National 
Science Foundation USDA = U.S. Department of Agriculture; USDOE = U.S. Department of Energy
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The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring cobalt, its metabolites, and other biomarkers of exposure and effect to 
cobalt. The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is to 
identify well-established methods that are used as the standard methods of analysis.  Many of the 
analytical methods used for environmental samples are the methods approved by federal agencies and 
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other 
methods presented in this chapter are those that are approved by groups such as the Association of 
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).  
Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits and/or to improve accuracy and precision. 
7.1 BIOLOGICAL MATERIALS  
Entry of cobalt and its radioisotopes into the human body can be gained through ingestion, inhalation, or 
penetration through skin. The quantities of cobalt within the body can be assessed through the use of 
bioassays that are comprised of either in vivo and/or in vitro measurements. In vivo measurements can be 
obtained through techniques that directly quantitate internally deposited cobalt using, for example, whole 
body counters.  These in vivo measurement techniques are commonly used to measure body burdens of 
cobalt radioisotopes (i.e., 60Co), but cannot be used to assess the stable isotope of cobalt (59Co). Instead, 
in vitro measurements provide an estimate of internally deposited cobalt (both the stable and radioactive 
isotopes), utilizing techniques that measure cobalt in body fluids, feces, or other human samples.  
Examples of these analytical techniques are given in NRCP Report No. 87 (1987) and are also listed in 
Tables 7-1 and 7-2. 
7.1.1 Internal Cobalt Measurements 
In vivo measurement techniques are the most direct and widely used approach for assessing the burden of 
cobalt radioisotopes within the body.  The in vivo measurement of these radioisotopes within the body is  
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Table 7-1. Analytical Methods for Determining Stable Cobalt in Biological 

Materials 

Sample Analytical Sample Percent 
matrix Preparation method method detection limit recovery Reference
Urine Direct injection 
Addition of magnesium 
nitrate and nitric acid matrix
modifiers and equal volume
dilution of sample with 
water 
Sample chelated with 
dithiocarbamic acid
derivative, solvent 
extracted 
Sample wet digested with 
acid and chelated with 2,3­
butanedion dioxide and 
complex preconcentrated 
at hanging mercury drop 
electrode 
Direct injection 
Whole Sample diluted with a 
blood homogenizer 
Sample wet digested with 
acid and chelated with 
2,3-butanedion dioxine and
complex preconcentrated 
at hanging mercury drop 
electrode 
 Sample acid digested, 
complexed with thiocyanate 
and N-phenylcinnamo­
hydroxamic acid and ex­
tracted into ethyl acetate 
Serum Direct injection 
GF-AAS with 
Zeeman back­
ground correction 
GF-AAS with 
Zeeman back­
ground correction 
GF-AAS with 
Zeeman back­
ground correction 
DPCSV 
GF-AAS with 
Zeeman back­
ground correction 
GF-AAS with D2 
background 
correction 
DPCSV 
Colorimetric
GF-AA with 
Zeeman back­
ground correction 
0.3 µg/L 
2.4 µg/L 
0.1 µg/L 
0.2 µg/L 
0.1 µg/L 
2 µg/L 
0.8 µg/L 
0.15 mg/L 
0.02 µg/L 
101% at Bouman et al. 
40µg/L 1986 
107.6% at Kimberly et al. 
50 µg/L 1987 
No data 	 Alexandersson 
1988; Ichikawa 
et al. 1985 
No data 	 Heinrick and 
Angerer 1984
No data 	 Sunderman et
al. 1989 
No data 	 Heinrick and 
Angerer 1984
No data 	 Heinrich and 
Angerer 1984
No data 	 Afeworki and 
Chandravanshi 
1987 
No data 	 Sunderman et
al. 1989 
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Table 7-1. Analytical Methods for Determining Stable Cobalt in Biological 

Materials 

Sample Analytical Sample Percent 
matrix Preparation method method detection limit recovery Reference
Blood or Acid digestion ICP-AES (NIOSH 10 µg/g 81% at NIOSH 1984
tissue method 8005) (blood); 110 µg/L 
0.2 µg/g (blood) 
(tissue)
D2 = deuterium; DPCSV = differential pulse cathodic stripping voltammetry; GF-AAS = graphite furnace atomic 
absorption spectrometry; ICP-AES = inductively coupled plasma-atomic emission spectrometry; NIOSH = National 
Institute for Occupational Safety and Health
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Table 7-2. Analytical Methods for Determining Radioactive Cobalt in Biological 

Samples 

Sample 
matrix Preparation method
Analytical 
method
Sample 
detection limita 
Percent 
recovery Reference
Urine Direct count of sample γ-spectrometry 
with NaI detector 
No data (<MDL) No data Miltenberger
et al. 1981 
Soft 
tissue 
Sample wet-ashed γ-spectrometry 
(NaI) 
No data No data Baratta et al. 
1969 
Sample directly counted in 
detector 
γ-spectrometry 5 pCi/g No data Rabon and 
Johnson 1973
Sample digested in acid, 
oxidized with HClO4, con­
centrated by precipitation 
with AMP, purified by resin
column, precipitated with 
hexachloroplatinic acid  
-counter 0.1 pCi/g 40–85% Nevissi 1992
Feces Direct count of sample γ-spectrometry No data No data Smith et al. 
1972 
Blood Red cells separated from 
plasma and washed  
γ-spectrometry 
with NaI detector 
No data No data Smith et al. 
1972 
a1 Bq=2.7x10-11 Ci=27 pCi 
AMP = ammonium molybdophosphate; MDL = minimum detectable level; NaI = sodium iodide 
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performed with various radiation detectors and associated electronic devices that are collectively known 
as whole body counters. These radiation detectors commonly utilize sodium iodide (NaI), hyperpure 
germanium, and organic liquid scintillation detectors to measure the 1,172 and 1,332 keV gamma rays
from the decay of 60Co. Because of the relatively low attenuation of the high energy gamma rays emitted 
from 60Co by most tissues, cobalt radioisotopes can easily be detected and quantified using whole body 
counting techniques (Lessard et al. 1984; NCRP 1987; Raghavendran et al. 1978; Smith et al. 1972; Sun 
et al. 1997). Many configurations of the whole body counter and scanning methods have been utilized, 
ranging from unshielded single-crystal field detectors to shielded, multi-detector scanning detectors 
(IAEA 1962, 1970, 1972, 1976, 1985; NCRP 1987).  Where appropriate, shielding of the room that 
houses the whole body counter and/or the detector is often used to increase the detection sensitivity of the 
equipment by minimizing background radiation.  Additionally, care must be exercised to insure that 
external contamination with radioactive cobalt or other gamma-emitting radioisotopes on the clothing or 
skin of the individual to be scanned has been removed.  Also, in vitro measurements of cobalt (see 
Section 7.1.2) are often used in conjunction with whole body counting when monitoring individuals 
working with cobalt, especially in conjunction with the assessment of individuals who have experienced 
accidental exposures to cobalt (Bhat et al. 1973). 
Calibration of whole body counters is achieved through the use of tissue-equivalent phantoms. These 
phantoms are constructed to mimic the shape and density of the anatomical structure using tissue 
equivalent materials such as water-filled canisters or masonite (Barnaby and Smith 1971; Bhat et al. 1973; 
Sun et al. 1997). For example, the bottle mannequin absorber (BOMAB) consists of a series of water-
filled polyethylene canisters constructed into seated or reclined human forms (Sun et al. 1997).  60Co 
standards are measured either as point sources along the phantom or dissolved within the water-filled 
canisters. Comparisons of the actual counts obtained from the phantom to the known activity of the 
cobalt standards are used to determine the efficiency of the counting technique and, thus, provide the 
basis for calibrating the technique.  Even so, differences in whole body measurement techniques, 
calibration methods, and background radiation count calculations between different laboratories can 
complicate the direct comparisons of body burden measurements and clearance rates for cobalt 
radioisotopes and should be taken into consideration when comparing data obtained from independent 
laboratories. 
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7.1.2 External Measurements 
In vitro analyses of cobalt are routinely performed in situations where in vivo analyses can not be 
obtained or in support of an in vivo monitoring program.  Urine and feces are the preferred samples for in 
vitro analyses of cobalt, although other sample types, such as tissue, bone, or blood, can also be used on a 
more limited basis.  Urine provides for an analysis of soluble (inorganic) cobalt, fecal analysis can be 
used to assess the cobalt (organic) that is eliminated into the gut or the fraction of ingested cobalt not 
absorbed by the gut, and tissue/blood/bone are used to assess whole or regional body burdens of cobalt 
(NCRP 1987; Smith et al. 1972). 
The analytical methods for determining the stable cobalt isotope, 59Co, in biological matrices are given in 
Table 7-1. For accurate determination of cobalt, contamination of samples during sample collection, 
storage, and treatment must be avoided, particularly for biological samples containing low levels of 
cobalt. Cobalt contamination in blood samples has been reported from disposable syringes and technical-
grade anticoagulants. Menghini needles, often used for liver biopsy, and mortar, pestles, and grinding
devices used for homogeneous mixing may contaminate samples.  Other sources of contamination may be 
collection and storage containers and chemical reagents used for preparing samples.  In fact, sample 
contamination was responsible for erroneous reports in the earlier literature of grossly high levels of 
cobalt in biological specimens of unexposed persons.  Therefore, blanks should always be run with the 
samples.  
The commonly used classical methods for determining stable cobalt in biological samples are 
polarographic and colorimetric methods.  Details about these methods are given by Saltzman and Keenan 
(1957). Since these older methods have interference problems and are unsuitable for determining low 
levels of cobalt in many biological samples, the samples are pretreated before quantification.  
Precipitation, chelation, chromatography, and ion-exchange are some of the methods used for this 
purpose. In recent years, the two single-element instrumental techniques most frequently used methods 
for determining cobalt are graphite furnace-atomic absorption spectrometry (GF-AAS) (also called 
electrothermal atomic absorption spectrometry) and differential pulse anodic stripping voltammetry
(DPAVS). Multi-element techniques commonly used for cobalt determination are neutron activation 
analysis and inductively coupled plasma-atomic emission spectrometry (ICP-AES).  Several other 
methods are available for determining stable cobalt in biological samples; these include x-ray
fluorescence and Spark source mass spectrometry (Adeloju et al. 1985; Smith and Carson 1981). 
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For the in vitro analysis of cobalt radioisotopes in human samples, the majority of the analytical methods 
measure the cobalt radioisotopes directly in the samples, without the requirement for an extensive sample 
preparation procedure, using gamma spectrometry techniques.  Of the cobalt radioisotopes that have been 
detected in the environment (e.g., 57Co, 58Co, and 60Co), 60Co is the most common.  Consequently, most of 
the analytical methods that will be described in this chapter are those developed for the detection and 
quantitation of 60Co in biological (see Table 7-2) and environmental samples (see Table 7-4). 
The radiochemical analysis of 60Co in urine has been used in conjunction with whole body scanning
methods to assess acute and long-term body burdens of this isotope.  The analysis of 60Co in urine is the 
same as that described for a standardized method of analysis of cesium radioisotopes in urine (Gautier 
1983).  A urine sample of approximately 2 L is collected (either over 24 hours or before and after 
bedtime) and a 1-L aliquot is transferred to a Marinelli beaker for counting in a gamma-ray spectrometer 
(Gautier 1983).  This simple procedure offers high recoveries of cobalt (98%) and the minimum detection 
sensitivity (100 pCi/L [3.7 Bq/L]) that is required to evaluate individuals for exposures to radioactive 
cobalt (Gautier 1983).  Direct counting methods are also used for the analysis of cobalt radioisotopes in 
tissues, feces, and blood (Smith et al. 1972, Table 7-2).  However, some of these methods may require 
sample preparation to reduce volume or increase concentration. 
Accuracy of in vivo and in vitro measurements of cobalt is determined through the use of standard, 
certified solutions or radioactive sources with known concentrations or activities of cobalt.  Certified 
standards for stable cobalt can be obtained through a number of commercial sources.  The primary source 
of certified cobalt radioisotope standards is the National Institute of Standards and Technology (NIST).  
Gamma ray point sources for 60Co (SRM 4200, 60,000 Bq [1.6 µCi] and SRM 4207, 300,000 Bq
[56 µCi]) and standard solutions of 60Co (SRM 4233, 600,000 Bq/g [16 µCi/g]) are available from NIST.  
Also, the determination of accuracy of a method often requires standard reference materials (SRMs).  
Unfortunately, very few biological SRMs are available.  An SRM for cobalt in animal muscle is available 
from the International Atomic Energy Agency (IAEA), Vienna; an SRM for bovine liver (SRM-1577) is 
available from NIST (formerly the National Bureau of Standards) (Adeloju et al. 1985; Smith and Carson 
1981). 
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7.2 ENVIRONMENTAL SAMPLES 
There are two common approaches for measuring cobalt in the environment.  Cobalt radioisotopes can 
either be measured directly in the field (in situ) using portable survey instruments or samples can be 
procured from the field and returned to the laboratory for quantitation.  However, quantitation of the 
stable cobalt isotope 59Co in environmental samples is generally conducted in the laboratory. 
7.2.1 Field Measurements of Cobalt 
In situ measurement techniques are extremely useful for the rapid characterization of radionuclide 
contamination in the environment, such as soils, sediments, and vegetation, or when monitoring personnel 
for exposure to radionuclides.  The measurement of gamma-ray-emitting radionuclides, like cobalt, in the 
environment is conducted with portable survey instruments such as Gieger-Mueller detectors, sodium
iodide scintillation detectors, and gamma-ray spectrometers.  However, the use of gamma-ray
spectrometers in field survey equipment is preferred for measuring cobalt in the field because of its 
selectivity and sensitivity.  The relatively high energy and penetrability of the gamma ray that is emitted 
during the decay of 60Co provides an advantage for assessing the level of cobalt both on and below the 
surface using portable field survey instruments such as the gamma-ray spectrometer.  These gamma-ray
spectrometers are equipped with a high purity germanium detector that is able to selectively and 
sensitively differentiate the 1,173 and 1,332 keV gamma rays emitted from 60Co from the gamma-rays
emitted from other radionuclides, for example 40K or 137Cs (USNRC 1997).  Minimum detectable 
activities (MDAs) of 0.005 Bq/g (0.05 pCi/g) for 60Co are routinely achieved using p-type germanium
gamma-ray spectrometers with 10-minute counting times (USNRC 1997).  However, counting errors can 
occur where the simultaneous detection of the 1,173 and 1,332 keV gamma rays produces a sum peak at 
2,505 keV or a count in the continuum between the individual peaks and the sum peak (APHA 1998; 
USNRC 1997). These errors can be minimized by changing the geometry of the detector or the distance 
of the detector from the source of radioactivity. Computational methods have been derived to aid in 
determining the concentrations and distributions of 60Co in different soil types and depths (USNRC 
1997).  The concentrations and distributions of 60Co that have been derived from the computational 
analysis of the survey data are often verified by laboratory-based analyses of soil samples procured from
the survey area. 
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7.2.2 Laboratory Analysis of Environmental Samples  
Analytical methods for quantifying stable cobalt and cobalt radioisotopes in environmental samples (e.g. 
air, water, soil, and biota) are summarized in Tables 7-3 (59Co) and 7-4 (60Co).  The methods that are 
commonly used in the analysis of stable cobalt are based on instrumental analytical techniques, such as 
atomic absorption spectrometry (AAS), instrumental neutron activation analysis (INAA), and mass 
spectrometry (MS).  The analysis of 60Co can be determined either as total mass or total activity, 
depending on the analytical technique that is used.  Typically, radiochemical methods of analysis 
employing gamma-ray spectrometry techniques are used to quantitate 60Co in environmental samples. 
Analytical methods for determining stable cobalt in environmental samples are given in Table 7-3.  Since 
cobalt exists in the particulate form in the atmosphere, it is sampled by drawing air through a metal-free 
filter (usually cellulose ester membrane), and the metal is quantified in the collected particles.  Sample 
treatment prior to quantification is important for environmental samples.  For example, the use of sodium
carbonate for dry ashing plant materials results in poor cobalt recovery.  Low-temperature ashing may be 
inadequate for some samples, and losses may occur during rigorous dry ashing. Wet ashing is the 
preferred method when sample treatment is necessary.  Wet extraction with dilute nitric acid is most 
suitable for analyzing cobalt in dust samples.  In some samples, the determination of soluble and 
insoluble cobalt is important, and analytical methods used to determine cobalt in filtered and unfiltered 
samples are available for this purpose.  
As in the case of biological samples, contamination of environmental samples during sample collection, 
storage, and treatment should be avoided.  Loss of cobalt from aqueous samples due to adsorption on
storage containers should be avoided by using polyethylene or similar containers and acidifying the 
solution to the proper pH (Smith and Carson 1981).  Because of its rapidity, accuracy, and low detection 
limit, GF-AAS with Zeeman background correction is the most commonly used method for quantifying
cobalt in environmental samples.  To meet the detection limits of the available analytical methods, 
preconcentration prior to quantification may be necessary for some samples (e.g., seawater).  A few 
commonly used methods for determining cobalt in environmental samples are given in Table 7-3.  Other 
less frequently used methods are inductively coupled plasma-mass spectrometry (ICP-MS) (Henshaw 
et al. 1989; McLaren et al. 1985), gas, liquid, and ion chromatography with colorimetric, electron capture, 
and electrochemical detection (Bond and Wallace 1984; Carvajal and Zienius 1986; Cheam and Li 1988; 
King and Fritz 1987; Schaller and Neeb 1987), photoacoustic spectroscopy with colorimetry (Kitamori  
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Table 7-3. Analytical Methods for Determining Stable Cobalt in Environmental 

Samples 

Sample 
Sample Analytical detection Percent 
matrix Preparation method method limit recovery Reference
Air Weighed filter irradiated INAA 0.17 µg/m3 No data Haddad and 
(workplace) in a reactor Zikovsky 
1985 
Sample filter digested Flame-AAS with 0.4 µg/m3 98% with 12– NIOSH 1984 
by wet acid ashing background 96 µg spiked 
correction (NIOSH filter 
method 7027) 
Sample filter digested ICP-AES (NIOSH 0.5 µg/m3 95–100% with NIOSH 1984 
by wet acid ashing method 7300) 2.5– 
1,000 spiked 
filter 
Water (low Direct injection GF-AAS with <0.5 µg/L 93–115% at Fishman 
ionic strength) Zeeman or 8.5–30 µg/L et al. 1986 
deuterium back­
ground correction 
Lake water Sample complexed with ICP-AES <0.004 µg/L No data Nojiri et al. 
8-hydroxyquinoline 1985 
absorbed on a column, 
desorbed and digested 
with acid 
Rainwater Sample preconcentrated PIXE 0.08 µg/L No data Hansson 
onto polystyrene films et al. 1988 
by spray-drying 
Seawater Sample complexed with GF-AAS with 0.0002 µg/L 90% Nakashima 
8-hydroxyquinoline Zeeman back­ et al. 1988 
absorbed on a column, ground correction 
desorbed and digested 
with acid 
Water and Direct aspiration of Flame-AAS (EPA 0.05 mg/L 97–98% at 0.2– EPA 1983 
waste water sample method 219.1) 5.0 mg/L 
Direct injection GF-AAS with 1 µg/L No data EPA 1983 
background 
correction (EPA 
method 219.2)
Groundwater Direct aspiration Flame-AAS with 0.05 mg/L 97–98% at 0.2– EPA 1986b 
or leachate background 5.0 mg/L 
correction (EPA 
method 7200) 
Groundwater Direct injection GF-AAS with 1 µg/L No data EPA 1986b 
or leachate background 
correction (EPA 
method 7201) 
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Table 7-3. Analytical Methods for Determining Stable Cobalt in Environmental 

Samples 

Sample 
Sample Analytical detection Percent 
matrix Preparation method method limit recovery Reference
Food Sample digested with GF-AAS with 1.88 µg/L in 100–107% at Barbera and 
acid background dissolved 0.2–0.6 mg/kg Farre 1988 
correction extract (leaves, liver) 
Milled Wheat Wet ashing (HNO3), ET-AAS 20 ng/L approximately González et
preconcentration and 100% al. 2000 
chelation 
AAS = atomic absorption spectrometry; EPA = Environmental Protection Agency; ET-AAS = electrothermal atomic 
absorption spectrometry; GF-AAS= graphite furnace atomic absorption spectrometry; ICP-AES = inductively coupled 
plasma-atomic emission spectrometry; INAA = instrumental neutron activation analysis; NIOSH = National Institute 
for Occupational Safety and Health; PIXE = photon induced x-ray emission
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Table 7-4. Analytical Methods for Determining Radioactive Cobalt 
in Environmental Samples 
Sample 
Sample detection Percent 
matrix Preparation method Analytical method limita recovery Reference
Air Direct count of sample γ-spectrometry with 0.001 pCi/m3 No data USAEC 1974a 
collected on paper filter  Ge/Li detector 
Air Sample filter ashed Scintillation counter No data No data De Franceschi 
with NaI detector et al. 1974 
Drinking Direct count of sample γ-spectrometry with <2 pCi/L 99% APHA 1998 
water Ge detector 
Drinking Direct count of sample γ-spectrometry 2 pCi/L No data USAEC 1974b 
water 
Water Direct count of sample γ-spectrometry with 2 pCi/L No data ASTM 1999 
Ge/Li detector 
Water Direct count of sample γ-spectrometry 10 pCi/L No data Cahill et al. 
1972 
Seawater Sample concentrated Scintillation 50 fCi/L 92–95% Hiraide et al. 
using continuous-flow detector 1984 
coprecipitation-flotation 
separation technique 
Sediments Sample dried and ground γ-spectrometry 0.04 pCi/g No data Cahill et al. 
1972 
Fish Samples dried and ashed γ-spectrometry 0.001 pCi/g No data Cushing et al. 
(DW) 1981 
Mollusc Samples dried and ashed γ-spectrometry <0.01 pCi/g No data De Franceschi 
et al. 1976 
a1 Bq=2.7x10-11 Ci=27 pCi 
DW = dry weight; Ge/Li = lithium drifted geranium; NaI = sodium iodide 
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et al. 1986), electrothermal vaporization with ICP-AES (Malinski et al. 1988) and chemiluminescence 
with spectrofluorimetry (Jones et al. 1989). 
Analytical methods for determining cobalt radioisotopes in the environment are shown in Table 7-4.  The 
analysis of cobalt in air is based on quantifying cobalt within aerosols or particles that become trapped on 
cellulose (paper) or glass fiber filters after a calibrated amount of air is passed through the filters.  Since 
the cobalt radioisotopes do not occur naturally, but may be released as a result of nuclear weapons testing 
(which has been discontinued for several years), neutron-activation of specific materials (e.g., cobalt 
containing alloys used in piping of nuclear reactors), or a severe core damage accident in a nuclear plant, 
the amounts of these isotopes within the ambient environment are near or below the minimum detectable 
levels for these isotopes (DOE 1995). However, trace amounts of 60Co can be detected in air, water, and 
sediments within or near nuclear weapons or fuel production facilities, nuclear reactors, and nuclear waste 
storage sites (DOE 1995; Boccolini et al. 1976; USAEC 1973).  Analysis of cobalt radioisotopes in air 
filters, water, sediments, vegetation, and biota can be performed directly using gamma-ray spectrometry,
or following some sample preparation (e.g., drying, ashing, or extraction) (Boccolini et al. 1976; Cahill et 
al. 1972; Cushing 1981; Hiraid et al. 1984; Windham and Phillips 1973). 
The detection limits, accuracy, and precision of any analytical methodology are important parameters in 
determining the appropriateness of a method for quantifying a specific analyte at the desired level of 
sensitivity within a particular matrix.  The Lower Limit of Detection (LLD) has been adopted to refer to 
the intrinsic detection capability of a measurement procedure (sampling through data reduction and 
reporting) to aid in determining which method is best suited for the required sample quantitation (USNRC 
1984).  Several factors influence the LLD, including background, size or concentration of sample, 
detector sensitivity and recovery of desired analyte during sample isolation and purification, level of 
interfering contaminants, and, particularly, counting time.  Because of these variables, the LLDs between 
laboratories, utilizing the same or similar measurement procedures, will vary. 
The accuracy of a measurement technique in determining the quantity of a particular analyte in 
environmental samples is greatly dependent on the availability of standard reference materials.  Several 
SRMs for cobalt in environmental samples are also available.  Some of these are coal, fly ash, diet, and 
orchard leaf SRMs available from NIST.  The Community Bureau of Reference, European Communities 
offers SRMs for cobalt in sludges, and an SRM for cobalt in thin polymer films is available from NIST 
for x-ray fluorescence analysis in aerosol particle samples (Dzubay et al. 1988; Miller-Ihli and Wolf 
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1986; Schramel 1989; Smith and Carson 1981; Tinsley et al. 1983).  Gamma ray point sources for 60Co 
(SRM 4200, 60,000 Bq [1.6 µCi] and SRM 4207, 300,000 Bq [56 µCi]) and standard solutions of 60Co 
(SRM 4233, 600,000 Bq/g [16 µCi/g]) are available from NIST. 
7.3 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of cobalt is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of cobalt.  
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.    Cobalt concentrations in blood 
or urine can serve as exposure indicator (Alexandersson 1988; Ichikawa et al. 1985; Scansetti et al. 1985).
The available analytical methods are capable of determining the levels of cobalt in both the blood and
urine of normal and occupationally exposed persons (Table 7-1).  For the quantitation of cobalt 
radioisotopes, whole body counters can be used to assess radioactive cobalt body burdens that have 
occurred both from acute and chronic exposures to cobalt radioisotopes (Bhat et al. 1973; NCRP 1987).
In vitro analytical methods are available for analyzing cobalt radioisotopes in urine, feces, and tissues 
obtained from normal and occupationally exposed persons (Table 7-2). 
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Sensitive serum protein responses were found in animals exposed to cobalt at levels below those that 

produce hematopoietic effects. This unique serum protein response to cobalt exposure includes an 

increase in alpha globulin fractions of serum proteins and associated serum neuraminic acid.  Details of 

this effect are given in Chapters 2 and 3.  If similar changes occur in humans, this measurement may
 
provide the earliest indications of effects of cobalt exposure.  The available analytical methods are 

capable of determining these effects of cobalt exposure. 

Methods for Determining Parent Compounds and Degradation Products in Environmental 

Media. Analytical methods with good sensitivity and specificity are available for determining cobalt in 

air, water, soil, and other environmental media (Table 7-3).  Analytical methods for cobalt, like those for 

most metals, measure total metal content rather than the particular compound.  Therefore, analytical 

methods do not generally differentiate between the parent compound and a transformation product as 

would be the case, for example, were cobalt oxide to be converted to cobalt sulfate.  (An exception to this 

would be the case of radioactive decay in which the parent could be readily distinguished from the decay
 
product.) Analytical methods with the capability of distinguishing between different cobalt species would 

be important an important tool for assessing the fate of cobalt compounds in the environment.  However, 

methods for quantifying specific cobalt compounds were not found in the literature.   

The levels of the parent compound or its reaction products in different environmental media can be used 

to assess the exposure to cobalt by humans through the inhalation of air and ingestion of food and 

drinking water. In the case of cobalt, a correlation between its levels in environmental media (e.g., 

occupational air) and in biological tissues and body fluids has been found (Alexandersson 1988; Ichikawa 

et al. 1985; Scansetti et al. 1985).  Therefore, it is possible to estimate the total body burden of cobalt in 

workers exposed to airborne cobalt vapor and fumes from its concentration in workplace air. 

For cobalt radioisotopes, analytical methods also exist that have good sensitivity and specificity for 

determining radioactive cobalt in air, water, soil, and other environmental media are available (Table 7-4).  

Because 60Co decays to the stable element 60Ni, there is no need to develop methods to detect and 

quantify the decay products. 
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7.3.2 Ongoing Studies 
Two studies involving analytical techniques for cobalt was listed in the Federal Research in Progress 
database (FEDRIP 2002, 2004).  N.J. Miller-Ihli and co-workers of the Agricultural Research Service in 
Beltsville, Maryland are developing single and multielement methods for the determination of trace 
elements of nutritional and health concern. This work will develop new/improved methods permitting 
direct analysis of solids by GF-AAS and ICP-MS, as well as methods for the determination of different 
chemical forms of these elements by coupling capillary zone electrophoresis with inductively coupled 
plasma mass spectrometry (ICP-MS).  This research is supported by the U.S. Department of Agriculture 
(USDA) Agricultural Research Service.  B.T. Jones of Wake Forest University in Winston-Salem, North 
Carolina along with C. Calloway of Winthrop College, South Carolina, are working to develop a novel, 
low-cost, portable instrument for the simultaneous determination of trace radioactive elements in nuclear 
forensic samples.  The instrument to be developed is expected to provide analytical figures comparable to 
ICP-MS, but the instrument is much lower cost and more portable.  The specific objectives of the project 
include determination of the analytical figures of merit for elements including cobalt, cesium, and 
strontium, and analysis of real samples such as soil, urban dust, water, and agricultural materials. 
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International and national guidelines and state regulations regarding exposure to stable cobalt and its 
compounds are summarized in Table 8-1.  The regulations regarding radioactive cobalt are summarized in 
Table 8-2. 
Stable Cobalt.  An MRL of 1x10-4 mg cobalt/m3 has been derived for chronic-duration inhalation 
exposure. The MRL is based on a NOAEL of 0.0053 mg cobalt/m3 for decreased respiratory function in 
exposed workers (Nemery et al. 1992). An MRL of 1x10-2 mg/kg-day has been derived for intermediate-
duration oral exposure, based on a LOAEL of 1 mg/kg-day for polycythemia in human volunteers (Davis 
and Fields 1958).  No other inhalation or oral MRLs were derived. 
The EPA has not derived an RfC or RfD for cobalt and compounds.  Similarly, no cancer classification 
has been performed by the EPA (IRIS 2000).  The American Conference of Governmental Industrial 
Hygienists (ACGIH) has given cobalt a classification of A3, confirmed animal carcinogen with unknown 
relevance to humans, and established an 8-hour time-weighted average (TWA) of 0.02 mg/m3 for 
occupational exposure (ACGIH 2000). The Occupational Safety and Health Administration (OSHA) has 
promulgated an 8-hour permissible exposure limit (PEL) of 0.1 mg/m3 (OSHA 2001e), and the National 
Institute for Occupational Safety and Health (NIOSH) recommends an 8-hour TWA of 0.05 mg/m3 
(NIOSH 2001). IARC (2001b) reports that cobalt and cobalt compounds are possibly carcinogenic to 
humans (Group 2B), based on sufficient evidence for cobalt metal and cobalt oxides and limited evidence 
for cobalt chloride and cobalt sulfate. 
Cobalt and its compounds are regulated by the Clean Water Effluent Guidelines for the following 
industrial point sources:  nonferrous metal manufacturing, asbestos, timber products processing, paving 
and roofing, paint formulating, ink formulating, gum and wood, carbon black, and battery manufacturing 
(EPA 1988). 
Radioactive Cobalt.  No MRLs were derived for inhalation or oral exposure to radioactive cobalt.  MRLs 
for acute and chronic exposure to ionizing radiation exist (Agency for Toxic Substances and Disease 
Registry 1999) and are applicable to cobalt.  The EPA has not derived an RfC or RfD for radioactive 
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Table 8-1. Regulations and Guidelines Applicable to Stable Cobalt 
Agency Description 	 Information Reference 
INTERNATIONAL
Guidelines: 
IARC Carcinogenicity classification 
Cobalt and cobalt compoundsa 
NATIONAL
Regulations and
Guidelines: 
a. 	Air 
ACGIH TLV-TWA 
Cobalt, elemental, and inorganic 
compounds (as Co) 
NIOSH REL (TWA) 
Cobalt metal, dust, and fumes
 (as Co) 
IDLH 
Cobalt metal, dust, and fumes
 (as Co) 
OSHA PEL (8-hour TWA) for general industry 
Cobalt metal, dust, and fumes
 (as Co) 
PEL (8-hour TWA) for construction 
industry
Cobalt metal, dust, and fumes
 (as Co) 
PEL (8-hour TWA) for shipyard 
industry
Cobalt metal, dust, and fumes
 (as Co) 

USC HAP (cobalt compounds) 

b. 	Water 
EPA NPDES permit application testing 
requirements; conventional and 
nonconventional pollutants required to 
be tested by existing dischargers if 
expected to be present 
BPT effluent limitations 
Maximum for 1 day
Average of daily values for 
30 consecutive days 
 Groundwater monitoring 
 Suggested method 
 6010 
 7200 
 7201 
Group 2Bb 
0.02 mg/m3 
0.05 mg/m3 
20 mg/m3 
0.1 mg/m3 
0.1 mg/m3 
0.1 mg/m3 
3x10-4 kg/kkg 
1.2x10-4 kg/kkg 
PQL 
70 µg/L 
500 µg/L 
10 µg/L 
IARC 2001b 
ACGIH 2000 
NIOSH 2001 
OSHA 2001e 
29CFR1910.1000 
Table Z
OSHA 2001d 
29CFR1926.55
OSHA 2001c 
29CFR1915.1000 
USC 2001a 
42USC7412 
 EPA 2001g 
40CFR122 
Appendix D 
Table IV 
EPA 2001b 
40CFR415.652
EPA 2001d 
40CFR264 
Appendix IX
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Table 8-1. Regulations and Guidelines Applicable to Stable Cobalt 
Agency Description Information Reference 
NATIONAL (cont.) 
c. 	Food 
FDA 
d. 	Other 
ACGIH 
EPA 
EPA 
Drug products withdrawn or removed 
from the market for reasons of safety
or effectiveness 
New drug status accorded through 
rulemaking procedures 
Over-the-counter drugs; recommended 
warning and caution statement for 
cobalt as a cobalt salt 
Substances generally recognized as 
safe; trace minerals added to animal 
feeds 
Substances prohibited from use in 
human food 
Carcinogenicity classification 
Cobalt, elemental, and inorganic 
compounds (as Co)  
BEI 
Cobalt in urine—end of shift at
 end of workweek 
Cobalt in blood—end of shift at
 end of workweek 
Carcinogenicity classification 
RfC 
RfD 
Toxic chemical release reporting; 
Community Right-to-Know; effective 
date 
 Hazardous waste; identification and 
listing 
TSCA; health and safety data reporting 
Municipal solid waste landfills;
hazardous constituent for detection 
monitoring 
 Suggested method 
 6010 
 7200 
 7201 
Reportable quantity (cobalt 
compounds) 
All drug products containing 
cobalt salts (except 
radioactive forms of cobalt 
and its salts and cobalamin 
and its derivatives) 
Cobalt preparations intended 
for use by man
Required on articles 
containing ≥0.5 µg per dose 
and ≥2 µg per 24-hour period
Cobalt acetate
Cobalt carbonate
Cobalt chloride
Cobalt oxide 
Cobalt sulfate 
Cobaltous salts and its 
derivatives 
A3c 
15 µg/L 
1 µg/L 
No data 
01/01/87
Contain ≤1 ppmv in synthesis
gas fuel generated from 
hazardous waste 
PQL 
70 µg/L 
500 µg/L 
10 µg/L 
1 pound 
FDA 2000a 
21CFR216.24
FDA 2000b 
21CFR310.502
(a)(7) 
FDA 2000e 
21CFR369.20
FDA 2000f 
21CFR582.20
FDA 2000g 
21CFR189.120
ACGIH 2000 
IRIS 2000 
 EPA 2001c 
40CFR372.65(a) 
EPA 2001e 
40CFR261.38
(b)(5) 
EPA 2001j 
40CFR716.120
EPA 2001f 
40CFR258 
Appendix I and II 
EPA 2001h 
40CFR302.4 
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Table 8-1. Regulations and Guidelines Applicable to Stable Cobalt 
Agency Description 	 Information Reference 
NATIONAL (cont.) 
USC Superfund imposition of tax on cobalt $4.45 per ton USC 2001c 
26USC4661 
Exemption of tax imposed on recycled  USC 2001b 
cobalt 26USC4662 
STATE
Regulations and
Guidelines 
a. 	Air 
Alabama HAP (cobalt compounds) BNA 2001 
Alaska Air contaminant standard (TWA) BNA 2001 
Cobalt metal, dust, and fumes 0.05 mg/m3 
California Airborne contaminant (cobalt metal,  BNA 2001 
dust, and fumes) 
HAP (cobalt compounds) BNA 2001 
Toxic air contaminant (cobalt CA Air Resources 
compounds) Board 2000
Colorado HAP (cobalt metal, dust, and fumes) BNA 2001 
“High-concern” pollutant (cobalt and  BNA 2001 
compounds) 
Reportable pollutants (cobalt metal, CO Dept. of Public 
dust, and fumes) Health and 
Environment 2000 
Connecticut HAP—hazard limiting value (cobalt BNA 2001 
metal, dust, and fumes) 
 8 hours 
 30 minutes 
2 µg/m3 
10 µg/m3 
 Delaware Reportable quantities DE Air Quality 
 Cobalt carbonyl 1 pound Management 2000 
 Cobaltous sulfamate 1,000 pounds 
 Cobalt, ((2,2'-(ethane­ 1 pound 
 diylbis(nitrilomethylidyne) 
Hawaii Air contaminant limit (PEL-TWA) 
Cobalt metal, dust, and fumes 0.05 mg/m3 
BNA 2001 
HAP (cobalt compounds) BNA 2001 
Idaho TAP non-carcinogenic increments ID Dept. of 
Cobalt carbonyl and cobalt Environmental Quality 
 hydrocarbonyl (as Co) 
OEL 
EL 
AAC (24-hour average) 
1x10-1 mg/m3 
7x10-3 pounds/hour 
5x10-3 mg/m3 
2000 
Cobalt metal, dust, and fumes
OEL 
EL 
AAC (24-hour average) 
5x10-2 mg/m3 
3.3x10-3 pounds/hour 
2.5x10-3 mg/m3 
Illinois Toxic air contaminant (cobalt) IL EPA 2000a 
Kansas HAP (cobalt compounds) KS Dept. of Health 
and Environment 
2000 
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Table 8-1. Regulations and Guidelines Applicable to Stable Cobalt 
Agency Description Information Reference 
STATE (cont.)
Kentucky
Louisiana 
Maine 
Maryland
Michigan 
Minnesota 
Missouri 
 Montana 
Nebraska 
New Mexico
New York 
North Carolina
Ohio 
Oregon 
Rhode Island 
South Carolina
Texas 
Vermont 
Washington 
HAP (cobalt compounds) 

Toxic air pollutant (cobalt compounds 

Emissions standards 

Toxic air pollutant (cobalt compounds) 

High concern toxic air pollutants 

(cobalt compounds) 

HAP threshold (cobalt metal and 

cobalt carbonyl) 

HAP (cobalt compounds) 

Occupational air contaminant (cobalt 

metal, dust, and fumes) 

HAP (cobalt compounds and cobalt) 

Toxic air pollutant (cobalt metal, dust, 

and fumes [as Co]) 
OEL 
Emissions 
Annual guideline concentrations 
Dangerous air contaminants (TLV) for 
cobalt metal, dust, and fumes
HAP (cobalt compounds) 
Transition limits (PEL) 
Cobalt metal, dust, and fumes
Final rule limits (TWA) 
Cobalt metal, dust, and fumes
PEL-TWA (cobalt metal, dust, and 
fumes) 
TRI 

Air contaminant (cobalt metal, dust, 

and fumes) 

HAP (cobalt compounds) 

Toxic air emissions (MAC) for cobalt 

compounds 

HAP (cobalt metal, dust, and fumes) 

HAP (cobalt compounds) 

Hazardous ambient air standards 

 Cobalt compounds 

Annual average 

Averaging time
 
Action level 

Class B TAP and ASIL 
(24-hour average) 
Cobalt metal, dust and fumes 
Cobalt carbonyl and cobalt 
 hydrocarbonyl 
2,000 pounds 
0.1 tons/year 
0.1 mg/m3
1x10-1 mg/m3 
6.67x10-3 pounds/hour 
5x10-3 µg/m3 
0.1 mg/m3
0.1 mg/m3 
0.05 mg/m3 
0.05 mg/m3
0.1 mg/m3
0.25 µg/m3
0.1 mg/m3
0.12 µg/m3 
24 hours 
6.2x10-3 pounds/8 hours 
0.17 µg/m3 
0.33 µg/m3 
BNA 2001 
BNA 2001 
BNA 2001 
BNA 2001 
 BNA 2001 
BNA 2001 
BNA 2001 
 BNA 2001 
BNA 2001 
BNA 2001 
NYS Dept. of 
Environmental
Conservation 2000 
 BNA 2001 
BNA 2001 
BNA 2001 
 BNA 2001 
Ohio EPA 2000 
 BNA 2001 
BNA 2001 
 BNA 2001 
 BNA 2001 
BNA 2001 
BNA 2001 
WA Dept. of Ecology
2000 
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Table 8-1. Regulations and Guidelines Applicable to Stable Cobalt 
Agency Description Information Reference 
STATE (cont.)
 Wisconsin 
b. 	Water 
 Alabama 
 Arizona 
Arkansas 
California 
Colorado
 Delaware
Illinois 
Kentucky
 Louisiana 
 Massachusetts 
 Minnesota 
Thresholds for HAPs 
 Cobalt carbonyl 
Cobalt metal, dust, and fumes
HAP—existing sources 
AAC <25 feet 
AAC ≥25 feet 
Groundwater monitoring (cobalt) 
 Suggested methods 
 6010 
 7200 
 7201 
Drinking water guideline 
Groundwater monitoring (cobalt) 
 Suggested methods 
 6010 
 7200 
 7201 
Chemicals known to cause cancer or 
reproductive toxicity; date of initial 
appearance on the list 
Cobalt metal powder 
 Cobalt[II] oxide 
 Cobalt sulfate heptahydrate 
Groundwater standard (cobalt)
Groundwater monitoring (cobalt) 
 Suggested methods 
 6010 
 7200 
 7201 
Groundwater quality standards for 
Class II 
Hazardous waste constituent for 
groundwater monitoring (cobalt) 
Groundwater monitoring (cobalt) 
 Suggested methods 
 6010 
 7200 
 7201 
Groundwater monitoring (cobalt) 
 Suggested methods 
 6010 
 7200 
 7201 
Drinking water guideline 
Groundwater protection hazardous 
constituent for cobalt (total) 
0.1 tons/year 
0.1 tons/year 
4.08x10-3 pounds/hour 
1.704x10-2 pounds/hour 
PQL 
70 µg/L 
500 µg/L 
10 µg/L 
0.70 µg/L  
PQL 
70 µg/L 
500 µg/L 
10 µg/L 
07/01/92
07/01/92
06/02/00
0.05 mg/L 
PQL 
70 µg/L 
500 µg/L 
10 µg/L 
1 mg/L 
PQL 
70 µg/L 
500 µg/L 
10 µg/L 
PQL 
70 µg/L 
500 µg/L 
10 µg/L 
2 µg/L 
BNA 2001 
WI Dept. of Natural 
Resources 1999 
BNA 2001 
FSTRAC 1999
BNA 2001 
Cal/EPA 2000 
BNA 2001 
BNA 2001 
IL EPA 2000b 
 BNA 2001 
BNA 2001 
BNA 2001 
FSTRAC 1995
 BNA 2001 
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Table 8-1. Regulations and Guidelines Applicable to Stable Cobalt 
Agency Description Information Reference 
STATE (cont.)
Missouri Water quality standards 
 Livestock, wildlife watering 
 Groundwater 
1x103 µg/L 
1x103 µg/L 
BNA 2001 
New Mexico Standards for groundwater of 0.05 mg/L BNA 2001 
10,000 mg/L TDS concentration or 
less (cobalt) 
New York Groundwater monitoring (cobalt) BNA 2001 
 Suggested methods PQL 
 6010 70 µg/L 
 7200 500 µg/L 
 7201 10 µg/L 
Tennessee Effluent limitations—daily maximum 10 mg/L BNA 2001 
concentration (cobalt) 
 Wisconsin Drinking water guideline 40 µg/L FSTRAC 1999
Groundwater standards (cobalt) BNA 2001 
 Enforcement standard 40 µg/L 
Preventive action limit 8 µg/L 
c. Food No data 
d. Other 
Alabama Detection limit values for comparable 4.6 mg/kg at BNA 2001 
fuel specification for cobalt; 10,000 BTU/pound 
concentration limit 
Arizona Soil remediation levels (cobalt) 
 Residential 
 Non-residential
4.6x103 mg/kg 
9.7x104 mg/kg 
BNA 2001 
Arkansas Detection limit values for comparable 4.6 mg/kg at BNA 2001 
fuel specification for cobalt; 10,000 BTU/pound 
concentration limit 
Solid waste management (cobalt) BNA 2001 
 Suggested methods PQL 
 6010 70 µg/L 
 7200 500 µg/L 
 7201 10 µg/L 
California Characteristics of toxicity for cobalt BNA 2001 
and cobalt compounds 
 STLC 80 mg/L 
 TTLC 8,000 mg/kg (wet-weight) 
Chemicals known to cause cancer or 07/01/92 BNA 2001 
reproductive toxicity (cobalt metal 
powder); initial appearance on the list 
Hazardous substance (cobalt, cobalt  BNA 2001 
carbonyl, and cobalt hydrocarbonyl) 
Delaware Detection limit values for comparable 4.6 mg/kg at BNA 2001 
fuel specification for cobalt; 10,000 BTU/pound 
concentration limit 
Florida Toxic substance in the workplace  BNA 2001 
(cobalt metal, dust, and fumes) 
Georgia Soil concentration (cobalt) 20 mg/kg BNA 2001 
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Table 8-1. Regulations and Guidelines Applicable to Stable Cobalt 
Agency Description Information Reference 
STATE (cont.)
Illinois Analytical parameters and required
quantitation limits for cobalt 
 Water 
BNA 2001 
Soil 
Method 
50 µg/L 
10 mg/kg 
6010A 
Indiana Constituent subject to assessment 
monitoring (cobalt [total and 
dissolved]) 
 BNA 2001 
Maine Screening standards for beneficial use 
(cobalt) 
5,875 mg/kg (dry weight) BNA 2001 
 Michigan Identification and listing of hazardous 
waste (cobalt) 
When in the form of 
100 microns or less 
BNA 2001 
 Minnesota Hazardous substance  BNA 2001 
Cobalt metal, dust, and fumes
 (as Co) 
Cobalt carbonyl (as Co) 
Cobalt, elemental and inorganic 
compounds (as Co) 
Cobalt hydrocarbonyl (as Co)
Missouri Hazardous constituent (cobalt [total]) BNA 2001 
New Jersey Hazardous substance 
 Cobalt 
 BNA 2001 
 Cobalt carbonyl 
 Cobalt compounds 
New York Occupational lung disease; hard metal 
disease 
Cobalt BNA 2001 
Ohio Toxic release inventory BNA 2001 
Oklahoma Fertilizer labels and labeling; minimum 
percentage accepted for registration 
(cobalt) 
5x10-4 percent BNA 2001 
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Table 8-1. Regulations and Guidelines Applicable to Stable Cobalt 
Agency Description Information Reference 
Oregon Toxic substance (cobalt) BNA 2001 
Pennsylvania Hazardous substance (cobalt and  BNA 2001 
cobalt fumes) 
aCobalt compounds: includes cobalt(II) carbonate, cobalt(II) chloride, cobalt(II) nitrate, cobalt(II) oxide, cobalt(II,III)
 
oxide, cobalt(III) oxide, and cobalt(II) sulfate 

bGroup 2B: possibly carcinogenic to humans 

cA3: confirmed animal carcinogen with unknown relevance to humans  

AAC = acceptable ambient concentrations; ACGIH = American Conference of Governmental Industrial Hygienists; 

ASIL = acceptable source impact level; BEI = biological exposure indices; BNA = Bureau of National Affairs; 

BPT = best practicable control technology; BTU = British thermal unit; CFR = Code of Federal Regulations; 

EL = emissions levels; EPA = Environmental Protection Agency; FDA = Food and Drug Administration; 

FSTRAC = Federal-State Toxicology and Risk Analysis Committee; HAP = hazardous air pollutant; 

IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life and health; 

IRIS = Integrated Risk Information System; MAC = maximum allowable concentration; NIOSH = National Institute for 

Occupational Safety and Health; NPDES = National Pollutant Discharge Elimination System; OEL = occupational 

exposure limit; OSHA = Occupational Safety and Health Administration; PEL = permissible exposure limit; 

PQL = practical quantitation limit; REL = recommended exposure limit; RfC = reference concentration; 

RfD = reference dose; STLC = soluble threshold limit concentrations; TAP = toxic air pollutant; TDS = total dissolved 

solids; TLV = threshold limit value; TRI = Toxic Release Inventory; TSCA = Toxic Substances Control Act; 

TTLC = total threshold limit concentrations; TWA = time-weighted averages; USC = United States Code
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Table 8-2. 
8. REGULATIONS
Regulations and Guidelin
 AND ADVISORIES 
es Applicable to Radioactive Cobalt 
Agency Description Information Reference 
INTERNATIONAL
Guidelines: 
IARC Carcinogenicity classification Group 1 (carcinogenic to 
humans) 
IARC 2001b 
ICRP Occupational dose limits; 
effective dose 
20 mSv per year, averaged 
over defined periods of 5 years 
ICRP 1991 
Annual equivalent dose 
Lens of the eye 
Skin 
150 mSv 
500 mSv 
Hands and feet 500 mSv 
General population dose limits; 
effective dose 
1 mSv in a year ICRP 1991 
Annual equivalent dose 
Lens of eye 
Skin 
15 mSv 
50 mSv 
WHO Drinking water quality No data 
NATIONAL
Regulations and 
Guidelines: 
a. Air 
ACGIH All radiation exposures must 
be kept as low as reasonably 
achievable 
 ACGIH 2000
 Effective dose ACGIH 2000
Any single year 
Averaged over 5 years 
50 mSv 
20 mSv per year 
Annual equivalent dose 
Lens of the eye 
 Skin 
150 mSv 
500 mSv 
Hands and feet 500 mSv 
Embryo-fetus exposures once 
the pregnancy is known 
Monthly equivalent dose 
Dose to the surface of 
0.5 mSv 
2 mSv for the remainder of the 
women’s abdomen (lower 
trunk) 
Intake of radionuclide 
pregnancy  
1/20 of the ALI 
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8. REGULATIONS AND ADVISORIES 
Table 8-2. Regulations and Guidelines Applicable to Radioactive Cobalt 
Agency Description Information Reference 
NATIONAL (cont.)
 DOE Radiation standards DOE 2000 
 Inhalation DAC (µCi/mL) 
55Co 
56Co 
57Co 
58mCo 
58Co 
60mCo 
60Co 
61Co 
62mCo 
Class Wa 
1x10-6 
1x10-7 
1x10-6 
4x10-5 
5x10-7 
2x10-3 
7x10-8 
3x10-5 
7x10-5 
Class Yb
1x10-6 
8x10-8 
3x10-7 
3x10-5 
3x10-7 
1x10-3 
1x10-8 
2x10-5 
7x10-5 
10CFR835 
Appendix A 
Radiation standards for air 1x10-3 DOE 2000 
immersion DACc (µCi/mL) for 
60mCo 
10CFR835 
Appendix C 
NIOSH REL No data 
USNRC Effluent concentrations—air 
55Co 
Class Wd 
Class Ye
56Co 
Class Wd 
Class Ye
57Co 
Class Wd 
Class Ye
58Co 
Class Wd 
Class Ye
58mCo 
Class Wd 
Class Ye
60Co 
Class Wd 
Class Ye
60mCo 
Class Wd 
Class Ye
61Co 
Class Wd 
Class Ye
62mCo 
Class Wd 
Class Ye
ALI (µCi/mL) 
4x10-9 
4x10-9 
4x10-10 
3x10-10 
4x10-9 
9x10-10 
2x10-9 
1x10-9 
1x10-7 
9x10-8 
2x10-10 
5x10-11 
6x10-6 
4x10-6 
9x10-8 
8x10-8 
2x10-7 
2x10-7 
USNRC 2001k 
10CFR20
Appendix B 
Table 2 
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8. REGULATIONS AND ADVISORIES 
Table 8-2. Regulations and Guidelines Applicable to Radioactive Cobalt 
Agency Description Information	 Reference 
NATIONAL (cont.)
 USNRC Occupational values 
Inhalation 
55Co 
Class Wd 
Class Ye
56Co 
Class Wd 
Class Ye
57Co 
Class Wd 
Class Ye
58Co 
Class Wd 
Class Ye
58mCo 
Class Wd 
Class Ye
60Co 
Class Wd 
Class Ye
60mCo 
Class Wd 
Class Ye
61Co 
Class Wd 
Class Ye
62mCo 
Class Wd 
Class Ye
OSHA Safety and health regulations 
for construction—ionizing
radiation 
Toxic and hazardous 
substances—ionizing radiation
b. 	Water 
EPA Drinking water standards 
Beta particle and photon 
activity (formerly man-made
radionuclides)
 MCL 
Caner risk at 10-4 
Gross alpha particle activity 
MCL 
Caner risk at 10-4 
ALI (µCi) 
3x103 
3x103 
3x102 
2x102 
3x103 
7x102 
1x103 
7x102 
9x104 
6x104 
2x102 
3x101 
4x106 
3x106 
6x104 
6x104 
2x105 
2x105 
4 mrem 
4 mrem/year 
15 pCi/L 
15 pCi/L 
USNRC 2001k 
10CFR20
DAC (µCi/mL) Appendix B 
1x10-6 Table 1 
1x10-6 
1x10-7 
8x10-8 
1x10-6 
3x10-7 
5x10-7 
3x10-7 
4x10-5 
3x10-5 
7x10-8 
1x10-8 
2x10-3 
1x10-3 
3x10-5 
2x10-5 
7x10-5 
6x10-5 
 OSHA 2001e
29CFR1926.53 
 OSHA 2001d
29CFR1910.1096 
EPA 2000 
Carcinogenic classification Group A (human carcinogen) 
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8. REGULATIONS AND ADVISORIES 
Table 8-2. Regulations and Guidelines Applicable to Radioactive Cobalt 
Agency Description Information	 Reference 
NATIONAL (cont.)
 USNRC Effluent concentrations 
 Water 
55Co 
Class Wd 
56Co 
Class Wd 
57Co 
Class Wd 
58Co 
Class Wd 
58mCo 
Class Wd 
60Co 
Class Wd 
60mCo 
Class Wd 
61Co 
Class Wd 
62mCo 
Class Wd 
Releases to sewers—monthly 
average concentration 
55Co 
Class Wd 
56Co 
Class Wd 
57Co 
Class Wd 
58Co 
Class Wd 
58mCo 
Class Wd 
60Co 
Class Wd 
60mCo 
Class Wd 
61Co 
Class Wd 
62mCo 
Class Wd 
c. 	Food and Drug 
FDA Ionizing radiation for the 
treatment of poultry feed and 
poultry feed ingredients 
(energy sources ) 
 Requirements regarding
certain radioactive drugs for 
58Co or 60Co 
ALI (µCi/mL) 
2x10-5 
6x10-6 
6x10-5 
2x10-5 
8x10-4 
3x10-6 
2x10-2 
3x10-4 
7x10-4 
ALI (µCi/mL) 
2x10-4 
6x10-5 
6x10-4 
2x10-4 
8x10-3 
3x10-5 
2x10-1 
3x10-3 
7x10-3 
Ioninzing radiation is limited to 
gamma rays from sealed units 
of 60CO 
Labeled cyanocobalamin for 
use in intestinal absorption 
studies
USNRC 2001k 
10CFR20
Appendix B 
Table 2 
USNRC 2001k 
10CFR20
Appendix B 
Table 3 
FDA 1999 
21CFR579.40 
FDA 2000d 
21CFR310.503(c) 
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8. REGULATIONS AND ADVISORIES 
Table 8-2. Regulations and Guidelines Applicable to Radioactive Cobalt 
Agency Description Information Reference 
NATIONAL (cont.)
FDA Sources of radiation used for  FDA 2000c 
inspection of food, packaged 
food, and controlling food 
processing 
21CFR179.21 
(a)(2)
d. Other 
DOE Values for establishing sealed 
radioactive source 
DOE 2000 
10CFR835 
accountability and radioactive 
material posting and labeling 
requirements 
56Co 
Activity (µCi) 
4.0x101 
Appendix E 
57Co 2.3x102 
58Co 1.4x102 
60Co 1.8x101 
DOT Activity values (Ci) 
55Co 
A1 
13.5 
A2 
13.5 
DOT 2001a 
49CFR173.435 
56Co 8.11 8.11 Table 
57Co 216 216 
58mCo 1080 1080 
58Co 
60Co 
27.0 
10.8 
27.0 
10.8 
Superfund, reportable quantity 
(Ci) (pounds)
55Co 10 
DOT 2001b 
49CFR172.101 
Appendix A
56Co 10 Table 2 
57Co 
58Co 
100 
10 
58mCo 
60Co 
1,000 
10 
60mCo 
61Co 
62mCo 
1,000 
1,000 
1,000 
EPA Carcinogenicity classification 
RfC 
No data IRIS 2000 
RfD 
Annual possession quantities 
for environmental compliance 
(Ci/year) 
56Co 
Solid 
2.3 
Gas 
2.3x10-6 
Liquid/ 
Powder 
2.3x10-3 
EPA 2001a 
40CFR61
Appendix E 
Table 1 
57Co 1.8x1041.8x10-2 1.8x101 
58Co 2.52.5x10-6 2.5x10-3 
58mCo 2.32.3x10-6 2.3x10-3 
60Co 4.6x1044.6x10-2 4.6x101 
60mCo 7.0x1067.0 7.0x103 
61Co 9.8x1059.8x10-1 9.8x102 
  
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
  
   
   
   
   
 
 
 
 
 
 
 
   
  
   
   
   
   
 
 
 
 
 
 
 
   
  
   
   
   
   
 
 
 
 
 
 
 
   
  
  
  
  
 
 
 
 
 
 
  
 
  
  
  
  
 
 
 
 
 
COBALT 295 
8. REGULATIONS AND ADVISORIES 
Table 8-2. Regulations and Guidelines Applicable to Radioactive Cobalt 
Agency Description Information Reference 
NATIONAL (cont.)
EPA Concentration levels for EPA 2001a 
environmental compliance 
(Ci/m3)
56Co 1.8x10-13 
40CFR61
Appendix E 
Table 2 
57Co 1.3x10-12 
58Co 6.7x10-13 
58mCo 1.2x10-10 
60Co 1.7x10-14 
60mCo 4.3x10-9 
61Co 4.5x10-9 
 Carcinogenicity—slope factors EPA 2002 
Lifetime risk per pCi—
 ingestion 
Water 
EPA 2002 
57Co 1.04x10-12 
58mCo 2.95x10-12 
58Co 1.26x10-13 
60Co 1.57x10-11 
Lifetime risk per pCi—
 ingestion 
Food 
EPA 2002 
57Co 1.49x10-12 
58mCo 4.18x10-12 
58Co 1.83x10-13 
60Co 2.23x10-11 
Lifetime risk per pCi—
 ingestion 
Soil 
EPA 2002 
57Co 2.78x10-12 
58mCo 7.44x10-12 
58Co 3.47x10-13 
60Co 4.03x10-11 
Lifetime risk per pCi—
 inhalation 
EPA 2002 
57Co 2.09x10-12 
58mCo 5.99x10-12 
58Co 6.88x10-14 
60Co 3.58x10-11 
External exposure— 
risk/year per pCi/g soil 
57Co 3.55x10-7 
EPA 2002 
58mCo 4.48x10-6 
58Co 1.00x10-12 
60Co 1.24x10-5 
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8. REGULATIONS AND ADVISORIES 
Table 8-2. Regulations and Guidelines Applicable to Radioactive Cobalt 
Agency Description Information Reference 
NATIONAL (cont.)
 EPA Superfund, reportable 
quantities (Ci) (pounds) 
55Co 
56Co 
10 
10 
EPA 2001i 
40CFR302.4
Appendix B 
57Co 
58mCo 
58Co 
100 
1,000 
10 
60mCo 
60Co 
1,000 
10 
61Co 
62mCo 
1,000 
1,000 
NCRP Occupational exposures NCRP1993 
Effective dose limits 
Annual 50 mSv 
Cummulative 10 mSv x age 
Equivalent dose annual 
limits 150 mSv 
Lens of eye 
Skin, hands, and feet 
500 mSv 
Public exposures (annual) 
Effective dose limits, 1 mSv 
continuous or frequent 
exposure 
Effective dose limits, 5 mSv 
 infrequent exposures
Equivalent dose limits 
Lens of eye 
Skin, hands, and feet 
15 mSv 
50 mSv 
Embryo and fetus 
 exposures (monthly) 
Effective dose limit 0.5 mSv 
USNRC Activity values for 
radionuclides (Ci)
55Co 
A1 
13.5 
A2 
13.5 
USNRC 2001a 
10CFR71
56Co 8.11 8.11 
57Co 216 216 
58mCo 
58Co 
1080 
27.0 
1080 
27.0 
60Co 10.8 10.8 
Byproduct material listing; 
exempt concentrations 
Liquid and solid 
 concentration (µCi/mL2)
57C 5x10-3 
USNRC 2001e 
10CFR30.70 
Schedule A 
58C 1x10-3 
60C 5x10-4 
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8. REGULATIONS AND ADVISORIES 
Table 8-2. Regulations and Guidelines Applicable to Radioactive Cobalt 
Agency Description Information Reference 
NATIONAL (cont.)
USNRC Byproduct material listing (µCi)
58mCo 
58Co 
60Co 
Byproduct material listing (Ci)
58mCo 
58Co 
60Co 
Items containing byproduct 
material listing—60Co (µCi)
 Electron tubes 
Spark gap irradiators 
 Medical use—60Co as a 
source for brachytherapy 
 Occupational values—oral 
ingestion 
55Co 
Class Wd 
56Co 

Class Wd 

Class Ye
 
57Co 

Class Wd 

Class Ye
 
58Co 

Class Wd 

Class Ye
 
58mCo 

Class Wd 

60Co 

Class Wd 

Class Ye
 
60mCo 

Class Wd 

St. wall 

61Co 

Class Wd 

Class Ye
 
62mCo 

Class Wd 

St. wall 

10 
10 
1 
Column If Column IIg 
100 1.0 
1.0 0.01 
0.1 1x10-4 
1.0 
1.0 
As a sealed source in needles 
and applicator cells for topical, 
interstitial, and intracavitary 
treatment of cancer 
ALI (µCi) 
1x103 
5x102 
4x102 
8x103 
4x103 
2x103 
1x103 
6x104 
5x102 
2x102 
1x106 
1x106 
2x104 
2x104 
5x104 
4x104 
USNRC 2001b 
10CFR30.71 
Schedule B 
USNRC 2001c 
10CFR33.100
Schedule A 
USNRC 2001d 
10CFR30.15(a)(8) 
USNRC 2001h 
10CFR35.400
USNRC 2001k 
10CFR20
Appendix B 
Table 1 
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8. REGULATIONS AND ADVISORIES 
Table 8-2. Regulations and Guidelines Applicable to Radioactive Cobalt 
Agency Description Information	 Reference 
NATIONAL (cont.)
USNRC Quantities of radioactive USNRC 2001g 
material requiring labeling 10CFR30
(µCi) Appendix B
58mCo 10 
58Co 10 
60Co 1 
Quantities of licensed material 	 USNRC 2001i 
requiring labeling (µCi) 10CFR20
55Co Appendix C
56Co 100 
57Co 10 
58mCo 100 
58Co 1,000
60mCo 100 
60Co 1,000
61Co 1 
62mCo 1,000 
1,000 
Quantities of radioactive USNRC 2001j 
materials requiring need for an 10CFR30.72 
emergency plan Schedule C 
 Release fraction 0.001% 
 Quantity (Ci) 5,000 
 Radioactive waste USNRC 2001l 
classification 10CFR61.55 
Class A (Ci/m3) 
60Co ≤700 
Reports of individual USNRC 2001f 
monitoring—processing or 10CFR20.2206 
manufacturing for distribution, (a)(7)
byproduct material in 
quantities exceeding
60Co (Ci) 1.0 
STATE
Regulations and 
Guidelines: 
a. 	Air 
Alabama HAP—radionuclides BNA 2001 
California HAP—radionuclides BNA 2001 
 Hawaii HAP—radionuclides BNA 2001 
Illinois Toxic air contaminant—  BNA 2001 
radionuclides 
 Kansas HAP—radionuclides BNA 2001 
Kentucky HAP—radionuclides BNA 2001 
 Minnesota HAP—radionuclides BNA 2001 
 Missouri HAP—radionuclides BNA 2001 
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8. REGULATIONS AND ADVISORIES 
Table 8-2. Regulations and Guidelines Applicable to Radioactive Cobalt 
Agency Description Information Reference 
STATE (cont.)
 Nebraska HAP—radionuclides BNA 2001 
New York HAP—radionuclides BNA 2001 
Rhode Island HAP—radionuclides BNA 2001 
Wyoming HAP—radionuclides BNA 2001 
aClass W: refers to the approximate length of retention in the pulmonary region which is 10–100 days for this class 
bClass Y: refers to the approximate length of retention in the pulmonary region which is greater than 100 days for this 
class 
cAir immersion DAC values: based on a stochastic dose limit of 5 rems (0.05 Sv) per year or a nonstochastic (organ) 
dose limit of 50 rems (0.5 Sv) per year 
dClass W: all compounds except those given for Y 
eClass Y: oxides, hydroxides, halides, and nitrates 
fColumn I: gas concentration 
gColumn II: liquid and solid concentration 
ACGIH = American Conference of Governmental Industrial Hygienists; ALI = annual limits on intake; BNA = Bureau 
of National Affairs; CFR = Code of Federal Regulations; DAC = derived air concentrations; DOE = Department of 
Energy; DOT = Department of Transportation; EPA = Environmental Protection Agency; FDA = Food and Drug 
Administration; IARC = International Agency for Research on Cancer; ICRP = International Commission on 
Radiological Protection; IRIS = Integrated Risk Information System; mSv = millisievert; NCRP = National Council on
Radiation Protection; NIOSH = National Institute for Occupational Safety and Health; OSHA = Occupational Safety
and Health Administration; PEL = permissible exposure limit; REL = recommended exposure limit; RfC = reference 
concentration; RfD = reference dose; TLV = threshold limit value; TWA = time-weighted averages; USNRC = U.S. 
Nuclear Regulatory Commission; WHO = World Health Organization 
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8. REGULATIONS AND ADVISORIES 
cobalt (IRIS 2000).  Slope factors have been derived for exposure to cobalt radioisotopes (EPA 2002). 
The slope factors for 60Co are 1.57x10-11, 2.23x10-11, and 4.03x10-11/pCi for ingestion of water, food, and  
soil, respectively.  The slope factor for inhalation exposure is 3.58x10-11/pCi, and 1.24x10-5/year/pCi/g 
soil for external exposure. The slope factors for 58Co are 1.26x10-13,, 1.83x10-13,, and 3.47x10-13/pCi for 
ingestion of water, food, and soil, respectively.  The slope factor for inhalation exposure is 6.88x10-14/pCi
for inhalation exposure, and 1.00x10-12/year/pCi/g soil for external exposure.  The slope factors for 58mCo 
are 2.95x10-12,, 4.18x10-12,, and 7.44x10-12/pCi for ingestion of water, food, and soil, respectively.  The 
slope factor for inhalation exposure is 5.99x10-14/pCi for inhalation exposure, and 4.48x10-6/year/pCi/g 
soil for external exposure. The slope factors for 57Co are 1.04x10-12, 1.49x10-12, and 2.78x10-12/pCi for 
ingestion of water, food, and soil, respectively.  The slope factor for inhalation exposure is 2.09x10-12/pCi
for ingestion, and 3.55x10-7/year/pCi/g soil for external exposure. 
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Some terms in this glossary are generic and may not be used in this profile. 
Absorbed Dose, Chemical—The amount of a substance that is either absorbed into the body or placed in 
contact with the skin. For oral or inhalation routes, this is normally the product of the intake quantity and 
the uptake fraction divided by the body weight and, if appropriate, the time, expressed as mg/kg for a 
single intake or mg/kg/day for multiple intakes.  For dermal exposure, this is the amount of material 
applied to the skin, and is normally divided by the body mass and expressed as mg/kg.   
Absorbed Dose, Radiation—The mean energy imparted to the irradiated medium, per unit mass, by
ionizing radiation.  Units: rad (rad), gray (Gy). 
Absorbed Fraction—A term used in internal dosimetry.  It is that fraction of the photon energy (emitted 
within a specified volume of material) which is absorbed by the volume.  The absorbed fraction depends 
on the source distribution, the photon energy, and the size, shape and composition of the volume. 
Absorption—The process by which a chemical penetrates the exchange boundaries of an organism after 
contact, or the process by which radiation imparts some or all of its energy to any material through which 
it passes. 
Absorption Coefficient—Fractional absorption of the energy of an unscattered beam of x- or gamma-
radiation per unit thickness (linear absorption coefficient), per unit mass (mass absorption coefficient), or 
per atom (atomic absorption coefficient) of absorber, due to transfer of energy to the absorber.  The total 
absorption coefficient is the sum of individual energy absorption processes (see Compton Effect, 
Photoelectric Effect, and Pair Production). 
Absorption Coefficient, Linear—A factor expressing the fraction of a beam of x- or gamma radiation 
absorbed in a unit thickness of material.  In the expression I=Ioe-µx, Io is the initial intensity, I the intensity
of the beam after passage through a thickness of the material x, and µ is the linear absorption coefficient. 
Absorption Coefficient, Mass—The linear absorption coefficient per cm divided by the density of the 
absorber in grams per cubic centimeter.  It is frequently expressed as µ/ρ, where µ is the linear absorption 
coefficient and ρ the absorber density.
Absorption Ratio, Differential—Ratio of concentration of a nuclide in a given organ or tissue to the 
concentration that would be obtained if the same administered quantity of this nuclide were uniformly
distributed throughout the body. 
Activation—The process of making a material radioactive by bombardment with neutrons or protons. 
Activity—The number of radioactive nuclear transformations occurring in a material per unit time (see 
Curie, Becquerel). The term for activity per unit mass is specific activity. 
Activity Median Aerodynamic Diameter (AMAD)—The diameter of a unit-density sphere with the 
same terminal settling velocity in air as that of the aerosol particle whose activity is the median for the 
entire size distribution of the aerosol.
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Acute Exposure, Chemical—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Acute Exposure, Radiation—The absorption of a relatively large amount of radiation (or intake of a 
radioactive material) over a short period of time. 
Acute Radiation Syndrome—The symptoms which taken together characterize a person suffering from 
the effects of intense radiation.  The effects occur within hours or days. 
Ad libitum—Available in excess and freely accessible.  
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit surface area or 
per unit weight of organic carbon of a specific particle size in the soil or sediment to the concentration of 
the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)—See Distribution Coefficient. 
Alpha Particle—A positively charged particle ejected spontaneously from the nuclei of some radioactive 
elements.  It is identical to a helium nucleus, i.e., 2 neutrons and two protons, with a mass number of 4 
and an electrostatic charge of +2. 
Alpha Track—The track of ionized atoms (pattern of ionization) left in a medium by an alpha particle 
that has traveled through the medium. 
Annihilation (Positron-Electron)—An interaction between a positive and a negative electron in which 
they both disappear; their rest mass, being converted into electromagnetic radiation (called annihilation 
radiation) with two 0.51 MeV gamma photons emitted at an angle of 180E to each other. 
Annual Limit on Intake (ALI)—The derived limit for the amount of radioactive material taken into the 
body of an adult worker by inhalation or ingestion in a year.  It is the smaller value of intake of a given 
radionuclide in a year by the reference man that would result in a committed effective dose equivalent of 
5 rem or a committed dose equivalent of 50 rem to any organ or tissue. 
Atom—The smallest particle of an element that cannot be divided or broken up by chemical means.  It 
consists of a central core called the nucleus, which contains protons and neutrons and an outer shell of 
electrons. 
Atomic Mass (u)—The mass of a neutral atom of a nuclide, usually expressed in terms of "atomic mass 
units." The "atomic mass unit" is one-twelfth the mass of one neutral atom of carbon-12; equivalent to 
1.6604x10-24 g. 
Atomic Mass Number—See Mass Number. 
Atomic Number—The number of protons in the nucleus of an atom.  The "effective atomic number" is 
calculated from the composition and atomic numbers of a compound or mixture.  An element of this 
atomic number would interact with photons in the same way as the compound or mixture.  (Symbol: Z). 
Atomic Weight—The weighted mean of the masses of the neutral isotopes of an element expressed in 
atomic mass units. 
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Attenuation—A process by which a beam from a source of radiation is reduced in intensity by
absorption and scattering when passing through some material. 
Attenuation Coefficient—The fractional reduction in the intensity of a beam of radiation as it passes 
through an absorbing medium.  It may be expressed as reduction per unit distance, per unit mass 
thickness, or per atom, and is called the linear, mass, or atomic attenuation coefficient, respectively. 
Auger Effect—The emission of an electron from the extranuclear portion of an excited atom when the 
atom undergoes a transition to a less excited state. 
Background Radiation—The amount of radiation to which a member of the general population is 
exposed from natural sources, such as terrestrial radiation from naturally occurring radionuclides in the 
soil, cosmic radiation originating from outer space, and naturally occurring radionuclides deposited in the 
human body.
Becquerel (Bq)—International System of Units unit of activity and equals that quantity of radioactive 
material in which one transformation (disintegration) occurs per second (see Units). 
 Terabecquerel (TBq)—One trillion becquerel. 

 Gigabecquerel (GBq)—One billion becquerel. 

 Megabecquerel (MBq)—One million becquerel. 

 Kilobecquerel (kBq))—One thousand becquerel.

 Millibecquerel (mBq)—One-thousandth of a becquerel. 

 Microbecquerel (µBq)—One-millionth of a becquerel. 

Beta Particle—An electron that is emitted from the nucleus of an atom during one type of radioactive 
transformation.  A beta particle has a mass and charge equal in magnitude to that of the electron.  The 
charge may be either +1 or -1.  Beta particles with +1 charges are called positrons (symbolized β+), and 
beta particles with -1 charges are called negatrons (symbolized β-). 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
Biologic Effectiveness of Radiation—See Relative Biological Effectiveness. 
Biological Half-time—The time required for a biological system, such as that of a human, to eliminate by 
natural process half of the amount of a substance (such as a chemical substance, either stable or 
radioactive) that has entered it. 
Biomagnification—The progressive increase in the concentration of a bioaccumulated chemical in 
organisms as that chemical is passed from the bottom to the top of the food web. 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
Body Burden, Chemical—The total amount of a chemical found in an animal or human body. 
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Body Burden, Radioactivity—The amount of radioactive material found in an animal or human body. 
Bone Seeker—Any compound or ion which migrates in the body and preferentially deposits into bone. 
Branching—The occurrence of two or more modes by which a radionuclide can undergo radioactive 
decay.  For example, 214Bi can undergo alpha or beta minus decay, 64Cu can undergo beta minus, beta 
plus, or electron capture decay.  An individual atom of a nuclide exhibiting branching disintegrates by one 
mode only. The fraction disintegrating by a particular mode is the "branching fraction" for that mode.  
The "branching ratio" is the ratio of two specified branching fractions (also called multiple 
disintegration). 
Bremsstrahlung—X rays that are produced when a charged particle accelerates (speeds up, slows down, 
or changes direction) in the strong field of a nucleus. 
Buildup Factor—The ratio of the radiation intensity, including both primary and scattered radiation, to
the intensity of the primary (unscattered) radiation. 
Cancer Effect Level (CEL)—The lowest dose of chemical or radiation in a study, or group of studies, 
that produces significant increases in the incidence of cancer (or tumors) between the exposed population 
and its appropriate control.
Capture, Electron—A mode of radioactive decay involving the capture of an orbital electron by its 
nucleus. Capture from a particular electron shell, e.g., K or L shells, is designated as "K-electron capture" 
or "L-electron capture." 
Capture, K-Electron—Electron capture from the K shell by the nucleus of the atom.  Also loosely used 
to designate any orbital electron capture process. 
Carcinogen—A chemical or radiation that is capable of inducing cancer. 
Carcinoma—Malignant neoplasm composed of epithelial cells, regardless of their derivation. 
Case-Control Study—A type of epidemiological study which examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest 
some potential topics for scientific research but are not actual research studies. 
Cataract—A clouding of the crystalline lens of the eye which obstructs the passage of light. 
Ceiling Value—A concentration of a substance that should not be exceeded, even temporarily. 
Charged Particle—A nuclear particle, atom, or molecule carrying a positive or negative charge. 
Chronic Exposure—A long-term, continuous exposure to a chemical or radioactive material.  For 
example, exposure to a chemical for 365 days or more, as specified in the Toxicological Profiles. 
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Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
Collective Dose—The sum of the individual doses received in a given period of time by a specified 
population from exposure to a specified source of radiation.  Collective dose is expressed in units such as 
man-rem and person-sievert. 
Compton Effect—An attenuation process observed for x- or gamma radiation in which an incident 
photon interacts with an orbital electron of an atom to produce a recoil electron and a scattered photon 
whose energy is less than the incident photon. 
Containment—The confinement of a chemical or radioactive substance in such a way that it is prevented 
from being dispersed from its container or into the environment, or is released only at a specified rate. 
Contamination—Deposition of a stable or radioactive substance in any place where it is not desired. 
Cosmic Rays—High-energy particulate and electromagnetic radiations that originate outside the earth's 
atmosphere and interact with the atmosphere to produce a shower of secondary cosmic rays. 
Count (Radiation Measurements)—The external indication of a radiation-measuring device designed to 
enumerate ionizing events.  It refers to a single detected event.  The term “count rate” refers to the total 
number registered in a given period of time.  The term is sometimes erroneously used to designate a 
disintegration, ionizing event, or voltage pulse. 
Counter, Gas-flow Proportional (GPC)—An instrument for detecting beta particle radiation.  Beta 
particles are detected by ionization of the counter gas which results in an electrical impulse at an anode 
wire. 
Counter, Geiger-Mueller (GM counter)—Highly sensitive, gas-filled radiation-measuring device that 
detects (counts) individual photons or particulate radiation. 
Counter, Scintillation—The combination of a crystal or phosphor, photomultiplier tube, and associated 
circuits for counting light emissions produced in the phosphors by ionizing radiation.  Scintillation 
counters generally are more sensitive than GM counters for gamma radiation. 
Counting, Cerenkov—Relatively energetic β-particles pass through a transparent medium of high 
refractive index and a highly-directional, bluish-white light ("Cerenkov" light) is emitted.  This light is 
detected using liquid scintillation counting equipment.  
Cross-sectional Study—A type of epidemiological study of a group or groups which examines the 
relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
Curie (Ci)—A unit of radioactivity.  One curie equals that quantity of radioactive material in which there 
are 3.7x1010 nuclear transformations per second. The activity of 1 gram of radium is approximately 1 Ci. 
Attocurie (aCi)—One-thousandth of a femtocurie (3.7x10-8 disintegrations per second). 
 Femtocurie (fCi)—One-billionth of a microcurie (3.7x10-5 disintegrations per second).
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 Megacurie (MCi)—One million curies (3.7x1016 disintegrations per second). 
 Microcurie (µCi)—One-millionth of a curie (3.7x104 disintegrations per second). 
 Millicurie (mCi)—One-thousandth of a curie (3.7x107 disintegrations per second). 
 Nanocurie (nCi)—One-billionth of a curie (3.7x101 disintegrations per second). 
 Picocurie (pCi)—One-millionth of a microcurie (3.7x10-2 disintegrations per second). 
Daughter Products—See Progeny and Decay Product 
Decay Chain or Decay Series—A sequence of radioactive decays (transformations) beginning with one 
nucleus. The initial nucleus, the parent, decays into a daughter or progeny nucleus that differs from the 
first by whatever particles were emitted during the decay.  If further decays take place, the subsequent 
nuclei are also usually called daughters or progeny.  Sometimes, to distinguish the sequence, the daughter 
of the first daughter is called the granddaughter, etc. 
Decay Constant (λ)—The fraction of the number of atoms of a radioactive nuclide which decay in unit 
time (see Disintegration Constant). 
Decay Product, Daughter Product, Progeny—A new nuclide formed as a result of radioactive decay.  
A nuclide resulting from the radioactive transformation of a radionuclide, formed either directly or as the 
result of successive transformations in a radioactive series.  A decay product (daughter product or 
progeny) may be either radioactive or stable. 
Decay, Radioactive—Transformation of the nucleus of an unstable nuclide by spontaneous emission of 
radiation, such as charged particles and/or photons (see Disintegration). 
Delta Ray—An electron removed from an atom of a medium that is irradiated, or through which 
radiation passes, during the process of ionization (also called secondary electron).  Delta rays cause a 
track of ionizations along their path. 
Derived Air Concentration (DAC)—The concentration of radioactive material in air that, if breathed by
the reference man for a working year of 2000 hours under conditions of light work (at a rate of 1.2 liters 
of air per hour), would result in an intake of one ALI (see Annual Limit on Intake). 
Deterministic Effect—A health effect, the severity of which varies with the dose and for which a 
threshold is believed to exist (also called a non-stochastic effect). 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical or radiation prior to conception (either parent), during prenatal development, 
or postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any
point in the life span of the organism. 
Disintegration Constant—Synonymous with decay constant.  The fraction of the number of atoms of a 
radioactive material that decays per unit time (see Decay Constant.) 
Disintegration, Nuclear—A spontaneous nuclear transformation (radioactivity) characterized by the 
emission of energy and mass from the nucleus.  When large numbers of nuclei are involved, the process is 
characterized by a definite half-life (see Transformation, Nuclear). 
Distribution Coefficient (Kd)—Describes the distribution of a chemical between the solid and aqueous 
phase at thermodynamic equilibrium, is given as follows: 
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[C]
K = s d [C]w , Units = (L solution)/(kg solid),  
where [C]s is the concentration of the chemical associated with the solid phase in units of (mg)/(kg solid), 
and [C]w is the concentration of the chemical in the aqueous phase in units of (mg)/(L solution).  As the 
magnitude of Kd decreases, the potential mobility of the chemical to groundwater systems increases and 
vice versa. 
Dose—A general term denoting the quantity of a substance, radiation, or energy absorbed.  For special 
purposes it must be appropriately qualified.  If unqualified, it refers to radiation absorbed dose. 
Absorbed Dose—The energy imparted to matter by ionizing radiation per unit mass of irradiated 
material at the place of interest.  The unit of absorbed dose is the rad.  One rad equals 100 ergs 
per gram.  In SI units, the absorbed dose is the gray which is 1 J/kg (see Rad). 
Cumulative Dose (Radiation)—The total dose resulting from repeated or continuous exposures 
to radiation. 
Dose Assessment—An estimate of the radiation dose to an individual or a population group usually by
means of predictive modeling techniques, sometimes supplemented by the results of measurement. 
Dose Equivalent (DE)—A quantity used in radiation safety practice to account for the relative biological 
effectiveness of the several types of radiation.  It expresses all radiations on a common scale for 
calculating the effective absorbed dose.  The NRC defines it as the product of the absorbed dose, the 
quality factor, and all other modifying factors at the location of interest.  ICRP has changed its definition 
to be the product of the absorbed dose and the radiation weighting factor.  (The unit of dose equivalent is 
the rem.  In SI units, the dose equivalent is the sievert, which equals 100 rem.) 
Dose, Fractionation—A method of administering therapeutic radiation in which relatively small doses 
are given daily or at longer intervals. 
Dose, Protraction—A method of administering therapeutic radiation by delivering it continuously over a 
relatively long period at a low dose rate. 
Dose, Radiation—The amount of energy imparted to matter by ionizing radiation per unit mass of the 
matter, usually expressed as the unit rad, or in SI units, the gray.  100 rad'1 gray (Gy) (see Absorbed 
Dose). 
Committed Dose Equivalent (HT,50)—The dose equivalent to organs or tissues of reference (T) 
that will be received from an intake of radioactive material by an individual during the 50 years 
following the intake. 
Committed Effective Dose Equivalent (HE,50)—The sum of the products of the weighting 
factors applicable to each of the body organs or tissues that are irradiated and the committed dose 
equivalent to those organs or tissues. 
Effective Dose —A dose value that attempts to normalize the detriment to the body (for cancer 
mortality and morbidity, hereditary effects, and years of life lost) from a non-uniform exposure to 
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that of a uniform whole body exposure.  Effective dose is calculated as the sum of products of the 
equivalent dose and the tissue weighting factor (wT) for each tissue exposed.  (E = ∑DT,R wR wT)). 
Effective Dose Equivalent (HE)—This dose type is limited to internal exposures and is the sum
of the products of the dose equivalent to the organ or tissue (HT) and the weighting factors (wT) 
applicable to each of the body organs or tissues that are irradiated.  (HE = ∑wT HT). 
Equivalent Dose—A dose quantity that places the biological effect of all radiation types on a 
common scale for calculating tissue damage.  Alpha particles, for example, are considered to 
cause 20 times more damage than gamma rays.  Equivalent dose is calculated as the sum of 
products of the average absorbed dose (in gray) in an organ or tissue (DT,R) from each type of 
radiation and the radiation weighting factor (wR) for that radiation (∑DT,R wR). 
External Dose—That portion of the dose equivalent received from radiation sources outside the 
body. 
Internal Dose—That portion of the dose equivalent received from radioactive material taken into 
the body. 
Limit—A permissible upper bound on the radiation dose. 
Maximum Permissible Dose (MPD)—The greatest dose equivalent that a person or specified 
part thereof shall be allowed to receive in a given period of time. 
Median Lethal Dose (MLD)—Dose of radiation required to kill, within a specified period 
(usually 30 days), 50% of the individuals in a large group of animals or organisms.  Also called 
the LD50, or LD50/30 if for 30 days. 
Threshold Dose—The minimum absorbed dose that will produce a detectable degree of any
given effect. 
Tissue Dose—Absorbed dose received by tissue in the region of interest, expressed in rad (see 
Dose, Gray, and Rad). 
Dose Rate—The amount of radiation dose delivered per unit time.  Generically, the rate at which 
radiation dose is delivered to any material or tissue. 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
Dosimetry—Quantification of radiation doses to cells, tissues, organs, individuals or populations 
resulting from radiation exposures. 
Early Effects (of radiation exposure)—Effects that appear within 60 days of an acute exposure. 
Electron—A stable elementary particle having an electric charge equal to ±1.60210x10-19 C (Coulombs) 
and a rest mass equal to 9.1091x10-31 kg. A positron is a positively charged "electron" (see Positron). 
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Electron Volt—A unit of energy equivalent to the energy gained by an electron in passing through a 
potential difference of one volt.  Larger multiple units of the electron volt are frequently used:  keV for 
thousand or kilo electron volts; MeV for million or mega electron volts (eV).  1 eV=1.6x10-12 erg. 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurred. The terms, as used here, include malformations and variations, altered growth, and in
utero death. 
Energy—Capacity for doing work.  Gravitationally, "potential energy" is the energy inherent in a mass 
because of its spatial relation to other masses.  Chemically or radiologically, “potential energy” is the 
energy released when a chemical reaction or radiological transformation goes to completion.  "Kinetic 
energy" is the energy possessed by a mass because of its motion (SI unit: joules): 
Binding Energy (Electron)—The amount of energy that must be expended to remove an 
electron from an atom. 
Binding Energy (Nuclear)—The energy represented by the difference in mass between the sum
of the component parts and the actual mass of the nucleus.  It represents the amount of energy
that must be expended to break a nucleus into its component neutrons and protons. 
Excitation Energy—The energy required to change a system from its ground state to an excited 
state. Each different excited state has a different excitation energy. 
Ionizing Energy—The energy required to knock an electron out of an atom.  The average energy
lost by electrons or beta particles in producing an ion pair in air or in soft tissue is about 34 eV. 
Radiant Energy—The energy of electromagnetic radiation, such as radio waves, visible light, x 
and gamma rays. 
Enrichment, Isotopic—An isotopic separation process by which the relative abundances of the isotopes 
of a given element are altered, thus producing a form of the element that has been enriched in one or more 
isotopes and depleted in others.  In uranium enrichment, the percentage of uranium-235 in natural 
uranium can be increased from 0.7% to >90% in a gaseous diffusion process based on the different 
thermal velocities of the constituents of natural uranium (234U, 235U, 238U) in the molecular form UF6. 
EPA Health Advisory—An estimate of acceptable drinking water levels for a chemical substance based 
on health effects information. A health advisory is not a legally enforceable federal standard, but serves 
as technical guidance to assist federal, state, and local officials. 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.   
Equilibrium, Radioactive—In a radioactive series, the state which prevails when the ratios between the 
activities of two or more successive members of the series remains constant. 
Secular Equilibrium—If a parent element has a very much longer half-life than the daughters 
(so there is not appreciable change in its amount in the time interval required for later products to 
attain equilibrium) then, after equilibrium is reached, equal numbers of atoms of all members of 
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the series disintegrate in unit time.  This condition is never exactly attained, but is essentially
established in such a case as 226Ra and its transformation series to stable 206Pb. The half-life of 
226Ra is about 1,600 years; of 222Rn, approximately 3.82 days, and of each of the subsequent 
members, a few minutes.  After about a month, essentially the equilibrium amount of radon is 
present; then (and for a long time) all members of the series disintegrate the same number of 
atoms per unit time.  At this time, the activity of the daughter is equal to the activity of the parent. 
Transient Equilibrium—If the half-life of the parent is short enough so the quantity present 
decreases appreciably during the period under consideration, but is still longer than that of 
successive members of the series, a stage of equilibrium will be reached after which all members 
of the series decrease in activity exponentially with the period of the parent.  At this time, the 
ratio of the parent activity to the daughter activity is constant. 
Equilibrium, Electron—The condition in a radiation field where the energy of the electrons entering a 
volume equals the energy of the electrons leaving that volume. 
Excitation—The addition of energy to a system, thereby transferring it from its ground state to an excited 
state. Excitation of a nucleus, an atom, or a molecule can result from absorption of photons or from
inelastic collisions with other particles.  The excited state of an atom is an unstable or metastable state and
will return to ground state by radiation of the excess energy. 
Exposure (Chemical)—Contact of an organism with a chemical or physical agent.  Exposure is 
quantified as the amount of the agent available at the exchange boundaries of the organism (e.g., skin, 
lungs, gut) and available for absorption. 
Exposure (Radiation)—Subjection to ionizing radiation or to a radioactive material.  For example, 
exposure in air is a measure of the ionization produced in air by x or gamma radiation; the sum of the 
electric charges on all ions of one sign produced in air when all electrons liberated by photons in a 
volume of air are completely stopped in air (dQ), divided by the mass of the air in the volume (dm). The 
unit of exposure in air is the roentgen, or coulomb per kilogram (SI units). One roentgen is equal to 
2.58x10-4 coulomb per kilogram (C/kg). 
Fission, Nuclear—A nuclear transformation characterized by the splitting of a nucleus into at least two 
other nuclei with emission of several neutrons, accompanied by the release of a relatively large amount of 
energy. 
Gamma Ray, Penetrating—Short wavelength electromagnetic radiation of nuclear origin. 
Genetic Effect of Radiation—Inheritable change, chiefly mutations, produced by the absorption of 
ionizing radiation by germ cells.  Genetic effects have not been observed in any human population 
exposed at any dose level. 
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
Gray (Gy)—SI unit of absorbed dose, 1 J/kg.  One gray equals 100 rad (see Units). 
Half-life, Effective—See Half-Time, Effective. 
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Half-life, Radioactive—Time required for a radioactive substance to lose 50% of its activity by decay.  
Each radio-nuclide has a unique physical half-life.  Known also as physical half-time and symbolized as 
Tr or Trad. 
Half-time, Biological—Time required for an organ, tissue, or the whole body to eliminate one-half of any 
absorbed substance by regular processes of elimination.  This is the same for both stable and radioactive 
isotopes of a particular element, and is sometimes referred to as half-time, symbolized as tbiol or Tb. 
Half-time, Effective—Time required for a radioactive element in an organ, tissue, or the whole body to 
be diminished 50% as a result of the combined action of radioactive decay and biological elimination, 
symbolized as Te or Teff. 
Biological half-time × Radioactive half-lifeEffective half-time = Biological half-time + Radioactive half-life 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects. 
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals. 

Immunological Effects—Functional changes in the immune response. 

In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.  Literally, “in 

glass.” 

In Vivo—Occurring within the living organism.  Literally, “in life.” 

Intensity—Amount of energy per unit time passing through a unit area perpendicular to the line of 

propagation at the point in question.
 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
Internal Conversion—Process in which a gamma ray knocks an electron out of the same atom from
which the gamma ray was emitted.  The ratio of the number of internal conversion electrons to the 
number of gamma quanta emitted in the de-excitation of the nucleus is called the "conversion ratio." 
Ion—Atomic particle, atom or chemical radical bearing a net electrical charge, either negative or positive. 
Ion Pair—Two particles of opposite charge, usually referring to the electron and positive atomic or 
molecular residue resulting after the interaction of ionizing radiation with the orbital electrons of atoms. 
Ionization—The process by which a neutral atom or molecule acquires a positive or negative charge. 
Primary Ionization—(1) In collision theory:  the ionization produced by the primary particles as 
contrasted to the "total ionization" which includes the "secondary ionization" produced by delta 
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rays.  (2) In counter tubes:  the total ionization produced by incident radiation without gas 
amplification. 
Specific Ionization—Number of ion pairs per unit length of path of ionizing radiation in a 
medium; e.g., per centimeter of air or per micrometer of tissue.
Total Ionization—The total electric charge of one sign on the ions produced by radiation in the 
process of losing its kinetic energy. For a given gas, the total ionization is closely proportional to 
the initial ionization and is nearly independent of the nature of the ionizing radiation.  It is 
frequently used as a measure of absorption of radiation energy. 
Ionization Density—Number of ion pairs per unit volume. 
Ionization Path (Track)—The trail of ion pairs produced by an ionizing particle in its passage through 
matter. 
Ionizing Radiation—Any radiation capable of knocking electrons out of atoms and producing ions.  
Examples: alpha, beta, gamma and x rays, and neutrons. 
Isobars—Nuclides having the same mass number but different atomic numbers.
Isomers—Nuclides having the same number of neutrons and protons but capable of existing, for a 
measurable time, in different quantum states with different energies and radioactive properties.  
Commonly the isomer of higher energy decays to one with lower energy by the process of isomeric 
transition. 
Isotopes—Nuclides having the same number of protons in their nuclei, and hence the same atomic
number, but differing in the number of neutrons, and therefore in the mass number.  Identical chemical 
properties exist in isotopes of a particular element.  The term should not be used as a synonym for nuclide 
because isotopes refer specifically to different nuclei of the same element. 
 Stable Isotope—A nonradioactive isotope of an element. 
Joule—The S.I. unit for work and energy.  It is equal to the work done by raising a mass of one newton 
through a distance of one meter (J = Nm), which corresponds to about 0.7 ft-pound. 
Kerma (k)—A measure of the kinetic energy transferred from gamma rays or neutrons to a unit mass of 
absorbing medium in the initial collision between the radiation and the absorber atoms.  The SI unit is 
J/kg. The special name of this unit is the rad (traditional system of units) or Gray (SI). 
Labeled Compound—A compound containing one or more radioactive atoms intentionally added to its 
structure. By observations of radioactivity or isotopic composition, this compound or its fragments may
be followed through physical, chemical, or biological processes.
Late Effects (of radiation exposure)—Effects which appear 60 days or more following an acute 
exposure.
LD50/30—The dose of a chemical or radiation expected to cause 50% mortality in those exposed within 
30 days. For radiation, this is about 350 rad (3.5 gray) received by humans over a short period of time. 
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Lethal Concentration(Lo) (LCLo)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals. 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population 
within a specified time, usually 30 days. 
Lethal Dose(Lo) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that is 
expected to have caused death in humans or animals within a specified time, usually 30 days. 
Lethal Dose(50) (LD50)—The dose of a chemical which has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
Linear Energy Transfer (LET)—A measure of the energy that a charged particle transfers to a material 
per unit path length.  
Average LET—The energy of a charged particle divided by the length of the path over which it 
deposits all its energy in a material.  This is averaged over a number of particles. 
High-LET—Energy transfer characteristic of heavy charged particles such as protons and alpha 
particles where the distance between ionizing events is small on the scale of a cellular nucleus. 
Low-LET—Energy transfer characteristic of light charged particles such as electrons produced 
by x and gamma rays where the distance between ionizing events is large on the scale of a 
cellular nucleus. 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest dose of chemical in a study, or group 
of studies, that produces statistically or biologically significant increases in frequency or severity of 
adverse effects between the exposed population and its appropriate control. 
Lung Clearance Class (fast, F; medium, M; slow, S)—A classification scheme for inhaled material 
according to its rate of clearance from the pulmonary region of the lungs to the blood and the 
gastrointestinal tract. 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
Mass Numbers (A)—The number of nucleons (protons and neutrons) in the nucleus of an atom.
Minimal Risk Level—An estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse noncancerous effects over a specified duration of exposure. 
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Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population. 
Mutagen—A substance that causes changes (mutations) in the genetic material in a cell.  Mutations can 
lead to birth defects, miscarriages, or cancer. 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
substance. 
Neutrino (ν)—A neutral particle of infinitesimally small rest mass emitted during beta plus or beta minus 
decay.  This particle accounts for conservation of energy in beta plus and beta minus decays.  It plays no 
role in damage from radiation. 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a substance at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
Nuclear Reactor—A power plant that heats the medium (typically water) by using the energy released 
from the nuclear fission of uranium or plutonium isotopes instead of burning coal, oil, or natural gas.  All 
of these sources of energy simply heat water and use the steam which is produced to turn turbines that 
make electricity or propel a ship. 
Nucleon—Common name for a constituent particle of the nucleus.  Applied to a proton or neutron. 
Nuclide—A species of atom characterized by the constitution of its nucleus.  The nuclear constitution is 
specified by the number of protons (Z), number of neutrons (N), and energy content; or, alternatively, by
the atomic number (Z), mass number A(N+Z), and atomic mass.  To be regarded as a distinct nuclide, the 
atom must be capable of existing for a measurable time.  Thus, nuclear isomers are separate nuclides, 
whereas promptly decaying excited nuclear states and unstable intermediates in nuclear reactions are not 
so considered. 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) which represents the best estimate of relative risk (risk as a ratio of the 
incidence among subjects exposed to a particular risk factor divided by the incidence among subjects who 
were not exposed to the risk factor).  An odds ratio of greater than 1 is considered to indicate greater risk 
of disease in the exposed group compared to the unexposed. 
Pair Production—An absorption process for x- and gamma radiation in which the incident photon is 
absorbed in the vicinity of the nucleus of the absorbing atom, with subsequent production of an electron 
and positron pair (see annihilation).  This reaction can only occur for incident photon energies exceeding 
1.02 MeV. 
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Parent—Any radionuclide nuclide which, upon disintegration, yields a new nuclide (termed the progeny
or daughter), either directly or as a later member of a radioactive series. 
Permissible Exposure Limit (PEL)—A maximum allowable atmospheric level of a substance in 
workplace air averaged over an 8-hour shift. 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models: data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments 
which, in general, do not represent real, identifiable anatomic regions of the body whereas the 
physiologically-based model compartments represent real anatomic regions of the body.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism. Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism and excretion of chemicals by the body. 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically-based dose-
response model which quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance. 
Physiologically Based Pharmacokinetic (PBPK) Model—A model comprising a series of 
compartments representing organs or tissue groups with realistic weights and blood flows.  These models 
require a variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output,
alveolar ventilation rates and, possibly membrane permeabilities.  The models also utilize biochemical 
information such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also 
called biologically based tissue dosimetry models. 
Photoelectric Effect—An attenuation process observed for x and gamma radiation in which an incident 
photon interacts with a tightly bound inner orbital electron of an atom delivering all of its energy to knock
the electron out of the atom.  The incident photon disappears in the process. 
Photon—A quantum of electromagnetic energy (E) whose value is the product of its frequency (ν) in 
hertz and Planck's constant (h).  The equation is:  E = hν. 
Population dose—See Collective dose.
Positron—A positively charged electron. 
Potential, Ionization—The energy expressed as electron volts (eV) necessary to separate one electron 
from an atom, resulting in the formation of an ion pair. 
Power, Stopping—A measure of the ability of a material to absorb energy from an ionizing particle 
passing through it; the greater the stopping power, the greater the energy absorbing ability (see Linear 
Energy Transfer). 
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Progeny—The decay product or daughter products resulting after a radioactive decay or a series of 
radioactive decays.  The progeny can also be radioactive, and the chain continues until a stable nuclide is 
formed. 
Proton—Elementary nuclear particle with a positive electric charge equal numerically to the charge of 
the electron and a rest mass of 1.007 mass units. 
Quality—A term describing the distribution of the energy deposited by a particle along its track; 
radiations that produce different densities of ionization per unit intensity are said to have different 
"qualities." 
Quality Factor (Q)—The linear-energy-transfer-dependent factor by which absorbed doses are 
multiplied to obtain (for radiation protection purposes) a quantity that expresses - on a common scale for 
all ionizing radiation - the approximate biological effectiveness of the absorbed dose. 
Type of radiation Quality Factor 
X, gamma, or beta 1 
Alpha particles 20
Neutrons of unknown energy 10 
High energy protons 10 
Rad—The traditional unit of absorbed dose equal to 100 ergs per gram, or 0.01 joule per kilogram (0.01 
Gy) in any medium (see Absorbed Dose). 
Radiation—The emission and propagation of energy through space or through a material medium in the 
form of waves (e.g., the emission and propagation of electromagnetic waves, or of sound and elastic 
waves). The term radiation or radiant energy, when unqualified, usually refers to electromagnetic 
radiation. Such radiation commonly is classified according to frequency, as microwaves, infrared, visible 
(light), ultraviolet, and x and gamma rays (see Photon.) and, by extension, corpuscular emission, such as 
alpha and beta radiation, neutrons, or rays of mixed or unknown type, as cosmic radiation. 
Radiation, Annihilation—Photons produced when an electron and a positron unite and cease to 
exist. The annihilation of a positron-electron pair results in the production of two photons, each 
of 0.51 MeV energy. 
Radiation, Background—See Background Radiation. 
Radiation, Characteristic (Discrete)—Radiation originating from an excited atom after removal 
of an electron from an atom.  The wavelength of the emitted radiation is specific, depending only
on the element and particular energy levels involved. 
Radiation, External—Radiation from a source outside the body. 
Radiation, Internal—Radiation from a source within the body (as a result of deposition of 
radionuclides in body tissues). 
Radiation, Ionizing—Any electromagnetic or particulate radiation capable of producing ions, 
directly or indirectly, in its passage through matter (see Radiation). 
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Radiation, Monoenergetic—Radiation of a given type in which all particles or photons originate 
with and have the same energy. 
Radiation, Scattered—Radiation which during its passage through a substance, has been 
deviated in direction. It may also have been modified by a decrease in energy. 
Radiation, Secondary—A particle or ray that is produced when the primary radiation interacts 
with a material, and which has sufficient energy to produce its own ionization, such as 
bremsstrahlung or electrons knocked from atomic orbitals with enough energy to then produce 
ionization (see Delta Rays). 
Radiation Weighting Factor (also called Quality Factor)—In radiation protection, a factor (1 for x-
rays, gamma rays, beta particles; 20 for alpha particles) weighting the absorbed dose of radiation of a 
specific type and energy for its effect on tissue. 
Radioactive Material—Material containing radioactive atoms. 
Radioactivity—Spontaneous nuclear transformations that result in the formation of new elements.  These 
transformations are accomplished by emission of alpha or beta particles from the nucleus or by the 
capture of an orbital electron. Each of these reactions may or may not be accompanied by a gamma 
photon. 
Radioactivity, Artificial—Man-made radioactivity produced by particle bombardment or 
nuclear fission, as opposed to naturally occurring radioactivity.
Radioactivity, Induced—Radioactivity produced in a substance after bombardment with 
neutrons or other particles.  The resulting activity is "natural radioactivity" if formed by nuclear 
reactions occurring in nature and "artificial radioactivity" if the reactions are caused by man. 
Radioactivity, Natural—The property of radioactivity exhibited by more than 50 naturally
occurring radionuclides. 
Radioisotope—An unstable or radioactive isotope of an element that decays or disintegrates 
spontaneously, emitting radiation.   
Radionuclide—Any radioactive isotope of any element.  Approximately 5,000 natural and artificial 
radioisotopes have been identified. 
Radiosensitivity—Relative susceptibility of cells, tissues, organs, organisms, or any living substance to 
the injurious action of radiation.  Radiosensitivity and its antonym, radioresistance, are used 
comparatively, rather than absolutely. 
Reference Dose (RfD)—An estimate of the daily exposure of the human population to a potential hazard 
that is likely to be without risk of deleterious effects during a lifetime.  The RfD is operationally derived 
from the NOAEL (from animal and human studies) by a consistent application of uncertainty factors that 
reflect various types of data used to estimate RfDs and an additional modifying factor, which is based on 
a professional judgment of the entire database on the chemical.  The RfDs are not applicable to non-
threshold effects such as cancer. 
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Relative Biological Effectiveness (RBE)—The RBE is a factor used to compare the biological 
effectiveness of absorbed radiation doses (i.e., rad) due to different types of ionizing radiation.  More 
specifically, it is the experimentally determined ratio of an absorbed dose of a radiation in question to the 
absorbed dose of a reference radiation (typically 60Co gamma rays or 200 kVp x rays) required to produce 
an identical biological effect in a particular experimental organism or tissue (see Quality Factor). 
Rem—The traditional unit of dose equivalent that is used in the regulatory, administrative, and 
engineering design aspects of radiation safety practice.  The dose equivalent in rem is numerically equal 
to the absorbed dose in rad multiplied by the quality factor (1 rem is equal to 0.01 sievert). 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
CERCLA. Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an amount 
established by regulation either under CERCLA or under Sect. 311 of the Clean Water Act.  Quantities 
are measured over a 24-hour period. 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system. 
Roentgen (R)—A unit of exposure (in air) to ionizing radiation.  It is the amount of x or gamma rays
required to produce ions carrying 1 electrostatic unit of electrical charge in 1 cubic centimeter of dry air 
under standard conditions.  Named after William Roentgen, a German scientist who discovered x rays in 
1895. 
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
Self-Absorption—Absorption of radiation (emitted by radioactive atoms) by the material in which the 
atoms are located; in particular, the absorption of radiation within a sample being assayed. 
Short-Term Exposure Limit (STEL)—The maximum concentration to which workers can be exposed 
for up to 15 minutes continually.  No more than four excursions are allowed per day, and there must be at 
least 60 minutes between exposure periods.  The daily TLV-TWA may not be exceeded. 
SI Units—The International System of Units as defined by the General Conference of Weights and 
Measures in 1960. These units are generally based on the meter/kilogram/second units, with special 
quantities for radiation including the becquerel, gray, and sievert. 
Sickness, Acute Radiation (Syndrome)—The complex symptoms and signs characterizing the condition 
resulting from excessive exposure of the whole body (or large part) to ionizing radiation.  The earliest of 
these symptoms are nausea, fatigue, vomiting, and diarrhea, and may be followed by loss of hair 
(epilation), hemorrhage, inflammation of the mouth and throat, and general loss of energy.  In severe 
cases, where the radiation dose is relatively high (over several hundred rad or several gray), death may
occur within two to four weeks.  Those who survive six weeks after exposure of a single high dose of 
radiation may generally be expected to recover. 
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Sievert (Sv)—The SI unit of any of the quantities expressed as dose equivalent. The dose equivalent in 
sieverts is equal to the absorbed dose, in gray, multiplied by the quality factor (1 sievert equals 100 rem).  
The sievert is also the SI unit for effective dose equivalent, which is the sum of the products of the dose 
equivalent to each organ or tissue and its corresponding tissue weighting factor. 
Specific-Activity—Radioactivity per unit mass of a radionuclide, expressed, for example, as Ci/gram or 
Bq/kilogram.
Specific Energy—The actual energy per unit mass deposited per unit volume in a small target, such as 
the cell or cell nucleus, as the result of one or more energy-depositing events.  This is a stochastic 
quantity as opposed to the average value over a large number of instance (i.e., the absorbed dose). 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
Stochastic Effect—A health effect that occurs randomly and for which the probability of the effect 
occurring, rather than its severity, is assumed to be a linear function of dose without a threshold (also 
called a nondeterministic effect). 
Stopping Power—The average rate of energy loss of a charged particle per unit thickness of a material or 
per unit mass of material traversed. 
Surface-seeking Radionuclide—A bone-seeking internal emitter that deposits and remains on the bone 
surface for a long period of time, although it may eventually diffuse into the bone mineral.  This contrasts 
with a volume seeker, which deposits more uniformly throughout the bone volume. 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Target Theory (Hit Theory)—A theory explaining some biological effects of radiation on the basis that 
ionization, occurring in a discrete volume (the target) within the cell, directly causes a lesion which 
subsequently results in a physiological response to the damage at that location.  One, two, or more "hits" 
(ionizing events within the target) may be necessary to elicit the response. 
Teratogen—A chemical that causes birth defects. 
Threshold Limit Value (TLV®)—The maximum concentration of a substance to which most workers 
can be exposed without adverse effect.  TLV is a term used exclusively by the ACGIH.  Other terms used 
to express similar concepts are the MAC (Maximum Allowable Concentration) and PEL (Permissible 
Exposure Limits). 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
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Tissue Weighting Factor (Wt)—Organ- or tissue-specific factor by which the equivalent dose is 
multiplied to give the portion of the effective dose for that organ or tissue.  Recommended values of 
tissue weighting factors are: 
Tissue/Organ Tissue Weighting Factor 
Gonads 0.70 
Bone marrow (red) 0.12 
Colon 0.12 
Lung 0.12 
Stomach 0.12 
Bladder 0.05 
Breast 0.05 
Liver 0.05 
Esophagus 0.05 
Thyroid 0.05 
Skin 0.01 
Bone surface 0.01 
Remainder (adrenals, brain, upper large 0.05 
intestine, small intestine, pancreas, spleen, 
thymus, and uterus) 
Toxic Dose (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, which 
is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution and elimination of toxic compounds in the living organism. 
Toxicosis—A diseased condition resulting from poisoning.
Transformation, Nuclear—The process of radioactive decay by which a nuclide is transformed into a 
different nuclide by absorbing or emitting particulate or electromagnetic radiation. 
Transition, Isomeric—The process by which a nuclide decays to an isomeric nuclide (i.e., one of the 
same mass number and atomic number) of lower quantum energy.  Isomeric transitions (often abbreviated 
I.T.) proceed by gamma ray and internal conversion electron emission. 
Tritium—The hydrogen isotope with one proton and two neutrons in the nucleus (Symbol: 3H).  It is 
radioactive and has a physical half-life of 12.3 years. 
Unattached Fraction—That fraction of the radon daughters, usually 218Po and 214Po, which has not yet 
attached to a dust particle or to water vapor. As a free atom, it has a high probability of being exhaled and 
not retained within the lung.  It is the attached fraction which is primarily retained. 
Uncertainty Factor (UF)—A factor used in operationally deriving the RfD from experimental data.  UFs 
are intended to account for (1) the variation in sensitivity among the members of the human population,
(2) the uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating 
from data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using 
LOAEL data rather than NOAEL data.  Usually each of these factors is set equal to 10. 
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Units, Prefixes—Many units of measure are expressed as submultiples or multiples of the primary unit 
(e.g., 10-3 curie is 1 mCi and 103 becquerel is 1 kBq). 
Factor Prefix Symbol Factor Prefix Symbol 
10-18 atto A 103 kilo k
10-15 femto F 106 mega M 
10-12 pico p 109 giga G 
10-9 nano N 1012 tera T 
10-6 micro Μ 1015 peta P 
10-3 milli M 1018 exa E 
10-2 centi C 
Units, Radiological—
Units Equivalents 
Becquerel* (Bq) 1 disintegration per second = 2.7x10-11 Ci
Curie (Ci) 3.7x1010 disintegrations per second = 3.7x1010 Bq 
Gray* (Gy) 1 J/kg = 100 rad 
Rad (rad) 100 erg/g = 0.01 Gy
Rem (rem) 0.01 sievert 
Sievert* (Sv) 100 rem
*International Units, designated (SI) 
Working Level (WL)—Any combination of short-lived radon daughters in 1 liter of air that will result in 
the ultimate emission of 1.3x105 MeV of potential alpha energy. 
Working Level Month (WLM)—A unit of exposure to radon daughters corresponding to the product of 
the radon daughter concentration in Working Level (WL) and the exposure time in nominal months 
(1 nominal month = 170 hours).  Inhalation of air with a concentration of 1 WL of radon daughters for 
170 working hours results in an exposure of 1 WLM.
X rays—Penetrating electromagnetic radiations whose wave lengths are very much shorter than those of 
visible light. They are usually produced by bombarding a metallic target with fast electrons in a high 
vacuum.  X rays (called characteristic x rays) are also produced when an orbital electron falls from a high 
energy level to a low energy level. 
Zero-Threshold Linear Hypothesis (or No-Threshold Linear Hypothesis)—The assumption that a 
dose-response curve derived from data in the high dose and high dose-rate ranges may be extrapolated 
through the low dose and low dose range to zero, implying that, theoretically, any amount of radiation 
will cause some damage. 
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APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or 
action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level 
above the MRL does not mean that adverse health effects will occur. 
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
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are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with 
participation from other federal agencies and comments from the public.  They are subject to change as 
new information becomes available concomitant with updating the toxicological profiles.  Thus, MRLs in 
the most recent toxicological profiles supersede previously published levels.  For additional information 
regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease 
Registry, 1600 Clifton Road NE, Mailstop F-32, Atlanta, Georgia 30333. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Cobalt 
CAS Number: 10026-24-1 
Date: March 2004 
Profile Status: Final 
Route: [x] Inhalation [ ] Oral 
Duration: [ ] Acute   [ ] Intermediate   [x] Chronic 
Key to figure: 26 
Species: human 
Minimal Risk Level: 1x10-4 [ ] mg/kg/day  [ ] ppm [x] mg/m3 
Reference: 
Nemery B, Casier P, Roosels D, et al.  1992.  Survey of cobalt exposure and respiratory health in 
diamond polishers.  Am Rev Respir Dis 145:610-616. 
Experimental design: 
Nemery et al. (1992) conducted a cross-sectional study of cobalt exposure and respiratory effects in 
diamond polishers.  The study group was composed of 194 polishers working in 10 different workshops.  
In two of these workshops (#1, 2), the workers used cast iron polishing disks almost exclusively, and in 
the others, they used cobalt-containing disks primarily.  The number of subjects from each workshop 
varied from 6 to 28 and the participation rate varied from 56 to 100%.  The low participation in some
workshops reflects the fact that only workers who used cobalt disks were initially asked to be in the study, 
rather than a high refusal rate (only eight refusals were documented).  More than a year after the polishing 
workshops were studied, an additional three workshops with workers engaged in sawing diamonds, 
cleaving diamonds, or drawing jewelry were studied as an unexposed control group (n=59 workers).  
Subjects were asked to fill out a questionnaire regarding employment history, working conditions, 
medical history, respiratory symptoms, and smoking habits, to give a urine sample for cobalt 
determination, and to undergo a clinical examination and lung function tests.  Both area air samples and 
personal air samples were collected (always on a Thursday).  Sampling for area air determinations started 
2 hours after work began and continued until 1 hour before the end of the work day. Personal air samples 
were collected from the breathing zone of a few workers per workshop for four successive 1-hour periods. 
Air samples were analyzed for cobalt and iron.  In addition, personal air samplers were used to sample the 
air 1 cm above the polishing disks.  These samples were analyzed for the entire spectrum of mineral and 
metallic compounds.  Air samples were not obtained at one of the polishing workshops (#4), but this 
workshop was reported to be almost identical to an adjoining workshop (#3) for which samples were 
obtained. Urinary cobalt levels were similar between workers in these two workshops, so exposure was 
considered to be similar as well.  It is important to note that the study authors suggested that the available 
methods used for air sampling may have underestimated the exposure levels. 
There was a good correlation (R=0.92) between the results of area and personal air sampling, with area air 
sampling reporting lower concentrations than personal air samples in all workshops except one (#9) 
(Nemery et al. 1992).  In this workshop, personal air samples appeared to be artificially low in
comparison to area air samples and urinary cobalt levels of the workers.  When this workshop was 
excluded, there was a good correlation (R=0.85–0.88) between urinary cobalt and cobalt in the air.  Based 
on urinary cobalt levels, the concentration of cobalt expected in personal air samples from workshop #9 
was about 45 µg/m3 (the mean value actually reported was 6 µg/m3). The polishing workshops were 
divided into two groups: those with low exposure to cobalt (#1–5, n=102) and those with high exposure to 
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cobalt (#6–10, n=91).  Mean cobalt exposure concentrations were 0.4, 1.6, and 10.2 µg/m3 by area air 
sampling and 0.4, 5.3, and 15.1 µg/m3 by personal air sampling in the control, low-exposure, and high-
exposure groups, respectively.  The inclusion of the apparently biased personal air samples from
workshop #9 means that the reported mean cobalt exposure in the high-exposure group obtained by
personal air sampling (15.1 µg/m3) may be lower than the true value.  Air concentrations of iron were 
highest in the two polishing workshops that used iron disks and the sawing workshop (highest value 
=62 µg/m3), and were not correlated with cobalt levels.  Analysis of samples taken near the disks showed 
the presence of cobalt, with occasional traces of copper, zinc, titanium, manganese, chromium, silicates, 
and silicon dioxide.  No tungsten was detected.  There is a possibility that some workers had previously
been exposed to asbestos, since pastes containing asbestos had been used in the past to glue the diamonds 
onto holders.  However, the degree of asbestos exposure had apparently been insufficient to produce 
functional impairment.  The researchers considered cobalt to be the only relevant exposure.  Smoking 
habits were similar in workers from the high-exposure, low-exposure, and control groups.  Duration of 
exposure was not discussed. 
Effects noted in study and corresponding doses: 
Workers in the high-exposure group were more likely than those in the other groups to complain about 
respiratory symptoms; the prevalences of eye, nose, and throat irritation and cough, and the fraction of 
these symptoms related to work, were significantly increased in the high-exposure group (Nemery et al. 
1992).  Workers in the high-exposure group also had significantly reduced lung function compared to 
controls and low-exposure group workers, as assessed by FVC (forced vital capacity), FEV1 (forced 
expiratory volume in 1 second), MMEF (forced expiratory flow between 25 and 75% of the FVC), and 
mean PEF (peak expiratory flow rate), although the prevalence of abnormal values did not differ 
significantly between exposure categories.  Results in the low-exposure group did not differ from
controls. Two-way analysis of variance was used to show that the effect on spirometric parameters in the 
high exposure group was present in both men and women.  Women seemed to be affected more than men, 
but the interaction between exposure and sex was not significant.  Smoking was found to exert a strong 
effect on lung function, but lung function level remained negatively correlated with exposure to cobalt, 
independently of smoking.
Dose and end point used for MRL derivation: 
[x] NOAEL  [ ] LOAEL
Nemery et al. (1992) established a NOAEL of 0.0053 mg cobalt/m3 for effects on pulmonary function 
(decreased values upon spirometric examination). 
Uncertainty Factors used in MRL derivation: 
[x] 1 [ ] 3 [ ] 10  (for use of a NOAEL)
[x] 1 [ ] 3  [ ] 10  (for extrapolation from animals to humans) 

[ ] 1  [ ] 3  [x] 10  (for human variability) 

The chronic inhalation MRL for cobalt is derived as follows: 
MRL = NOAEL[ADJ] ÷ UF
MRL = 0.0013 mg cobalt/m3 ÷ 10 
MRL = 1x10-4 mg cobalt/m3 
Was a conversion used from ppm in food or water to a mg/body weight dose? No. 
Was a conversion used from intermittent to continuous exposure? If so, explain: 
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0.0053 mg cobalt/m3 * (8 hours/24 hours) * (5 days/7 days) = 0.0013 mg cobalt/m3 continuous exposure. 
If an inhalation study in animals, list the conversion factors used in determining human equivalent dose: 
NA. 
Other additional studies or pertinent information which lend support to this MRL: 
Necrosis and inflammation of the respiratory tract epithelium (larynx, trachea, bronchioles, nasal 
turbinates) were reported in rats exposed to 19 mg cobalt/m3 and mice exposed to 1.9 mg cobalt/m3 (and 
above) as cobalt sulfate over 16 days (NTP 1991).  Exposure of rats and mice to cobalt as cobalt sulfate 
for 13 weeks resulted in adverse effects on all parts of the respiratory tract, with the larynx being the most 
sensitive part (NTP 1991). At concentrations of ≥0.11 mg cobalt/m3, rats and mice had squamous 
metaplasia of the larynx. Histiocytic infiltrates in the lung were also reported at similar levels in both the 
rats and mice.  In rats, chronic inflammation of the larynx was found at ≥0.38 mg cobalt/m3, and more 
severe effects on the larynx, nose, and lung were reported at higher exposures.  In mice, acute 
inflammation of the nose was found at ≥1.14 mg cobalt/m3, and more severe effects on the larynx, nose, 
and lung were reported at higher exposures. 
Exposure of rats and mice to aerosols of cobalt (as cobalt sulfate) at concentrations from 0.11 to 1.14 mg
cobalt/m3 for 2 years resulted in a spectrum of inflammatory, fibrotic, and proliferative lesions in the 
respiratory tract of male and female rats and mice (NTP 1998).  Squamous metaplasia of the larynx
occurred in rats and mice at exposure concentrations of ≥0.11 mg cobalt/m3, with severity of the lesion 
increasing with increased exposure concentration.  Hyperplastic lesions of the nasal epithelium occurred 
in rats at concentrations of ≥0.11 mg cobalt/m3, and in mice at concentrations of ≥0.38 mg cobalt/m3. 
Both sexes of rats had greatly increased incidences (>90% incidence) of alveolar lesions at all exposure 
levels, including inflammatory changes, fibrosis, and metaplasia.  Similar changes were seen in mice at 
all exposure levels, though the changes in mice were less severe. 
Both studies by NTP (1991, 1998) failed to define a NOAEL, with the lowest concentration examined 
(0.11 mg/m3) a LOAEL for a variety of respiratory effects.  If an MRL were to be calculated based upon 
these studies, it would be as follows: 
Duration adjustment: 0.11 mg cobalt/m3 * (6 h/24 h) * (5 d/7 d) = 0.020 mg cobalt/m3 continuous 
exposure. 
Calculation of human equivalent concentration: 
If fractional depositions in humans and animals are assumed to be equal, then: 
RDDR = VE(animal)/SET(animal) ÷ VE(human)/SET(human) = 0.24 m3/day / 15 cm2 ÷ 20 m3/day / 200 cm2 
RDDR = 0.16 
LOAEL[HEC] = LOAEL[ADJ] * RDDR
= 0.020 mg cobalt/m3 * 0.16 = 0.0032 mg cobalt/m3 
To the LOAEL[HEC], an uncertainty factor of 300 (10 for use of a LOAEL, 3 for animal to human 
extrapolation, and 10 for human variability) to derive an MRL of 1x10-5 mg/m3. This number is an order 
of magnitude lower than the number derived from the Nemery et al. (1992) data, reflecting the fact that it 
is derived from animal data, not from a human study, and is based on a LOAEL, not a NOAEL.  As the 
Nemery et al. (1992) study was a well-performed study in humans that defined a NOAEL and LOAEL, it 
was selected as the basis for derivation of the MRL. 
Agency Contact (Chemical Manager):  Obaid Faroon D.V.M., Ph.D. 
  
 
 
 
 
 
 
 
 
   
  
 
     
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
    
COBALT  A-6 
APPENDIX A 
MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Cobalt 
CAS Number: 10026-24-1 
Date: March 2004 
Profile Status: Final 
Route: [ ] Inhalation [x] Oral 
Duration: [ ] Acute   [x] Intermediate  [ ] Chronic 
Key to figure: 30 
Species: human 
Minimal Risk Level: 1x10-4 [x] mg/kg/day  [  ] ppm [  ] mg/m3 
Reference: 
Davis, J.E. and Fields, J.P.  1958.  Experimental production of polycythemia in humans by administration 
of cobalt chloride.  Proc Soc Exp Biol Med 99:493-495. 
Experimental design: 
Six apparently normal men, ages 20–47, were administered a daily dose of cobalt chloride, administered 
as a 2% solution diluted in either water or milk, for up to 22 days.  Five of the six received 150 mg cobalt 
chloride per day for the entire exposure period, while the sixth was started on 120 mg/day and later 
increased to 150 mg/day.  Blood samples were obtained daily from free-flowing punctures of fingertips at 
least 2 hours after eating, and at least 15 hours after the last dosage of cobalt.  Blood was analyzed for red 
blood cell counts, hemoglobin percentage, leukocyte counts, reticulocyte percentages, and thrombocyte 
counts. 
Effects noted in study and corresponding doses:  
Exposure to cobalt resulted in the development of polycythemia in all six subjects, with increases in red 
blood cell numbers ranging from 0.5 to 1.19 million (~16–20% increase above pre-treatment levels).  
Polycythemic erythrocyte counts returned to normal 9–15 days after cessation of cobalt administration.  
Hemoglobin levels were also increased by cobalt treatment, though to a lesser extent than the erythrocyte 
values, with increases of 6–11% over pretreatment values.  In five of the six subjects, reticulocyte levels 
were elevated, reaching at least twice the pre-experiment values.  Thrombocyte and total leukocyte counts 
did not deviate significantly from pretreatment values. 
Dose end point used for MRL derivation:
[ ] NOAEL [x] LOAEL 
Davis and Fields (1958) identified a LOAEL of 150 mg cobalt chloride per day for increased levels of 
erythrocytes in volunteers.  150 mg cobalt chloride/day corresponds to ~1 mg Co/kg/day, assuming a 
reference body weight of 70 kg.  Available animal studies, presented below, lend support to this LOAEL, 
having demonstrated LOAEL values within half an order of magnitude of that identified by Davis and 
Fields (1958). 
Uncertainty factors used in MRL derivation:
[ ] 1  [ ] 3  [x] 10  (for use of a LOAEL) 
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[x] 1 [ ] 3  [ ] 10  (for extrapolation from animals to humans) 
[ ] 1  [ ] 3  [x] 10  (for human variability) 
The intermediate oral MRL for cobalt is derived as follows: 
MRL = LOAEL ÷ UF 
MRL = 1 mg cobalt/kg-day ÷ 100 
MRL = 1x10-2 mg cobalt/kg-day
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No. 
Was a conversion used from intermittent to continuous exposure? If so, explain: No. 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable. 
Other additional studies or pertinent information that lend support to this MRL: 
No other studies of the effect of intermediate oral cobalt exposure on erythrocyte levels in healthy human 
subjects were identified in a search of the literature.  Treatment of pregnant women for 90 days with 0.5– 
0.6 mg cobalt/kg/day as cobalt chloride did not prevent the reduction in hematocrit and hemoglobin levels 
often found during pregnancy (Holly 1955).  However, treatment of anephric patients (with resulting 
anemia) with 0.16–1.0 mg cobalt/kg/day daily as cobalt chloride for 3–32 weeks resulted in increased 
levels of circulating erythrocytes and a decreased need for transfusions (Duckham and Lee 1976b; Taylor 
et al. 1977). While these studies provide additional evidence that exposure to cobalt can increase 
erythrocyte levels in humans, the fact that the patients were anephric makes definitive interpretation of the
results more difficult. 
Roche and Layrisse (1956) exposed volunteers to similar levels (150 mg CoCl2/day) of cobalt, and 
reported a reversible decrease in uptake of 131I by the thyroid.  The decreased uptake is believed to result 
from cobalt blocking the organic binding of iodine (Paley et al. 1958).  This observation adds support to 
the choice of effect level, as a similar exposure resulted in measurable effects in volunteers, though
whether the changes in iodine uptake operate through the same mechanisms as the changes in erythrocyte 
numbers has not been determined. 
Stanley et al. (1947) exposed groups (n=4, 6 for controls) of 6 Sprague-Dawley rats to 0, 0.62, 2.5, or 
10 mg cobalt/kg/day (0, 2.5, 10, or 40 mg/kg-day of CoCl2@6H2O) in gelatin capsules for 8 weeks.  Blood 
counts and hemoglobin levels were examined at the beginning of the experiment and at 2-week intervals.  
Rats exposed to 0.62 mg cobalt/kg-day showed no change in erythrocyte number.  At 2.5 mg cobalt/kg­
day, a progressive increase in erythrocyte number was seen, increasing up to a maximum of 17% above 
pretreatment values on week 6.  At the highest exposure level, a progressive increase in erythrocyte 
numbers was seen, reaching 29% above pretreatment values at 8 weeks of exposure.  Statistical analyses 
of the group means were not provided, and the study provided only mean values of the measurements, 
precluding statistical analysis.  However, if a 10% change is assumed to be an effect level, exposure to 
2.5 mg cobalt/kg-day was the LOAEL for this study, with a NOAEL of 0.62 mg cobalt/kg-day. 
Krasovskii and Fridyland (1971) exposed groups of rats to 0, 0.05, 0.5, or 2.5 mg Co/kg/day for up to
7 months.  In the 2.5 mg/kg-day group, a persistent increase in erythrocyte levels was seen.  The increase 
was transient in the 0.5 mg/kg/day rats, and was not present in rats exposed to 0.05 mg/kg/day. However, 
numerical data were not presented and statistical significance was not reported. 
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A number of other studies in animals have reported increases in erythrocyte levels following intermediate
oral administration of cobalt compounds (see the LSE table for further details of these studies).  However, 
the majority of them have considerable methodological limitations, including examination of either very
high exposure levels or only one exposure level, limited reporting of results, or limited or no statistical 
analysis. 
Whether or not polycythemia, a condition wherein an excess of erythrocytes is produced, constitutes an 
adverse effect is open to interpretation.  At the levels seen in the available studies, and in particular in the 
Davis and Fields (1958) study, the subjects would be expected to be asymptomatic.  However, data on the 
long-term effects of elevated erythrocyte levels are not available.  As such, this end point was considered 
an adverse effect as a health-protective assumption, and was utilized as a critical end point for MRL 
derivation. 
Agency Contact (Chemical Manager): Obaid Faroon D.V.M., Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical name: Radioactive Cobalt 
CAS number: Multiple 
Date:March 2004 
Profile status: Final 
Route: [ ] Inhalation [ ] Oral [x] External
Duration: [x] Acute [ ] Intermediate [ ] Chronic 
Species: Human 
Minimal Risk Level: 4 [ ] mg/kg/day  [ ] ppm [ ] mg/m3 [x] mSv (400 mrem) 
References: 
Schull WJ, Otake M, Yoshimaru H.  1988. Effect on intelligence test score of prenatal exposure to 
ionizing radiation in Hiroshima and Nagasaki:  A comparison of the T65DR and DS86 dosimetry 
systems.  Radiation Effects Research Foundation (RERF) Technical Report No. 3-88.  Hirroshima, Japan.  
NTIS Report Number:  DE89-906462. 
Burt C. 1966. The genetic determination of differences in intelligence: A study of monozygotic twins 
reared together and apart. Brit J Psychol 57(1&2):137-153. 
Experimental design: 
Schull et al. (1988) study:  Schull et al. (1988) evaluated the quantitative effect of exposure to ionizing 
radiation on the developing fetal and embryonic human brain.  The end point measured was changes in 
intelligence test scores. The effects on individuals exposed in utero to the atomic bombing of Hiroshima 
and Nagasaki were based on the original PE86 samples (n=1,759; data on available intelligence testing) 
and a clinical sample (n=1,598).  The original PE86 sample included virtually all prenatally exposed 
individuals who received tissue-absorbed doses of 0.50 Gy or more.  There were many more individuals 
in the dose range 0–0.49 Gy in the PE86 sample than in the clinical sample.  The clinical sample does not 
include children prenatally exposed at distances between 2,000 and 2,999 m in Hiroshima and Nagasaki.  
Children exposed at greater distances or not present in the city were selected as controls.  In 1955–1956, 
Tanaka-B (emphasis on word-sense, arithmetic abilities, and the like, which were associated with the 
more subtle processing of visual clues than their simple recognition and depended more on 
connectedness) and the Koga (emphasis on perception of spatial relationships) intelligence tests were 
conducted in Nagasaki and the Koga test in Hiroshima.   
Burt (1966) study:  This study determined differences in intelligence in monozygotic twins reared 
together (n=95) and apart (n=53).  All tests conducted in school consisted of (1) a group test of 
intelligence containing both non-verbal and verbal items, (2) an individual test (the London Revision of 
the Terman-Binet Scale) used primarily for standardization and for doubtful cases, and (3) a set of 
performance tests, based on the Pitner-Paterson tests and standardization.  The methods and standard 
remained much the same throughout the study.  Some of the reasons for separation of the twins were 
given as follows:  death of the mother (n=9), unable to bring them up properly, mother's poor health 
(n=12), unmarried (n=6), and economic difficulties.  The children were brought up by parents or foster 
parents (occupation ranged from unskilled to professional).  IQ scores in the study group ranged from
66 to 137.  The standard deviation of the group of separated monozygotic twins was reported at 15.3 as 
compared to 15.0 of ordinary siblings.  Twins brought up in different environments were compared with 
those brought up in similar circumstances. 
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Effects noted in study and corresponding doses:  
Schull et al. (1986) study:  No evidence of radiation-related effect on intelligence was observed among 
individuals exposed within 0–7 weeks after fertilization or in the 26th or subsequent weeks.  The highest 
risk of radiation damage to the embryonic and fetal brain occurs 8–15-weeks after fertilization under both 
dosimetric systems.  The regression of intelligence score on estimated DS86 uterine absorbed dose is 
linear with dose, and the diminution in intelligence score is 21–29 points per Gy for the 8–15-week group 
and 10–26 points per Gy for the 16–25-week group.  The results for 8–15 weeks applies regardless 
whether or not the mentally retarded individuals were included.  The cumulative distribution of test scores 
suggested a progressive shift downwards in individual scores with increasing exposure.  The mean IQ 
scores decrease significantly and systematically with uterine or fetal tissue dose within the 8–15- and  
16–25-week groups.  
In summary, analysis of intelligence test scores at 10–11 years of age of individuals exposed prenatally
showed that: 
•	 There is no evidence of a radiation-related effect on intelligence scores among those individuals 
exposed within 0–7 weeks of fertilization or in the 26th week of gestation and beyond; 
•	 The cumulative distribution of test scores suggests a progressive shift downwards in intelligence
scores with increasing exposure to ionizing radiation (dose-response relationship). 
•	 The most sensitive group was the 8–15 weeks exposure group. The regression in intelligence 
scores was found to be linear, with 1 Gy dose resulting in a 21–29 point decline in intelligence 
scores. 
•	 There was no indication of groups of individuals with differing sensitivities to radiation. 
Burt (1966) study:  The average intelligence of the twins measured on a conventional IQ scale (SD=15) 
was 97.8 for the separated monozygotes, 98.1 for monozygotes brought up together, 99.3 for the 
dizygotes as compared with 100.2 for the siblings, and 100.0 for the population as a whole.  The 
difference of 0.3 IQ point between the separated and unseparated identical twins is considered a NOAEL 
for this study. 
Dose endpoint used for MRL derivation:  
[x] NOAEL [ ] LOAEL 0.3 IQ point reduction in twins, between those raised together and those raised 
apart. 
Uncertainty factors (UF) used in MRL derivation:
[x] 1  [ ] 3  [ ] 10 (for use of a NOAEL)
[x] 1 [ ] 3  [ ] 10 (for extrapolation from animals to humans) 
[ ] 1  [x] 3  [ ] 10 (for human variability/sensitive population) 
Was a conversion factor used from ppm in food or water to a mg/body weight dose? If so, explain:  No. 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:  NA 
Was a conversion used from intermittent to continuous exposure? No. 
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Other additional studies or pertinent information that lend support to this MRL:  
Husen (1959) reported a study involving 269 pairs of Swedish monozygotic (identical) twins where the 
intrapair IQ difference was 4 IQ points for a combination of twins raised together and apart.  This is 
somewhat lower than the value of 7 IQ points for identical twins raised apart, and just larger than the 
range of IQ scores for Washington, DC children repetitively tested (Jacobi and Glauberman 1995).   
Supporting evidence for the acute MRL is provided by Jacobi and Glauberman (1995).  Children in the 
1st, 3rd, and 5th grades born in Washington, DC were tested, and average IQ levels of 94.2, 97.6, and 94.6, 
respectively, were reported.  The range of 3.4 IQ points is considered to be a LOAEL for this study,
which, if used for MRL derivation, would yield an MRL of 0.004 Sv (3.4 IQ points x 1 Sv/25 IQ points 
÷ 30 [10 for use of a LOAEL and 3 for a sensitive population]). 
Additional supporting evidence for the acute MRL is provided by Berger et al. 1997, in a case study of 
accidental radiation injury to the hand.  A Mexican engineer suffered an accidental injury to the hand 
while repairing an x-ray spectrometer.  The day after the accident, his symptoms included a tingling 
sensation and itching in the index and middle fingers.  On days 4 and 7, a "pinching" sensation, swelling, 
and slight erythema were observed.  By day 7, the tip of his index fingers was erythematous and a large 
blister developed with swelling on other fingers.  On day 10, examination by a physician showed that the 
lesions had worsened and the fingers and palms were discolored.  On day 10, he was admitted to the 
hospital where hyperbaric oxygen therapy was administered without success.  One month after the 
accident, the patient entered the hospital again with pain, discoloration, and desquamation of his hand.  
Clinical examination showed decreased circulation in the entire hand, most notably in the index and 
middle finger. Total white blood count decreased to 3,000/µL (normal range 4,300–10,800/µL).  
Cytogenic studies of peripheral blood lymphocytes revealed four dicentrics, two rings, and eight 
chromosomal fragments in the 300 metaphases studied.  The estimated whole body dose was reported to 
be 0.382 Gy (38.2 rad).  This dose is a potential LOAEL for acute ionizing radiation and would yield an 
MRL of 0.004 Sv (0.38 Sv ÷100 [10 for use of LOAEL and 10 for sensitive human population]).   
The USNRC set a radiation exposure limit of 0.5 rem (50 mSv) for pregnant working women over the full
gestational period (USNRC 1991).  For the critical gestational period of 8–15 weeks, ATSDR believes 
that the conservative acute MRL of 4 mSv is consistent with the USNRC limit and could be applied to
either acute (0–14-day) or intermediate (15–365-day) exposure periods. 
Calculations
Given:  0.3 IQ point is a NOAEL.  A 1 Sv dose results in a 25 IQ point reduction (range=21–29 points; 

mean=25) and provides a conversion factor from IQ prediction to radiation dose.  Assume that the 

radiation dose and the subsequent reduction in IQ is a linear relationship. 

MRL = NOAEL x CF ÷ UF 

MRL = 0.3 x 1/25 ÷ 3 

MRL = 0.004 Sv = 4 mSv (400 mrem) 

Agency Contact (Chemical Manager):  Obaid Faroon D.V.M., Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Radioactive Cobalt 
CAS Number: Multiple 
Date: March 2004 
Profile Status: Final 
Route: [ ] Inhalation [ ] Oral [X] External
Duration: [ ] Acute   [ ] Intermediate   [X] Chronic 
Species: Human 
Minimal Risk Level: 1 [ ] mg/kg/day  [ ] ppm [ ] mg/m3 [X] mSv/year (100 mrem/year) 
Reference: BEIR V. 1990. Health effects of exposure to low levels of ionizing radiation.  Committee on 
the Biological Effects of Ionizing Radiations, National Research Council.  National Academy Press.  
Washington, DC. 
Experimental design: Not applicable 
Effects noted in study and corresponding doses: No individual studies were identified that could be used 
to base a chronic-duration external exposure MRL that did not result in a cancer-producing end point. 
However, two sources of information were identified that did provide doses of ionizing radiation that 
have not been reported to be associated with detrimental effects (NOAELs).  These sources provide 
estimates of background levels of primarily natural sources of ionizing radiation that have not been 
implicated in producing cancerous or noncancerous toxicological endpoints.  BEIR V states that the 
average annual effective dose to the U.S. population is 3.6 mSv/year.  A total annual effective dose 
equivalent of 3.6 mSv (360 mrem)/year to members of the U.S. population is obtained mainly by
naturally occurring radiation from external sources, medical uses of radiation, and radiation from
consumer products. The largest contribution (82%) is from natural sources, two-thirds of which is from
naturally occurring radon and its decay products.  Specific sources of this radiation are demonstrated in 
Table A-1. 
The annual dose of 3.6 mSv per year has not been associated with adverse health effects or increases in 
the incidences of any type of cancers in humans or other animals. 
Dose and end point used for MRL derivation:  3.6 mSv/year 
[X] NOAEL [ ] LOAEL 3.6 mSv/year
Uncertainty Factors used in MRL derivation: 
[X] 1 [ ] 3  [ ] 10 (for use of a NOAEL) 
[X] 1 [ ] 3  [ ] 10 (for extrapolation from animals to humans) 

[ ] 1  [X] 3  [ ] 10 (for human variability) 

Was a conversion used from ppm in food or water to a mg/body weight dose? No. 
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Table A-1. Average Annual Effective Dose Equivalent from Ionizing Radiation to a 

Member of the U.S. Populationa
 
Effective dose equivalent 
Percent of total 
Source mSv dose 
Natural 
Radonb 2.0 55 
Cosmic 0.27 8.0 
Terrestrial 0.28 8.0 
Internal 0.39 11 
Total natural 3.0 82 
Artificial 
Medical 
X-ray 0.39 11 
Nuclear 0.14 4.0 
Consumer 0.10 3.0 
products
Other 
Occupational <0.01 <0.3 
Nuclear fuel <0.01 <0.03 
cycle 
Fallout <0.01 <0.03 
Miscellaneousc <0.01 <0.03 
Total artificial 0.63 18 
Total natural 3.6 100 
and artificial 
aAdapted from BEIR V, Table 1-3 , page 18. 
bDose equivalent to bronchi from radon daughter products 
cDOE facilities, smelter, transportation, etc. 
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If an inhalation study in animals, list the conversion factors used in determining human equivalent dose: 
Not applicable. 
Was a conversion used from intermittent to continuous exposure? No. 
Other additional studies or pertinent information which lend support to this MRL: ICRP has developed 
recommended dose limits for occupational and public exposure to ionizing radiation sources.  The ICRP 
recommends limiting public exposure to 1 mSv/year (100 mrem/year), but does note that values at high 
altitudes above sea level and in some geological areas can sometimes be twice that value (≥2 mSv). In 
Annex C of ICRP 60, the commission provides data that suggests increasing the dose from 1 mSv to 
5 mSv results in a very small, but detectable, increase in age-specific human mortality rate.  ICRP states 
that the value of 1 mSv/year was chosen over the 5 mSv value because 5 mSv/year (500 mrem/year) 
causes this increase in age specific mortality rate, and 1 mSv/year (100 mrem/year) is typical of the 
annual effective dose from background, less radon (ICRP 1991).  The 1 mSv estimate may underestimate 
the annual exposure to external sources of ionizing radiation to the U.S. population, as it does not include 
radiation from radon.  Conversely, the 5 mSv estimate may be high, in that increases in mortality rate 
been reported. The most useful estimate appears to be the BEIR V estimate of 3.6 mSv, in that it 
accounts for an annual exposure to radon, is specific to the U.S. population, has not been associated with 
increases mortality, and it falls short of the 5 mSv value associated with small increases in human 
mortality. 
Calculations: 
MRL = NOAEL(ADJ) ÷ UF 
MRL = 3.6 mSv/year ÷ 3 
MRL = 1.20 mSv/year 
MRL = 1.0 mSv/year =100 mrem/year above background 
Agency Contact (Chemical Manager):  Obaid Faroon D.V.M., Ph.D. 
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Chapter 1 
Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Relevance to Public Health 
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight­
of-evidence discussions for human health end points by addressing the following questions. 
1. What effects are known to occur in humans? 
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section. 
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not 
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
COBALT  B-2 
APPENDIX B 
MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure. 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.10, "Interactions with Other Substances,” and Section 3.11, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.   
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 
in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure 
(LSE) Tables. 
Chapter 3 
Health Effects 
Tables and Figures for Levels of Significant Exposure (LSE) 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs). 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
LEGEND 
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See Sample LSE Table 3-1 (page B-6)
(1) 	 Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  Typically
when sufficient data exists, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Table 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures. 
(2) 	Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  
In this example, an inhalation study of intermediate exposure duration is reported.  For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure. 
(3) 	Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18). 
(4) 	 Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1). 
(5) 	Species. The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.5, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
(6) 	Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure 
regimen are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981). 
(7) 	System. This column further defines the systemic effects.  These systems include respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated. 
(8) 	NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").
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(9) 	LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. 
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs. 
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile. 
(11)	 CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases. 
(12)	 Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm. 
LEGEND 
See Sample Figure 3-1 (page B-7) 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
(13) Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated. 
(14) Health Effect. These are the categories of health effects for which reliable quantitative data 

exists. The same health effects appear in the LSE table. 

(15) Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
(16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the Table) to the MRL of 
0.005 ppm (see footnote "b" in the LSE table). 
(17)	 CEL. Key number 38r is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the 
LSE table. 
(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*). 
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(19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure. 
       
 
  
 
    
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reference 
10 
↓
Nitschke et al. 1981 
Wong et al. 1982 
NTP 1982 
NTP 1982 
Serious (ppm) 
(CEL, multiple
organs) 
(CEL, lung tumors, 
nasal tumors) 
(CEL, lung tumors, 
hemangiosarcomas) 
11 
↓
20 
10 
10 
LOAEL (effect) 
Less serious 
(ppm) 
9 
↓
10 (hyperplasia) 
SAMPLE 
NOAEL 
(ppm) 
8 
↓
3b 
System 
7 
↓
Resp 
Exposure 
frequency/ 
duration 
6 
↓
13 wk 
5 d/wk 
6 hr/d 
18 mo 
5 d/wk 
7 hr/d 
89-104 wk 
5 d/wk 
6 hr/d 
79-103 wk 
5 d/wk 
6 hr/d 
Species 
5 
↓
Rat 
Rat 
Rat 
Mouse 
TABLE 3-1.  Levels of Significant Exposure to [Chemical x] – Inhalation 
Key to figurea 
INTERMEDIATE EXPOSURE 
Systemic
18 
CHRONIC EXPOSURE 
Cancer
38 
39 
40 
a The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of  5x10-3 ppm; dose adjusted for intermittent exposure and divided 
by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).
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APPENDIX C.  ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
Some terms are generic and may not be used in this profile. 
ACGIH American Conference of Governmental Industrial Hygienists 
ACOEM American College of Occupational and Environmental Medicine 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AED atomic emission detection 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALI annual limit on intake 
ALT alanine aminotransferase
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
AOEC Association of Occupational and Environmental Clinics 
AP alkaline phosphatase 
APHA American Public Health Association 
AST aspartate aminotransferase
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria 
BAT best available technology 
BCF bioconcentration factor 
BEI Biological Exposure Index
BMD benchmark dose 
BMR benchmark response 
BSC Board of Scientific Counselors 
C centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
CL ceiling limit value 
CLP Contract Laboratory Program
cm centimeter 
CML chronic myeloid leukemia 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DAC derived air concentration 
DHEW Department of Health, Education, and Welfare 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
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DOE Department of Energy
DOL Department of Labor 
DOT Department of Transportation 
DOT/UN/ Department of Transportation/United Nations/ 
NA/IMCO     North America/International Maritime Dangerous Goods Code 
DWEL drinking water exposure level 
ECD electron capture detection 
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
FR Federal Register 
FSH follicle stimulating hormone 
g gram
GC gas chromatography
gd gestational day
GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
ILO International Labor Organization 
IRIS Integrated Risk Information System
Kd adsorption ratio 
kg kilogram
kkg metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 
LT50 lethal time, 50% kill 
m meter 
MA trans,trans-muconic acid 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
  
 
 
 
 
  
  
 
 
COBALT C-3 
APPENDIX C 
MAL maximum allowable level 
mCi millicurie 
MCL maximum contaminant level 
MCLG maximum contaminant level goal 
MF modifying factor 
MFO mixed function oxidase 
mg milligram
mL milliliter 
mm millimeter 
mmHg millimeters of mercury
mmol millimole 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCEH National Center for Environmental Health 
NCI National Cancer Institute 
ND not detected 
NFPA National Fire Protection Association 
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
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OSW Office of Solid Waste, EPA 
OTS Office of Toxic Substances 
OW Office of Water 
OWRS Office of Water Regulations and Standards, EPA 
PAH polycyclic aromatic hydrocarbon 
PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit 
pg picogram
PHS Public Health Service 
PID photo ionization detector 
pmol picomole 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS pretreatment standards for new sources 
RBC red blood cell 
REL recommended exposure level/limit 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase 
SIC standard industrial classification 
SIM selected ion monitoring 
SMCL secondary maximum contaminant level 
SMR standardized mortality ratio 
SNARL suggested no adverse response level 
SPEGL Short-Term Public Emergency Guidance Level 
STEL short term exposure limit 
STORET Storage and Retrieval 
TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC total organic carbon 
TPQ threshold planning quantity
TRI Toxics Release Inventory
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States
USDA United States Department of Agriculture 
USGS United States Geological Survey
USNRC United States Nuclear Regulatory Commission 
VOC volatile organic compound 
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WHO 

> 
≥
= 
< 
≤
% 
α
β
γ
δ
µm
µg 
q1* 
– 
+ 
(+) 
(–) 
APPENDIX C 
white blood cell 
World Health Organization 
greater than 
greater than or equal to 
equal to 
less than 
less than or equal to 
percent 
alpha 
beta 
 gamma 
delta 
 micrometer 
microgram
cancer slope factor 
negative 
positive 
weakly positive result 
weakly negative result 
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APPENDIX D.  OVERVIEW OF BASIC RADIATION PHYSICS, CHEMISTRY, 

AND BIOLOGY 

Understanding the basic concepts in radiation physics, chemistry, and biology is important to the 
evaluation and interpretation of radiation-induced adverse health effects and to the derivation of radiation 
protection principles. This appendix presents a brief overview of the areas of radiation physics,
chemistry, and biology and is based to a large extent on the reviews of Mettler and Moseley (1985), 
Hobbs and McClellan (1986), Eichholz (1982), Hendee (1973), Cember (1996), and Early et al. (1979). 
D.1 RADIONUCLIDES AND RADIOACTIVITY 
The substances we call elements are composed of atoms.  Atoms in turn are made up of neutrons, protons 
and electrons: neutrons and protons in the nucleus and electrons in a cloud of orbits around the nucleus.  
Nuclide is the general term referring to any nucleus along with its orbital electrons.  The nuclide is 
characterized by the composition of its nucleus and hence by the number of protons and neutrons in the 
nucleus. All atoms of an element have the same number of protons (this is given by the atomic number) 
but may have different numbers of neutrons (this is reflected by the atomic mass numbers or atomic 
weight of the element).  Atoms with different atomic mass but the same atomic numbers are referred to as 
isotopes of an element. 
The numerical combination of protons and neutrons in most nuclides is such that the nucleus is quantum
mechanically stable and the atom is said to be stable, i.e., not radioactive; however, if there are too few or 
too many neutrons, the nucleus is unstable and the atom is said to be radioactive.  Unstable nuclides 
undergo radioactive transformation, a process in which a neutron or proton converts into the other and a 
beta particle is emitted, or else an alpha particle is emitted.  Each type of decay is typically accompanied 
by the emission of gamma rays.  These unstable atoms are called radionuclides; their emissions are called 
ionizing radiation; and the whole property is called radioactivity.  Transformation or decay results in the 
formation of new nuclides some of which may themselves be radionuclides, while others are stable 
nuclides. This series of transformations is called the decay chain of the radionuclide.  The first 
radionuclide in the chain is called the parent; the subsequent products of the transformation are called 
progeny, daughters, or decay products. 
In general there are two classifications of radioactivity and radionuclides:  natural and artificial (man­
made). Naturally-occurring radioactive materials (NORMs) exist in nature and no additional energy is 
necessary to place them in an unstable state.  Natural radioactivity is the property of some naturally
occurring, usually heavy elements, that are heavier than lead.  Radionuclides, such as radium and 
uranium, primarily emit alpha particles.  Some lighter elements such as carbon-14 and tritium (hydrogen­
3) primarily emit beta particles as they transform to a more stable atom.  Natural radioactive atoms 
heavier than lead cannot attain a stable nucleus heavier than lead.  Everyone is exposed to background 
radiation from naturally-occurring radionuclides throughout life.  This background radiation is the major 
source of radiation exposure to man and arises from several sources.  The natural background exposures 
are frequently used as a standard of comparison for exposures to various artificial sources of ionizing 
radiation. 
Artificial radioactive atoms are produced either as a by-product of fission of uranium or plutonium atoms 
in a nuclear reactor or by bombarding stable atoms with particles, such as neutrons or protons, directed at 
the stable atoms with high velocity.  These artificially produced radioactive elements usually decay by
emission of particles, such as positive or negative beta particles and one or more high energy photons 
(gamma rays).  Unstable (radioactive) atoms of any element can be produced. 
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APPENDIX D 
Both naturally occurring and artificial radioisotopes find application in medicine, industrial products, and 
consumer products. Some specific radioisotopes, called fall-out, are still found in the environment as a 
result of nuclear weapons use or testing.
D.2 RADIOACTIVE DECAY
D.2.1 Principles of Radioactive Decay
The stability of an atom is the result of the balance of the forces of the various components of the nucleus.  
An atom that is unstable (radionuclide) will release energy (decay) in various ways and transform to 
stable atoms or to other radioactive species called daughters, often with the release of ionizing radiation.  
If there are either too many or too few neutrons for a given number of protons, the resulting nucleus may
undergo transformation.  For some elements, a chain of daughter decay products may be produced until 
stable atoms are formed.  Radionuclides can be characterized by the type and energy of the radiation 
emitted, the rate of decay, and the mode of decay.  The mode of decay indicates how a parent compound 
undergoes transformation. Radiations considered here are primarily of nuclear origin, i.e., they arise from
nuclear excitation, usually caused by the capture of charged or uncharged nucleons by a nucleus, or by the 
radioactive decay or transformation of an unstable nuclide.  The type of radiation may be categorized as 
charged or uncharged particles, protons, and fission products) or electromagnetic radiation (gamma rays
and x rays).  Table D-1 summarizes the basic characteristics of the more common types of radiation 
encountered. 
D.2.2 Half-Life and Activity
For any given radionuclide, the rate of decay is a first-order process that is constant, regardless of the 
radioactive atoms present and is characteristic for each radionuclide.  The process of decay is a series of 
random events; temperature, pressure, or chemical combinations do not effect the rate of decay.  While it 
may not be possible to predict exactly which atom is going to undergo transformation at any given time, it 
is possible to predict, on average, the fraction of the radioactive atoms that will transform during any
interval of time. 
The activity is a measure of the quantity of radioactive material.  For these radioactive materials it is 
customary to describe the activity as the number of disintegrations (transformations) per unit time.  The 
unit of activity is the curie (Ci), which was originally related to the activity of one gram of radium, but is 
now defined as that quantity of radioactive material in which there are: 
1 curie (Ci) = 3.7x1010 disintegrations (transformations)/second (dps) or 2.22x1012 disintegrations 
(transformations)/minute (dpm). 
The SI unit of activity is the becquerel (Bq); 1 Bq = that quantity of radioactive material in which there is 
1 transformation/second. Since activity is proportional to the number of atoms of the radioactive 
material, the quantity of any radioactive material is usually expressed in curies, regardless of its purity or 
concentration. The transformation of radioactive nuclei is a random process, and the number of 
transformations is directly proportional to the number of radioactive atoms present.  For any pure 
radioactive substance, the rate of decay is usually described by its radiological half-life, TR, i.e., the time 
it takes for a specified source material to decay to half its initial activity.  The specific activity is the 
activity of a radionuclide per mass of that radionuclide.  If properly qualified, it can refer to activity per 
unit mass of related materials, such as the element itself or a chemical compound labeled with the 
radionuclide.  The higher the specific activity of a radioisotope, the faster it is decaying.
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The activity of a radionuclide at time t may be calculated by: 
-0.693t/Trad A = Aoe
where A is the activity in dps or curies or becquerels, Ao is the activity at time zero, t is the time at which 
measured, and Trad is the radiological half-life of the radionuclide (Trad and t must be in the same units of 
time). The time when the activity of a sample of radioactivity becomes one-half its original value is the 
radioactive half-life and is expressed in any suitable unit of time. 
Table D-1. Characteristics of Nuclear Radiations 
Typical Path lengthb 
Radiation Rest massa Charge energy range Air Solid Comments 
Alpha (α) 4.00 amu +2 4–10 MeV 5–10 cm 25–80 µm Identical to ionized 
He nucleus 
Negatron (β–) 5.48x10-4 amu; –1 0–4 MeV 0–10 m 0–1 cm Identical to electron 
0.51 MeV 
Positron (β+) 5.48x10-4 amu; +1 0-4 MeV 0–10 m 0–1 cm Identical to electron 
0.51 MeV except for sign of 
charge 
Neutron 1.0086 amu; 0 0–15 MeV b b Free half-life: 16 
939.55 MeV min 
X ray (e.m.  – 0 5 keV–100 keV b b Photon from
photon) transition of an
electron between 
atomic orbits 
Gamma (p) – 0 10 keV–3 MeV b b Photon from
nuclear(e.m.  photon) 
transformation 
a The rest mass (in amu) has an energy equivalent in MeV that is obtained using the equation E=mc2, where 1 amu = 932 MeV. 
b Path lengths are not applicable to x- and gamma rays since their intensities decrease exponentially; path lengths in solid tissue
are variable, depending on particle energy, electron density of material, and other factors. 
 amu = atomic mass unit; e.m. = electromagnetic; MeV = Megaelectron Volts 
The specific activity is a measure of activity, and is defined as the activity of a radionuclide per mass of 
that radionuclide. This activity is usually expressed in curies per gram and may be calculated by
curies/gram = 1.3x108 / (Trad) (atomic weight)  or 
[3.577 x 105 x mass(g)] / [Trad  x atomic weight]
where Trad is the radiological half-life in days. 
In the case of radioactive materials contained in living organisms, an additional consideration is made for 
the reduction in observed activity due to regular processes of elimination of the respective chemical or 
biochemical substance from the organism.  This introduces a rate constant called the biological half-life 
(Tbiol) which is the time required for biological processes to eliminate one-half of the activity. This time 
is virtually the same for both stable and radioactive isotopes of any given element. 
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Under such conditions the time required for a radioactive element to be halved as a result of the combined 
action of radioactive decay and biological elimination is the effective clearance half-time: 
Teff = (Tbiol x Trad) / (Tbiol + Trad). 
Table D-2 presents representative effective half-lives of particular interest. 
Table D-2. Half-Lives of Some Radionuclides in Adult Body Organs 
Half-lifea 
Radionuclide Critical organ Physical Biological Effective 
Uranium 238
Hydrogen 3b 
Kidney
Whole body
4,460,000,000 y
12.3 y 
4 d 
10 d 
4 d 
10 d 
(Tritium)
Iodine 131 Thyroid 8 d 80 d 7.3 d 
Strontium 90 Bone 28 y 50 y 18 y
Plutonium 239 Bone surface 24,400 y 50 y 50 y
Lung 24,400 y 500 d 474 d 
Cobalt 60 Whole body 5.3 y 99.5 d 95 d 
Iron 55 Spleen 2.7 y 600 d 388 d 
Iron 59 Spleen 45.1 d 600 d 42 d 
Manganese 54 Liver 303 d 25 d 23 d 
Cesium 137 Whole body 30 y 70 d 70 d 
ad = days, y = years
bMixed in body water as tritiated water 
D.2.3 Interaction of Radiation with Matter 
Both ionizing and nonionizing radiation will interact with materials; that is, radiation will lose kinetic 
energy to any solid, liquid or gas through which it passes by a variety of mechanisms.  The transfer of 
energy to a medium by either electromagnetic or particulate radiation may be sufficient to cause 
formation of ions. This process is called ionization.  Compared to other types of radiation that may be 
absorbed, such as ultraviolet radiation, ionizing radiation deposits a relatively large amount of energy into 
a small volume. 
The method by which incident radiation interacts with the medium to cause ionization may be direct or 
indirect. Electromagnetic radiations (x rays and gamma photons) are indirectly ionizing; that is, they give 
up their energy in various interactions with cellular molecules, and the energy is then utilized to produce a 
fast-moving charged particle such as an electron.  It is the electron that then may react with a target 
molecule.  This particle is called a “primary ionizing particle.  Charged particles, in contrast, strike the 
tissue or medium and directly react with target molecules, such as oxygen or water.  These particulate 
radiations are directly ionizing radiations.  Examples of directly ionizing particles include alpha and beta 
particles. Indirectly ionizing radiations are always more penetrating than directly ionizing particulate 
radiations. 
Mass, charge, and velocity of a particle, as well as the electron density of the material with which it 
interacts, all affect the rate at which ionization occurs.  The higher the charge of the particle and the lower 
the velocity, the greater the propensity to cause ionization.  Heavy, highly charged particles, such as alpha 
particles, lose energy rapidly with distance and, therefore, do not penetrate deeply.  The result of these 
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interaction processes is a gradual slowing down of any incident particle until it is brought to rest or 
"stopped" at the end of its range. 
D.2.4 Characteristics of Emitted Radiation 
D.2.4.1 Alpha Emission.    In alpha emission, an alpha particle consisting of two protons and two 
neutrons is emitted with a resulting decrease in the atomic mass number by four and reduction of the 
atomic number of two, thereby changing the parent to a different element.  The alpha particle is identical 
to a helium nucleus consisting of two neutrons and two protons.  It results from the radioactive decay of 
some heavy elements such as uranium, plutonium, radium, thorium, and radon.  The alpha particles 
emitted by a given radionuclide have the same energy and intensity combination.  Most of the alpha 
particles that are likely to be found have energies in the range of about 4 to 8 MeV, depending on the 
isotope from which they came. 
The alpha particle has an electrical charge of +2.  Because of this double positive charge and their size, 
alpha particles have great ionizing power and, thus, lose their kinetic energy quickly.  This results in very
little penetrating power. In fact, an alpha particle cannot penetrate a sheet of paper.  The range of an 
alpha particle (the distance the charged particle travels from the point of origin to its resting point) is 
about 4 cm in air, which decreases considerably to a few micrometers in tissue.  These properties cause 
alpha emitters to be hazardous only if there is internal contamination (i.e., if the radionuclide is inside the 
body). 
D.2.4.2 Beta Emission. A beta particle (&) is a high-velocity electron ejected from a disintegrating 
nucleus. The particle may be either a negatively charged electron, termed a negatron (&-) or a positively
charged electron, termed a positron (&+).  Although the precise definition of "beta emission" refers to 
both &- and &+, common usage of the term generally applies only to the negative particle, as distinguished
from the positron emission, which refers to the &+ particle. 
D.2.4.2.1 Beta Negative Emission.  Beta particle (&-) emission is another process by which a 
radionuclide, with a neutron excess achieves stability.  Beta particle emission decreases the number of 
neutrons by one and increases the number of protons by one, while the atomic mass number remains 
unchanged.1  This transformation results in the formation of a different element.  The energy spectrum of 
beta particle emission ranges from a certain maximum down to zero with the mean energy of the 
spectrum being about one-third of the maximum.  The range of betas is much less in tissue than in air.  
Beta negative emitting radionuclides can cause injury to the skin and superficial body tissues, but mostly
present an internal contamination hazard. 
D.2.4.2.2 Positron Emission.    In cases in which there are too many protons in the nucleus, positron 
emission may occur.  In this case a proton may be thought of as being converted into a neutron, and a 
positron (&+) is emitted.1  This increases the number of neutrons by one, decreases the number of protons 
by one, and again leaves the atomic mass number unchanged.  The gamma radiation resulting from the 
annihilation (see glossary) of the positron makes all positron emitting isotopes more of an external 
radiation hazard than pure & emitters of equal energy. 
D.2.4.2.3 Gamma Emission.    Radioactive decay by alpha, beta, or positron emission, or electron 
capture often leaves some of the energy resulting from these changes in the nucleus.  As a result, the 
nucleus is raised to an excited level.  None of these excited nuclei can remain in this high-energy state.  
Nuclei release this energy returning to ground state or to the lowest possible stable energy level.  The 
energy released is in the form of gamma radiation (high energy photons) and has an energy equal to the 
change in the energy state of the nucleus.  Gamma and x rays behave similarly but differ in their origin; 
1 Neutrinos also accompany negative beta particles and positron emissions 
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gamma emissions originate in the nucleus while x rays originate in the orbital electron structure or from
rapidly changing the velocity of an electron (e.g., as occurs when shielding high energy beta particles or 
stopping the electron beam in an x ray tube). 
D.3 ESTIMATION OF ENERGY DEPOSITION IN HUMAN TISSUES 
Two forms of potential radiation exposures can result: internal and external.  The term exposure denotes 
physical interaction of the radiation emitted from the radioactive material with cells and tissues of the 
human body.  An exposure can be "acute" or "chronic" depending on how long an individual or organ is 
exposed to the radiation.  Internal exposures occur when radionuclides, which have entered the body (e.g.,
through the inhalation, ingestion, or dermal pathways), undergo radioactive decay resulting in the 
deposition of energy to internal organs.  External exposures occur when radiation enters the body directly
from sources located outside the body, such as radiation emitters from radionuclides on ground surfaces, 
dissolved in water, or dispersed in the air.  In general, external exposures are from material emitting 
gamma radiation, which readily penetrate the skin and internal organs.  Beta and alpha radiation from
external sources are far less penetrating and deposit their energy primarily on the skin's outer layer.  
Consequently, their contribution to the absorbed dose of the total body dose, compared to that deposited
by gamma rays, may be negligible. 
Characterizing the radiation dose to persons as a result of exposure to radiation is a complex issue.  It is 
difficult to: (1) measure internally the amount of energy actually transferred to an organic material and to 
correlate any observed effects with this energy deposition; and (2) account for and predict secondary
processes, such as collision effects or biologically triggered effects, that are an indirect consequence of 
the primary interaction event. 
D.3.1 Dose/Exposure Units 
D.3.1.1 Roentgen.    The roentgen (R) is a unit of x or gamma-ray exposure and is a measured by the 
amount of ionization caused in air by gamma or x radiation.  One roentgen produces 2.58x10-4 coulomb 
per kilogram of air.  In the case of gamma radiation, over the commonly encountered range of photon 
energy, the energy deposition in tissue for a dose of 1 R is about 0.0096 joules (J) /kg of tissue. 
D.3.1.2 Absorbed Dose and Absorbed Dose Rate.    The absorbed dose is defined as the energy
imparted by radiation to a unit mass of the tissue or organ.  The unit of absorbed dose is the rad; 1 rad = 
100 erg/gram = 0.01 J/kg in any medium.  An exposure of 1 R results in a dose to soft tissue of 
approximately 0.01 J/kg. The SI unit is the gray which is equivalent to 100 rad or 1 J/kg.  Internal and 
external exposures from radiation sources are not usually instantaneous but are distributed over extended 
periods of time.  The resulting rate of change of the absorbed dose to a small volume of mass is referred 
to as the absorbed dose rate in units of rad/unit time. 
D.3.1.3 Working Levels and Working Level Months.    Working level (WL) is a measure of the 
atmospheric concentration of radon and its short-lived progeny.  One WL is defined as any combination 
of short-lived radon daughters (through polonium-214), per liter of air, that will result in the emission of 
1.3x105 MeV of alpha energy.  An activity concentration of 100 pCi radon-222/L of air, in equilibrium
with its daughters, corresponds approximately to a potential alpha-energy concentration of 1 WL.  The 
WL unit can also be used for thoron daughters.  In this case, 1.3x105 MeV of alpha energy (1 WL) is 
released by the thoron daughters in equilibrium with 7.5 pCi thoron/L.  The potential alpha energy
exposure of miners is commonly expressed in the unit Working Level Month (WLM).  One WLM 
corresponds to exposure to a concentration of 1 WL for the reference period of 170 hours, or more 
generally
WLM = concentration (WL) x exposure time (months)  (one “month” = 170 working hours). 
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D.3.2 Dosimetry Models 
Dosimetry models are used to estimate the dose from internally deposited to radioactive substances.  The 
models for internal dosimetry consider the amount of radionuclides entering the body, the factors 
affecting their movement or transport through the body, distribution and retention of radionuclides in the 
body, and the energy deposited in organs and tissues from the radiation that is emitted during spontaneous 
decay processes.  The dose pattern for radioactive materials in the body may be strongly influenced by the 
route of entry of the material.  For industrial workers, inhalation of radioactive particles with pulmonary
deposition and puncture wounds with subcutaneous deposition have been the most frequent.  The general 
population has been exposed via ingestion and inhalation of low levels of naturally occurring 
radionuclides as well as radionuclides from nuclear weapons testing. 
The models for external dosimetry consider only the photon doses (and neutron doses, where applicable) 
to organs of individuals who are immersed in air or are exposed to a contaminated object.   
D.3.2.1 Ingestion.    Ingestion of radioactive materials is most likely to occur from contaminated 
foodstuffs or water or eventual ingestion of inhaled compounds initially deposited in the lung. Ingestion 
of radioactive material may result in toxic effects as a result of either absorption of the radionuclide or 
irradiation of the gastrointestinal tract during passage through the tract, or a combination of both.  The 
fraction of a radioactive material absorbed from the gastrointestinal tract is variable, depending on the 
specific element, the physical and chemical form of the material ingested, and the diet, as well as some 
other metabolic and physiological factors.  The absorption of some elements is influenced by age, usually 
with higher absorption in the very young. 
D.3.2.2 Inhalation.    The inhalation route of exposure has long been recognized as being a major 
portal of entry for both nonradioactive and radioactive materials.  The deposition of particles within  the 
lung is largely dependent upon the size of the particles being inhaled.  After the particle is deposited, the 
retention will depend upon the physical and chemical properties of the dust and the physiological status of 
the lung.  The retention of the particle in the lung depends on the location of deposition, in addition to the 
physical and chemical properties of the particles.  The converse of pulmonary retention is pulmonary
clearance. There are three distinct mechanisms of clearance which operate simultaneously.  Ciliary
clearance acts only in the upper respiratory tract.  The second and third mechanisms act mainly in the 
deep respiratory tract.  These are phagocytosis and absorption.  Phagocytosis is the engulfing of foreign 
bodies by alveolar macrophages and their subsequent removal either up the ciliary "escalator" or by
entrance into the lymphatic system.  Some inhaled soluble particles are absorbed into the blood and 
translocated to other organs and tissues. 
D.3.3 Internal Emitters 
An internal emitter is a radionuclide that is inside the body.  The absorbed dose from internally deposited 
radionuclide depends on the energy absorbed per unit mass by the irradiated tissue.  For a radionuclide 
distributed uniformly throughout an infinitely large medium, the concentration of absorbed energy must 
be equal to the concentration of energy emitted by the radionuclide.  An infinitely large medium may be 
approximated by a tissue mass whose dimensions exceed the range of the particle.  All alpha and most 
beta radiation will be absorbed in the organ (or tissue) of reference.  Gamma-emitting radionuclide 
emissions are penetrating radiation, and a substantial fraction of gamma energy may be absorbed in 
tissue. The dose to an organ or tissue is a function of the effective retention half-time, the energy released 
in the tissue, the amount of radioactivity initially introduced, and the mass of the organ or tissue. 
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D.4 BIOLOGICAL EFFECTS OF RADIATION 
When biological material is exposed to ionizing radiation, a chain of cellular events occurs as the ionizing 
particle passes through the biological material.  A number of theories have been proposed to describe the 
interaction of radiation with biologically important molecules in cells and to explain the resulting damage 
to biological systems from those interactions.  Many factors may modify the response of a living 
organism to a given dose of radiation.  Factors related to the exposure include the dose rate, the energy of 
the radiation, and the temporal pattern of the exposure.  Biological considerations include factors such as 
species, age, sex, and the portion of the body exposed.  Several excellent reviews of the biological effects 
of radiation have been published, and the reader is referred to these for a more in-depth discussion 
(Brodsky 1996; Hobbs and McClellan 1986; ICRP 1984; Mettler and Moseley 1985; Rubin and Casarett 
1968). 
D.4.1 Radiation Effects at the Cellular Level 
According to Mettler and Moseley (1985), at acute doses up to 10 rad (100 mGy), single strand breaks in 
DNA may be produced.  These single strand breaks may be repaired rapidly.  With doses in the range of 
50–500 rad (0.5–5 Gy), irreparable double-stranded DNA breaks are likely, resulting in cellular 
reproductive death after one or more divisions of the irradiated parent cell.  At large doses of radiation, 
usually greater than 500 rad (5 Gy), direct cell death before division (interphase death) may occur from
the direct interaction of free-radicals with essential cellular macromolecules.  Morphological changes at 
the cellular level, the severity of which are dose-dependent, may also be observed.
The sensitivity of various cell types varies. According to the Bergonie-Tribondeau law, the sensitivity of 
cell lines is directly proportional to their mitotic rate and inversely proportional to the degree of 
differentiation (Mettler and Moseley 1985).  Rubin and Casarett (1968) devised a classification system
that categorized cells according to type, function, and mitotic activity.  The categories range from the 
most sensitive type, "vegetative intermitotic cells", found in the stem cells of the bone marrow and the 
gastrointestinal tract, to the least sensitive cell type, "fixed postmitotic cells," found in striated muscles or 
long-lived neural tissues. 
Cellular changes may result in cell death, which if extensive, may produce irreversible damage to an 
organ or tissue or may result in the death of the individual.  If the cell recovers, altered metabolism and 
function may still occur, which may be repaired or may result in the manifestation of clinical symptoms.  
These changes may also be expressed at a later time as tumors or cellular mutations, which may result in 
abnormal tissue. 
D.4.2 Radiation Effects at the Organ Level 
In most organs and tissues the injury and the underlying mechanism for that injury are complex and may
involve a combination of events.  The extent and severity of this tissue injury are dependent upon the 
radiosensitivity of the various cell types in that organ system.  Rubin and Casarett (1968) describe and 
schematically display the events following radiation in several organ system types.  These include:  a 
rapid renewal system, such as the gastrointestinal mucosa; a slow renewal system, such as the pulmonary
epithelium; and a nonrenewal system, such as neural or muscle tissue.  In the rapid renewal system, organ 
injury results from the direct destruction of highly radiosensitive cells, such as the stem cells in the bone 
marrow. Injury may also result from constriction of the microcirculation and from edema and 
inflammation of the basement membrane, designated as the histohematic barrier, which may progress to 
fibrosis. In slow renewal and nonrenewal systems, the radiation may have little effect on the parenchymal 
cells, but ultimate parenchymal atrophy and death over several months result from fibrosis and occlusion 
of the microcirculation. 
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D.4.3 Low Level Radiation Effects 
Cancer is the major latent harmful effect produced by ionizing radiation and the one that most people 
exposed to radiation are concerned about.  The ability of alpha, beta, and gamma radiation to produce 
cancer in virtually every tissue and organ in laboratory animals has been well-demonstrated.  The 
development of cancer is not an immediate effect.  Radiation-induced leukemia has the shortest latent 
period at about 2 years, while other radiation induced cancers, such as osteosarcoma, have latent periods 
greater than 20 years. The mechanism by which cancer is induced in living cells is complex and is a topic 
of intense study.  Exposure to ionizing radiation can produce cancer at any site within the body; however, 
some sites appear to be more common than others, such as the breast, lung, stomach, and thyroid.   
DNA is the major target molecule during exposure to ionizing radiation.  Other macromolecules, such as 
lipids and proteins, are also at risk of damage when exposed to ionizing radiation.  The genotoxicity of 
ionizing radiation is an area of intense study, as damage to the DNA is ultimately responsible for many of 
the adverse toxicological effects ascribed to ionizing radiation, including cancer.  Damage to genetic 
material is basic to developmental or teratogenic effects, as well.  However, for effects other than cancer, 
there is little evidence of human effects at low levels of exposure. 
D.5 UNITS IN RADIATION PROTECTION AND REGULATION 
D.5.1 Dose Equivalent (or Equivalent Dose) 
Dose equivalent (as measured in rem or sievert) is a special radiation protection quantity that is used for 
administrative and radiation safety purposes to express the absorbed dose in a manner which considers the 
difference in biological effectiveness of various kinds of ionizing radiation.  ICRP (1990) changed this 
term to equivalent dose, but it has not yet been adopted by the USNRC or DOE.   
The USNRC defines the dose equivalent, H, as the product of the absorbed dose, D, and the quality
factor, Q, at the point of interest in biological tissue.  This relationship is expressed as H = D x Q.  The 
dose equivalent concept is applicable only to doses that are not great enough to produce biomedical 
effects. 
The quality factor or radiation weighting factor is a dimensionless quantity that depends in part on the 
stopping power for charged particles, and it accounts for the differences in biological effectiveness found 
among the types of radiation.  Originally relative biological effectiveness (RBE) was used rather than Q 
to define the quantity, rem, which was of use in risk assessment.  The generally accepted values for 
quality factors and radiation weighting factors for various radiation types are provided in Table D-3.  The 
dose equivalent rate is the time rate of change of the dose equivalent to organs and tissues and is 
expressed as rem/unit time or sievert/unit time. 
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Table D-3. Quality Factors (Q) and Absorbed Dose Equivalencies 
Type of radiation Quality factor (Q) Radiation weighting factor (wr)* 
X, gamma, or beta radiation 1 1 
Alpha particles, multiple- 20 0.05 
charged particles, fission 
fragments and heavy particles of 
unknown charge 
Neutrons (other than thermal >> 10 20 
100 keV to 2 MeV), protons, 
alpha particles, charged 
particles of unknown energy
Neutrons of unknown energy 10 
High-energy protons 10 0.1 
Thermal neutrons 5 
*Absorbed dose in rad equal to 1 rem or the absorbed dose in gray equal to 1 sievert. 
Source: USNRC. 2004. Standards for the protection against radiation, table 1004(b).1.  10 CFR 20.1004.  U.S. Nuclear
 
Regulatory Commission, Washington, D.C. NCRP 1993 

D.5.2 Relative Biological Effectiveness 
RBE is used to denote the experimentally determined ratio of the absorbed dose from one radiation type 
to the absorbed dose of a reference radiation required to produce an identical biologic effect under the 
same conditions. Gamma rays from cobalt-60 and 200–250 kVp x-rays have been used as reference 
standards. The term RBE has been widely used in experimental radiobiology, and the term quality factor 
(or radiation weighting factor) used in calculations of dose equivalents for radiation safety purposes 
(ICRP 1977; NCRP 1971; UNSCEAR 1982).  Any RBE value applies only to a specific biological end 
point, in a specific exposure, under specific conditions to a specific species.  There are no generally
applicable values of RBE since RBEs are specific to a given exposure scenario. 
D.5.3 Effective Dose Equivalent (or Effective Dose) 
The absorbed dose is usually defined as the mean energy imparted per unit mass to an organ or tissue.  
This represents a simplification of the actual problem.  Normally when an individual ingests or inhales a 
radionuclide or is exposed to external radiation that enters the body (gamma), the dose is not uniform
throughout the whole body.  The simplifying assumption is that the detriment will be the same whether 
the body is uniformly or non-uniformly irradiated.  In an attempt to compare detriment from absorbed 
dose of a limited portion of the body with the detriment from total body dose, the ICRP (1977) has 
derived a concept of effective dose equivalent.  ICRP (1990) changed this term to effective dose, but it
has not yet been adopted by the USNRC or DOE. 
The effective dose equivalent, HE, is 
HE = (the sum of) Wt Ht 
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where Ht is the dose equivalent (or equivalent dose) in the tissue t, Wt is the tissue weighting factor in that 
tissue, which represents the estimated proportion of the stochastic risk resulting from tissue, t, to the 
stochastic risk when the whole body is uniformly irradiated for occupational exposures under certain 
conditions (ICRP 1977). Tissue weighting factors for selected tissues are listed in Table D-4. 
D.5.4 SI Units 
The ICRU (1980), ICRP (1984), and NCRP (1985) now recommend that the rad, roentgen, curie, and rem
be replaced by the SI units: gray (Gy), Coulomb per kilogram (C/kg), Becquerel (Bq), and sievert (Sv), 
respectively. The relationship between the customary units and the international system of units (SI) for 
radiological quantities is shown in Table D-5. 
Table D-4. Tissue Weighting Factors for Calculating Effective Dose  

Equivalent and Effective Dose for Selected Tissues
 
Tissue weighting factor 
Tissue NCRP115/ ICRP60 USNRC/ICRP26 
Bladder 0.05 – 
Bone marrow 0.12 0.12 
Bone surface 0.01 0.03 
Breast 0.05 0.15 
Colon 0.12 – 
Esophagus 0.05 – 
Gonads 0.20 0.25 
Liver 0.05 – 
Lung 0.12 0.12 
Skin 0.01 – 
Stomach 0.12 – 
Thyroid 0.05 0.03 
Remainder 0.05 0.30 
Total 1.00 1.00 
ICRP60 = International Commission on Radiological Protection, 1990 Recommendations of the ICRP  
NCRP115 = National Council on Radiation Protection and Measurements. 1993. Risk Estimates for Radiation Protection, 
Report 115.  Bethesda, Maryland
USNRC = Nuclear Regulatory Commission, Title 10, Code of Federal Regulations, Part 20 
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Table D-5. Comparison of Common and SI Units for Radiation Quantities 
Customary
Quantity units Definition SI units Definition 
Activity (A) curie (Ci) 3.7x1010 becquerel (Bq) s-1 
transformations s­
1 
Absorbed dose (D) rad 10-2 Jkg-1 gray (Gy) Jkg-1 
-1 -1Absorbed dose rate rad per second 10-2 Jkg-1s gray per second  Jkg-1 s
(Ď) (rad s-1) (Gy s-1) 
Dose equivalent (H) rem 10-2 Jkg-1 sievert (Sv) Jkg-1 
-1 -1Dose equivalent rate rem per second 10-2 Jkg-1s sievert per second Jkg-1 s
( ) (rem s-1) (Sv s-1) 
Effective dose rem 10-2 Jkg-1 Sievert (Sv) Jkg-1 
Equivalent dose (H) rem 10-2 Jkg-1 Sievert (Sv) Jkg-1 
Linear energy kiloelectron 1.602x10-10 Jm-1 kiloelectron volts 1.602x10-10 Jm-1 
transfer (LET) volts per per micrometer 
micrometer (keV µm-1) 
(keV µm-1) 
Jkg-1 = Joules per kilogram; Jkg-1s-1 = Joules per kilogram per second; Jm-1 = Joules per meter; s-1 = per second 
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